The burden of disease and injury in Australia 2003 by Begg, Stephen et al.
	 	
	
 
This is the published version 
 
Begg, Stephen, Vos, Theo, Barker, Bridget, Stevenson, Chris, Stanley, Lucy 
and Lopez, Alan D. 2007, The burden of disease and injury in Australia 2003, 
Australian Institute of Health and Welfare, [Canberra, A. C. T.]. 
 
 
 
 
 
 
 
Available from Deakin Research Online 
 
http://hdl.handle.net/10536/DRO/DU:30046702	
	
	
	
	 	
	
	
	
Reproduced with the kind permission of the copyright owner 
	
 
 
 
 
 
Copyright: 2007, Australian Institute of Health and Welfare 
 
 
The burden of disease and
injury in Australia 2003
The Australian Institute of Health and Welfare is Australia’s national health and welfare statistics and
information agency. The Institute’s mission is better health and wellbeing for Australians through better
health and welfare statistics and information.
Please note that as with all statistical reports there is the potential for minor revisions of data in this
report over its life. Please refer to the online version at <www.aihw.gov.au/bod>.
1School of Population Health, University of Queensland, Brisbane
2Australian Institute of Health and Welfare, Canberra
AIHW cat. no. PHE  82
The burden of disease and
injury in Australia 2003
Stephen Begg1, Theo Vos1, Bridget Barker1,
Chris Stevenson2, Lucy Stanley1 and
Alan D Lopez1
May 2007 
© Australian Institute of Health and Welfare 2007
This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be
reproduced without prior written permission from the Australian Institute of Health and Welfare.
Requests and enquiries concerning reproduction and rights should be directed to the Head,
Business Promotion and Media Unit, Australian Institute of Health and Welfare, GPO Box 570,
Canberra ACT 2601.
A complete list of the Institute’s publications is available from the Institute’s website
<www.aihw.gov.au>.
ISBN  978 1 74024 648 4
Suggested citation
Begg S, Vos T, Barker B, Stevenson C, Stanley L, Lopez AD, 2007. The burden of disease and injury
in Australia 2003. PHE 82. Canberra: AIHW.
Australian Institute of Health and Welfare
Board Chair
Hon. Peter Collins, AM, QC
Director
Penny Allbon
Any enquiries about or comments on this publication should be directed to:
John Goss
Australian Institute of Health and Welfare
GPO Box 570
Canberra ACT 2601
Phone: (02) 6244 1151
Email: burdenofdisease@aihw.gov.au
Published by the Australian Institute of Health and Welfare
Printed by Canprint Communications
vForeword
Exactly a decade ago, the results of the first Global Burden of Disease (GBD) Study were
published by Harvard University on behalf of the World Health Organization and the World
Bank. These organisations and several countries then became interested in applying the GBD
approach to better inform health policy, leading to a series of country studies on all
continents. Probably the most technically competent and comprehensive of these were the
Australian studies, led by Colin Mathers, for Australia as a whole, and Theo Vos for the state
of Victoria. These analyses were based around 1996 data and have been widely used to
inform priority setting and health policy debates in Australia.
As a result of these initial studies, governments across Australia have become interested in
using the burden of disease framework to help quantify health needs. There have also been
advances in methods over the past ten years and greater interest among the health policy
community in information about the burden of disease in population subgroups. This has all
stimulated the need for a revised Australian burden of disease and injury study to update
and extend the initial efforts.
This report responds to that need. Some of the world’s leading researchers in burden of
disease studies, with extensive experience in national applications of the methods, have
joined the University of Queensland to create the great focus of expertise reflected in this
study. Building on the analytical framework of previous studies, the report includes a
number of important extensions of the framework that are highly relevant for policy. They
include disease projections, small area analyses and state-level burden of disease results.
Also, better methods around comorbidity and risk factor assessment have much improved
the scientific basis of the findings reported here.
This comprehensive study will undoubtedly meet the need for detailed information about
the burden of disease and injury in Australia and its jurisdictions, about the principal causes
of that burden, and how it is changing. But it alone is not enough. With rising pressure on
health budgets, governments will increasingly rely not only on information about the burden
of disease and injury, but also on cost-effective ways of reducing that burden. This study is a
critical and fundamental step in that policy process and we expect it to be used widely to
help improve the health of all Australians.
Alan Lopez Penny Allbon
Professor of Medical Statistics and Director
Population Health, Australian Institute of Health and Welfare
The University of Queensland
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1Executive summary
Introduction
This report is the first complete assessment of the health of Australians to be released in the
new millennium.
The findings in this report identify the extent and distribution of health problems in
Australia, and quantify the contribution of key health risk factors to these problems.
Levels of death and disability from a comprehensive set of diseases, injuries and risks to
health are combined to measure the total health ‘burden’.
This report is the second of this type in Australia, the first having been released in 1999. It
expands the scope of that previous report and also presents for the first time:
• the differentials of health burden across areas and population groups in Australia
• the joint contribution of key health risks—including combined lifestyle, physiological,
social and environmental factors—on health
• an analysis of past trends of health burden and the likely health of Australians in
20 years from now should those trends continue.
The findings of this report describe the health loss due to disease and injury that is not
ameliorated by current treatment, rehabilitative and preventive efforts of the health system
and society generally. Thus they represent the ‘unmet’ challenges of the health system and
are best interpreted as opportunities for health gain.
By providing a comprehensive database of all relevant epidemiological and burden
parameters through time, the report will benefit health policy development and research in
relation to preventive and curative health interventions, health care expenditure projections,
and further assessments of health burden in the period before the next major update.
The study upon which the report is based was funded by the Australian Government
Department of Health and Ageing. A report specifically examining the burden of disease and
injury in Aboriginal and Torres Strait Islander people will be published separately.
2Key findings
Total burden of disease and injury
The key measure used in this report to measure the total burden of disease and injury is the
‘disability-adjusted life year’ (DALY). It describes the amount of time lost due to both fatal
and non-fatal events, that is, years of life lost due to premature death coupled with years of
‘healthy’ life lost due to disability.
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• In 2003, more than 2.63 million years of ‘healthy’ life (that is, DALYs) were lost due to
the burden of disease and injury in Australia.
• Cancers (19%) and cardiovascular disease (18%) were the leading causes of the burden of
disease and injury in Australia in 2003, accounting for 37% of the total burden.
Four-fifths of that burden was from premature deaths. For the first time, cancer has
overtaken cardiovascular disease as the greatest cause of burden in Australia.
• Lung, colorectal and breast cancer were the leading specific causes of the burden of
cancer.
• Ischaemic heart disease, stroke, and peripheral vascular disease were the leading specific
causes of cardiovascular burden.
• Mental disorders and neurological & sense disorders were the next largest contributors,
together accounting for a further 25% of the total health burden. Less than one-fifth of
that burden was from premature deaths.
• Anxiety & depression, alcohol abuse, and personality disorders dominated the burden of
mental disorders.
3• Dementia, adult-onset hearing loss, and vision loss were the leading causes of burden
due to neurological & sense disorders.
• Anxiety & depression also carries a risk of ischaemic heart disease and suicide,
increasing the total burden due to the combined category of anxiety & depression from
7.3% to 8.2%.
• Diabetes also carries a risk of ischaemic heart disease and stroke, increasing the total
burden of diabetes from 5.5% to 8.3%, and making it the fourth largest contributor to
overall burden after cancer, CVD and mental disorders.
• The eight national health priority conditions—asthma, cancer, cardiovascular disease,
diabetes mellitus, injuries, mental health, arthritis and musculoskeletal conditions, and
dementia—accounted for 72.8% of the total burden in 2003.
• Distribution of the burden between the sexes was roughly equal except for injuries (70%
of the burden in males) and musculoskeletal (58% of the burden in females).
• The five leading specific causes of burden in men were ischaemic heart disease (11.1%),
Type 2 diabetes (5.2%), anxiety & depression (4.8%), lung cancer (4.0%) and
stroke (3.9%).
• The five leading specific causes of burden in women were anxiety & depression (10.0%),
ischaemic heart disease (8.9%), stroke (5.1%), Type 2 diabetes (4.9%) and
dementia (4.8%).
• Disability from all diseases and injuries resulted in a loss of 1.5% of healthy time lived by
children, increasing with age to 14.7% in those aged 65 to 69 years, to 41.5% in the very
aged.
Fatal burden
•  ‘Life expectancy’ estimates the average years of life that a person can expect to live given
current risks of mortality. In 2003 in Australia, life expectancy at birth was 80.7 years
(78.3 years for males and 83.2 years for females).
• Fatal burden—measured in years of life lost (YLL)—accounted for 49% of the total
burden of disease and injury in Australia in 2003.
• Cancers (32.0%), cardiovascular disease (29.0%) and injuries (11.0%) were responsible for
almost three-quarters of the fatal burden.
• Males experienced 55% of total fatal burden. The five leading specific causes of mortality
burden among men were ischaemic heart disease (18.2%), lung cancer (7.3%), suicide &
self-inflicted injury (5.4%), stroke (5.1%) and colorectal cancer (3.9%).
• Females experienced 45% of total fatal burden. The five leading specific causes of
mortality burden among women were ischaemic heart disease (15.7%), stroke (8.5%),
breast cancer (7.0%), lung cancer (5.5%) and colorectal cancer (4.2%).
Non-fatal burden
• ‘Health adjusted life expectancy’ (HALE) estimates the average years of equivalent
‘healthy life’ that a person can expect to live. In 2003 in Australia, the average HALE was
72.9 years (70.6 years for males and 75.2 years for females), with 9.7% of life expectancy
at birth lost due to disability.
• Non-fatal burden—measured in years of ‘healthy’ life lost due to disability (YLD)—
accounted for 51% of the total burden of disease and injury in Australia in 2003.
4• Mental disorders (24%) and neurological & sense disorders (19%) contributed most to
non-fatal burden.
• The five leading specific causes of non-fatal burden among men were anxiety &
depression (10.0%), Type 2 diabetes (8.5%), adult-onset hearing loss (6.5%), asthma
(4.2%) and dementia (3.9%).
• The five leading specific causes of non-fatal burden among women were anxiety &
depression (18.1%), Type 2 diabetes (7.2%), dementia (6.4%), asthma (4.5%) and
ischaemic heart disease (3.3%).
Age patterns and total burden
Distribution of population and burden (DALYs) by five broad age groups, Australia, 2003
Age group Population(a)
Per cent
of total DALYs
Per cent
of total
0–14 years 3,979,410 20.0  221,536 8.4
15–44 years 8,622,610 43.4  633,260 24.1
45–64 years 4,733,808 23.8  681,566 25.9
65–74 years 1,349,949 6.8  428,904 16.3
75 years and over 1,195,692 6.0  667,504 25.4
Total 19,881,469 100.0  2,632,770 100.0
(a) Estimated resident population figures as at 30 June 2003 (ABS cat. no. 3201.0).
• Adults aged 45 to 64 years comprised 23.8% of the population in 2003 and experienced
the largest proportion (25.9%) of disease and injury burden across key age groups.
Cancer (28%), cardiovascular disease (16%) and neurological disorders (10%) accounted
for more than half the total burden in this age group. Almost half of the burden was due
to mortality.
• Adults aged over 75 years comprised 6.0% of the population but experienced the second
highest proportion of burden (25.4%). Cardiovascular disease (34%) and cancer (19%)
accounted for more than half of the burden. Overall, 68% of the burden was due to
mortality.
• Adults aged 15 to 44 years represented the largest age group (43.4% of the population)
and experienced 24.1% of the burden. Mental disorders (36%) and injuries (17%)
accounted for more than half of the total burden in this age group. Mortality contributed
29% to the burden in this age group.
• Children aged 0-14 years comprised 20.0% of the population and experienced 8.4% of the
total burden of disease and injury (DALY) in Australia in 2003. Twenty-three per cent of
this burden was due to mental disorders, 18% to chronic respiratory disorders, and 16%
to neonatal conditions. About one-quarter of the burden was due to mortality.
4
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5Health risks
Individual and joint burden (DALYs) attributable to 14 selected risk factors by broad cause group,
Australia, 2003
 Broad cause group
 Cancer CVD Mental
Neuro-
logical Injury Diabetes Other
All
causes
Total burden (‘000)  499.4  473.8  350.5  312.8  185.1  143.8  667.4 2,632.8
Attributable burden (%)(a)
Tobacco  20.1  9.7 — –0.6  0.5 —  8.9 7.8
High blood pressure —  42.1 — — — — — 7.6
High body mass  3.9  19.5 — — —  54.7  1.1 7.5
Physical inactivity  5.6  23.7 — — —  23.7  >–0.1 6.6
High blood cholesterol —  34.5 — — — — — 6.2
Alcohol
Harmful effects  3.1  0.9  9.7 —  18.1 —  <0.1  3.3
Beneficial effects — –5.6 — — — —  >–0.1 –1.0
Net effects  3.1 –4.7  9.7 —  18.1 —  <0.1 2.3
Low fruit & vegetable
consumption  2.0  9.6 — — — —  >–0.1 2.1
Illicit drugs —  <0.1  8.0 —  3.6 —  2.5 2.0
Occupational exposures &
hazards  3.1  0.4 —  0.8  4.7 —  3.4 2.0
Intimate partner violence  0.5  0.3  5.5  0.1  2.5 —  0.2 1.1
Child sexual abuse  <0.1  <0.1  5.8 —  1.4 —  <0.1 0.9
Urban air pollution  0.8  2.7 — — — —  0.4 0.7
Unsafe sex  1.0 — — — — —  1.4 0.6
Osteoporosis — — — —  2.4 — — 0.2
Joint effect(b)  32.9  69.3  26.9  0.2  31.7  60.1  17.2 32.2
(a) Attributable burden within each column is expressed as a percentage of total burden for that column.
(b) Figures for joint effects are not column totals. See Section 4.1 for further details.
Findings on the amount of burden in 2003 that was attributable to current and past
exposures to risks to health considered the following:
• Lifestyle behaviours (tobacco smoking, physical inactivity, alcohol consumption, low
fruit and vegetable consumption, use of illicit drugs, and unsafe sex)
• Physiological states (high body mass, high blood pressure, high cholesterol, and
osteoporosis)
• Social and environmental factors (occupational exposures and hazards, intimate partner
violence, child sexual abuse, and urban air pollution).
The 14 risks together explained 32.2% of the total burden of disease and injury in Australia in
2003.
• Tobacco was responsible for the greatest disease burden in Australia (7.8% of total
burden), followed by high blood pressure (7.6%), high body mass (7.5%), physical
inactivity (6.6%), and high blood cholesterol (6.2%).
6• The five leading risks in males in 2003 were tobacco (9.6%), high blood pressure (7.8%),
high body mass (7.7%), high blood cholesterol (6.6%) and physical inactivity (6.4%).
• Among women the leading risks were high blood pressure (7.3%), high body mass
(7.3%), physical inactivity (6.8%), high blood cholesterol (5.8%) and tobacco (5.8%).
This report sets out for the first time the combined or ‘joint’ effect of these risks on health,
accounting for the fact that many risks share complex causal pathways. It is difficult to
quantify the exact contribution of each risk to the combined totals, but the proportion of total
burden that is ‘explained’ by multiple risks within each disease and injury category can be
reported with sufficient accuracy.
• Ten risks were associated with cancer and together explained 32.9% of the cancer
burden. The majority was explained by tobacco but also included the effect of physical
inactivity, high body mass, and alcohol consumption.
• Twelve risks were associated with cardiovascular disease and together explained 69.3%
of the disease burden; for ischaemic heart disease this figure was 85.2%. High blood
pressure and high blood cholesterol were the largest contributors.
• Three risks were associated with neurological and sensory disorders and together
explained 0.2% of the burden from these disorders. This reflects a lack of knowledge
about causation in this group.
• Two risks were associated with Type 2 diabetes and together explained 60.1% of the total
burden. High body mass was by far the largest contributor (54.7%) followed by physical
inactivity (23.7%).
• The burden associated with harmful alcohol consumption (3.2%) was partially offset by
the cardiovascular disease prevented by safe levels of alcohol consumption (–0.9%). This
protective factor only becomes apparent after 45 years of age, whereas the harmful
effects of alcohol are apparent at all ages.
Differentials in burden across Australia
• This report shows for the first time that there are differentials across Australia in the
proportion of life expectancy lost due to disability. There was a strong socioeconomic
gradient in this measure, and differentials with respect to remoteness were also apparent
but not as large.
• Health-adjusted life expectancy (HALE) in 2003 in Australia was 72.9 years (70.6 for
males and 75.2 for females), with an average 9.7% of life expectancy at birth lost due to
disability.
• Across states and territories, the proportion of life expectancy lost due to disability
ranged from 7.7% in the ACT to 10.6% in South Australia. The NT had almost twice the
rate of total burden of the ACT due to a higher rate of burden for most causes, but
particularly cardiovascular disease, diabetes, and injury.
• Across socioeconomic quintiles, the proportion of life expectancy lost due to disability
ranged from 8.7% in the highest quintile to 10.6% in the lowest. The 31.7% greater
burden for the most disadvantaged population compared to the highest was due to
higher rates of burden for most causes, but particularly mental disorders and
cardiovascular disease.
7Health-adjusted life expectancy (HALE) and life expectancy at birth lost due to disability by area
and sex, Australia, 2003
Health-adjusted life expectancy (HALE) (years)
At birth At age 60
Life expectancy
at birth
lost due to disability (%)
Area Males Females Persons Males Females Persons Males Females Persons
Jurisdiction
NSW 70.5 75.3 72.9 17.1 20.6 18.9 9.8 9.5 9.6
Vic 71.1 75.4 73.2 17.5 20.8 19.2 9.6 9.4 9.5
Qld 70.5 75.3 72.8 17.0 20.4 18.7 10.1 9.7 9.9
WA 71.5 75.6 73.5 17.5 20.6 19.1 9.6 9.6 9.6
SA 69.3 74.2 71.7 16.4 20.0 18.3 10.8 10.5 10.6
Tas 68.8 73.7 71.3 16.3 19.7 18.1 10.2 9.8 10.0
NT 65.8 70.2 67.7 12.6 15.1 13.6 10.0 10.6 10.3
ACT 73.9 77.8 75.9 18.9 21.9 20.5 7.8 7.5 7.7
Socioeconomic quintile
Low 68.7 73.8 71.2  16.1 19.7 17.9  10.7 10.4 10.6
Moderately
low 69.5 74.6 72.0 16.4 20.1 18.2 10.2 9.9 10.1
Average 69.9 74.6 72.2 16.6 20.1 18.4  10.0 9.8 9.9
Moderately
high 71.4 75.9 73.6 17.6 20.8 19.3 9.7 9.1 9.4
High 73.8 77.2 75.5 19.2 21.9 20.6 8.7 8.7 8.7
Remoteness
Major cities 71.3 75.6 73.5 17.5 20.8 19.2 9.6 9.4 9.5
Regional 69.6 74.5 72.0  16.5 20.1 18.3  10.3 9.8 10.1
Remote 67.3 72.3 69.5  15.4 18.5 16.8  10.8 11.3 11.0
Australia 70.6 75.2 72.9  17.1 20.5 18.9  9.8 9.6 9.7
• Based on remoteness, the proportion of life expectancy lost due to disability ranged from
9.5% in major cities to 11.0% in remote areas. The 26.5% greater burden for remote areas
compared to major cities reflected a higher burden per person from most causes but
particularly injuries.
Trends—past, present and future
This report presents an analysis of health trends over a 30-year period, based on the past
decade and projected trends of health burden if these trends continued over the next
20 years.
• The average years of ‘healthy life’ a person can expect to live (HALE) will grow at a
slower rate than life expectancy over the next 20 years. If past trends in morbidity and
mortality continue, HALE will increase 0.22% annually and life expectancy 0.24%
annually. This is partly because declines in mortality will be accompanied by a
somewhat smaller decline in time that is lost to disability.
8• The rate of disability will actually decline in most age groups, except for those 80 years
and over, where it is expected to increase and thereby offset some of the gains for
younger age groups. The growing rate of disability in the oldest age group mostly comes
from expected increases in diabetes and neurological conditions.
Key implications
Key implications of the report’s findings include:
• Ageing of Australia’s population will result in increasing numbers of people with
disability from diseases more common in older ages such as dementia, Parkinson’s
disease, hearing and vision loss, and osteoarthritis. This will increase demand for
services in the home, community care, residential aged care and palliative care sectors.
• Cardiovascular disease has been overtaken by cancer as the major cause of burden in
Australia. This has been largely as a result of programs which have reduced smoking
and facilitated the use of therapies to lower cholesterol and blood pressure levels, as well
as better treatment of existing cardiovascular disease. It is likely that additional gains
could be made through increasing the coverage of these interventions.
• Cancer is expected to retain its share of total health burden. Age-standardised rates of
death and disability are expected to fall, but cancer will remain the largest contributor to
the health burden in 20 years time.
• There is likely to be strong growth in the burden of diabetes over the next 20 years,
mostly as a direct consequence of increasing levels of obesity. The disability
consequences of increasing obesity will be magnified as fatality rates for people with
diabetes continue to decline. This increased survival will mean an increase in the risk of
people developing other largely non-fatal but disabling consequences of diabetes such as
renal failure and vision loss.
• Australia is likely to benefit from further efforts towards expanding the range of effective
prevention and treatment strategies for all causes of burden, while recognising that the
returns for these efforts can take time to be realised. Only in recent years, for example,
have smoking-related cancers started to decline as the result of several decades of
successful tobacco control programs.
91 Introduction
1.1 Purpose
The study upon which this report is based is the first complete assessment of the health of
Australians in the new millennium and the second study in this country with comparable
objectives. The original study, the results of which continue to be used widely in policy and
research environments, was conducted by the Australian Institute of Health and Welfare
(AIHW: Mathers et al. 1999) and provided a comprehensive overview of disease and injury
burden for the year 1996. Increasing demand for a contemporary picture of health status in
Australia led, in 2003, to an Australian Government-funded collaboration between the
University of Queensland and the Australian Institute of Health and Welfare (AIHW), the
aim of which was to update and expand the original work.
The objectives of this collaboration were to report on the following:
• full burden of disease and injury results for the year 2003 by age group, sex and cause
• projections of disease and injury burden 20 years into the future
• improved models for attributing disease and injury burdens to risk factors
• subnational estimates of burden for state and territory jurisdictions, socioeconomic
quintiles, remoteness categories and small areas
• the burden of disease and injury in Aboriginal and Torres Strait Islander populations.
This report presents the main findings of this collaboration and meets the above objectives,
except the last which is covered in a separate report.
1.2 Background
Changes in demography and technology are placing increasing pressure on the health
budgets of developed countries around the world. Mortality and fertility rates have
decreased consistently over recent decades, resulting in increases in life expectancy and the
proportion of total population alive at old and very old ages (AIHW 2006). In addition,
developments in knowledge and medical technology are contributing to a growing demand
for health services and, in many cases, to higher costs of providing these services. In
Australia and elsewhere, these factors have brought into focus the need for more rigorous
debate about how health systems can achieve their dual objectives of maximising health
gains for given levels of expenditure and maintaining fair and equitable access to health
services.
Improving the evidence base that informs this debate is critical if health systems are to be
meaningfully held to account. Such an agenda requires contributions from a number of
areas, including:
• detailed assessments of the size and impact of health problems in a population,
including information on the causes of loss of health in the population (in terms of both
diseases and injury, and risk factors or broader determinants)
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• information on inequalities in health status, health determinants, and access to and use
of health services (including prevention and treatment services)
• information on health expenditure and health infrastructure (a national system of health
accounts) detailing the availability of resources for health improvement and the current
use of these resources
• information on the cost-effectiveness of available technologies and strategies for
improving health
• information on current levels of investment in health research and development, and on
the opportunities for investment with the greatest likelihood of developing new or
improved interventions that best remedy major health problems.
This report contributes to the development of such an agenda in Australia by providing a
detailed and internally consistent assessment of the incidence, prevalence, duration,
mortality and burden for an exhaustive and mutually exclusive set of major diseases and
injuries experienced in this country. The burden from these causes is quantified for various
subpopulations, risks to health and points in time using a summary measure of population
health that combines both fatal and non-fatal health outcomes, and includes comorbidity
adjustments to account for individuals who simultaneously experience multiple conditions.
This assessment provides an unprecedented level of detail on the magnitude and
distribution of health problems in contemporary Australia. Although solutions to these
problems are not addressed explicitly in the following chapters, the analyses described
encompass a methodology that is increasingly being used in Australia and elsewhere to
assess health outcomes both for descriptive purposes and in comparative analyses of the
costs and effectiveness of particular health interventions. The report can be regarded,
therefore, as an important foundation for further work on improving health system
performance in Australia.
1.3 Summary measures of population health
Summary measures of population health are measures that combine information on
mortality and non-fatal health outcomes into a single number to represent one or more
dimensions of health at a population level (Field & Gold 1998). In the past 15 years, there has
been a marked increase in interest in the development, calculation and use of summary
measures. The range of potential applications includes:
• comparing health conditions or overall health status between two populations or the
same population over time
• quantifying health inequalities
• ensuring that non-fatal health outcomes receive appropriate policy attention
• measuring the magnitude of different health problems using a common currency
• analysing the benefits of health interventions for use in cost-effectiveness studies
• providing information to help set priorities for health planning, public health programs,
research and development, and professional training (Murray et al. 1999b).
Most summary measures fall into one of two broad groups: health ‘expectancies’ and health
‘gaps’. Both groups use time (either lived in health states or lost through premature death
and illness) as the unifying ‘currency’ for combining the impact of mortality and non-fatal
health outcomes. Another common feature is the requirement for explicit or implicit choices
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in their application: mortality-based indicators, for example, exclude considerations
regarding non-fatal loss of health; indicators of potential years of life lost ignore deaths
beyond an arbitrary age (for example 65 years); and indicators of disability-free life
expectancy do not place any positive value on years lived with disability.
Health ‘gap’ measures, in particular, quantify the gap between a population’s actual health
status and some ‘ideal’ or reference status. The most widely known example of such a
measure, and the one used in this report, is the disability-adjusted life year or DALY.
Another measure commonly used in economic evaluations but not in population health
status assessments is the Quality Adjusted Life Year (QALY).
1.4 Disability-Adjusted Life Years
The DALY was first developed to provide information to support health policy and priority
setting at a global level. The concept was developed as part of a comprehensive assessment
of global health for the year 1990 in what became known as the Global Burden of Disease or
GBD study (Murray & Lopez 1996a, 1996b; World Bank 1993). It has since become
synonymous with ‘burden of disease’ and the terms tend to be used interchangeably.
The DALY was originally intended to:
• allow estimates of health effects to be mapped to causes, either in terms of disease and
injury, or risk factors and broader social determinants
• provide a common measure for estimating population health effects and
cost-effectiveness of interventions
• use common values and health standards for all regions of the world
• provide a common measure for fatal and non-fatal health outcomes.
In this way, the DALY extends the concept of potential years of life lost due to premature
death (PYLL) by including equivalent years of ‘healthy’ life lost by virtue of being in states of
poor health or disability. A DALY for a disease or health condition is calculated as the sum
of the years of life lost due to premature mortality (YLL) in the population and the
equivalent ‘healthy’ years lost due to disability (YLD) for incident cases of the health
condition:
DALY = YLL + YLD
where YLL = number of deaths x standard life expectancy at age of death and
YLD = incidence x duration x severity weight.
The loss of healthy life due to health conditions (YLD) requires estimation of the incidence of
the disabling health condition (disease or injury) in the specified time period. For each new
case, the number of years of healthy life lost is obtained by multiplying the average duration
of the condition (to remission or death) by a severity weight that quantifies the equivalent
loss of healthy years of life due to living with the health condition or its sequelae. The YLD is
as an incidence-based measure, therefore, which captures the future health consequences of
new cases of disease and injury that occur in the baseline year (2003 in this study). Such a
measure, when combined with YLL, enables the full ‘health loss’ of different diseases and
injuries to be compared and has most application in planning.
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Alternatively, health loss can be measured by counting it at the age it is lived. This is the
‘prevalent burden’ or prevalent years lost due to disability (PYLD) and is calculated thus:
PYLD = prevalence x severity weight
Prevalent burden is useful from a service utilisation or expenditure perspective and
measures the amount of disability (but not the fatal burden) being experienced in a
population at a point in time.
From the perspective of the International Classification of Functioning, Disability and Health
(ICF) (see <www3.who.int/icf/icftemplate.cfm>) the YLD measures the impact of a health
condition on an individual’s functioning, now and into the future. Functioning includes the
functional and structural integrity of the human body as well as activities undertaken by
people and participation in life situations.
Interpreting the DALY
The DALY methodology provides a way to link information on disease causes and occurrence to
information on both short-term and long-term health outcomes, including activity limitations and
restrictions in participation in usual roles, and death. The burden of disease methodology is designed
to inform health policy about the prevention and treatment (cure or reduction in severity) of adverse
health outcomes. It is not designed to inform policy for the provision of social support or welfare
services for people with long-term disability.
When using the DALY for the first time, Murray and Lopez sought to make explicit the value
choices that they had to make in their application of a summary measure at a global level.
For example, they chose to use the same life expectancy ‘ideal’ standard for all population
subgroups across the globe, whether or not their current life expectancy was lower than that
of other groups. They also excluded all non-health characteristics (such as race,
socioeconomic status or occupation), apart from age and sex, from consideration in
calculating lost years of healthy life. Most importantly, they used the same severity weight
for everyone living a year in a specified health state. These and other aspects of the DALY
are described in further detail in Chapter 2.
1.5 Burden of disease analysis in Australia
Since its introduction, burden of disease analysis has been applied in an increasing number
of international and national settings; for example, it was used for a period by the World
Health Organization (WHO) to inform global health planning (WHO 2002). Burden of
disease analysis has a particularly strong history in Australia. The first study by the AIHW
assessed the burden of disease and injury in Australia for the year 1996 (AIHW: Mathers et
al. 1999). Starting in June 1998, the first study was partly funded by the then Commonwealth
Department of Health and Aged Care and was conducted in parallel with a state-level
analysis for Victoria by the Victorian Department of Human Services (DHS 1999a, 1999b).
Both project teams worked together closely on methods and analyses.
This work represented the first attempt to carry out a systematic and comprehensive analysis
of over 170 disease and injury categories in this country. It also substantially extended the
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international work on burden of disease in many areas, as shown by the fact that a number
of its methodological advancements were subsequently picked up in the GBD 2000 work at
WHO (Mathers et al. 2004). Since then, burden of disease analysis has been undertaken in
most jurisdictions throughout Australia, at varying levels of detail. The update of the
Victorian Burden of Disease study for the year 2001 (DHS 2005) deserves special mention as
a number of disability models and data sources were shared between the researchers
working on that project and those working on the present study.
This study was conducted in close consultation with relevant jurisdictional stakeholders, and
the national and jurisdictional estimates in this report are intended to complement existing
estimates from individual State and Territory based burden of disease studies. Because of
somewhat different estimating methods and data sources, the jurisdictional estimates in this
report may differ somewhat from State and Territory based estimates. This does not mean
that one estimate is more correct than the other, but reflects the uncertainties inherent in any
analysis which attempts to estimate burden for over 170 conditions.
1.6 Burden in Aboriginal and Torres Strait Islander
peoples
Findings about Aboriginal and Torres Strait Islander peoples are not covered in this report,
the primary focus of which is on the health status of Australians as a whole. This is not a
problem for most of the comparisons presented, although special caution should be taken
when interpreting the results of Chapter 5 on health differentials, particularly the estimates
for remote areas and the Northern Territory. The higher proportion of Indigenous people in
these areas explains most of the greater health loss in these areas compared with those where
the proportion of Indigenous people is lower. However, the contribution of Indigenous
populations to this loss has not been quantified in this report. Readers seeking to know such
comparisons are referred to the companion report on the burden of disease and injury in
Aboriginal and Torres Strait Islander peoples.
1.7 Structure of report
Details of the specific methodological developments of this study are presented in Chapter 2.
Chapter 3 provides an overview of the total burden of disease and injury in Australia, by
cause, age and sex. Chapter 4 provides estimates of the burden of disease and injury
attributable to selected risk factors in Australia. Chapter 5 shows how the burden of disease
and injury across Australia varies according to where people live and their socioeconomic
status. Chapter 6 presents the past, present and projected burden of disease and injury in
Australia and Chapter 7 provides a general discussion of the major findings.
Technical notes on the methods used for estimating non-fatal health outcomes and
attributing risk are presented in Appendixes 1 and 2, respectively. Annex table 1 summarises
the disease and injury categories used and their respective International Classification of
Diseases codes. Annex table 2 summarises the primary data sources used to construct the
core set of results. Tabulations of the core results are included in Annex tables 3 to 9. More
detailed tabulations of the core results are available in Annex tables 10 to 25, which are
available on the web at <www.aihw.gov.au/bod>.
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Readers should note that every attempt was made to identify the best available information
in the preparation of this report, and to consult as widely as possible on decisions about
methods, assumptions and data sources. For some aspects of the study, however, it was not
possible with the resources available to go beyond simple models and assumptions about
some key parameters. For many disease models, not all required information was available
and analyses drew on information from overseas or expert opinion. In the projections work,
trends in disease occurrence were nonexistent for many conditions. The results presented in
the following chapters, therefore, represent a complex synthesis of information, judgment
and, in some cases, even speculation. It is hoped that further improvements over time in
methods, models and data will result in increasing accuracy and certainty in estimates of
burden of disease and injury in Australia. The authors at the University of Queensland and
the Australian Institute of Health and Welfare welcome suggestions for such improvements.
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2 Methodological developments
This chapter discusses the key methodological considerations that underpin the findings
presented throughout the report.  Readers who are only interested in these findings can skip
to chapters 3 through 7 and return to this chapter at a later time. Those wishing to
understand the ways in which the methodological challenges were resolved are encouraged
to read on. The chapter begins by outlining some solutions to various methodological issues
that are unavoidable in the application of the burden of disease and injury framework,
including social value choices, causal attribution and comorbidity. It concludes with a
description of the specific methods that were adopted to derive the findings on risks to
health, burden across time and differentials in burden.
2.1 Social value choices
The burden of disease and injury framework encompasses some obviously normative
characteristics (that is, it incorporates certain value judgments about how things ought to be).
This is because its main measure (the disability-adjusted life year or DALY) comprises only a
selection of all possible parameters that could be used to characterise health, and the
numerical weighting given to each parameter implies a judgment about its relative
importance to the total measure. These judgments have come to be known collectively as
‘social value choices’. While the implications of certain choices over others are important and
sometimes contested, as reflected by the growing literature in this area (Anand & Hanson
1997; Reidpath et al. 2003; Williams 1999), such considerations are beyond the scope of this
chapter. The purpose here is to provide a brief discussion of the key choice that differs from
the previous study. Readers are referred elsewhere for a more in-depth discussion on the
merits of the other social value choices (Murray et al. 2002).
As mentioned in the previous chapter, the DALY is a health gap measure that requires an
ideal against which to quantify the gap between current patterns of mortality and a
counterfactual scenario in which all mortality is averted until very old age. The steering
committee of the previous Australian Burden of Disease and Injury Study requested that
projected life expectancy, based on a cohort life table (which takes into account past trends in
mortality) for Australia, be used to define the mortality ‘gap’ for the purposes of calculating
the years of life lost due to premature mortality (YLL). Until then, the standard that had been
used in all burden of disease studies was based on the Coale and Demeny West level 26
model life table (Coale & Guo 1989), chosen after observing the highest life expectancy
recorded for any nation (82.5 years for women in Japan at the time).  It was then assumed
that the minimum male–female ‘biological’ difference in survival potential was in the order
of 2.5 years, but because there was no male schedule with a life expectancy of 80 years, the
standard for males was based on the Coale and Demeny West level 25 schedule for females
(Murray & Lopez 1996a).
The cohort life tables for Australia used in the 1996 study and the standard life tables used in
other studies are very similar, and the substitution of one for the other would have had little
effect on the final results. This is particularly true for discounted YLL, where the small
differences in time lost would have been even further reduced by a time discount rate of 3%,
although some differences were observable if undiscounted YLL were compared.  For the
current study, however, the situation is complicated by the fact that life expectancy in
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Australia has changed since 1996 (an increase of 0.25 years and 0.3 years per annum for
females and males, respectively).  If the projected cohort life expectancy were to be used
again, the mortality gap would be somewhat different because the projected cohort life
expectancy based on changes in mortality rates to 2003 would be different from the old
cohort life expectancy, which was based on changes in mortality rates to 1996. While the
difference is not great, it does not aid comparisons to have a standard that is continually
changing. Thus the current advisory committee has recommended a return to the
internationally recognised standard used in most other burden of disease studies.
It is worth noting here that the life table for a population that actually achieves the ‘ideal
standard’ (that is, no mortality until age 82.5 in females and 80 in males) would be very
different from the standard life table. It is best to view the choice of the standard life table,
therefore, as a weighting for age at death, without reference to the properties of the life table
used to derive these weights.
All other social value choices remain as they were in the previous study (Table 2.1): uniform
age weights and a discount rate of 3% were applied, and a combination of disability weights
from the original GBD study (Murray & Lopez 1996a) and the Disability Weights for
Diseases in the Netherlands study (Stouthard et al. 1997) were used. For some health states,
there was no equivalent in either the Dutch or GBD set of weights, or the weights that appear
in the published material seemed implausible. In these instances, the weights that were
specifically derived for the previous Australian studies were applied. Unfortunately, a study
to determine local weights for the range of health states most relevant to Australia was not
able to be done. The complete list of weights is available at <www.aihw.gov.au/bod>.
Table 2.1: Social value choices used in the calculation of DALYs, 1996 study and present study
Choice 1996 study Present study
Mortality counterfactual Projected life expectancy based on
cohort life tables for Australia in 1996
International standard first reported in Murray &
Lopez 1996a
Age weighting Uniform Uniform
Discount rate 3% 3%
Source of disability
weights
Murray & Lopez 1996a,
Stouthard et al. 1997 and locally derived
Murray & Lopez 1996a,
Stouthard et al. 1997 and locally derived
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Box 2.1: Interpreting a disability weight
To place a value on the time lived in non-fatal health states, health state weights are used to formalise
and quantify social preferences for different states of health. Depending on how these weights are
derived, they are referred to as disability weights, quality-adjusted life year (QALY) weights, health
state valuations, health state preferences or health state utilities. QALY weights are measured as a
number on a scale of 0 – 1, where 0 is assigned to a state comparable to death and 1 is assigned to a
state of ideal health. This assignment for the DALY (where 0 = perfect health and 1 = death) is the
complement to 1, compared to that used for the QALY, because the QALY measures equivalent
healthy years lived, whereas the DALY measures loss of health.
Although the disability weights used in DALY calculations quantify societal preferences for different
health states, the weights do not represent the lived experience of any disability or health state, or
imply any societal value for the person in a disability or health state. Rather, they quantify societal
preferences for health states in relation to the societal ideal of good health. Thus, a weight for
paraplegia of 0.57 does not mean that a person in this health state is ‘half-dead’, that they experience
their life as halfway between life and death, or that society values them less as a person compared
with ‘healthy’ people. It means that, on average, society judges a year with blindness (weight 0.43) to
be preferable to a year with paraplegia (weight 0.57), and a year with paraplegia to be preferable to a
year with unremitting unipolar major depression (weight 0.76). It also means that, on average,
society would prefer a person to have a year in good health followed by death than a year with
paraplegia followed by death. Society would also prefer to restore a person with paraplegia to good
health rather than restore a person’s sight if the costs of cure are the same for the two interventions.
2.2 Causal attribution
There are two traditions for causal attribution of health outcomes or states: categorical
attribution and counterfactual analysis (Mathers et al. 2001).  In categorical attribution, an
event such as death is attributed to a single cause (such as a disease or risk factor) or group
of causes according to a defined set of rules, such as the International Classification of
Disease (ICD) system for attributing causes of death (WHO 1992). In counterfactual analysis,
the contribution of one or a group of risk factors to disease or mortality is estimated by
comparing the current or future disease burden with the levels that would be expected under
some alternative hypothetical scenario (referred to as the counterfactual). This study uses
both approaches: categorical attribution for attributing burden to diseases and injuries,
which is discussed below, and counterfactual analysis for attributing burden to more distal
risks to health, which is discussed in a subsequent section.
Estimates of burden are typically attributed to a comprehensive set of disease and injury
‘entities’ (for example ischaemic heart disease or falls). These entities represent the smallest
unit of disaggregation in the analysis and are referred to in this report as ‘specific causes’ or
‘conditions’. Each entity is mutually exclusive and belongs to one of a number of ‘broad
cause groups’, most of which correspond to chapter-level headings of the ICD (for example
cardiovascular disease or intentional injuries). Each broad cause group, in turn, belongs to
one of three broad clusters:
• Group I: Communicable, maternal, neonatal and nutritional conditions
• Group II: Non-communicable diseases
• Group III: Injuries.
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Annex Table 1 defines the classifications used in this study in terms of ICD-10 codes, most of
which are consistent with the classifications used by WHO in the GBD2000 project (Mathers
et al. 2004).  A comparison of the ICD-10 list and the one based on ICD-9 used in the
previous study is available at <www.aihw.gov.au/bod>.
Categorising deaths
The ICD has its origins in the preparation of mortality statistics, and standard death statistics
use the categorical approach to causal attribution. While any number of conditions may be
recorded on a death certificate, the ICD allows for only one to be selected for primary
tabulation purposes. This single cause is referred to as the ‘underlying cause of death’ and is
intended to represent the condition, event or circumstances without the occurrence of which
the person would not have died. The concept of underlying cause has been central to
mortality coding and comparable international mortality reporting over the 100-year period
that the ICD has been used for such purposes.
Box 2.2: Death registration in Australia
Registration of deaths in Australia is the responsibility of the state and territory Registrars of Births,
Deaths and Marriages. Information on the cause of death is supplied by the medical practitioner
certifying the death or a coroner. Other information about the deceased is supplied by a relative or
other person acquainted with the deceased or by an official of the institution where the death
occurred. Registration of death is a legal requirement in Australia, and compliance is almost
complete. The information is provided by the Registrars to the Health and Vitals Unit at the
Queensland office of the Australian Bureau of Statistics (ABS) for coding and compilation into
national statistics. The ABS began automated coding of death certificates using software known as
the Mortality Medical Data System (MMDS) in 1997 and has made available multiple causes of
death data coded in ICD-10 for all years since that time. Before 1997, only underlying cause of death
data are available. The MMDS was developed by the National Center for Health Statistics in the
United States of America to facilitate the coding of all causes of death reported on death certificates,
and the designation of the underlying cause of death according to ICD criteria.
The availability of an unambiguous set of rules, such as can be found in the ICD, does not
alter the fact that the accuracy of the information to which these rules are applied is
dependent on several factors: the availability and quality of the clinical evidence at the time
of certification; the thoroughness and diligence with which physicians and coroners record
this information on the death certificate; and the quality of the system used to transcribe
information from death certificates and translate this information to ICD codes. Australia is
regarded as having a high-quality system of registration by international standards and this
is reflected by one measure of quality, the proportion of total deaths coded to non-specific
underlying causes of death. The small amount of non-specific coding that does occur is
confined mainly to the ill-defined sections of the cardiovascular disease, cancer and injury
chapters, with only a very small proportion of deaths being coded to the general signs and
symptoms chapter. However, with the exception of a few studies on sensitivity and
specificity in relation to specific conditions, relatively little is known about the frequency
with which Australian doctors attribute the correct underlying cause to the majority of
deaths. It is likely that accuracy varies with the location of the death (for example in an
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institutional setting versus at home), but the assumption that inaccuracies tend to cancel each
other out at the population level is largely speculative and is an area deserving of further
research.
While this study largely followed the ICD concept of ‘underlying cause’ in the categorisation
of deaths, in some cases deaths were reallocated to more specific or different categories to
ensure consistency with the estimates for years lost due to disability (YLD). For example, the
proportion of liver cancer and liver cirrhosis mortality that is attributable to hepatitis was
redistributed to the hepatitis B and hepatitis C categories in the core results. Similarly, data
on the underlying cause of renal failure from the Australia and New Zealand Dialysis and
Transplant Registry (ANZDATA) was used to redistribute renal failure deaths to nephritis &
nephrosis, diabetes mellitus, injuries, congenital conditions, cancers and infectious diseases.
It is important to note that for many conditions there is a difference between the number of
deaths attributed to the disease and amount of excess mortality that occurs in prevalent cases
of the disease. This is often due to comorbidity and the fact that diseases may cluster in
people exposed to the same risk factors that also affect the risk of dying from other causes.
Examples of this are schizophrenia, where part of the excess risk is due to the high
prevalence of smoking and diseases associated with the usually lower socioeconomic status
of people with chronic and severe mental disease; and cardiovascular disease, where the
main lifestyle risk factors also increase the risk of dying from diabetes and some cancers.
For the overall cause of death structure presented in this report, recorded underlying causes
of death were used, subject to the redistribution algorithms discussed below. In the disease
modelling discussed in Appendix 1, however, best available estimates of excess mortality
were used in order to derive the most accurate estimates of disease duration.
Redistributing non-specific causes of death
In keeping with established ‘burden of disease’ methods,  attempts were made to remove
possible distortions to the reported overall cause of death structure by reallocating deaths
with certain codes known to be problematic to valid and specific underlying causes of death.
The rationale for not taking reported causes of death at face value is that policy objectives are
best served by information that is corrected for possible sources of systematic bias. By world
standards, the extent of distortions in cause of death information in Australia is small
(around 6–10%, depending on what codes are included in this definition). In some areas,
however, there are obvious anomalies that require specific attention.
Murray and Lopez (1996a) were the first to provide convincing evidence that a significant
and varying proportion of ischaemic heart disease deaths are coded in many countries to
ill-defined codes such as heart failure. They argued that this, in part, helps to explain the
French paradox in which mortality from ischaemic heart disease in France is comparatively
low despite high levels of exposure in the French population to risks known to be associated
with this disease. In fact, many ischaemic heart disease deaths are most probably being
coded to heart failure or other equally non-specific cardiovascular causes. Policy is better
served by correcting this misclassification error.
Various redistribution algorithms to correct non-specific cause of death coding have been
developed in response to these considerations throughout the world. In the previous
Australian Burden of Disease and Injury Study, for example, a number of decisions were
made about what to do with problem coding based on local considerations regarding the
cause of death collection system at the time. One of the guiding principles of the present
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study was not to change past decisions such as these unnecessarily, unless there were
compelling reasons to do so, such as new evidence.
In the period since the completion of the previous study, the vital registration system in
Australia has changed in two significant respects. First, the ABS moved from the coding of
mortality using version 9 of the ICD to version 10 in 1997. Second, at the same time, the ABS
implemented automated coding of mortality statistics using software developed in the
United States. The use of this system allows multiple cause of death coding (that is, coding of
the underlying cause of death as well as all other associated causes recorded on the death
certificate by the certifying medical practitioner), significantly enhancing the amount of
information on official mortality files (see Box 2.2). To facilitate an assessment of the impact
of these changes, the ABS retained the old system of coding for a period of two years, thus
providing an invaluable resource for researchers trying to assemble comparable data on
causes of death in Australia over time.
The availability of this additional information has allowed known problematic codes to be
examined in much greater detail than has been possible in the past. It has also allowed the
identification of some areas where possible new coding anomalies are emerging. The most
glaring of these is the much greater number of deaths being coded to pneumonia under the
new system. In the seven years to 1997, there were around 1,700 deaths from this condition
annually. With the advent of automated coding, this number has risen to around 3,300
deaths annually. Such dramatic shifts are not due to changes in underlying disease
frequency, but are rather an artefact of a greater preference under the new system to code
deaths to this category (manual coders, on the other hand, were probably more likely to
attribute an underlying chronic condition). Rather than correcting for this large
discontinuity, which would then need to be repeated in the future to ensure comparability,
the coding for these deaths was left unchanged. This explains the rapid rise in lower
respiratory tract infections from 1993 to 2003 described in Chapter 6.
The other area where a discontinuity of this magnitude is apparent is the greater
preponderance under the new system to code deaths due to external causes to ‘exposure to
unspecified factor’ (ICD-10 code X59).  Analysis of the dual-coded data revealed that the
majority of these deaths in the elderly were in fact coded to ‘falls’ under the old system. In
this instance, an additional allocation algorithm was applied whereby deaths coded to this
category (around 0.6% of all deaths) were reallocated to ‘falls’ if they also had a ‘fracture’
code in the multiple cause of death data (AIHW: Cripps & Carman 2001). This approach was
also used for ‘unspecified septicaemia’ (ICD-10 code A419), whereby deaths in this category
(again, around 0.6% of all deaths) were reallocated to ‘nephritis & nephrosis’ if they also had
an ‘acute renal failure’ code (ICD-10 code N17).
Another area where the new system may be in error is in the assigning of inappropriate
underlying causes where another code would have been more informative. For example, in
the 7-year period to 2003, 548 deaths were coded to tobacco dependence as an underlying
cause. Likewise, 885 deaths were coded to obesity and 2,072 to hypercholesterolaemia and
dyslipidaemia over the same period. These codes are most appropriately regarded as risk
factors for more specific underlying disease processes and preferably should not be used in
primary underlying cause of death tabulations. The number of deaths coded to these
categories is likely to substantially underestimate the true mortality attributable to these
risks (which is estimated in this report using very different methods, as discussed in
Appendix 2). Deaths coded to tobacco dependence were therefore redistributed across lower
respiratory tract infections, mouth and oropharynx cancers, lung cancer, ischaemic heart
disease, stroke, other cardiovascular disease, chronic obstructive pulmonary disease (COPD)
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and other chronic respiratory diseases based on a probability analysis of multiple-cause
information over the period 1997 to 2003. Obesity was allocated to ‘other endocrine &
metabolic disorders’ and the other two codes (about 300 deaths per year) to ‘ill-defined
cardiovascular disease’, which was ultimately reapportioned to specific cardiovascular
diseases (largely ischaemic heart disease).
The probability approach using multiple causes of death information was also applied to two
other categories: ‘ill-defined nutritional’ (ICD-10 codes E64 and E639) and ‘essential
hypertension’ (ICD-10 code I10). The first (representing 0.1% of all deaths) was redistributed
across lower respiratory tract infections, other endocrine & metabolic disorders, dementia,
other chronic respiratory diseases, and nephritis & nephrosis. The second (accounting for
0.2% of all deaths) was redistributed across all specific cardiovascular diseases.
Useful though it is, multiple cause of death information provides no new insights about
three known problematic areas: ill-defined cancer, ill-defined injury and ill-defined
non-injury deaths. It turns out that these deaths are assigned non-specific codes precisely
because there is very little other information of relevance either on the death certificate or
through coronial investigations (in the case of external causes) to make a more accurate
determination. In the previous study these causes were allocated to specific cause groupings
on a pro-rata basis on the assumption that the proportional distribution within these
groupings reflected the most likely probabilities for causal attribution to a specific cause.
There is no new evidence to alter these decisions. These causes and the cause groupings to
which they were proportionately redistributed are listed in Table 2.2.
Table 2.2: Ill-defined causes of death and specific cause groupings to which they were allocated on
a pro rata basis
Ill-defined cause(a) Per cent of all causes Specific cause groupings(a)
Ill-defined malignant neoplasms(b) 1.92 All specific cancer sites
Uterus cancer—unspecified(b) 0.04 Cervix cancer
Corpus uteri cancer
Other anaemias 0.06 Haemolytic anaemia
Other non-deficiency anaemia
Ill-defined non-injuries (i.e. diseases)(a) 0.39 All specific non-injury causes
Ill-defined unintentional accidents (no
fracture)(b) 0.11 All specific unintentional injury causes
(a) Refer to Annex Table 1 for the ICD-10 codes that correspond to these cause categories.
(b) Denotes a redistribution decision derived from the previous Australian Burden of Disease and Injury Study.
Based on an assessment of cause of death statistics in Australia over a 25-year period,
including the seven years of multiple causes of death information to 2003, a number of
redistribution decisions were retained from the previous study, largely because there was no
compelling reason to do otherwise. The list of these causes and the corresponding specific
causes to which they are proportionately redistributed is outlined in Table 2.3.
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Alternative categories
In order to present the burden for mutually exclusive categories, decisions had to be made
on how to classify sometimes closely linked conditions while still adhering to ICD rules.
Chapter 3, however, presents alternative calculations of the burden (Table 3.20) due to
certain disease entities that otherwise are split across a number of categories in the main
disease and injury tabulations. The three entities are intellectual disability, renal failure and
vision disorders, although other groupings are also possible (for example heart failure).
Underlying causes of intellectual disability are various and include Down syndrome, central
nervous system defects, birth trauma, low birth weight, infection, injury, brain tumours,
chromosomal causes, epilepsy and autism. Renal failure can be attributed to diabetes, some
cancers, congenital conditions and injury.
Alternative calculations are also presented for diabetes and depression & anxiety because
these conditions are themselves risk factors for other causes of disability. The alternative
estimate for diabetes includes the proportion of burden from ischaemic heart disease and
stroke that is due to this disease. Likewise, for depression & anxiety the proportions of
ischaemic heart disease and suicide caused by this condition are attributed. A new approach
in this study, also, is that suicide is attributed to a range of mental and substance use
disorders rather than to depression alone. These alternative calculations appear under the
relevant disease or injury group subheading.
2.3 Comorbidity and health
It is not uncommon for two or more conditions to occur simultaneously in a person, either by
chance or because the conditions are related to each other. This is referred to as
‘comorbidity’. Independent comorbidity is the situation where the probability of having two
or more conditions simultaneously equals the product of the probabilities for having each of
the conditions. Dependent comorbidity, on the other hand, refers to the situation where the
probability of having two or more diseases is greater than the product of the probabilities for
each disease, reflecting common causal pathways (for example common risk factors causing
both diabetes and heart disease) and also that one disease may increase the risk of another.
Both types of comorbidity are problematic for burden of disease estimation because the
available disability weights are almost exclusively derived for a condition as it exists
independently from other conditions. Little attention has been directed towards estimating
weights for comorbid (or coexisting) conditions due to the enormity of the task. The severity
of health states associated with two or more conditions in combination may not simply be
the sum of the disability weights for each of the conditions. In many cases it is likely to be
less than the sum, but in some cases there may be exacerbating effects on health of having
the combined set of conditions. For example, the experience of symptomatic grade 2
osteoarthritis of the hip and severe vision loss together is probably not as disabling as the
addition of the two weights for these health states (0.14 and 0.43, respectively). The
experience of the latter with profound deafness, however, may be equal to or even more
disabling than the summation approach would suggest.
In contrast to the GBD 1990 study, an attempt was made in the original Australian studies to
accommodate this phenomenon by adjusting the disability weights for the 21 most common
non-fatal conditions of older age (for example hearing loss, osteoarthritis, heart conditions,
and diabetes). A multiplicative model was used to estimate weights for comorbid conditions,
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and the change in total weight deducted from the weight for the milder of the conditions (see
Box 2.3). Mental health problems are less prevalent at older ages, apart from dementia, and
no attempt was made to adjust for mental–physical comorbidities, although comorbidity
between mental disorders was accounted for.
A key assumption in the implementation of this adjustment procedure was that the
prevalence of a set of comorbid conditions is equal to the product of the individual
prevalences of these conditions. In other words, dependent comorbidity was not considered.
More recent work as part of the GBD 2000 study, however, suggests that dependence is
important and has a non-trivial impact on final results (Mathers et al. 2006). As a result, it
was decided to incorporate the empirical evidence, limited though it is, on disease
dependence into the overall corrections for comorbidity.
Box 2.3: Combining disability weights
The simplest approach to estimating the disability weight for the combined conditions 1 and 2 is to
assume that the health state valuations (1 – disability weight) are multiplicative, so that the
combined weight is more severe than the weight for either condition on its own but less than if they
were simply added together, and remains bounded by 0 and 1. The disability weight for the combined
conditions 1 and 2 is given by:
( ) ( )2121 DW1DW11DW −×−−=+
 This formula can be generalised to deal with more than two causes as follows:
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where Π denotes the product operator.
In the original Australian studies, this method was used to derive a composite weight for comorbid
conditions. In the case of two conditions, the weight for the most severe condition remained
unchanged, while the weight for the milder condition was deemed to be the balance of the composite
weight minus the weight for the more severe condition. For example, if a person has symptomatic
grade 2 osteoarthritis of the hip or knee (0.14) and severe vision loss (0.43), the composite weight for
both conditions is 0.51 and the adjusted weight for the osteoarthritis is 0.08.
In the current study the disability weights are proportionately reduced for each comorbid state.
The approach taken in this study was to determine the numbers of people for every
combination of causes of ill-health measured by the major Australian health surveys and in
the National Hospital Morbidity Database. While none of these data sources contained
information on every cause of interest, each overlapped in the causes they did provide
information on, at least to some degree. This allowed comorbidity to be simulated across the
full range of causes by deriving conditional probabilities on causes common to two or more
surveys and generating an artificial cohort of people based on these probabilities. The
assumption was that the correlations observed in self-report surveys and hospital diagnoses
are reasonable proxies for the co-occurrence of disability in these samples, even though these
data sources may not accurately reflect the actual levels of disease at the population level.
Unlike the previous study, this study did not incorporate a severity hierarchy of the
disability weights by causes. Instead, a proportional downward adjustment was made to the
disability weight of each coexisting cause. The proportion used to deflate individual
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disability weights was the total adjusted disability weight divided by the total unadjusted
disability weight for each cause and all possible combinations. A further consideration that
has not been explicitly addressed in previous work is that when a disability weight changes
with advancing age (due to comorbidity corrections or for some other reason), incident YLD
should be calculated to incorporate these changes. In other words, if the duration of a
condition is 20 years, incident YLD should be calculated using the disability weight that is
relevant to each age above the age of incidence until the 20-year duration has been reached,
rather than using the weight at the age of incidence for the whole 20-year period. This
correction was implemented in the present study.
2.4 Risks to health
Reliable and comparable assessments of the impact on population of exposure to health risks
are fundamental to prevention and health promotion activities. Until relatively recently,
health risk assessment has been conducted in the context of the methodological traditions of
individual risk factors, with little regard to achieving consistency between these traditions
when combining results. In the original Australian study, for example, the criteria for
evaluating the scientific evidence on prevalence, causality and hazard size varied greatly
among the 10 health risks assessed, resulting in lack of comparability between the estimated
population health impacts of these risks.
Techniques for attributing outcomes to health risks have advanced considerably in recent
times, particularly through the contribution of the Comparative Risk Assessment (CRA)
project. This was a large-scale effort by international panels of experts under the direction of
the World Health Organization (WHO) to collect the most up-to-date information on the
prevalence of exposure to health risks and the relationship between these exposures and
health outcomes. WHO dedicated its 2002 World Health Report to describing the results of
this effort (WHO 2002), and subsequently published a two-volume book containing detailed
information on each of the 22 health risks covered by the project (Ezzati et al. 2004a, 2004b).
The key advances of the CRA approach over previous attempts to attribute burden to health
risks are:
1. A consistent theoretical framework that uses the ‘hypothetical minimum’ as the
counterfactual against which burden due to a risk is calculated.
2. Inclusion of continuous risk variables that previously were categorical in nature, that is,
taking into account the full range of risk from elevated blood pressure, serum cholesterol,
body mass index (BMI) or inadequate fruit and vegetable intake rather than defining
thresholds for hypertension, hypercholesterolaemia, underweight/obesity and low fruit
and vegetable consumption.
3. A more systematic review of the international literature on the impact of risk factors on
health outcomes, including estimates of relative risk for a unit of increase in continuous
risk factors.
4. A theoretical framework and provisional methods for estimating the joint effects of
multiple risks to health.
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Explicit ‘counterfactuals’
Estimating the health risks associated with exposure to a particular hazard in a population is
typically undertaken with reference to an alternative or ‘counterfactual’ distribution of
exposure (for example exposed versus not exposed). While different counterfactual
distributions may be used for different purposes (Murray and Lopez (1999) identify at least
four of potential interest), an important contribution of the CRA project was to seek
consistency in the definition and use of this distribution across each of the 22 risks analysed.
In burden of disease and injury studies, the counterfactual of greatest relevance to the
question ‘How much of this health outcome is due to that exposure?’ is the ‘theoretical
minimum’ risk distribution. This is defined as the distribution of exposure that would yield
the lowest possible risk in a population (for example zero tobacco use) and is useful for
determining how much of current burden is due to past exposure to a particular hazard (the
light grey area of Figure 2.1). This is distinct from intervention analyses, which are typically
interested in how much future burden could realistically be avoided by shifting current
exposure through the implementation of a particular intervention (various scenarios
depicted in the dark grey area of Figure 2.1).
 Figure 2.1: Conceptual model for health risk assessment which identifies unavoidable burden
 due to past exposures (light grey), avoidable burden due to current and future exposure (dark
 grey) and burden unrelated to risk (mid-grey at bottom).
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While simple enough to operationalise in the context of hazards for which absence of
exposure is indeed the lowest possible risk, the concept of ‘no exposure’ is problematic when
lack of exposure is not meaningful, as is the case for blood pressure, cholesterol and body
mass. Before the CRA project, this issue was avoided by the categorisation of these hazards
into normal and abnormal (for example hypercholesterolaemia, hypertension, overweight or
obesity). Although relevant from a clinical management perspective, this approach is likely
to underestimate the population-level attributable burden; even though the elevation in risk
at levels of exposure below these cut-points may be small, the large numbers of people at
these levels contribute substantially to total population-level risk. The approach advocated
by the CRA researchers was to respect the continuous nature of these hazards by assessing
risk across the full distribution of exposure experienced by a population.  This meant
defining ‘theoretical minimum’ distributions even for hazards for which lack of exposure is
not meaningful, which they did by drawing on evidence from very low-risk populations in
the literature (Ezzati et al. 2003).
Joint risk attribution
Another area where the CRA project made an important contribution was the joint
attribution of risks. Health risk assessment before this project typically provided information
about burden attributable to a hazard in isolation from other hazards. The difficulty with this
approach is that if several analyses are added together it can appear as if more than 100% of
total burden for any one disease or injury is being accounted for by the hazards in
combination. This is not an error in the individual risk attribution method itself but rather it
is an issue of interpretation. Individual risk attribution analyses should not be added
together, although this can be a difficult message to convey, particularly when they are
presented together.
Estimating the joint effects of multiple risks is complex in practice for several reasons. First,
some of the effects of the more distal factors (for example physical inactivity) are mediated
through more proximal factors (for example via high BMI and from BMI via high blood
pressure). Estimating the joint effects of more distal and proximal factors requires knowledge
of independent hazards of the distal ones and the amount of risk mediated through proximal
risk factors. Second, the hazard due to a risk factor may depend on the presence of other risk
factors (effect modification). Third, there may be correlation between exposures to various
risk factors, because they are affected by the same distal factors and social dynamics.
The approach used to estimate joint population attributable fractions (PAFs) in this study is
based on methods developed for the CRA, in which the assumption is made that health risks
are biologically independent and uncorrelated. This is, of course, an over-simplification, as
some risks are not biologically independent (for example physical inactivity and BMI), and
various exposures are highly correlated (for example smokers also tend to be drinkers).
However, it allows the joint PAF for n number of risks to be expressed as:
)1(1PAFjoint
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where PAFi is the PAF of individual risk factors.
The second term in the right-hand side of this equation (that is, the product of all [1 – PAFi]
terms) is the fraction of burden not attributable to any of the n risk factors. One minus this
term is the fraction attributable to the combined effects of the n risk factors.
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For instance, inadequate intake of fruit and vegetables and high BMI increase the risk of
colon cancer. Assuming there is no dependence or correlation between these two risks, if the
PAF for fruit and vegetable intake is 0.20 and the PAF for BMI is 0.10, the burden attributable
to the two risks equals 1 – ( 1 – 0.2) x ( 1 – 0.1 ) = 1 – 0.8 x 0.9 = 0.28.
Epidemiological studies on the effects of high BMI, physical inactivity, and low fruit and
vegetable consumption on cardiovascular disease risk have illustrated some attenuation of
the effects after adjustment for more proximal factors (for example blood pressure or
cholesterol) (Berlin & Colditz 1990; Blair et al. 2001; Eaton 1992; Gaziano et al. 1995; Jarrett et
al. 1982; Jousilahti et al. 1999; Khaw & Barrett-Connor 1987; Liu & Manson 2001; Manson et
al. 1990; Rosengren et al. 1999; Tate et al. 1998). This attenuation confirms that some of the
hazard of the more distal factors operates by increasing levels of risk in factors closer in the
causal pathway to the disease. The attenuation varies among studies but is consistently less
than one-half of the excess risk (that is, RR - 1) of the more distal factors. An upper bound of
50% is used in this study as the proportion of the excess risk from BMI, physical activity and
fruit and vegetable intake that is mediated through proximal factors that are themselves
among the risks being analysed. For example, if the relative risk of BMI for diabetes is 4 for a
particular level of BMI exposure, for the joint effects calculation a relative risk of (4 – 1) x 0.5
+ 1 = 2.5 is used to calculate the PAF that eventually feeds into the equation on the previous
page. Joint risk factor estimates for cardiovascular disease are not very sensitive even to large
variations in this assumption of attenuation (Ezzati et al. 2004a).
The burden attributable to both child sexual assault and intimate partner violence is
estimated in this study for the first time. Evidence suggests that girls who experience child
sexual abuse are more likely than non-abused girls to experience intimate partner violence
(Mouzos & Makkai 2004). In the joint effects analysis for these exposures, the burden due to
child sexual abuse and intimate partner violence is calculated as the sum of the PAFs for
exposure to child sexual abuse only, exposure to intimate partner violence only, and the
combined state of exposure to both risks.
2.5 Past, present and future burden
Forecasts about the future play an important role in shaping public policy. For example, an
important consequence of economic development has been improvements in health,
particularly among the elderly. Better health, in turn, has led to greater economic
development and more people surviving to old age. Together with decreasing fertility, this
has contributed to ‘population ageing’.
There is increasing analysis being undertaken in relation to the long-term sustainability of
public finances in the context of these widespread demographic trends across the developed
world. Under the Charter of Budget Honesty Act 1998, the Australian Government is
required to prepare an Intergenerational Report (IGR) that assesses the long-term
sustainability of current Government policies over the next 40 years, and to take account of
the financial implications of demographic change. The first IGR was released on 14 May 2002
as part of the 2002–03 Federal Budget (Budget Paper No. 5) and considered future health care
costs based on expected demographic trends and projected Australian Government
expenditure on health services, represented as a proportion of gross domestic product
(GDP), for the period 2002 to 2041.
Likely trends in disease occurrence were not explicitly accounted for in the IGR as the
analytical projections were based on historical trends in major health expenditure program
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groupings (medical benefits, pharmaceutical benefits and hospitals) at selected ages. It is
optimistic to assume that simply because underlying changes in disease occurrence were
embedded within the historical data on expenditure that they are therefore plausibly
reflected in these analyses. An analysis that explicitly takes account of changes in both
disease occurrence and per unit expenditure at the level of individual diseases is likely to
provide much firmer ground upon which to base estimates of future health expenditure.
Common to both approaches, of course, is the assumption that the rate of change in policy
responses to emerging problems in the future is consistent with the rate observed in the
historical period upon which the projections are based (that is, ‘business as usual’). If these
dynamics change, expectations with regard to the future will consequently change.
One objective of the present study was to address the need for comprehensive health
projections in Australia by analysing the most likely changes in burden of disease and injury
to the year 2023. The past is a good (but far from perfect) predictor of the future and an
important by-product of such work is a comprehensive analysis of past trends in disease
occurrence. To pre-empt the inevitable requests for information on the past, this part of the
study was extended to include ‘back-casting’ of disease burden as well. This has the logical
appeal of ensuring consistency between estimates of past, present and future disease burden.
More importantly, it may limit the potential for misinterpretation should people compare
these current and future burden estimates with results based on alternative methods. The
inevitable comparison that people will make between the results presented in this report and
those of the previous Australian Burden of Disease and Injury Study should be regarded in
this light.
Australia has an excellent vital registration system by international standards and, with few
exceptions (for example pneumonia), observable trends in vital events over time are
arguably the most reliable and consistently recorded information on changes in the
frequency of diseases and injuries that result in death. Previous work (Barendregt et al. 2003)
has shown that the complete epidemiology of a disease is ultimately a function of only three
parameters: incidence (the hazard of getting the disease), remission (the ‘hazard’ of being
cured from having the disease) and case-fatality (the hazard of dying as a consequence of
having the disease). For most chronic diseases, cause-specific mortality is influenced by only
two of these—incidence and case-fatality—with remission having little if any role. It follows,
therefore, that any epidemiological parameter of interest for a chronic disease can be
‘back-cast’ from a point in time for which the complete epidemiology of that disease is
known simply by making assumptions about the relative contribution of incidence and case-
fatality to the observed changes in mortality.
This idea also applies to projections, providing one is willing to make predictions about
cause-specific mortality into the future. Since it has already been argued that cause-specific
mortality is a reliable and consistently recorded source of information on changes in disease
frequency in many cases, cause-specific mortality is a sound starting point for projecting the
epidemiology of a disease. Other approaches that are based on predicting incidence from
risk factors may have more intuitive appeal but are more tenuous as they involve multiple
assumptions about disease–exposure relationships and future exposure trajectories.
The methods used in this study involved a number of separate analytical or computational
steps. A brief outline of the overall approach is presented below. More complete details are
provided in subsequent sections of the report as indicated.
1. Baseline models for over 170 diseases and injuries for Australia in 2003 were developed
as part of the core set of analyses for the present study. Appendix 1 discusses each of
these models in detail.
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2. Trends in observed cause-specific mortality over the period 1979 to 2003 were analysed
and projected into the future using a combination of regression techniques.
3. For mostly fatal conditions, each baseline disease model was extrapolated backwards and
forwards in time based on assumptions about the relative contribution of incidence and
case-fatality to changes in mortality. Baseline models for mostly non-fatal conditions
were extrapolated based on assumptions about changes in incidence only. The complete
epidemiology of each was then estimated separately in a fully dynamic model that
accounted for changes in all-cause mortality as well as changes in incidence and
case-fatality (where appropriate) so that incidence, prevalence and duration by age, sex
and cause was described over the past as well as into the future.
4. Absolute numbers of incident and prevalent cases were derived by applying the rates
from the above analyses to the ABS ‘Series 8’ projection series population estimates (ABS
2003d). This series assumes a high net overseas migration of 125,000 annually, constant
improvements in life expectancy (low mortality assumption), and a total fertility rate
declining to 1.6 by 2011 and then remaining constant.
Incident and prevalent YLD for each disease were calculated for non-baseline periods by
applying durations and extrapolated numbers of incident and prevalent cases from the
dynamic model to disability weights that were corrected for probabilities of comorbidity in
2003. Years of life lost (YLL) for non-baseline periods were calculated directly from observed
deaths in the past and projected deaths into the future.
Mortality trends and projections
Observed all-cause mortality rates for the period 1979 to 2003 were extrapolated into the
future using simple log-linear Poisson regression. Cause-specific mortality data for the same
period were then collapsed into 51 clinically meaningful conditions, or groups of conditions.
Multinomial logistic regression was used to model changes in the contribution of each group
as a proportion of all-cause mortality, with changes in absolute levels of all-cause mortality
expressed as the natural log of the rate per unit of population. These models were used to
predict the future cause-specific structure of mortality based on projected all-cause mortality
rates. Separate analyses were done for each age group and sex.
Among the causes analysed, cardiovascular disease, cancers, chronic obstructive pulmonary
disease (COPD), diabetes, alcohol-related conditions, road traffic accidents, falls, suicide and
homicide showed significant mortality trends. The apparent trend in dementia mortality was
ignored because: (a) there has been a shift in coding practices with more deaths being
attributed to dementia; (b) the prevalence data from international epidemiological studies
showed no clear change over time; (c) the case-fatality was unlikely to have changed much
over time as there are no effective life-saving interventions.
Incidence and case-fatality
Mortality trends for cancers, COPD, diabetes, alcohol-related conditions, road traffic
accidents, falls, suicide and homicide were assumed to be fully due to changes in incidence.
Incidence trends for these causes were therefore adjusted to reflect changes in mortality over
the projection period, with case-fatality being held constant. Findings from Unal et al. (2004)
suggest that 58% of the drop in cardiovascular mortality observed in England and Wales was
due to a drop in incidence and the remaining 42% due to a reduction in case-fatality. The
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same proportions were assumed to apply in this study to all cardiovascular disease over the
projection period.
Changes in the diagnostic criteria for Type 2 diabetes in surveys and a paucity of
representative survey data meant that there was no direct measurement of trends of Type 2
diabetes in Australia from which to project the incidence of this disease.  Body mass index
(BMI, defined as body weight in kilograms divided by the square of height in metres),
overwhelmingly the main risk factor for Type 2 diabetes, however, has been measured
consistently at various points over recent time. The approach taken in this study, therefore,
was to translate historical trends in BMI into expected changes in diabetes incidence
following the risk attribution methods described in the WHO Comparative Risk Assessment
project.
Haby and colleagues (2006) analysed trends in BMI using data from five measurement
surveys: the three National Heart Foundation Risk Factor Prevalence studies in the 1980s, the
National Nutrition Survey of 1995 and the AusDiab study in 1999 and 2000. Projected mean
BMI by age group and sex was derived from Haby and colleagues’ regression model of the
mean of log-transformed BMI values on age, birth cohort and sex. Similar techniques were
applied to the standard deviations of BMI values so as to fully describe the expected change
in the distribution of this risk into the future (a change which can be characterised as a
broadening of the distribution in the tail towards the highest BMI values rather than at the
other end of the distribution with low values).
The population-level risk of diabetes is simply the area under the curve represented by the
distribution of BMI multiplied by the relevant relative risk of developing diabetes at each
level of BMI. This is easiest to derive using integration techniques. Proportional changes in
the size of this area over time represent changes in the incidence of diabetes resulting from
changes in BMI. Ni Mhurchu and colleagues (2006) undertook a meta-analysis of results
from the Asia-Pacific Cohort Study collaboration and report the relative risk of developing
diabetes for each unit increase in BMI by age and sex. Using these relative risks and the
predicted BMI distributions derived above, changes in the incidence of diabetes were
estimated over the projection period. For consistency with CRA methods, a theoretical
minimum distribution of BMI (mean of 21 and standard deviation of 1) was incorporated
into the calculations, below which no excess risk of diabetes was assumed.
Information on trends in case-fatality rates amongst people with diabetes is scarce. In the
absence of such information, an assumption was made that at least half the mortality in these
people is due to vascular causes and is subject to the same factors that influence
cardiovascular disease mortality more generally. Changes in case-fatality for diabetes,
therefore, were assumed to reflect half the trends in case-fatality for cardiovascular disease,
which were estimated to be decreasing over the projection period. The combined effect of
increasing BMI and decreasing case-fatality was a considerable increase in the incidence of
Type 2 diabetes, and an even greater increase in future prevalence.
Non-fatal conditions
Mortality trend data are not relevant for conditions that are largely non-fatal. These include
mental, sense organ and musculoskeletal disorders. The only mental health survey in
Australia was carried out in 1997 and hence there are no trend data. Internationally there is
no clear evidence of trends due to a paucity of mental health survey data collected using
comparable diagnostic tools and criteria. Therefore no trends were assumed. Similarly, no
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disease trends were applied to hearing loss (only one community survey), and the various
causes of vision loss and musculoskeletal disorders (no evidence for trends).
2.6 Differentials in burden
The high demand for information on health differentials, both between and within
populations, is one measure of the obvious public policy implications of such information.
For example, knowing that the gap in life expectancy at birth between Aboriginal and Torres
Strait Islander Australians and other Australians is demonstrably very large is a sound basis
for new initiatives to improve Indigenous health. One of the aims of the original study was
to develop estimates of disease burden for different groups within the Australian
population. To this end, the final report presented preliminary analyses of inequalities in
disease burden by level of socioeconomic disadvantage, although it was not possible to
complete a comprehensive analysis of non-fatal burden within the time available. An
objective of the current project was to extend these analyses by providing a more complete
picture of disease burden for a much greater range of subgroups within the Australian
population.
The methods used in this study build on the first comprehensive attempt to describe ‘small
area’ variability in health status across Victoria (DHS 2006), and are in the methodological
tradition of describing differences in health across population subgroups. Murray and
colleagues (1999a) differentiate this from descriptions of ‘health inequalities’, a term they
reserve for analysis of the variation in health status across individuals in a population
(analogous to analyses of income inequality, which measure the distribution of income at the
level of individuals). While health inequalities are sometimes regarded as synonymous with
subgroup differences in health in the literature, analyses of the latter are based on subgroup
averages and as such can mask the true extent of inequalities between individuals.
Categorising geographic areas
The most disaggregated geographic information on place of usual residence for most
Australian health data is the Statistical Local Area (SLA), and this geographic entity is used
as the unit of analysis for this component of the study. For various reasons, SLA names and
boundaries are revised over time, the most substantial revision occurring as a result of local
government amalgamations in the early 1990s. To achieve geographic consistency, all data,
regardless of year, were analysed in terms of ASGC definitions for the year 2001 (ASGC, or
Australian Standard Geographical Classification, being the reference used to define SLAs)
(ABS 2001a). Data defined in terms of SLAs fragmented as a result of boundary revisions
were reapportioned using information from the 2001 Census on the proportion of each old
SLA population residing in each current SLA after the redrawing of the boundaries. Irregular
coding in data arising from such revisions was resolved on a case-by-case basis using historic
documentation provided by the ABS. Estimated mid-year resident population figures for
each SLA by year (1999 to 2003), 5-year age groups (0, 5…85+) and sex were obtained from
the ABS.
The ASGC 2001 provides for the classification of SLAs in terms of both socioeconomic status
and remoteness. Socioeconomic status can be determined from one of four socioeconomic
indexes for areas (SEIFA indexes) developed by the ABS from the 2001 Census using
principal component methods on attributes such as low income, low educational attainment,
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high levels of public sector housing, high unemployment, and jobs in relatively unskilled
occupations (ABS 2001b). This study uses the index of disadvantage that is functionally
equivalent to the Index of Relative Socioeconomic Disadvantage derived from the 1996
Census. This index is estimated at a collector-district level to be normally distributed at a
national level, and can be population-weighted to derive values for ASGC 2001 SLAs.
Socioeconomic quintiles were derived by ranking SLAs in order of disadvantage index then
grouping them into five categories such that each category contains approximately 20% of
the total Australian population.
Remoteness can be determined from the Accessibility/Remoteness Index of Australia
(ARIA+) developed by the Australian Government Department of Heath and Ageing and
the National Centre for Social Applications of Geographic Information Systems (GISCA), and
subsequently incorporated into ASGC 2001 (ABS 2001a). ARIA+ is a continuous varying
index with values ranging from 0 (high accessibility) to 15 (high remoteness), and is based on
road distance measurements from 11,879 populated localities to the nearest service centre.
Index values for each locality have been interpolated to a 1 km grid so that all areas of
Australia have an index value and scores for larger areas such as SLAs can be derived. Each
SLA was classified into one of three groups based on the following standard cut-points as
defined in ASGC 2001: Major cities (0–0.20), Regional (>0.20–5.92) and Remote (>5.92).
Estimating burden for subpopulations
One category of information readily available for disaggregating national estimates of
burden to subpopulations is data on observed variations in event frequency for any
aggregation from the level of the SLA and above. This includes the National Mortality
dataset, the National Hospital Morbidity Database and the National Cancer Statistics
Clearing House dataset. The other category comprises information that can be tabulated by
state or territory jurisdiction, disadvantage quintile or remoteness category, but cannot be
disaggregated below these strata. Most surveys (for example the National Health Survey, the
Survey on Disability, Ageing and Carers, the National Survey of Mental Health and
Wellbeing, and the Australian Diabetes Obesity and Lifestyle Study (AusDiab)) and
published data tabulations fit this description. The primary objective with either category
was to derive relativities between whatever level of disaggregation was possible, and to
ensure that these relativities were as accurate as possible and not simply an artefact of small
numbers. Of less concern was the absolute level of disease occurrence being reported,
because these would be constrained by national estimates.
The adopted strategy was intended to ensure consistency in the use of the available
information and to ensure sufficient numbers at each level of the analysis. First, all sources
were assessed for whether they could provide simple state/territory jurisdiction proportions
(preferably by sex, but not necessarily by age) for any condition in the study’s list of diseases
and injuries. Most sources could provide this information. Next, they were assessed for
plausibility as a valid proxy for variability in disease occurrence across a 15-cell matrix
comprising five SEIFA categories and three remoteness categories. Not as many sources
could provide this information and, of these, a few could provide information on only one
dimension (that is, either SEIFA or remoteness, but not both). Age-standardised rates were
then calculated for each cell of observed data, and these were divided by the crude rate for
the whole matrix to derive 15 cell-specific standardised rate ratios. In matrices with only one
dimension, ratios for the observed dimension were held constant across the missing
dimension.
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This estimation process means that the estimates of deaths of cancer cases in a particular SLA
are not the same as the actual deaths or cancer cases in that SLA, but are synthetic estimates
which reflect the rates of deaths and cancer in SLAs of similar type.
Having determined possible sources for two pieces of information (state/territory
proportions and matrices of rate ratios), an assessment was made for each disease and injury
category as to whether there was agreement between sources (if there were more than one)
and which information seemed sufficiently robust in terms of underlying numbers. For
conditions with a predominantly fatal burden, preference was given to information derived
from mortality data. For other conditions, preference was given to the data source upon
which the national disability model was based.
Each condition was then assigned a single source to be used to derive the proportion of
national incidence cases that would be expected to occur in each state and territory. If no
source could be identified, the number of incident cases was unconstrained at this step in the
disaggregation. The implied jurisdiction-specific rate (or national rate where jurisdiction
numbers were unconstrained) was then distributed to subpopulations within the jurisdiction
using one of the matrices of rate ratios derived in the previous step. If no matrix was
available, rates were held constant across subpopulations within jurisdictions. Derived
incident cases were then rescaled to be consistent with jurisdiction totals where applicable,
and ultimately national totals. Deaths were treated in the same way as incident cases.
The final step was to derive prevalent cases and duration for each condition and its sequelae
for each subpopulation within jurisdictions. An automated implementation of the equations
underlying DisMod (an epidemiological modelling software package) was applied to
subpopulation-specific incidence rates and national assumptions regarding remission and
case-fatality to derive these parameters. In order to derive accurate durations, one of 15 sets
of all-cause mortality rates was used according to the SEIFA and remoteness category of the
subpopulation. All subpopulation-specific prevalent cases and YLD (both incident and
prevalent) were then rescaled to be consistent with national totals.
Subpopulation comparisons in this report
This report is limited to the following subpopulation comparisons:
1. state and territory jurisdictions
2. remoteness categories
3. socioeconomic quintiles.
While the analyses were aimed at disaggregating national burden estimates to the level of
the SLA, there was no intention to disseminate results at this level of detail. In addition to the
potential privacy considerations of the data providers, the release of such information may
be misleading given the methods used. Rather, the authors and various jurisdictional
stakeholders are working to regroup the data into meaningful aggregations of SLAs for
specific health policy and planning purposes.
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3 Burden of disease and injury in
Australia
This chapter discusses the burden of disease and injury in Australia in 2003 by fatal and non-
fatal burden, sex, age and leading broad cause group. The numbers presented in this chapter
should not be compared with those presented in the previous report (AIHW: Mathers et al.
1999) due to substantially different methods for many of the disability models. Readers who
are interested in gaining an understanding of changes in burden over time are referred to
Chapter 6 which discusses trends in population health over a 30-year period.
3.1 Disability-adjusted life years
Cancer, cardiovascular disease and mental disorders were the leading causes of total burden
of disease and injury in Australia in 2003 (Figure 3.1). Cancer and cardiovascular disease
accounted for 37% of the total burden; for both causes, four-fifths of this burden was from
mortality. Mental disorders and neurological & sense disorders were the next largest
contributors, together accounting for a further quarter of the total burden. The contribution
of mortality to the burden from these two groups was small, highlighting the importance of
including non-fatal health outcomes in population health measurement.
Overall, half the total burden (49%) was due to mortality and the distribution between the
sexes was roughly equal for most causes, with injuries (70% of the burden in males) and
musculoskeletal disorders (58% of the burden in females) the exceptions.
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Figure 3.1: Burden (DALYs) by broad cause group expressed as: (a) proportions of total,
(b) proportions by sex, and (c) proportions due to fatal and non-fatal outcomes, Australia,
2003
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Total burden in absolute terms increased at a relatively constant rate until age 75 (Figure
3.2b), while the burden per head of population continued to rise exponentially, with small
but significant peaks in childhood and early adulthood (Figure 3.2a). Injuries in males and
mental disorders were the main cause groups until middle age and accounted for the
majority of total burden in early adulthood, after which cancer, cardiovascular disease and
neurological & sense disorders were more prominent. The contribution from cancer peaked
at age 70 then declined, leaving cardiovascular disease as the major cause of burden in the
elderly (Figure 3.2b).
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 group, Australia, 2003
The burden due to specific disease and injury categories reflected the more general picture at
the broad cause group level. Ischaemic heart disease was the largest single cause in males,
accounting for 11.1% of the total male burden (Table 3.1). For females, anxiety & depression
was the leading cause, accounting for 10.0% of the total female burden. Ischaemic heart
disease, stroke, Type 2 diabetes and dementia were the next four leading causes of DALYs in
females. In males, Type 2 diabetes, anxiety & depression, lung cancer and stroke were the
next four leading causes.
Seven health areas have been identified by the Commonwealth, state and territory
governments for priority attention as National Health Priority Areas: asthma, cancer,
cardiovascular disease, diabetes mellitus, injuries, mental health, and arthritis and
musculoskeletal conditions.  In addition, dementia is an Australian Government health
priority. In 2003, these eight health groupings accounted for 72.8% of the total burden, 17 of
the 20 leading conditions for males and 15 of the 20 leading conditions for females.
Ra
te
pe
r1
,0
00
Nu
mb
er
(th
ou
sa
nd
s)
38
Total burden in absolute terms increased at a relatively constant rate until age 75 (Figure
3.2b), while the burden per head of population continued to rise exponentially, with small
but significant peaks in childhood and early adulthood (Figure 3.2a). Injuries in males and
mental disorders were the main cause groups until middle age and accounted for the
majority of total burden in early adulthood, after which cancer, cardiovascular disease and
neurological & sense disorders were more prominent. The contribution from cancer peaked
at age 70 then declined, leaving cardiovascular disease as the major cause of burden in the
elderly (Figure 3.2b).
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The burden due to specific disease and injury categories reflected the more general picture at
the broad cause group level. Ischaemic heart disease was the largest single cause in males,
accounting for 11.1% of the total male burden (Table 3.1). For females, anxiety & depression
was the leading cause, accounting for 10.0% of the total female burden. Ischaemic heart
disease, stroke, Type 2 diabetes and dementia were the next four leading causes of DALYs in
females. In males, Type 2 diabetes, anxiety & depression, lung cancer and stroke were the
next four leading causes.
Seven health areas have been identified by the Commonwealth, state and territory
governments for priority attention as National Health Priority Areas: asthma, cancer,
cardiovascular disease, diabetes mellitus, injuries, mental health, and arthritis and
musculoskeletal conditions.  In addition, dementia is an Australian Government health
priority. In 2003, these eight health groupings accounted for 72.8% of the total burden, 17 of
the 20 leading conditions for males and 15 of the 20 leading conditions for females.
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Table 3.1: Leading causes of burden (DALYs) by sex, Australia, 2003
Rank Males DALYs
Per
cent of
total  Females DALYs
Per cent
of total
1 Ischaemic heart disease  151,107 11.1 Anxiety & depression 126,464 10.0
2 Type 2 diabetes  71,176 5.2 Ischaemic heart disease 112,390 8.9
3 Anxiety & depression  65,321 4.8 Stroke 65,166 5.1
4 Lung cancer  55,028 4.0 Type 2 diabetes 61,763 4.9
5 Stroke 53,296 3.9 Dementia 60,747 4.8
6 COPD  49,201 3.6 Breast cancer 60,520 4.8
7 Adult-onset hearing loss  42,653 3.1 COPD 37,550 3.0
8 Suicide & self-inflicted injuries  38,717 2.8 Lung cancer 33,876 2.7
9 Prostate cancer 36,547 2.7 Asthma 33,828 2.7
10 Colorectal cancer  34,643 2.5 Colorectal cancer 28,962 2.3
11 Dementia  33,653 2.5 Adult-onset hearing loss 22,200 1.8
12 Road traffic accidents  31,028 2.3 Osteoarthritis 20,083 1.6
13 Asthma  29,271 2.1 Personality disorders 16,339 1.3
14 Alcohol abuse 27,225 2.0 Migraine 15,875 1.3
15 Personality disorders  16,248 1.2 Back pain 15,188 1.2
16 Schizophrenia  14,785 1.1 Lower respiratory tract infections 14,233 1.1
17 Osteoarthritis 14,495 1.1 Falls 13,269 1.0
18 Back pain  14,470 1.1 Parkinson’s disease 13,189 1.0
19 Melanoma 13,734 1.0 Schizophrenia 12,717 1.0
20 Parkinson’s disease  13,664 1.0 Rheumatoid arthritis 12,062 1.0
Table 3.2 compares burden by broad cause groups in 2003 with total health system
expenditures in 2000–01. This table is included to illustrate a misunderstanding about the
relationship between health expenditure and health outcomes. It is sometimes argued, for
example, that the proportion of total expenditure that is committed to a particular health
problem should be commensurate in some way to its contribution to total burden. This is not
necessarily the case.
Burden estimates describe the health problems that remain in a population in spite of all
currently implemented prevention and treatment strategies. Large expenditure for a cause
with a small burden is money well spent if that expenditure reflects an efficient health
service response to what otherwise would have been a much larger problem. Oral
conditions, for example, account for only 0.9% of total burden but consume 6.7% of total
expenditure ($3.4 billion). This commitment of resources may well represent a good
investment if it keeps the burden from oral conditions at low levels and that without it, the
burden would be much higher. If, on the other hand, some of this expenditure is not
impacting on the burden, because it is being directed towards cosmetic or ineffective
services, for example, or there are inefficiencies in the delivery of oral health services, then
the conclusion may be less sanguine.
The real test of whether an investment has been worthwhile depends on the change in
burden resulting from the expenditure as well as the opportunity cost of that expenditure to
investments in other areas of the health sector. Exploring this requires information on the
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effectiveness and costs associated with all current prevention and treatment strategies.  Such
analyses are beyond the scope of this report.
The proportion of burden for a particular health problem vis-a-vis expenditure, therefore, is
more appropriately used as one argument amongst others for prioritising research into the
development of new treatment and preventive interventions, and into assessing the
effectiveness of these interventions. It should not be used to prioritise existing treatment and
preventive activities.
Table 3.2: Burden (DALYs) in 2003 and expenditure in 2000–01 by broad cause group, Australia
DALYs in 2003 Expenditure in 2000–01(a)
Cause No. (thousands) Per cent $ (millions) Per cent
Neoplasms(b) 510.3 19.4 2,918 5.8
Cardiovascular disease 473.8 18.0 5,479 10.9
Mental disorders 350.5 13.3 3,741 7.5
Neurological & sense disorders 312.8 11.9 4,942 9.9
Respiratory disease(c) 222.2 8.4 3,742 7.5
Injuries 185.1 7.0 4,013 8.0
Diabetes mellitus 143.8 5.5 812 1.6
Musculoskeletal diseases 105.5 4.0 4,634 9.2
Genitourinary diseases 65.2 2.5 2,076 4.1
Diseases of the digestive system 58.0 2.2 2,811 5.6
Infectious & parasitic diseases 44.7 1.7 1,224 2.4
Neonatal causes 34.6 1.3 358 0.7
Congenital anomalies 33.2 1.3 221 0.4
Endocrine & metabolic disorders 28.6 1.1 1,587 3.2
Oral conditions 24.5 0.9 3,372 6.7
Skin diseases 20.3 0.8 1,370 2.7
Maternal conditions 2.2 0.1 1,315 2.6
Other(d) 17.5 0.7 5,530 11.0
All causes  2,632.8 100.0 50,146 100.0
(a) Total health system expenditures from AIHW 2005c.
(b) Includes cancers (malignant neoplasms) and other (non-malignant) neoplasms.
(c) Includes chronic respiratory disease and acute respiratory infections.
(d) Includes ‘Signs, symptoms and ill-defined conditions’ which includes expenditure on diagnostic and other services for signs, symptoms and
ill-defined conditions where the cause of the problem is unknown and includes ‘other contact with the health system’ such as fertility control,
reproduction and development, elective plastic surgery, general prevention, screening and health examination; and treatment and aftercare
for unspecified disease.
3.2 Years of life lost
Years of life lost (YLL), or fatal burden, accounted for 49% of the total burden of disease and
injury in Australia in 2003 (Figure 3.1c). Cancers, cardiovascular disease and injuries were
responsible for almost three-quarters of this burden (Figure 3.3a). Since the 1996 study,
cancer has overtaken cardiovascular disease as the greatest cause of fatal burden as
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3.2 Years of life lost
Years of life lost (YLL), or fatal burden, accounted for 49% of the total burden of disease and
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responsible for almost three-quarters of this burden (Figure 3.3a). Since the 1996 study,
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cardiovascular mortality has declined much more than cancer mortality over the past three
to four decades. Males experienced 55% of the total fatal burden.
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Figure 3.3: Fatal burden (YLL) expressed as: (a) proportion by broad cause group, and
(b) proportion by sex for each broad cause group, Australia, 2003
As with total burden, fatal burden increased in absolute terms at a relatively constant rate
until age 75 (Figure 3.4b), while the burden per head of population continued to increase
exponentially, with small but important peaks in childhood and, in males, early adulthood
(Figure 3.4a). Injury was the main cause of fatal burden until age 35 and accounted for the
majority of fatal burden in early life, after which cancer and cardiovascular disease were
more prominent. The contribution from cancer peaked at age 70 then declined, leaving
cardiovascular disease as the major cause of fatal burden in the elderly (Figure 3.4b).
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Figure 3.4: Fatal burden (YLL) by age expressed as: (a) rates by sex, and (b) numbers by broad
cause group, Australia, 2003
Again, the fatal burden due to specific disease and injury categories reflected the more
general picture at the broad cause group level. Ischaemic heart disease was the disease
contributing most to YLL in both males and females. Stroke was the second largest disease
causing YLL in females, followed by breast cancer and lung cancer. In males, lung cancer
ranked second, followed by suicide & self-inflicted injuries, stroke, and colorectal cancer
(Table 3.3).
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Again, the fatal burden due to specific disease and injury categories reflected the more
general picture at the broad cause group level. Ischaemic heart disease was the disease
contributing most to YLL in both males and females. Stroke was the second largest disease
causing YLL in females, followed by breast cancer and lung cancer. In males, lung cancer
ranked second, followed by suicide & self-inflicted injuries, stroke, and colorectal cancer
(Table 3.3).
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Table 3.3: Leading causes of mortality burden (YLL) by sex, Australia, 2003
Rank Males YLL
Per cent
of total Females YLL
Per cent
of total
1 Ischaemic heart disease 128,991 18.2 Ischaemic heart disease  89,152 15.7
2 Lung cancer  51,505 7.3 Stroke  48,548 8.5
3 Suicide & self-inflicted injuries  38,434 5.4 Breast cancer  40,080 7.0
4 Stroke  36,152 5.1 Lung cancer  31,551 5.5
5 Colorectal cancer  27,997 3.9 Colorectal cancer  23,735 4.2
6 Road traffic accidents  26,674 3.8 COPD  21,025 3.7
7 COPD  26,183 3.7 Dementia  16,009 2.8
8 Prostate cancer  23,175 3.3 Lower respiratory tract infections  12,309 2.2
9 Type 2 diabetes  15,273 2.2 Type 2 diabetes  11,751 2.1
10 Hepatitis  12,524 1.8 Pancreas cancer  10,984 1.9
11 Alcohol abuse  11,449 1.6 Ovary cancer  10,946 1.9
12 Lower respiratory tract infections  11,221 1.6 Suicide & self-inflicted injuries  10,945 1.9
13 Pancreas cancer  11,136 1.6 Road traffic accidents  9,678 1.7
14 Brain cancer  10,718 1.5 Nephritis & nephrosis  9,521 1.7
15 Lymphoma  10,474 1.5 Lymphoma  8,324 1.5
16 Melanoma  10,108 1.4 Brain cancer  7,809 1.4
17 Leukaemia  10,039 1.4 Leukaemia  7,468 1.3
18 Oesophagus cancer  9,427 1.3 Hepatitis  6,534 1.1
19 Nephritis & nephrosis  9,336 1.3 Falls  5,845 1.0
20 Stomach cancer  8,209 1.2 Stomach cancer  5,609 1.0
3.3 Years lost due to disability
Years lost due to disability (YLD), or non-fatal burden, are typically calculated from
incidence cases in a base year and as such are to be interpreted as the number of healthy
years lost due to disability that will accrue into the future from new cases of disease and
injury in that base year. Incident non-fatal burden is added to fatal burden (YLL) to derive
total burden (DALYs). An alternative way of calculating non-fatal burden uses prevalent
cases as the basis. Prevalent non-fatal burden (PYLD) is to be interpreted as the number of
healthy years lost due to disability currently experienced by a population. This cannot be
added to fatal burden to derive total burden in the same way as incident non-fatal burden.
Both methods of calculating non-fatal burden are presented below. For all the other sections
of this report, references to non-fatal burden reflect incident non-fatal burden unless
otherwise specified.
Incident YLD
Incident non-fatal burden accounted for 51% of the total burden of disease and injury in
Australia in 2003 (Figure 3.1c). Mental, neurological and sense disorders contributed most,
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together accounting for 43% of this burden (Figure 3.5a). While cancer, cardiovascular
disease and injuries contributed 72% to the total fatal burden (Figure 3.3a), these causes did
not make a similar contribution to incident non-fatal burden. Incident non-fatal burden was
distributed equally between the sexes (Figure 3.5b).
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Figure 3.5: Non-fatal burden (YLD) expressed as: (a) proportion by broad cause group, and
(b) proportion by sex for each broad cause group, Australia, 2003
Incident non-fatal burden increased rapidly in absolute terms until early adulthood then
levelled out, while the rate per head of population continued increasing, but at a slower rate
than for fatal burden (Figure 3.6). Mental disorders were the main causes of incident non-
fatal burden until middle age and accounted for the majority of fatal burden in early life,
after which neurological & sense disorders were more prominent, accounting for the
majority of non-fatal burden in the elderly. Chronic respiratory conditions accounted for a
small but consistent proportion of incident non-fatal burden, with peaks in childhood due to
asthma and at older ages from chronic obstructive pulmonary disease (Figure 3.6).
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Anxiety & depression and Type 2 diabetes were the leading causes of incident non-fatal
burden in males and females (Table 3.4). Dementia was the third leading cause in females,
followed by asthma and ischaemic heart disease. In males, adult-onset hearing loss ranked
third, followed by asthma. Mental disorders accounted for six of the 20 leading causes of
incident non-fatal burden in males and three in females.
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Table 3.4: Leading causes of incident non-fatal burden (YLD) by sex, Australia, 2003
Rank Males YLD
Per cent
of total Females YLD
Per cent
of total
1 Anxiety & depression  65,208 10.0 Anxiety & depression  126,244 18.1
2 Type 2 diabetes  55,903 8.5 Type 2 diabetes  50,012 7.2
3 Adult-onset hearing loss  42,653 6.5 Dementia  44,738 6.4
4 Asthma  27,649 4.2 Asthma  31,405 4.5
5 Dementia  25,558 3.9 Ischaemic heart disease  23,238 3.3
6 COPD  23,018 3.5 Adult-onset hearing loss  22,200 3.2
7 Ischaemic heart disease  22,116 3.4 Breast cancer  20,440 2.9
8 Stroke  17,144 2.6 Osteoarthritis  19,775 2.8
9 Personality disorders  16,248 2.5 Stroke  16,619 2.4
10 Alcohol abuse  15,775 2.4 COPD  16,525 2.4
11 Schizophrenia  14,673 2.2 Personality disorders  16,339 2.3
12 Osteoarthritis  14,429 2.2 Migraine  15,868 2.3
13 Back pain  14,355 2.2 Back pain  15,129 2.2
14 Prostate cancer  13,372 2.0 Schizophrenia  12,577 1.8
15 Autism spectrum disorders  11,702 1.8 Rheumatoid arthritis  10,918 1.6
16 Parkinson’s disease  10,623 1.6 Parkinson’s disease  10,534 1.5
17 Refractive errors  8,241 1.3 Refractive errors  10,520 1.5
18 Peripheral vascular disease  7,965 1.2 Infertility  8,076 1.2
19 Heroin or polydrug abuse  7,498 1.1 Falls  7,424 1.1
20 Benign prostatic hypertrophy  7,378 1.1 Macular degeneration  7,259 1.0
Prevalent YLD
Figure 3.7 illustrates the prevalent non-fatal burden by age. The difference between
prevalent and incident non-fatal burden is most apparent for childhood conditions, such as
asthma and congenital disorders, and for chronic mental disorders, the incidence of which
peaks in childhood and early adulthood. Incident non-fatal burden at these life stages is
much larger compared to prevalent non-fatal burden because most incident cases of chronic
conditions at young ages are expected to remain prevalent cases at older ages. This explains
the shift to the right in the picture of prevalent non-fatal burden (Figure 3.7) compared to
incident non-fatal burden (Figure 3.6).
The rate of prevalent burden was lowest in children between 1 and 4 years of age (15 PYLD
per thousand) and increased to 147 in people aged 65 to 69 years and then to 415 per
thousand in people over the age of 95. In other words, disability from all diseases and
injuries resulted in a loss of 1.5% of healthy time lived by young children, increasing with
age to 14.7% in those 65 to 69 years and 41.5% in the very old.
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Table 3.4: Leading causes of incident non-fatal burden (YLD) by sex, Australia, 2003
Rank Males YLD
Per cent
of total Females YLD
Per cent
of total
1 Anxiety & depression  65,208 10.0 Anxiety & depression  126,244 18.1
2 Type 2 diabetes  55,903 8.5 Type 2 diabetes  50,012 7.2
3 Adult-onset hearing loss  42,653 6.5 Dementia  44,738 6.4
4 Asthma  27,649 4.2 Asthma  31,405 4.5
5 Dementia  25,558 3.9 Ischaemic heart disease  23,238 3.3
6 COPD  23,018 3.5 Adult-onset hearing loss  22,200 3.2
7 Ischaemic heart disease  22,116 3.4 Breast cancer  20,440 2.9
8 Stroke  17,144 2.6 Osteoarthritis  19,775 2.8
9 Personality disorders  16,248 2.5 Stroke  16,619 2.4
10 Alcohol abuse  15,775 2.4 COPD  16,525 2.4
11 Schizophrenia  14,673 2.2 Personality disorders  16,339 2.3
12 Osteoarthritis  14,429 2.2 Migraine  15,868 2.3
13 Back pain  14,355 2.2 Back pain  15,129 2.2
14 Prostate cancer  13,372 2.0 Schizophrenia  12,577 1.8
15 Autism spectrum disorders  11,702 1.8 Rheumatoid arthritis  10,918 1.6
16 Parkinson’s disease  10,623 1.6 Parkinson’s disease  10,534 1.5
17 Refractive errors  8,241 1.3 Refractive errors  10,520 1.5
18 Peripheral vascular disease  7,965 1.2 Infertility  8,076 1.2
19 Heroin or polydrug abuse  7,498 1.1 Falls  7,424 1.1
20 Benign prostatic hypertrophy  7,378 1.1 Macular degeneration  7,259 1.0
Prevalent YLD
Figure 3.7 illustrates the prevalent non-fatal burden by age. The difference between
prevalent and incident non-fatal burden is most apparent for childhood conditions, such as
asthma and congenital disorders, and for chronic mental disorders, the incidence of which
peaks in childhood and early adulthood. Incident non-fatal burden at these life stages is
much larger compared to prevalent non-fatal burden because most incident cases of chronic
conditions at young ages are expected to remain prevalent cases at older ages. This explains
the shift to the right in the picture of prevalent non-fatal burden (Figure 3.7) compared to
incident non-fatal burden (Figure 3.6).
The rate of prevalent burden was lowest in children between 1 and 4 years of age (15 PYLD
per thousand) and increased to 147 in people aged 65 to 69 years and then to 415 per
thousand in people over the age of 95. In other words, disability from all diseases and
injuries resulted in a loss of 1.5% of healthy time lived by young children, increasing with
age to 14.7% in those 65 to 69 years and 41.5% in the very old.
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Figure 3.7: Prevalent non-fatal burden (PYLD) by age expressed as: (a) rates by sex, and
(b) numbers by broad cause group, Australia, 2003
3.4 Age and sex patterns
In this section, the size and composition of burden is reported by five broad age groups
(Table 3.5).
Table 3.5: Distribution of population and burden (DALYs) by five broad age groups, Australia,
2003
Age group Population (a)
Per cent
of total  DALYs
Per cent
of total
0–14 years 3,979,410 20.0  221,536 8.4
15–44 years 8,622,610 43.4  633,260 24.1
45–64 years 4,733,808 23.8  681,566 25.9
65–74 years 1,349,949 6.8  428,904 16.3
75 years and over 1,195,692 6.0  667,504 25.4
Total 19,881,469 100.0  2,632,770 100.0
 (a) Estimated resident population figures as at 30 June 2003 (ABS cat. no. 3201.0).
Children aged 0–14 years
Children aged 0–14 years comprised 20.0% of the total population and experienced 8.4% of
the total burden of disease and injury in Australia in 2003 (Table 3.5). Twenty-three per cent
of this burden was due to mental disorders (that is anxiety & depression, attention-deficit
hyperactivity disorder and autism spectrum disorders), 18% due to chronic respiratory
conditions (mostly asthma) and 16% due to neonatal conditions. Less than a quarter of the
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burden was due to mortality (Figure 3.8). Males experienced 56% of the burden in this age
group.
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Figure 3.8: Burden (DALYs) in 0–14 year olds by broad cause group expressed as: (a) proportions
of total, (b) proportions by sex, and (c) proportions due to fatal and non-fatal outcomes, Australia,
2003
Asthma was the leading cause of burden for both males and females (Table 3.6). This was
followed by autism spectrum disorders, anxiety & depression, and low birth weight in
males. In females, anxiety & depression, low birth weight and birth trauma & asphyxia were
the next leading causes. The leading 10 causes of burden accounted for 58.7% of the total
burden in this age group.
Table 3.6: Leading causes of DALYs in 0–14 year olds by sex, Australia, 2003
Rank Males DALYs
Per cent
of total Females DALYs
Per cent
of total
1 Asthma  21,953 17.6 Asthma  16,490 17.0
2 Autism spectrum disorders  11,703 9.4 Anxiety & depression  15,507 16.0
3 Anxiety & depression  9,554 7.7 Low birth weight  7,142 7.4
4 Low birth weight  8,281 6.6 Birth trauma & asphyxia  4,221 4.4
5
Attention-deficit hyperactivity
disorder  7,082 5.7
Attention-deficit hyperactivity
disorder  2,840 2.9
6 Birth trauma and asphyxia  5,086 4.1 Epilepsy  2,446 2.5
7 Congenital heart disease  3,434 2.8 Congenital heart disease  2,202 2.3
8 Epilepsy  3,249 2.6 Autism spectrum disorders  2,056 2.1
9 Neonatal infections  2,156 1.7 Otitis media  1,377 1.4
10 Road traffic accidents  1,991 1.6 Road traffic accidents  1,336 1.4
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Older children and adults aged 15–44 years
Older children and adults aged 15–44 years comprised 43.4% of the total population and
experienced 24.1% of the total burden of disease and injury in Australia in 2003 (Table 3.5).
Over a third of the total burden in this age group was attributable to mental disorders, and
another 17% was due to injuries (Figure 3.9). There were considerable sex differences in this
age group, with females experiencing a greater share of the burden from neurological
disorders, chronic respiratory diseases, cancers and mental disorders than males. Males, on
the other hand, experienced more than three-quarters of the injury burden, partly because of
their greater inclination for risk taking. Overall, 29% of the burden in this age group was due
to mortality.
Mental
InjuriesCancer
Neuro-
logical
Cardio-
vascular
Chronic
respiratory
Other
36%
17%7%
7%
5%
5%
23%
Total
Injuries
Cardiovascular
Mental
Cancer
Chronic respiratory
Neurological
51%
78%
64%
45%
43%
43%
41%
49%
22%
36%
55%
57%
57%
59%
FemalesMales
Total
Injuries
Cancer
Cardiovascular
Neurological
Chronic respiratory
Mental
29%
80%
77%
63%
16%
10%
4%
71%
20%
23%
37%
84%
90%
96%
Non-fatalFatal
Figure 3.9: Burden (DALYs) in 15–44 year olds by broad cause group expressed as: (a) proportions
of total, (b) proportions by sex, and (c) proportions due to fatal and non-fatal outcomes, Australia,
2003
Anxiety & depression was by far the leading single cause of burden in both males and
females, followed by suicide & self-inflicted injuries and road traffic accidents in males, and
migraine and Type 2 diabetes in females (Table 3.7). Mental disorders made up half of the
top 10 leading causes of burden in males and three of the top 10 leading causes of burden in
females. The leading 10 ranked conditions accounted for 54.8% of the burden in this age
group.
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Table 3.7: Leading causes of DALYs in 15–44 year olds by sex, Australia, 2003
Rank Males DALYs
Per cent
of total Females DALYs
Per cent
of total
1 Anxiety & depression  42,237 13.0 Anxiety & depression  84,717 27.4
2 Suicide & self-inflicted injuries  27,592 8.5 Migraine  14,105 4.6
3 Road traffic accidents  22,845 7.1 Type 2 diabetes  12,487 4.0
4 Schizophrenia  14,376 4.4 Asthma  11,311 3.7
5 Alcohol abuse  13,953 4.3 Schizophrenia  11,064 3.6
6 Type 2 diabetes  12,868 4.0 Personality disorders  9,389 3.0
7 Heroin abuse  11,882 3.7 Breast cancer  9,068 2.9
8 Personality disorders  10,526 3.2 Infertility  8,057 2.6
9 Ischaemic heart disease  9,750 3.0 Suicide & self-inflicted injuries  7,174 2.3
10 COPD  6,840 2.1 Road traffic accidents  6,751 2.2
Adults aged 45–64 years
Adults aged 45–64 years comprised 23.8% of the total population and experienced 25.9% of
the total burden of disease and injury in Australia in 2003 (Table 3.5). Cancer, cardiovascular
disease and neurological disorders accounted for more than half of the total burden in this
age group. Males experienced a greater share of the burden than females for all causes except
mental disorders and musculoskeletal disorders (Figure 3.10). Overall, 49% of the burden in
this age group was due to mortality.
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Figure 3.10: Burden (DALYs) in 45–64 year olds by broad cause group expressed as:
(a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and
non-fatal outcomes, Australia, 2003
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Ischaemic heart disease was the leading cause of burden in males, followed by Type 2
diabetes and lung cancer (Table 3.8). In females, the top three causes were breast cancer,
anxiety & depression and Type 2 diabetes. The top 10 conditions accounted for 52.0% of total
burden in this age group.
Table 3.8: Leading causes of DALYs in 45–64 year olds by sex, Australia, 2003
Rank Males DALYs
Per cent
of total Females DALYs
Per cent
of total
1 Ischaemic heart disease  47,782 12.5 Breast cancer  32,012 10.7
2 Type 2 diabetes  32,741 8.6 Anxiety & depression  25,744 8.6
3 Lung cancer  20,861 5.5 Type 2 diabetes  22,299 7.5
4 Adult-onset hearing loss  20,847 5.5 Ischaemic heart disease  17,489 5.8
5 COPD  15,389 4.0 Lung cancer  13,475 4.5
6 Colorectal cancer  14,130 3.7 Adult-onset hearing loss  10,576 3.5
7 Stroke  13,800 3.6 COPD  10,422 3.5
8 Anxiety & depression  11,757 3.1 Colorectal cancer  9,808 3.3
9 Alcohol abuse  10,077 2.6 Stroke  9,693 3.2
10 Prostate cancer  8,953 2.3 Back pain  6,620 2.2
Adults aged 65–74 years
Adults aged 65–74 years comprised 6.8% of the total population and experienced 16.3% of
the total burden of disease and injury in Australia in 2003 (Table 3.5). Cancer and
cardiovascular disease accounted for over half of the total burden in this age group (Figure
3.11). Females experienced a greater share of the burden than males from musculoskeletal
conditions, while the reverse was true for all other broad cause groups. Overall, 60% of the
burden in this age group was due to mortality.
52
Cancer
Cardio-
vascular
Neuro-
logical
Chronic
respiratory
Diabetes
Musculo-
skeletal
Other
31%
23%15%
7%
6%
5%
14% Total
Cardiovascular
Cancer
Chronic respiratory
Diabetes
Neurological
Musculoskeletal
57%
61%
59%
56%
56%
52%
42%
43%
39%
41%
44%
44%
48%
58%
FemalesMales
Total
Cancer
Cardiovascular
Chronic respiratory
Diabetes
Neurological
Musculoskeletal
60%
83%
76%
61%
35%
13%
9%
40%
17%
24%
39%
65%
87%
91%
Non-fatalFatal
Figure 3.11: Burden (DALYs) in 65–74 year olds by broad cause group expressed as:
(a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and
non-fatal outcomes, Australia, 2003
Ischaemic heart disease, lung cancer and Type 2 diabetes were the leading causes of burden
in males, together accounting for 29% of total male burden (Table 3.9). In females, ischaemic
heart disease, Type 2 diabetes and breast cancer were the leading causes, accounting for 23%
of total burden. The top 10 conditions accounted for 56.3% of total burden in this age group.
Table 3.9: Leading causes of DALYs in 65–74 year olds by sex, Australia, 2003
Rank Males DALYs
Per cent
of total Females DALYs
Per cent
of total
1 Ischaemic heart disease  37,860 15.5 Ischaemic heart disease  21,052 11.4
2 Lung cancer  19,258 7.9 Type 2 diabetes  11,517 6.2
3 Type 2 diabetes  14,203 5.8 Breast cancer  10,445 5.7
4 Prostate cancer  11,950 4.9 Dementia  10,236 5.5
5 Adult-onset hearing loss  11,920 4.9 Lung cancer  9,937 5.4
6 COPD  11,693 4.8 Stroke  9,635 5.2
7 Stroke  10,938 4.5 COPD  8,855 4.8
8 Colorectal cancer  10,531 4.3 Colorectal cancer  7,513 4.1
9 Dementia  7,872 3.2 Osteoarthritis  6,088 3.3
10 Parkinson’s disease  3,958 1.6 Adult-onset hearing loss  5,834 3.2
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Older people aged 75 years and over
Older people aged 75 years and over comprised 6.0% of the total population and experienced
25.4% of the total burden of disease and injury in Australia in 2003 (Table 3.5).
Cardiovascular disease and cancer accounted for over half of the total burden in this age
group (Figure 3.12). Females experienced a greater share of the burden than males overall
and for all broad cause groups except chronic respiratory diseases and cancer. Overall, 68%
of the burden in this age group was due to mortality.
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Figure 3.12: Burden (DALYs) in those aged 75 years and over by broad cause group expressed
as: (a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-
fatal outcomes, Australia, 2003
Ischaemic heart disease, stroke and dementia were the leading causes of burden in males,
together accounting for 34% of total male burden (Table 3.10). In females, ischaemic heart
disease, dementia and stroke were the leading causes, accounting for 42% of total burden.
The top 10 conditions account for 60.9% of the total burden in this age group.
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Table 3.10: Leading causes of DALYs in those aged 75 years and over by sex, Australia, 2003
Rank Males DALYs
Per cent
of total Females DALYs
Per cent
of total
1 Ischaemic heart disease  55,680 19.3 Ischaemic heart disease  70,853 18.7
2 Stroke  21,834 7.5 Dementia  46,984 12.4
3 Dementia  21,095 7.3 Stroke  39,830 10.5
4 Prostate cancer  15,484 5.4 Type 2 diabetes  15,330 4.1
5 COPD  14,900 5.2 COPD  13,318 3.5
6 Lung cancer  13,533 4.7 Colorectal cancer  9,703 2.6
7 Type 2 diabetes  11,262 3.9 Lower respiratory tract infections  9,137 2.4
8 Colorectal cancer  8,442 2.9 Lung cancer  9,059 2.4
9 Adult-onset hearing loss  7,052 2.4 Breast cancer  8,995 2.4
10 Lower respiratory tract infections  6,395 2.2 Falls  7,814 2.1
3.5 Specific disease and injury categories
This section presents burden by 22 broad cause groupings (Table 3.11) and discusses the
eight largest of these in greater detail. The section ends with a short discussion on three
conditions (renal failure, vision loss and intellectual disability), the burden from which in the
previous sections is split across multiple subheadings depending on aetiology. However,
from a health service planning perspective there is value in presenting the aggregates for
these conditions.
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Table 3.11: Burden (YLD, YLL and DALYs) by broad cause group, Australia, 2003
Cause YLD
Per cent
of total YLL
Per cent
of total  DALYs
Per cent
of total
Cancers  87,463 6.5  411,953 32.2  499,416 19.0
Cardiovascular disease  104,429 7.7 369,365 28.9  473,794 18.0
Mental disorders  327,391 24.2 23,154 1.8  350,545 13.3
Neurological & sense disorders  258,638 19.1 54,127 4.2  312,766 11.9
Chronic respiratory diseases  115,398 8.5 71,339 5.6  186,737 7.1
Diabetes mellitus  111,536 8.2 32,295 2.5  143,831 5.5
Unintentional injuries  41,263 3.0 84,599 6.6  125,862 4.8
Musculoskeletal diseases  98,481 7.3 7,027 0.5  105,508 4.0
Genitourinary diseases  41,161 3.0 24,087 1.9  65,249 2.5
Intentional injuries  3,139 0.2 56,050 4.4  59,189 2.2
Diseases of the digestive system  30,246 2.2 27,710 2.2  57,957 2.2
Infectious & parasitic diseases  14,021 1.0 30,665 2.4  44,685 1.7
Acute respiratory infections  11,752 0.9 23,750 1.9  35,502 1.3
Neonatal causes  15,584 1.2 18,974 1.5  34,558 1.3
Congenital anomalies  16,331 1.2 16,897 1.3  33,228 1.3
Endocrine & metabolic disorders  14,968 1.1 13,598 1.1  28,565 1.1
Oral conditions  24,406 1.8 102 0.0  24,507 0.9
Skin diseases  18,130 1.3 2,173 0.2  20,302 0.8
Ill-defined conditions  8,781 0.6  2,536 0.2  11,317 0.4
Non-malignant neoplasms  3,209 0.2 7,694 0.6  10,903 0.4
Nutritional deficiencies  5,739 0.4 458 0.0  6,197 0.2
Maternal conditions  1,926 0.1 226 0.0  2,152 0.1
Total burden  1,353,992 100.0  1,278,778 100.0  2,632,770 100.0
Cancers
Cancer was responsible for 19.0% of the total burden of disease and injury in Australia in
2003 (Table 3.11), with lung, colorectal, breast and prostate cancer accounting for half of this
burden (Figure 3.13). Apart from the sex-specific cancers (that is, breast, cervical and uterine
cancers in females and prostate cancer in males), there were considerable sex differences in
the experience of cancer burden, with males having a greater share of the burden from
melanoma, colorectal cancer, lymphomas and lung cancer than females. The difference in
lung cancer between males and females was largely due to the higher prevalence of smoking
in males than females two or more decades ago. More than four-fifths of the total cancer
burden was due to mortality.
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Figure 3.13: Cancer burden (DALYs) by specific cause expressed as: (a) proportions of
total, (b) proportions by sex, and (c) proportions due to fatal and non-fatal outcomes,
Australia, 2003
Total cancer burden, both in absolute terms and when expressed as a rate per head of
population, increased exponentially until age 75, then declined (Figure 3.14). The
contribution from lung cancer was greatest at this age after which it declined in proportion
to other cancers. In males, the contribution from prostate cancer increased until old age,
whereas in females the contribution from breast cancer increased until age 60, then declined
in proportion to other cancers. The contribution from colorectal cancer was important across
all ages.
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Total cancer burden, both in absolute terms and when expressed as a rate per head of
population, increased exponentially until age 75, then declined (Figure 3.14). The
contribution from lung cancer was greatest at this age after which it declined in proportion
to other cancers. In males, the contribution from prostate cancer increased until old age,
whereas in females the contribution from breast cancer increased until age 60, then declined
in proportion to other cancers. The contribution from colorectal cancer was important across
all ages.
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Figure 3.14: Cancer burden (DALYs) by age expressed as: (a) rates by sex, and (b) numbers by
specific cause, Australia, 2003
Lung cancer was the fourth leading cause of overall burden in males, while prostate and
colorectal cancers were the ninth and tenth, respectively.  Breast cancer was the sixth leading
cause of overall burden in females, while lung cancer and colorectal cancer were eighth and
tenth, respectively (Table 3.1). Although cancer of the cervix was not a leading cause of death
in females, it is a cancer priority area because it is one of the few cancers where pre-
cancerous lesions can and have been cost-effectively detected and treated through an
organised screening program. Moreover, a vaccine against human papilloma virus has
become available that has the potential to further reduce the burden of cervical cancer over
time. This illustrates that burden information should be used with other evidence to
determine health service priorities.
Table 3.12: Cancer burden (YLD, YLL and DALYs) by specific cause, Australia, 2003
Cause YLD
Per cent
of total  YLL
Per cent
of total DALYs
Per cent
of total
Lung cancer 5,848 0.4  83,056 6.5 88,904 3.4
Colorectal cancer 11,873 0.9  51,732 4.0 63,605 2.4
Breast cancer 20,440 1.5  40,214 3.1 60,654 2.3
Prostate cancer 13,372 1.0  23,175 1.8 36,547 1.4
Pancreas cancer  561 0.0  22,119 1.7 22,680 0.9
Lymphoma 3,465 0.3  18,798 1.5 22,263 0.8
Other 31,905 2.4  172,859 13.5 204,763 7.8
Total cancer burden 87,463 6.5  411,953 32.2 499,416 19.0
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Cardiovascular disease
Cardiovascular disease were responsible for 18.0% the total burden of disease and injury in
Australia in 2003 (Table 3.11), with ischaemic heart disease and stroke accounting for over
four-fifths of this burden (Figure 3.15). These diseases were also in the five leading causes of
overall burden (Table 3.1). The contribution from ischaemic heart disease was greater in
males than in females, while the reverse was the case for stroke. Nearly four-fifths of total
cardiovascular burden was due to mortality.
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Figure 3.15: Cardiovascular burden (DALYs) by specific cause expressed as: (a) proportions
of total, (b) proportions by sex, and (c) proportions due to fatal and non-fatal outcomes,
Australia, 2003
In contrast to cancer, the total cardiovascular burden per head of population continued
increasing until old age. This resulted in a larger proportion of the absolute burden at older
ages than for cancer (Figure 3.16). Ischaemic heart disease dominated across all ages.
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In contrast to cancer, the total cardiovascular burden per head of population continued
increasing until old age. This resulted in a larger proportion of the absolute burden at older
ages than for cancer (Figure 3.16). Ischaemic heart disease dominated across all ages.
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Figure 3.16: Cardiovascular burden (DALYs) by age expressed as: (a) rates by sex, and
(b) numbers by specific cause, Australia, 2003
Table 3.13: Cardiovascular burden (YLD, YLL and DALYs) by specific cause, Australia, 2003
Cause YLD
Per cent
of total YLL
Per cent
of total  DALYs
Per cent
of total
Ischaemic heart disease 45,354 3.3  218,143 17.1 263,497 10.0
Stroke 33,763 2.5  84,699 6.6 118,462 4.5
Peripheral vascular disease 12,888 1.0  5,718 0.4 18,606 0.7
Inflammatory heart disease 3,689 0.3  12,215 1.0 15,904 0.6
Aortic aneurysm  209 0.0  11,129 0.9 11,338 0.4
Hypertensive heart disease  678 0.1  8,303 0.6 8,982 0.3
Other 7,848 0.6  29,157 2.3 37,005 1.4
Total cardiovascular burden 104,429 7.7  369,365 28.9 473,794 18.0
Mental disorders
Mental disorders were responsible for 13.3% of the total burden of disease and injury in
Australia in 2003 (Table 3.11), with anxiety & depression, alcohol abuse and personality
disorders accounting for almost three-quarters of this burden (Figure 3.17).  There were
marked sex differences in the mental illness burden for particular disorders. The burden
from anxiety & depression was twice as high for females as for males. Conversely, the
burden from substance abuse was more than three times as high in males as in females.
Eating disorders occurred mainly in females. Autism spectrum disorders were much more
common in males, with females having just 15% of the total burden from these conditions.
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Seven per cent of the burden from mental disorders was due to mortality, most of which was
accounted for by fatal outcomes associated with substance abuse.
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Figure 3.17: Mental disorder burden (DALYs) by specific cause expressed as: (a) proportions of
total, (b) proportions by sex, and (c) proportions due to fatal and non-fatal outcomes, Australia,
2003
The burden from mental disorders both in absolute terms and when expressed as a rate per
head of population was greater in early adulthood than at other ages (Figure 3.18). This was
partly due to the peak in new cases of chronic mental illnesses at this life stage, the burden of
which was experienced throughout adult life. Anxiety & depression contributed most until
age 60, after which the contribution from alcohol abuse and personality disorders was more
prominent.
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Figure 3.18: Mental disorder burden (DALYs) by age expressed as: (a) rates by sex, and
(b) numbers by specific cause, Australia, 2003
In males, anxiety & depression was the third leading cause of overall male burden, while
alcohol abuse was the fourteenth. In females, anxiety & depression was the leading cause of
overall female burden, while isolated personality disorders was the thirteenth (Table 3.1).
Anxiety & depression also carries with it an increased risk of ischaemic heart disease and
suicide. When this risk was accounted for, the burden attributable to anxiety & depression
increased from 7.3% to 8.2% of total burden (Table 3.14). The contribution of other mental
disorders to the burden of suicide follows in the section on injuries.
Table 3.14: Mental disorder burden (YLD, YLL and DALYs) by specific cause, Australia, 2003
Cause YLD
Per cent
of total  YLL
Per cent
of total DALYs
Per cent
of total
Anxiety & depression 191,452 14.1 334 0.0 191,786 7.3
Alcohol abuse 19,861 1.5 14,255 1.1 34,116 1.3
Personality disorders 32,587 2.4 — 0.0 32,587 1.2
Schizophrenia 27,250 2.0 252 0.0 27,502 1.0
Heroin or polydrug abuse 10,287 0.8 6,552 0.5 16,839 0.6
Autism spectrum disorders 13,756 1.0 110 0.0 13,866 0.5
Other 32,198 2.4 1,652 0.1 33,850 1.3
Total mental disorder burden 327,391 24.2 23,154 1.8 350,545 13.3
Ischaemic heart disease attributable to
anxiety & depression 1,399 0.1% 5,689 0.4% 7,088 0.3%
Suicide attributable to anxiety & depression 200 0.0% 16,708 1.3% 16,908 0.6%
Total burden attributable to anxiety &
depression 193,051 14.3% 22,731 1.8% 8.2%215,783
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Neurological and sense disorders
Neurological & sense disorders were responsible for 11.9% of the total burden of disease and
injury in Australia in 2003 (Table 3.11), with dementia, adult-onset hearing loss and vision
loss accounting for two-thirds of this burden (Figure 3.19). There were marked sex
differentials in the attribution of the neurological & sense disorder burden to particular
conditions. Females contributed three times as much to migraine and twice as much to
dementia than males. Conversely, the burden from hearing loss was twice as high in males
as in females. The greater preponderance of burden from dementia and vision disorders in
females was largely due to higher life expectancy in females than males. Only 17% of the
burden from neurological & sense disorders was due to mortality.
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Figure 3.19: Neurological & sense disorder burden (DALYs) by specific cause expressed
as: (a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and
non-fatal outcomes, Australia, 2003
The burden from neurological & sense disorders, both in absolute terms and when expressed
as a rate per head of population, increased with age, with a small but important peak in early
adulthood due to the contribution of migraine (Figure 3.20). The contribution from dementia
increased from middle age to more than half the burden in the elderly and was more
pronounced in females than in males. Conversely, the contribution from hearing loss
decreased with age and was more pronounced in males than in females. Vision loss made a
smaller but important contribution across all ages.
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Figure 3.19: Neurological & sense disorder burden (DALYs) by specific cause expressed
as: (a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and
non-fatal outcomes, Australia, 2003
The burden from neurological & sense disorders, both in absolute terms and when expressed
as a rate per head of population, increased with age, with a small but important peak in early
adulthood due to the contribution of migraine (Figure 3.20). The contribution from dementia
increased from middle age to more than half the burden in the elderly and was more
pronounced in females than in males. Conversely, the contribution from hearing loss
decreased with age and was more pronounced in males than in females. Vision loss made a
smaller but important contribution across all ages.
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Figure 3.20: Neurological & sense disorder burden (DALYs) by age expressed as: (a) rates by sex,
and (b) numbers by specific cause, Australia, 2003
Adult-onset hearing loss, dementia and Parkinson’s disease were the seventh, eleventh and
twentieth leading causes of overall male burden. In females, dementia was ranked the fifth
leading cause of overall female burden, with hearing loss, migraine and Parkinson’s disease
ranked eleventh, fourteenth and eighteenth (Table 3.1).
Table 3.15: Neurological & sense disorder burden (YLD, YLL and DALYs) by specific cause,
Australia, 2003
Cause YLD
Per cent
of total YLL
Per cent
of total  DALYs
Per cent
of total
Dementia 70,296 5.2  24,103 1.9 94,399 3.6
Adult-onset hearing loss 64,853 4.8  0 0.0 64,853 2.5
Vision loss 47,865 3.5  9 0.0 47,875 1.8
Parkinson’s disease 21,157 1.6  5,695 0.4 26,852 1.0
Migraine 21,841 1.6  7 0.0 21,848 0.8
Epilepsy 8,601 0.6  6,220 0.5 14,821 0.6
Other 24,025 1.8  18,092 1.4 42,118 1.6
Total neurological & sense
disorder burden 258,638 19.1  54,127 4.2 312,766 11.9
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Chronic respiratory diseases
Chronic respiratory diseases were responsible for 7.1% of total burden of disease and injury
in Australia in 2003 (Table 3.11), with chronic obstructive pulmonary disease and asthma
accounting for 46% and 34% of this burden, respectively (Figure 3.21). Males had a greater
share of chronic obstructive pulmonary disease burden than females because of the greater
prevalence of smoking in males 20 to 30 years ago. Fifty-four per cent of the burden from
chronic obstructive pulmonary disease was due to mortality, whereas only 6% of the asthma
burden was due to mortality.
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Figure 3.21: Chronic respiratory disease burden (DALYs) by specific cause expressed as:
(a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-
fatal outcomes, Australia, 2003
The burden from chronic respiratory diseases per head of population in both sexes was
higher in childhood than in middle age, after which it increased exponentially (Figure 3.22).
This was due to the high incidence of asthma in childhood, particularly in boys, and then
remission as the body matures. Chronic obstructive pulmonary disease, largely from
smoking, was the leading cause of chronic respiratory disease burden from middle age
onwards.
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The burden from chronic respiratory diseases per head of population in both sexes was
higher in childhood than in middle age, after which it increased exponentially (Figure 3.22).
This was due to the high incidence of asthma in childhood, particularly in boys, and then
remission as the body matures. Chronic obstructive pulmonary disease, largely from
smoking, was the leading cause of chronic respiratory disease burden from middle age
onwards.
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Figure 3.22: Chronic respiratory disease burden (DALYs) by age expressed as: (a) rates by sex,
and (b) numbers by specific cause, Australia, 2003
Chronic obstructive pulmonary disease was the sixth leading cause of overall male burden,
with asthma at thirteenth. In females, these conditions were ranked seventh and ninth in the
leading causes of overall female burden, respectively (Table 3.1).
Table 3.16: Chronic respiratory disease burden (YLD, YLL and DALYs) by specific cause,
Australia, 2003
Cause YLD
Per cent
of total YLL
Per cent
of total  DALYs
Per cent
of total
COPD 39,543 2.9 47,208 3.7  86,751 3.3
Asthma 59,054 4.4 4,045 0.3  63,100 2.4
Other 16,801 1.2 20,086 1.6  36,887 1.4
Total chronic respiratory disease
burden 115,398 8.5 71,339 5.6  186,737 7.1
Injuries
Injuries were responsible for 7.0% of the total burden of disease and injury in Australia in
2003 (Table 3.11), with suicide & self-inflicted injuries, road traffic accidents and falls
accounting for nearly two-thirds of this burden (Figure 3.23). The burden in males was
greater than females for most causes of injury. Males accounted for 73% of the burden due to
road traffic accidents and 78% for suicide & self-inflicted injuries. The burden from falls, on
the other hand, was equally distributed amongst males and females. Seventy-six per cent of
the overall injury burden was due to mortality.
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Figure 3.23: Injury burden (DALYs) by specific cause expressed as: (a) proportions of total,
(b) proportions by sex, and (c) proportions due to fatal and non-fatal outcomes, Australia,
2003
The injury burden in males was greater in early adulthood than at other ages, both in
absolute terms and when expressed as a rate per head of population (Figure 3.24). For
females, the absolute burden was greatest in the very young, while the rate increased with
age from a third of the male rate at early adulthood to similar levels at old age. The peak in
absolute burden in early adulthood was due to the high mortality from road traffic accidents
and suicide at this life stage. The distribution of injury burden by cause was similar between
males and females at all ages.
In males, suicide & self-inflicted injuries and road traffic accidents were the eighth and
twelfth leading cause of overall male burden. In females, only falls were in the 20 leading
causes of overall female burden at seventeenth (Table 3.1).
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Figure 3.24: Injury burden (DALYs) by age expressed as: (a) rates by sex, and (b) numbers by
specific cause, Australia, 2003
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The injury burden in males was greater in early adulthood than at other ages, both in
absolute terms and when expressed as a rate per head of population (Figure 3.24). For
females, the absolute burden was greatest in the very young, while the rate increased with
age from a third of the male rate at early adulthood to similar levels at old age. The peak in
absolute burden in early adulthood was due to the high mortality from road traffic accidents
and suicide at this life stage. The distribution of injury burden by cause was similar between
males and females at all ages.
In males, suicide & self-inflicted injuries and road traffic accidents were the eighth and
twelfth leading cause of overall male burden. In females, only falls were in the 20 leading
causes of overall female burden at seventeenth (Table 3.1).
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Figure 3.24: Injury burden (DALYs) by age expressed as: (a) rates by sex, and (b) numbers by
specific cause, Australia, 2003
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Suicide & self-inflicted injuries were responsible for 27% of the total injury burden in
Australia in 2003 (Figure 3.23), with anxiety & depression and alcohol abuse accounting for
nearly three-quarters of this burden (Figure 3.25). The burden in males was greater than in
females for all major causes of suicide & self-inflicted injury.
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Figure 3.25: Suicide burden (DALYs) by specific cause expressed as: (a) proportions of total,
(b) proportions by sex, and (c) proportions due to fatal and non-fatal outcomes, Australia, 2003
Table 3.17: Injury burden (YLD, YLL and DALYs) by specific cause, Australia, 2003
Cause YLD
Per cent
of total YLL
Per cent
of total  DALYs
Per cent
of total
Suicide & self-inflicted injuries  537 0.0  49,379 3.9 49,916 1.9
Road traffic accidents 6,073 0.4  36,352 2.8 42,425 1.6
Falls 13,995 1.0  12,391 1.0 26,386 1.0
Poisoning  326 0.0  11,720 0.9 12,046 0.5
Homicide & violence 2,597 0.2  6,624 0.5 9,221 0.4
Other transport accidents 2,873 0.2  5,728 0.4 8,601 0.3
Other 18,001 1.3  18,454 1.4 36,454 1.4
Total injury burden 44,402 3.3  140,648 11.0 185,050 7.0
Diabetes
Diabetes was responsible for 5.5% of the total burden of disease and injury in Australia in
2003 (Table 3.11), with Type 2 diabetes accounting for 92% of this burden. Eighty-five per
cent of the total diabetes burden was due to diabetes per se (that is, the experience of being
diabetic regardless of complications), with the remainder being due to complications such as
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neuropathy, peripheral vascular disease (PVD), and diabetic foot (Figure 3.26). Twenty-two
per cent of the total diabetes burden was due to mortality.
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Figure 3.26: Diabetes burden (DALYs) by specific cause expressed as: (a) proportions of
total, (b) proportions by sex, and (c) proportions due to fatal and non-fatal outcomes
The risk of burden from diabetes in both sexes increased linearly until age 85 then declined
(Figure 3.27). The contribution from diabetes per se dominated at all ages. Diabetes ranked
second and fourth in the 20 leading causes of burden for males and females, respectively
(Table 3.1).
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Figure 3.27: Diabetes burden (DALYs) by age expressed as: (a) rates by sex, and (b) numbers by
specific cause, Australia, 2003
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(Figure 3.27). The contribution from diabetes per se dominated at all ages. Diabetes ranked
second and fourth in the 20 leading causes of burden for males and females, respectively
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Figure 3.27: Diabetes burden (DALYs) by age expressed as: (a) rates by sex, and (b) numbers by
specific cause, Australia, 2003
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Diabetes also carries with it an increased risk of ischaemic heart disease and stroke. When
this risk was accounted for, the burden attributable to diabetes increased to 8.3% of total
burden (Table 3.18).
Table 3.18: Diabetes burden (YLD, YLL and DALYs) by specific cause, Australia, 2003
Cause YLD
Per cent
of total YLL
Per cent
of total  DALYs
Per cent
of total
Diabetes per se 89,252 6.6  32,295 2.5  121,547 4.6
Neuropathy  6,500 0.5  — 0.0  6,500 0.2
Peripheral vascular disease  5,917 0.4  — 0.0  5,917 0.2
Diabetic foot  3,672 0.3  — 0.0  3,672 0.1
Amputation  2,455 0.2  — 0.0  2,455 0.1
Retinopathy  1,258 0.1  — 0.0  1,258 0.0
Other(a)  2,483 0.2  — 0.0  2,483 0.1
Total diabetes burden  111,536 8.2  32,295 2.5  143,831 5.5
Ischaemic heart disease
attributable to diabetes 8,494 0.6  45,948 3.6 54,442 2.1
Stroke attributable to diabetes 3,985 0.3  16,260 1.3 20,245 0.8
Total burden attributable to
diabetes 124,015 9.2  94,503 7.4 218,518 8.3
 (a)  Includes renal failure.
Musculoskeletal diseases
Musculoskeletal diseases were responsible for 4.0% of the total burden of burden and injury
in Australia in 2003 (Table 3.11), with osteoarthritis, back pain and rheumatoid arthritis
accounting for over three-quarters of this burden (Figure 3.28). Only 7% of the
musculoskeletal burden was due to mortality. The sex difference evident in the burden due
to osteoarthritis and rheumatoid arthritis was mainly a result of the higher female life
expectancy, which in turn allowed for more incident cases of this disease. The lack of a
plausible physiological or occupational explanation for the large sex difference in burden
from occupational overuse syndrome (OOS) provides support to the notion that this
syndrome is not a single entity.
The risk of burden from musculoskeletal diseases in both sexes increased until age 80 then
declined (Figure 3.29). The contribution of back pain was relatively constant until age 70 then
declined in proportion to the contribution from osteoarthritis.
Osteoarthritis and back pain conditions ranked seventeenth and eighteenth in the 20 leading
causes of burden for males, and twelfth and fifteenth for females (Table 3.1).
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Figure 3.28: Musculoskeletal disease burden (DALYs) by specific cause expressed as:
(a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and
non-fatal outcomes, Australia, 2003
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Figure 3.29: Musculoskeletal disease burden (DALYs) by age expressed as: (a) rates by sex, and
(b) numbers by specific cause, Australia, 2003
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Table 3.19: Musculoskeletal disease burden (YLD, YLL and DALYs) by specific cause, Australia,
2003
Cause YLD
Per cent
of total YLL
Per cent
of total  DALYs
Per cent
of total
Osteoarthritis 34,204 2.5  374 0.0 34,578 1.3
Back pain 29,484 2.2  173 0.0 29,658 1.1
Rheumatoid arthritis 15,215 1.1  1,626 0.1 16,841 0.6
Slipped disc 6,089 0.4  31 0.0 6,120 0.2
Occupational overuse syndrome 4,953 0.4  — 0.0 4,953 0.2
Gout 1,813 0.1  175 0.0 1,988 0.1
Other 6,722 0.5  4,647 0.4 11,369 0.4
Total musculoskeletal disease
burden 98,481 7.3  7,027 0.5 105,508 4.0
Alternative categories for selected conditions
The burden from intellectual disability, renal failure and vision disorders was attributed to
multiple underlying causes in the primary listing of diseases and injuries and is therefore not
discussed explicitly in the above sections. The burden from intellectual disability, apart from
congenital conditions (for example Down syndrome), was divided among epilepsy, autism
spectrum disorders, infectious diseases, injuries, and perinatal conditions. The burden from
renal failure was divided among diabetic nephropathy, the injury category of medical
misadventure (analgesic nephropathy), and congenital conditions (dysplasia, polycystic
kidneys). The burden from total vision loss was divided among diabetic retinopathy,
glaucoma, cataract, refraction errors, age-related macular degeneration and other causes of
vision loss. The total burden from intellectual disability, renal failure and total vision loss
after re-aggregation was 1.7%, 2.6% and 2.1%, respectively (Table 3.20).
Table 3.20: Aggregated burden (YLD, YLL and DALYs) for selected conditions, Australia, 2003
Cause YLD
Per cent
of total  YLL
Per cent
of total DALYs
Per cent
of total
Intellectual disability 20,999 1.6  23,189 1.8 44,187 1.7
Renal failure 3,809 0.3 64,912 5.1 68,721 2.6
Total vision loss 50,671 3.7 4,868 0.4 55,539 2.1
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4 Risks to health in Australia
4.1 Overview
This chapter discusses the contribution of a number of health risks to the burden of disease
and injury in Australia for 2003. The analyses are not meant to be comprehensive since
choices had to be made about which risks to include on the basis of the availability of the
following:
1. Good evidence of a causal association between the exposure to the risk and the health
outcomes
2. Current estimates from reputable epidemiological studies of the relative risk involved
3. Reliable estimates of exposure in the Australian population to the health risk.
The outcome of these considerations was a set of 14 selected health risks as outlined in Table
4.1. Several important dietary factors were considered for inclusion (for example sodium and
saturated fat) as part of these deliberations, but were ultimately excluded due to inadequate
data on exposure. With the exception of low fruit and vegetable consumption, therefore, the
impact of ‘poor diet’ is measured indirectly through the assessments for high body mass,
blood cholesterol and blood pressure. Similarly, lack of data on prevalence and outcome
prevented estimation of the burden of intimate partner violence in males.
Table 4.1: Fourteen selected risks to health discussed in this report
Lifestyle behaviours Physiological states Social and environmental factors
1. Tobacco 7. High body mass 11. Urban air pollution
2. Alcohol 8. High blood pressure 12. Intimate partner violence
3. Physical inactivity 9. High blood cholesterol 13. Child sexual abuse
4. Illicit drugs 10. Osteoporosis 14. Occupational exposures & hazards
5. Low fruit and vegetable consumption
6. Unsafe sex
It is important to remember several points when interpreting the results in the following
sections.
Firstly, health risks tend to cluster around ‘high risk’ individuals who experience more than
one exposure (for example smokers tend to be drinkers). This combination of exposures may
produce higher or lower levels of overall risk as a result of complex interaction effects. The
analyses presented in this chapter do not explicitly account for these interactions, except to
the extent to which confounding was controlled for in the studies from which the exposure–
outcome relationships were derived.
Secondly, the causal paths between a number of related health risks and their eventual
health outcomes can be complicated. For example, physical inactivity can lead to obesity,
which can cause hypertension or high blood cholesterol, which can ultimately lead to
cardiovascular disease. Most of the analyses presented in this chapter only measure the effect
of a risk independent of the other exposures and irrespective of the risk’s place in a causal
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path. The important implication here is that such analyses are not additive. Using the
example above, the burden attributable to physical inactivity is estimated to be 23.7% of total
cardiovascular disease burden, while that for high body mass, high blood cholesterol and
high blood pressure was 19.5%, 34.5% and 42.1% of cardiovascular disease, respectively
(Table 4.2). The burden attributable to these health risks in combination, however, is not the
sum of burden from each risk (that is, the combined burden is not 119.9%). This is because
the combined effect of these risks has to be expressly calculated rather than derived from the
addition of their individual effects. Ignoring shared causal paths in this example leads to
obvious over-estimation of the combined effect.
To illustrate the total ‘explanatory’ power of the 14 risk factors, the chapter begins with an
analysis that accounts for many of the overlaps between risks that share causal paths. This is
done using the ‘joint effects’ method developed for the WHO Comparative Risk Assessment
project (Ezzati et al. 2004b). Sensitivity analyses indicate that overall results based on this
approach are relatively robust to the underlying assumptions; apportioning the combined
overall risk back to each contributing risk factor is more difficult, however, and is much
more sensitive to assumptions. Therefore, only the former analyses are presented in this
report. Further details on the methods used for estimating joint effects are provided in
Chapter 2.
4.2 Combined effect of 14 selected risks to health
The 14 selected risk factors presented in this chapter together explained 32.2% of the total
burden of disease and injury in Australia in 2003 (Table 4.2). These risk factors explained
35.1% and 29.1% of the total burden in males and females respectively (Table 4.3). This
indicates that there is considerable potential to further reduce burden in Australia through
interventions that target these health risks, each of which contribute to more than one health
outcome. Additional evidence on the (cost-) effectiveness of such interventions may guide
the setting of health service priorities to meet this objective.
Key findings about broad cause groups were:
• Ten of the risks were associated with cancer and together explained 32.9% of the total
burden from this cause. The majority was explained by tobacco. The contributions of the
other risk factors (physical inactivity, high body mass, alcohol, occupational exposure,
low fruit and vegetable consumption, air pollution and unsafe sex (through the link
between the human papilloma virus and cancer of the cervix)) were comparatively much
smaller.
• Twelve of the risks were associated with cardiovascular disease and together explained
69.3% of the burden from this group of causes; for ischaemic heart disease, this figure
was 85.2%. High blood pressure and high blood cholesterol were the largest
contributors, followed by physical inactivity, high body mass, tobacco, and low fruit and
vegetable consumption. The very low prevalence of smoking in elderly Australians, who
are most affected by cardiovascular disease, explains the relatively small contribution of
tobacco to this disease.
• Four of the risks were associated with mental disorders and together explained 26.9% of
the burden from this cause. Alcohol and illicit drugs contributed in roughly equal
proportions. Intimate partner violence and child sexual abuse contributed less but were
the only risks implicated in the large burden from anxiety and depression.
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• Three of the risks were associated with neurological and sense disorders, and together
explained only 0.2% of the burden from these disorders. This reflects lack of knowledge
about causation in this group. Ultraviolet light, causing cataract, is probably the most
obvious omitted risk factor in this disease category but the burden of cataract is small
because surgical treatment is widely available.
• Seven of the risks were associated with injury and together explained 31.7% of the
burden from this cause. Alcohol was by far the largest contributor, followed by
occupational exposures and hazards, illicit drugs, intimate partner violence,
osteoporosis, child sexual abuse, and tobacco.
• Two of the risks were associated with Type 2 diabetes (including the proportion of
cardiovascular disease caused by diabetes) and together explained 60.1% of the burden
from this cause. High body mass was by far the largest contributor to this disease.
Table 4.2: Individual and joint burden (DALYs) attributable to 14 selected risk factors by broad
cause group, Australia, 2003
 Broad cause group
 Cancer CVD Mental
Neuro-
logical Injury Diabetes Other
All
causes
Total burden (‘000)  499.4  473.8  350.5  312.8  185.1  143.8  667.4 2,632.8
Attributable burden (%)(a)
Tobacco  20.1  9.7 — –0.6  0.5 —  8.9 7.8
High blood pressure —  42.1 — — — — — 7.6
High body mass  3.9  19.5 — — —  54.7  1.1 7.5
Physical inactivity  5.6  23.7 — — —  23.7  >–0.1 6.6
High blood cholesterol —  34.5 — — — — — 6.2
Alcohol
Harmful effects  3.1  0.9  9.7 —  18.1 —  <0.1  3.3
Beneficial effects — –5.6 — — — —  >–0.1 –1.0
Net effects  3.1 –4.7  9.7 —  18.1 —  <0.1 2.3
Low fruit & vegetable
consumption  2.0  9.6 — — — —  >–0.1 2.1
Illicit drugs —  <0.1  8.0 —  3.6 —  2.5 2.0
Occupational exposures &
hazards  3.1  0.4 —  0.8  4.7 —  3.4 2.0
Intimate partner violence  0.5  0.3  5.5  0.1  2.5 —  0.2 1.1
Child sexual abuse  <0.1  <0.1  5.8 —  1.4 —  <0.1 0.9
Urban air pollution  0.8  2.7 — — — —  0.4 0.7
Unsafe sex  1.0 — — — — —  1.4 0.6
Osteoporosis — — — —  2.4 — — 0.2
Joint effect(b)  32.9  69.3  26.9  0.2  31.7  60.1  17.2 32.2
(a) Attributable burden within each column is expressed as a percentage of total burden for that column.
(b) Figures for joint effects are not column totals. See Section 4.1 for further details.
The 14 selected risk factors presented in this chapter had a differential impact on health in
terms of both sex and age (Table 4.3). In the 0–44 year-old age group, alcohol and illicit drugs
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The 14 selected risk factors presented in this chapter had a differential impact on health in
terms of both sex and age (Table 4.3). In the 0–44 year-old age group, alcohol and illicit drugs
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were the leading causes of burden in males, mental disorders (alcohol abuse, and heroin and
polydrug abuse) and injuries (suicide and self-inflicted injuries, and road traffic accidents)
being the predominant health outcomes from these risks. In this age group, 23.6% of total
male burden and 17.9% of total female burden was explained by the 14 risks in combination.
In females, intimate partner violence and child sexual abuse were the leading causes in this
age group, anxiety and depression and suicide and self-inflicted injuries being the
predominant health outcomes from these risks.
In the 45–64 year-old age group, high body mass and tobacco were the leading causes in both
sexes, Type 2 diabetes, ischaemic heart disease, stroke, lung cancer and chronic obstructive
pulmonary disease (COPD) being the predominant health outcomes from these risks. The
proportion of total burden in this age group that is explained by the 14 risks in combination
was 43.8% in males and 33.6% in females.
In the 65 years and over age group, high blood pressure was the leading cause in both sexes,
followed by tobacco in males and high blood cholesterol in females. The predominant health
outcomes from both high blood pressure and high blood cholesterol are ischaemic heart
disease and stroke. For tobacco, the predominant health outcomes are lung cancer and
COPD. The proportion of total burden in this age group that is explained by the 14 risks in
combination was 38.4% and 34.8% in males and females, respectively.
Table 4.3: Individual and joint burden (DALYs) attributable to 14 selected risk factors by sex and
age group, Australia, 2003
Males  Females
0–44 45–64 65+ All ages 0–44 45–64 65+ All ages
Total burden (’000)  448.8  382.5  533.4  1,364.6  406.0  299.1  563.0  1,268.2
Attributable burden (%)(a)
Tobacco  1.9  14.7  12.5  9.6  1.1  8.7  7.6  5.8
High blood pressure  0.8  7.8  13.8  7.8 <0.1  4.0  14.2  7.3
High body mass  3.3  13.3  7.5  7.7  2.6  12.1  8.1  7.3
Physical inactivity  1.8  9.0  8.5  6.4  1.9  8.4  9.6  6.8
High blood cholesterol  1.9  9.6  8.3  6.6  0.7  5.1  9.9  5.8
Alcohol
Harmful effects  8.1  5.5  1.8  4.9 2.2  2.4  0.8 1.6
Beneficial effects –0.3 –1.5 –1.5 –1.1 –0.2 –0.9 –1.5 –0.9
Net effects  7.8  4.0  0.3  3.8  2.0  1.4 –0.6  0.7
Low fruit & vegetable
consumption  0.8  4.1  3.3  2.7  0.3  1.7  2.2  1.5
Illicit drugs  5.7  1.9  0.6  2.7  2.4  1.1  0.4  1.2
Occupational exposures &
hazards  2.7  4.2  1.4  2.6  1.6  2.4  0.4  1.3
Intimate partner violence — — — —  4.8  2.8  0.3  2.3
Child sexual abuse  0.6  0.3  <0.1  0.3  3.4  1.7  <0.1  1.5
Urban air pollution  0.2  0.9  1.2  0.8  0.1  0.6  1.2  0.7
Unsafe sex  0.8  0.4  0.2  0.5  1.0  0.9  0.4  0.7
Osteoporosis —  <0.1  0.2  <0.1 —  <0.1  0.6  0.3
Joint effect(b)  23.6  43.8  38.4  35.1  17.9  33.6 34.8  29.1
(a) Attributable burden within each column is expressed as a percentage of total burden for that column.
(b) Figures for joint effects are not column totals. See Section 4.1 for further details.
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4.3 Individual contribution of 14 selected risks to
health
Tobacco
Tobacco was responsible for 7.8% of the total burden of disease and injury in Australia in
2003 (Table 4.4), with lung cancer, COPD and ischaemic heart disease accounting for more
than three-quarters of this burden (Figure 4.1). Of the 14 risk factors examined, tobacco was
responsible for the largest amount of burden across all ages in males (Table 4.3). Almost
two-thirds of the burden from tobacco was experienced by males due to the higher
prevalence 20 to 30 years ago of smoking in males compared with females. More than three-
quarters of the burden from tobacco was due to mortality (Figure 4.1). Because of the long
lag time between smoking and many of its ill effects on health, the health benefits of recent
favourable trends in smoking prevalence will not be fully realised until many years in the
future.
The rate of burden from tobacco per head of population increased with age until 75 and the
absolute burden was concentrated between the ages of 55 and 75. The contribution from lung
cancer dominated at most ages but was overtaken by contributions from COPD and
ischaemic heart disease in the elderly (Figure 4.2).
Table 4.4: Deaths and burden (DALYs) attributable to tobacco by specific cause, Australia, 2003
 Deaths DALYs
 Specific cause  Number  Per cent of total  Number  Per cent of total
 Lung cancer  6,309  4.8  72,213 2.7
 COPD  4,175  3.2  54,492 2.1
 Ischaemic heart disease  1,962  1.5  31,435 1.2
 Stroke  577  0.4  11,812 0.4
 Oesophagus cancer  572  0.4  6,248 0.2
 Other  1,916  1.4  28,588 1.1
Total attributable  15,511  11.7  204,788 7.8
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Figure 4.1: Burden (DALYs) attributable to tobacco by specific cause expressed as:
(a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and
non-fatal outcomes, Australia, 2003
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(b) numbers by specific cause, Australia, 2003
High blood pressure
High blood pressure was responsible for 7.6% of the total burden of disease and injury in
Australia in 2003 (Table 4.5), with ischaemic heart disease and stroke accounting for 93% of
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this burden (Figure 4.3). Of the 14 risk factors examined, high blood pressure was
responsible for the greatest amount of burden in the 65 years or over age group in both sexes
(Table 4.3). Overall, the burden from high blood pressure was somewhat greater in males
and 81% was due to mortality.
The rate of burden from high blood pressure per head of population increased with age and
the absolute burden was concentrated around old age (Figure 4.4). The contributions from
ischaemic heart disease and stroke dominated across all ages.
 Table 4.5: Deaths and burden (DALYs) attributable to high blood pressure by specific cause,
Australia, 2003
 Deaths DALYs
 Specific cause  Number  Per cent of total  Number  Per cent of total
 Ischaemic heart disease  14,089  10.7  125,461  4.8
 Stroke  6,603  5.0  59,962  2.3
 Other  1,812  1.4  13,893  0.5
Total attributable  22,504  17.0  199,315  7.6
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Figure 4.3: Burden (DALYs) attributable to high blood pressure by specific cause expressed as: (a)
proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-fatal outcomes,
Australia, 2003
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High body mass
The body mass index (BMI) is a measure of weight in kilograms over height in metres
squared and is typically categorised into under weight (BMI<20), normal weight
(20BMI<25), over weight (25BMI<30) and obese (BMI30). Rather than use these
categories, the health effects of ‘high body mass’ in the following analyses were estimated
using new methods in which BMI is measured on a continuous scale and risk is assessed
against a minimum counterfactual distribution with a mean of 21 and a SD of 1 (see
Appendix 2). This means that risk is attributed to all people in the population with a BMI of
greater than 21, with the degree of risk increasing exponentially above this value. The
consequence of this approach is that some of the attributable risk from high body mass
comes from the large proportion of the population that is not over weight or obese in the
conventional sense, but whose risk of disease is elevated, at least to some degree.
High body mass was responsible for 7.5%of the total burden of disease and injury in
Australia in 2003 (Table 4.6), with Type 2 diabetes and ischaemic heart disease (IHD)
accounting for almost three-quarters of this burden (Figure 4.5). Of the 14 risk factors
examined, high body mass accounted for the greatest amount of burden in the 45–64 year
age group in females (Table 4.3). The burden from high body mass was greater in males due
to the higher incidence of Type 2 diabetes itself and the associated cardiovascular
complications. Half of the burden from high body mass was due to mortality (Figure 4.5).
The rate of burden from high body mass per head of population increased with age; the
absolute burden was concentrated between the ages of 55 and 75. The contributions from
Type 2 diabetes and ischaemic heart disease dominate across all ages (Figure 4.6).
Ra
te
pe
r1
,0
00
Nu
mb
er
(th
ou
sa
nd
s)
80
Table 4.6: Deaths and burden (DALYs) attributable to high body mass by specific cause, Australia,
2003
 Deaths DALYs
 Specific cause  Number  Per cent of total  Number  Per cent of total
 Type 2 diabetes  1,381  1.0  78,688  3.0
 Ischaemic heart disease  4,914  3.7  66,533  2.5
 Stroke  1,528  1.2  22,218  0.8
 Colorectal cancer  721  0.5  9,920  0.4
 Breast cancer  379  0.3  7,125  0.3
 Other  602  0.5  13,148  0.5
Total attributable  9,525  7.2  197,632  7.5
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Figure 4.5: Burden (DALYs) attributable to high body mass by specific cause expressed as:
(a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-fatal
outcomes, Australia, 2003
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Figure 4.6: Burden (DALYs) attributable to high body mass by age expressed as: (a) rates by sex,
and (b) numbers by specific cause, Australia, 2003
Physical inactivity
Physical inactivity was responsible for 6.6% of the total burden of disease and injury in
Australia in 2003 (Table 4.7), with ischaemic heart disease, Type 2 diabetes and stroke
accounting for more than four-fifths of this burden. Overall, the burden from physical
inactivity was shared equally between the sexes. With the exception of diabetes, most of the
conditions attributable to physical inactivity were associated with high mortality (Figure 4.7).
The rate of burden from physical inactivity per head of population increased with age and
the absolute burden was concentrated around old age. The contributions from ischaemic
heart disease and Type 2 diabetes dominated across all ages (Figure 4.8).
Table 4.7: Deaths and burden (DALYs) attributable to physical inactivity by specific cause,
Australia, 2003
 Deaths DALYs
 Specific cause  Number  Per cent of total  Number  Per cent of total
 Ischaemic heart disease  8,739  6.6  88,617  3.4
 Type 2 diabetes  704  0.5  34,132  1.3
 Stroke  2,390  1.8  23,742  0.9
 Colorectal cancer  1,074  0.8  14,978  0.6
 Breast cancer  584  0.4  12,962  0.5
Total attributable  13,491  10.2  174,431  6.6
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Figure 4.7: Burden (DALYs) attributable to physical inactivity by specific cause expressed as:
(a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-fatal
outcomes, Australia, 2003
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Figure 4.8: Burden (DALYs) attributable to physical inactivity by age expressed as: (a) rates by
sex, and (b) numbers by specific cause, Australia, 2003
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Figure 4.8: Burden (DALYs) attributable to physical inactivity by age expressed as: (a) rates by
sex, and (b) numbers by specific cause, Australia, 2003
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High blood cholesterol
High blood cholesterol was responsible for 6.2% the total burden of disease and injury in
Australia in 2003 (Table 4.8), with ischaemic heart disease and stroke accounting for this
entire burden. Both ischaemic heart disease and stroke were associated with high mortality.
Overall, males experienced a slightly higher burden from high blood cholesterol than
females (Figure 4.9).
The rate of burden from high blood cholesterol per head of population increased with age
and the absolute burden was concentrated around old age. The contribution from ischaemic
heart disease dominated across all ages (Figure 4.10).
Table 4.8: Deaths and burden (DALYs) attributable to high blood cholesterol by specific cause,
Australia, 2003
 Deaths DALYs
 Specific cause  Number  Per cent of total  Number  Per cent of total
 Ischaemic heart disease  13,371  10.1  138,605  5.3
 Stroke  1,980  1.5  24,986  0.9
Total attributable  15,351  11.6  163,591  6.2
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Figure 4.9: Burden (DALYs) attributable to high blood cholesterol by specific cause expressed
as: (a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-fatal
outcomes, Australia, 2003
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Figure 4.10: Burden (DALYs) attributable to high blood cholesterol by age expressed as: (a) rates
by sex, and (b) numbers by specific cause, Australia, 2003
Alcohol
Alcohol has both hazardous and protective effects on health, and the age and sex distribution
of these effects varies in important ways. Of the 14 risk factors examined, alcohol was
responsible for the greatest amount of burden in males under the age of 45 (Table 4.3).
Alcohol harm was responsible for 3.2% of the total burden of disease and injury in Australia
in 2003. Alcohol also prevented 0.9% per cent of the total burden in 2003 (Table 4.9). The
benefits of alcohol consumption outweigh its harmful effects only in females over the age of
65. Given that the net impact of alcohol was to contribute to 2.3% of total burden, it is
important to understand that, even though moderate intake of alcohol may have beneficial
effects at middle and older ages, alcohol is harmful when taken in excess at all ages.
Alcohol abuse, road traffic accidents and suicide contributed two-thirds of the harm
attributed to alcohol (Figure 4.11).
This study reports a substantially lower health benefit due to alcohol compared to the
previous Australian burden study (AIHW: Mathers et al. 1999, AIHW: Ridolfo & Stevenson
2001) with only an estimated 2,346 deaths being prevented in 2003 compared to 7,157 deaths
in 1996. This is due to the previous study underestimating the number of people who abstain
from alcohol or drink less than 0.25 drinks per day.
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Figure 4.10: Burden (DALYs) attributable to high blood cholesterol by age expressed as: (a) rates
by sex, and (b) numbers by specific cause, Australia, 2003
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Table 4.9: Deaths and burden (DALYs) attributable to alcohol by specific cause, Australia, 2003
 Deaths DALYs
 Specific cause  Number  Per cent of total  Number  Per cent of total
 Harm
 Alcohol abuse 918  0.7 34,116  1.3
 Suicide & self-inflicted injuries 553  0.4 12,245  0.5
 Road traffic accidents 396  0.3 11,121  0.4
 Oesophagus cancer 368  0.3 4,594  0.2
 Breast cancer 184  0.1 4,152  0.2
 Other 1,012  0.8 19,207  0.7
Total attributable harm 3,430  2.6 85,435  3.2
Benefit
 Ischaemic heart disease –1,950 –1.5 –20,659 –0.8
 Stroke –380 –0.3 –3,451 –0.1
 Other –16 0.0 –233 0.0
Total attributable benefit –2,346 –1.8 –24,343 –0.9
 Total attributable 1,084  0.8 61,091  2.3
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Figure 4.11: Burden (DALYs) attributable to alcohol (alcohol harm) by specific cause expressed
as: (a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-fatal
outcomes, Australia, 2003
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Figure 4.12: Burden (DALYs) attributable to alcohol (alcohol harm) by age expressed as: (a) rates
by sex, and (b) numbers by specific cause, Australia, 2003
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Figure 4.13: Burden (DALYs) prevented due to alcohol (alcohol benefit) by specific cause
expressed as: (a) proportions of total, (b) proportions by sex, and (c) proportions due to
fatal and non-fatal outcomes, Australia, 2003
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Figure 4.12: Burden (DALYs) attributable to alcohol (alcohol harm) by age expressed as: (a) rates
by sex, and (b) numbers by specific cause, Australia, 2003
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Figure 4.13: Burden (DALYs) prevented due to alcohol (alcohol benefit) by specific cause
expressed as: (a) proportions of total, (b) proportions by sex, and (c) proportions due to
fatal and non-fatal outcomes, Australia, 2003
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Figure 4.14: Burden (DALYs) attributable to alcohol (alcohol benefit) by age expressed as:
(a) rates by sex, and (b) numbers by specific cause, Australia, 2003
Low fruit and vegetable consumption
Low fruit and vegetable consumption was responsible for 2.1% of the total burden of disease
and injury in Australia in 2003 (Table 4.10). Eating enough fruit and vegetables helps to
prevent cancers, ischaemic heart disease and, to a lesser extent, stroke. Sixty-nine per cent of
the burden from low fruit and vegetable consumption was due to ischaemic heart disease
and two-thirds was experienced by males, partly because males tend to eat less fruit and
vegetables than females, but also because males have a higher burden from ischaemic heart
disease than females. Overall, 81%of the burden from low fruit and vegetable consumption
was due to mortality.
The absolute burden from low fruit and vegetable consumption peaked between the age of
60 and 80 while the rate per head of population continued to increase until old age. The
contribution from ischaemic heart disease dominated at all ages (Figure 4.16).
Table 4.10: Deaths and burden (DALYs) attributable to low fruit and vegetable consumption by
specific cause, Australia, 2003
 Deaths DALYs
 Specific cause  Number  Per cent of total  Number  Per cent of total
 Ischaemic heart disease  3,219  2.4  37,981  1.4
 Stroke  605  0.5  7,346  0.3
 Lung cancer  463  0.3  5,956  0.2
 Other  281  0.2  3,977  0.2
 Total attributable  4,568  3.5  55,259  2.1
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Figure 4.15: Burden (DALYs) attributable to low fruit and vegetable consumption by specific
cause expressed as: (a) proportions of total, (b) proportions by sex, and (c) proportions due to
fatal and non-fatal outcomes, Australia, 2003
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Figure 4.16: Burden (DALYs) attributable to low fruit and vegetable consumption by age
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risk factors for conditions such as HIV/AIDS, hepatitis, low birth weight, inflammatory
heart disease, poisoning, and suicide and self-inflicted injuries. Almost three-quarters of the
burden from illicit drugs was experienced by males because males are more likely to both
use illicit drugs and adopt drug habits that put them at risk of dying. Overall, fifty-seven per
cent of the burden from illicit drugs was due to mortality (Figure 4.17).
The burden from illicit drugs, both in terms of rate per head of population and in absolute
terms, peaked in early adulthood when drug addiction usually begins. The contribution
from heroin dominated at this age but was overtaken by contributions from hepatitis B and
C with increasing age as the long-term effects of drug use begin to manifest (Figure 4.18).
Table 4.11: Deaths and burden (DALYs) attributable to illicit drugs by specific cause, Australia,
2003
 Deaths DALYs
 Specific cause  Number  Per cent of total  Number  Per cent of total
 Heroin & polydrug abuse  263  0.2  16,758  0.6
 Hepatitis C  759  0.6  11,709  0.4
 Cannabis abuse  0  0.0  5,206  0.2
 Suicide & self-inflicted injuries  204  0.2  4,458  0.2
 Hepatitis B  329  0.2  3,637  0.1
 Benzodiazepine abuse  1  0.0  2,656  0.1
 Other  149  0.1  7,040  0.3
 Total attributable  1,705  1.3  51,463  2.0
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Figure 4.17: Burden (DALYs) attributable to illicit drugs by specific cause expressed as:
(a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-
fatal outcomes, Australia, 2003
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Figure 4.18: Burden (DALYs) attributable to illicit drugs by age expressed as: (a) rates by sex, and
(b) numbers by specific cause, Australia, 2003
Occupational exposures and hazards
Occupational exposures and hazards were responsible for 2.0% of the total burden of disease
and injury in Australia in 2003 (Table 4.12). More than two-thirds of this burden was
experienced by males, mostly because occupational exposures and hazards occur in
industries dominated by male employment. Females, however, experienced 86% of the
burden from occupational overuse syndrome (OOS). Overall, 43% of the burden from
occupational exposures and hazards was due to mortality (Figure 4.19).
The burden from occupational exposures and hazards was concentrated in the working ages
and peaked in middle age, both in terms of rate per head of population and in absolute terms
(Figure 4.20).
Table 4.12: Deaths and burden (DALYs) attributable to occupational exposures and hazards by
specific cause, Australia, 2003
 Deaths DALYs
 Specific cause  Number  Per cent of total  Number  Per cent of total
 Cancer  1,154  0.9  15,559  0.6
 Back pain  1  0.0  7,806  0.3
 Occupational overuse syndrome — —  4,944  0.2
 COPD  111  0.1  4,563  0.2
 Road traffic accidents  124  0.1  2,975  0.1
 Other  264  0.2  15,515  0.6
 Total attributable  1,654  1.3  51,362  2.0
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Figure 4.18: Burden (DALYs) attributable to illicit drugs by age expressed as: (a) rates by sex, and
(b) numbers by specific cause, Australia, 2003
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Figure 4.19: Burden (DALYs) attributable to occupational exposures and hazards by specific
cause expressed as: (a) proportions of total, (b) proportions by sex, and (c) proportions due
to fatal and non-fatal outcomes, Australia, 2003
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Figure 4.20: Burden (DALYs) attributable to occupational exposures and hazards by age
expressed as: (a) rates by sex, and (b) numbers by specific cause, Australia, 2003
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Intimate partner violence
The attribution of burden to intimate partner violence was attempted only for females due to
insufficient evidence on prevalence and risk among males. While this risk is unlikely to be
zero, it is probably small in comparison with the risk experienced by females. Intimate
partner violence was responsible for 1.1% of the total burden of disease and injury in
Australia in 2003 (Table 4.13). Of the 14 risk factors examined, intimate partner violence
contributed most to the burden in females under the age of 45 (Table 4.3). Most of the burden
from intimate partner violence was due to anxiety and depression, and conditions arising
due to the associated increased use of tobacco, alcohol and illicit substances (Figure 4.21).
The burden from intimate partner violence, both in terms of rate per head of population and
in absolute terms, peaked at around age 30 then declined with age (Figure 4.22). The
contribution from anxiety and depression dominated throughout adulthood but was
overtaken by contributions from tobacco-related disease with increasing age as the effects of
higher smoking rates begin to manifest.
Table 4.13: Deaths and burden (DALYs) for females attributable to intimate partner violence by
specific cause, Australia, 2003
 Deaths DALYs
Specific cause  Number  Per cent of total  Number  Per cent of total
Anxiety & depression  3  0.0  18,358  0.7
Suicide & self-inflicted injuries  131  0.1  3,099  0.1
Lung cancer  89  0.1  1,477  0.1
Homicide & violence  35  0.0  1,260  0.0
COPD  49  0.0  1,114  0.0
 Other 128  0.1  4,051  0.2
 Total attributable  435  0.3  29,360  1.1
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Figure 4.21: Burden (DALYs) attributable to intimate partner violence by specific cause
expressed as: (a) proportions of total, (b) proportions by sex, and (c) proportions due to
fatal and non-fatal outcomes, Australia, 2003
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Figure 4.22: Burden (DALYs) attributable to intimate partner violence by age expressed as:
(a) rates by sex, and (b) numbers by specific cause, Australia, 2003
Child sexual abuse
Child sexual abuse was responsible for 0.9% of the total burden of disease and injury in
Australia in 2003 (Table 4.14). Ninety-four per cent of this burden was due to anxiety and
t   depres ion
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depression, suicide and self-inflicted injuries, and alcohol abuse. Of the 14 risk factors
examined, child sexual abuse was the second leading cause of burden in females under the
age of 45 (Table 4.3). Just over four-fifths of the burden from child sexual abuse was
experienced by females and 14% was due to mortality (Figure 4.23).
The burden from child sexual abuse, both in terms of rate per head of population and in
absolute terms, peaked at around 40 years-old then declined with age. The contribution from
anxiety and depression dominated at this age after which contributions from suicide and
self-inflicted injuries and alcohol abuse became increasingly important (Figure 4.24).
Table 4.14: Deaths and burden (DALYs) attributable to child sexual abuse by specific cause,
Australia, 2003
 Deaths DALYs
 Specific cause  Number  Per cent of total  Number  Per cent of total
 Anxiety and depression  7  0.0  19,133  0.7
 Suicide & self-inflicted injuries  103  0.1  2,258  0.1
 Alcohol abuse  24  0.0  730  0.0
 Other  62  0.0  1,392  0.1
 Total attributable  196  0.1  23,513  0.9
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Figure 4.23: Burden (DALYs) attributable to child sexual abuse by specific cause expressed
as: (a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-
fatal outcomes, Australia, 2003
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Figure 4.23: Burden (DALYs) attributable to child sexual abuse by specific cause expressed
as: (a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-
fatal outcomes, Australia, 2003
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Figure 4.24: Burden (DALYs) attributable to child sexual abuse by age expressed as: (a) rates by
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Urban air pollution
The health effects of urban air pollution are largely chronic conditions (such as ischaemic
heart disease, lung cancer and stroke) resulting from long-term exposure to this risk. There
may also be an additional burden from short-term exposure to abnormally high levels of
urban air pollution, although this risk is more controversial. Table 4.15 provides estimates for
both long-term and short-term effects; all other figures in this section reflect the long-term
effects only. Urban air pollution was responsible for 1.0% of the total burden of disease and
injury in Australia in 2003 (Table 4.15). Sixty-two per cent of the burden from urban air
pollution was due to cardiovascular disease (ischaemic heart disease and stroke) and 53% of
the burden from urban air pollution was experienced by males. Overall, 80% of the burden
from urban air pollution was due to mortality (Figure 4.25).
The absolute burden from urban air pollution peaked at age 80 while the rate per head of
population continued to increase until old age. The contribution from cardiovascular disease
dominated at all ages (Figure 4.26).
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Table 4.15: Deaths and burden (DALYs) attributable to urban air pollution by specific cause, Australia,
2003
 Deaths DALYs
Specific cause  Number  Per cent of total  Number  Per cent of total
Long-term
Ischaemic heart disease  959  0.7  8,483  0.3
Lung cancer  351  0.3  4,115  0.2
Stroke  432  0.3  3,738  0.1
COPD  184  0.1  2,654  0.1
Other  83  0.1  748  0.0
Total attributable to long-term
exposure
 2,009  1.5  19,738  0.7
Short-term
Total attributable to short-term
exposure
 1,046  0.8  7,781  0.3
Total attributable  3,056  2.3  27,519  1.0
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Figure 4.25: Burden (DALYs) attributable to urban air pollution (long-term effects) by specific
cause expressed as: (a) proportions of total, (b) proportions by sex, and (c) proportions due to
fatal and non-fatal outcomes, Australia, 2003
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Figure 4.26: Burden (DALYs) attributable to urban air pollution (long-term effects) by age
expressed as: (a) rates by sex, and (b) numbers by specific cause, Australia, 2003
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Unsafe sex
Unsafe sex was responsible for 0.6% of the total burden of disease and injury in Australia in
2003 (Table 4.16). Over two-thirds of this burden was due to cervix cancer and HIV/AIDS.
Sixty-three per cent of the burden from unsafe sex was due to mortality (Figure 4.27).
The burden from unsafe sex in males peaked in early adulthood due to the impact of HIV
infection, after which it declined and the long-term effects of hepatitis B infection began to
manifest. In females, the rate per head of population continued to increase with age and the
absolute burden was concentrated around middle age when the contribution from cervix
cancer dominated (Figure 4.28).
Table 4.16: Deaths and burden (DALYs) attributable to unsafe sex by specific cause, Australia, 2003
 Deaths DALYs
 Specific cause  Number  Per cent of total  Number  Per cent of total
 Cervix cancer  298  0.2  5,231  0.2
 HIV/AIDS  105  0.1  4,873  0.2
 Hepatitis B  225  0.2  2,499  0.1
 Other  26  0.0  2,293  0.1
 Total attributable  655  0.5  14,897  0.6
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Figure 4.27: Burden (DALYs) attributable to unsafe sex by specific cause expressed as:
(a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-
fatal outcomes, Australia, 2003
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Figure 4.28: Burden (DALYs) attributable to unsafe sex by age expressed as: (a) rates by sex, and
(b) numbers by specific cause, Australia, 2003
Osteoporosis
Osteoporosis was responsible for 0.2% of the total burden of disease and injury in Australia
in 2003 (Table 4.17). Almost all of this burden was due to falls and more than three-quarters
was experienced by females.  More than half of the burden from osteoporosis was due to
mortality (Figure 4.29).
The burden from osteoporosis was experienced from age 60 onwards. The contribution from
falls dominated at all ages (Figure 4.30).
Table 4.17: Deaths and burden (DALYs) attributable to osteoporosis by specific cause, Australia,
2003
 Deaths DALYs
 Specific cause  Number  Per cent of total  Number  Per cent of total
 Falls  534  0.4  4,329  0.2
 Other  10  0.0  58  0.0
 Total attributable  545  0.4  4,386  0.2
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Figure 4.29: Burden (DALYs) attributable to osteoporosis by specific cause expressed as:
(a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-
fatal outcomes, Australia, 2003
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Figure 4.30: Burden (DALYs) attributable to osteoporosis by age expressed as: (a) rates by sex,
and (b) numbers by specific cause, Australia, 2003
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Figure 4.29: Burden (DALYs) attributable to osteoporosis by specific cause expressed as:
(a) proportions of total, (b) proportions by sex, and (c) proportions due to fatal and non-
fatal outcomes, Australia, 2003
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Figure 4.30: Burden (DALYs) attributable to osteoporosis by age expressed as: (a) rates by sex,
and (b) numbers by specific cause, Australia, 2003
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5 Differentials in burden of disease and
injury across Australia
5.1 Overview
This chapter describes differentials in burden of disease and injury across Australia in terms
of the following stratifications of the population: state and territory jurisdictions,
socioeconomic quintiles and remoteness categories (major cities, regional and remote). The
chapter begins by comparing life expectancy and health-adjusted life expectancy (HALE)
across each subpopulation within these strata. It then discusses the main differentials
between subpopulations by leading causes of burden. Table 5.1 summarises for each
subpopulation the important demographic characteristics that influence these differentials.
Table 5.1: Selected demographic characteristics by area, Australia, 2003
Population(a) Per cent of population for area
Age group (years)
Area (’000)
Per cent
of
Australia  <15 15–59 60–79 80+ Males Indigenous(b) Low SES(c)
Jurisdiction
NSW  6,687.5 33.6 19.9 62.4 14.2 3.5 49.7  2.0  19.0
Vic  4,918.0 24.7 19.5 62.9 14.1 3.4 49.3  0.6  16.0
Qld  3,797.3 19.1 20.8 62.9 13.3 3.0 49.9  3.3  23.9
WA  1,952.5 9.8 20.4 64.0 12.8 2.8 50.0  3.3  22.5
SA  1,527.6 7.7 18.8 61.7 15.4 4.1 49.5  1.6  14.9
Tas  477.2 2.4 20.4 60.6 15.4 3.7 49.3  3.6  55.4
ACT  322.9 1.6 19.8 67.4 10.7 2.2 49.4  1.2  0.3
NT 198.4 1.0  25.4 67.4 6.5 0.7 52.5 28.8 28.4
Socioeconomic quintile
Low 3,917.1 19.7 21.9 61.5 13.7 2.9  50.0 n.a. n.a.
Mod. low  3,973.8 20.0 21.2 60.6 14.9 3.3 49.8 n.a. n.a.
Average 3,747.8 18.8 20.3 61.9 14.3 3.4  49.8 n.a. n.a.
Mod. high  4,097.3 20.6 19.4 64.5 13.0 3.1 49.6 n.a. n.a.
High 4,145.4 20.8 17.4 65.4 13.5 3.7  49.1 n.a. n.a.
Remoteness
Major cities 13,347.9 66.8 19.1 64.4 13.5 3.3 49.6  1.0  17.2
Regional  6,050.5 30.4 21.7 59.7 15.3 3.4 50.0  3.2  23.7
Remote  483.1 2.4 25.6 63.4 9.2 1.8 53.2  25.7  39.2
Australia 19,894.7 100.0 20.0 62.8 13.9 3.3 49.6  2.3  19.7
(a) Estimated resident population figures as at 30 June 2003 (ABS cat. no. 3201.0).
(b) Based on people identifying as Indigenous in the 2001 Census (ABS cat. no. 2019.0 – 2019.8).
(c) Based on Socio-Economic Indexes for Areas (SEIFA) (ABS cat. no. 2039.0.55.001).
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5.2 Health-adjusted life expectancy
HALE provides an estimate of the average years of equivalent ‘healthy’ life that a person can
expect to live at various ages. HALE is related to life expectancy, which provides an estimate
of the average years of life a person can expect to live at various ages given current risks of
mortality. HALE extends this concept by reducing the estimated duration by the proportion
of time spend at each age in states less than perfect health, adjusted for the relative severity
of those health states. The sum of prevalent years lost due to disability (PYLD) across all
causes is used to derive this ‘severity-weighted’ proportion for each age. Since the starting
point for HALE is a life table, life expectancy at birth for the various subpopulations
discussed in this chapter is presented first in Table 5.2.
Table 5.2: Life expectancy at birth by area and sex, Australia, 2003
Life expectancy at birth (years)
Area Males Females Persons
Jurisdiction
NSW 78.2 (78.0–78.3) 83.1 (83.0–83.3) 80.6 (80.5–80.8)
Vic 78.6 (78.4–78.8) 83.2 (83.0–83.4) 80.9 (80.8–81.0)
Qld 78.4 (78.2–78.6) 83.3 (83.1–83.5) 80.8 (80.7–81.0)
WA 79.0 (78.7–79.3) 83.7 (83.4–84.0) 81.3 (81.1–81.5)
SA 77.7 (77.3–78.0) 82.9 (82.5–83.2) 80.3 (80.0–80.5)
Tas 76.7 (76.1–77.3) 81.7 (81.1–82.2) 79.2 (78.8–79.6)
ACT 80.2 (79.4–80.9) 84.2 (83.4–84.9) 82.3 (81.7–82.8)
NT 73.1 (72.2–74.0) 78.6 (77.6–79.6) 75.5 (74.8–76.1)
Socioeconomic quintile
Low 76.9 (76.7–77.1) 82.3 (82.1–82.5) 79.6 (79.4–79.7)
Moderately low 77.4 (77.2–77.6) 82.8 (82.6–83.0) 80.0 (79.9–80.2)
Average 77.7 (77.5–77.9) 82.7 (82.5–82.9) 80.2 (80.0–80.3)
Moderately high 79.0 (78.8–79.2) 83.5 (83.3–83.7) 81.2 (81.1–81.4)
High 80.9 (80.6–81.1) 84.5 (84.3–84.7) 82.7 (82.5–82.8)
Remoteness
Major cities 78.8 (78.7–78.9) 83.5 (83.4–83.6) 81.2 (81.1–81.2)
Regional 77.5 (77.4–77.7) 82.7 (82.5–82.8) 80.0 (79.9–80.1)
Remote 75.4 (74.8–76.1) 81.5 (80.9–82.2) 78.1 (77.6–78.6)
Australia 78.3 (78.2–78.4) 83.2 (83.1–83.3) 80.7 (80.7–80.8)
When interpreting the results presented in this chapter it is important to keep in mind that
Indigenous people are a much greater proportion of the total population in the Northern
Territory and remote areas of Australia. This accounts for the much greater health loss in
these areas, although the contribution of Indigenous populations to this loss is not quantified
in this report. Readers seeking such comparisons are referred to the separate report on the
Indigenous component of this study. Once the Indigenous results are available separate
small area comparisons can be made for non-Indigenous people. This is relevant to health
102
5.2 Health-adjusted life expectancy
HALE provides an estimate of the average years of equivalent ‘healthy’ life that a person can
expect to live at various ages. HALE is related to life expectancy, which provides an estimate
of the average years of life a person can expect to live at various ages given current risks of
mortality. HALE extends this concept by reducing the estimated duration by the proportion
of time spend at each age in states less than perfect health, adjusted for the relative severity
of those health states. The sum of prevalent years lost due to disability (PYLD) across all
causes is used to derive this ‘severity-weighted’ proportion for each age. Since the starting
point for HALE is a life table, life expectancy at birth for the various subpopulations
discussed in this chapter is presented first in Table 5.2.
Table 5.2: Life expectancy at birth by area and sex, Australia, 2003
Life expectancy at birth (years)
Area Males Females Persons
Jurisdiction
NSW 78.2 (78.0–78.3) 83.1 (83.0–83.3) 80.6 (80.5–80.8)
Vic 78.6 (78.4–78.8) 83.2 (83.0–83.4) 80.9 (80.8–81.0)
Qld 78.4 (78.2–78.6) 83.3 (83.1–83.5) 80.8 (80.7–81.0)
WA 79.0 (78.7–79.3) 83.7 (83.4–84.0) 81.3 (81.1–81.5)
SA 77.7 (77.3–78.0) 82.9 (82.5–83.2) 80.3 (80.0–80.5)
Tas 76.7 (76.1–77.3) 81.7 (81.1–82.2) 79.2 (78.8–79.6)
ACT 80.2 (79.4–80.9) 84.2 (83.4–84.9) 82.3 (81.7–82.8)
NT 73.1 (72.2–74.0) 78.6 (77.6–79.6) 75.5 (74.8–76.1)
Socioeconomic quintile
Low 76.9 (76.7–77.1) 82.3 (82.1–82.5) 79.6 (79.4–79.7)
Moderately low 77.4 (77.2–77.6) 82.8 (82.6–83.0) 80.0 (79.9–80.2)
Average 77.7 (77.5–77.9) 82.7 (82.5–82.9) 80.2 (80.0–80.3)
Moderately high 79.0 (78.8–79.2) 83.5 (83.3–83.7) 81.2 (81.1–81.4)
High 80.9 (80.6–81.1) 84.5 (84.3–84.7) 82.7 (82.5–82.8)
Remoteness
Major cities 78.8 (78.7–78.9) 83.5 (83.4–83.6) 81.2 (81.1–81.2)
Regional 77.5 (77.4–77.7) 82.7 (82.5–82.8) 80.0 (79.9–80.1)
Remote 75.4 (74.8–76.1) 81.5 (80.9–82.2) 78.1 (77.6–78.6)
Australia 78.3 (78.2–78.4) 83.2 (83.1–83.3) 80.7 (80.7–80.8)
When interpreting the results presented in this chapter it is important to keep in mind that
Indigenous people are a much greater proportion of the total population in the Northern
Territory and remote areas of Australia. This accounts for the much greater health loss in
these areas, although the contribution of Indigenous populations to this loss is not quantified
in this report. Readers seeking such comparisons are referred to the separate report on the
Indigenous component of this study. Once the Indigenous results are available separate
small area comparisons can be made for non-Indigenous people. This is relevant to health
103
policy in that there is a raft of Indigenous health issues that is distinct from the health issues
of the general population living in remote areas.
HALE was calculated for subpopulations using the PYLD estimated for each population
separately, as discussed in Chapter 2. Total HALE at birth across Australia in 2003 was
70.6 years for males, 75.2 years for females and 72.9 years for both sexes combined (Table
5.3). The figures for both sexes ranged from 67.7 to 75.9 years across state and territory
jurisdictions, 71.2 to 75.5 years across socioeconomic quintiles and 69.5 to 73.5 years across
remoteness categories.
Table 5.3: Health-adjusted life expectancy (HALE) and life expectancy at birth lost due to disability
by area and sex, Australia, 2003
Health-adjusted life expectancy (HALE) (years)
At birth At age 60
Life expectancy
at birth
lost due to disability (%)
Area Males Females Persons Males Females Persons Males Females Persons
Jurisdiction
NSW 70.5 75.3 72.9  17.1 20.6 18.9 9.8 9.5 9.6
Vic 71.1 75.4 73.2  17.5 20.8 19.2 9.6 9.4 9.5
Qld 70.5 75.3 72.8 17.0 20.4 18.7 10.1 9.7 9.9
WA 71.5 75.6 73.5  17.5 20.6 19.1 9.6 9.6 9.6
SA 69.3 74.2 71.7  16.4 20.0 18.3  10.8 10.5 10.6
Tas 68.8 73.7 71.3  16.3 19.7 18.1  10.2 9.8 10.0
NT 65.8 70.2 67.7  12.6 15.1 13.6  10.0 10.6 10.3
ACT 73.9 77.8 75.9  18.9 21.9 20.5 7.8 7.5 7.7
Socioeconomic quintile
Low 68.7 73.8 71.2  16.1 19.7 17.9  10.7 10.4 10.6
Moderately
low 69.5 74.6 72.0 16.4 20.1 18.2 10.2 9.9 10.1
Average 69.9 74.6 72.2 16.6 20.1 18.4 10.0 9.8 9.9
Moderately
high 71.4 75.9 73.6 17.6 20.8 19.3 9.7 9.1 9.4
High 73.8 77.2 75.5 19.2 21.9 20.6 8.7 8.7 8.7
Remoteness
Major cities 71.3 75.6 73.5 17.5 20.8 19.2 9.6 9.4 9.5
Regional 69.6 74.5 72.0  16.5 20.1 18.3  10.3 9.8 10.1
Remote 67.3 72.3 69.5  15.4 18.5 16.8  10.8 11.3 11.0
Australia 70.6 75.2 72.9  17.1 20.5 18.9 9.8 9.6 9.7
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When the difference between life expectancy and HALE is expressed as a proportion of life
expectancy, this represents the proportion of remaining life that is lost due to disability.
Hereafter this is referred to as PLD (proportion of life expectancy lost due to disability). PLD
at birth is the most commonly reported figure, although it can be calculated at any age and
increases with age (Figure 5.1).
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Figure 5.1: Proportion of life expectancy lost due to disability (%) by age and sex, Australia, 2003
This report shows for the first time that there are differentials in PLD at birth across
Australia (Table 5.3). There was a strong socioeconomic gradient in this measure, with the
lowest socioeconomic quintile losing 10.6% of life expectancy at birth through disability and
the highest losing only 8.7%. Differentials with respect to remoteness category were also
apparent but not as large, with remote areas losing 11.0% and major cities losing 9.5%. With
respect to state and territory jurisdictions, the Australian Capital Territory had the lowest
PLD at birth at 7.7% and South Australia had the highest at 10.6%.
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Figure 5.2: Life expectancy at birth (years) versus proportion of life expectancy at birth lost due
to disability (%) by area, Australia, 2003
Figure 5.2 shows the inverse relationship between life expectancy at birth and PLD, with
subpopulations experiencing the highest life expectancy also having the lowest PLD. In other
words, longevity is associated with lower average levels of disability throughout the life
span.
The remainder of this chapter presents health differentials across these subpopulations using
the standard burden metric of disability-adjusted life years—(DALYs). All rates per head of
population were standardised to remove the effect of different age structures between
populations. This standard technique is used when comparing populations whereby the age-
specific rates of the populations of interest are applied to the age structure of a reference
population before comparisons are made.
5.3 State and territory differentials
The proportion of burden experienced by each state and territory jurisdiction was roughly
proportional to the population size, with New South Wales accounting for the largest
proportion (34.0%), followed by Victoria (24.8%) and Queensland (18.6%) (Table 5.4). Males
experienced more of this burden than females in all jurisdictions except the Australian
Capital Territory where it was more equally distributed between the sexes. In all
jurisdictions except Tasmania, slightly more of total burden was due to non-fatal causes.
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Table 5.4: Burden (DALYs) for state/territory jurisdictions by proportions of total, proportions by
sex and proportions due to mortality, Australia, 2003
Area DALYs (’000) Per cent of total Per cent male Per cent fatal burden
NSW  895.8  34.0  51.9  49.5
Vic  651.6  24.8  50.9  48.9
Qld  488.5  18.6  53.0  46.9
SA  234.3  8.9  51.5  48.7
WA  236.8  9.0  51.7  46.6
Tas  73.4  2.8  51.6  51.4
NT  22.9  0.9  58.5  46.6
ACT  29.5  1.1  50.4  47.5
Australia  2,632.8  100.0  51.8  48.6
There were important differentials in burden experienced per head of population between
jurisdictions. After age standardisation, the Northern Territory had almost twice the rate of
total burden of the Australian Capital Territory for both males and females. This was due to
higher rates of burden for most causes, but particularly for cardiovascular disease, diabetes
and injuries (Figure 5.3).
0
50
100
150
200
NT Tas SA Qld NSW Vic WA ACT NT Tas SA Vic NSW Qld WA ACT
Males Females
Cancer Cardiovascular Chronic respiratory Diabetes
Injuries Mental Neurological Other
Ra
te
 pe
r 1
,0
00
Figure 5.3: Age-standardised DALY rates per 1,000 by state/territory jurisdiction, broad cause
group and sex, Australia, 2003
Table 5.5 provides a comparison between burden rates for jurisdictions and the national
average for the 10 leading broad causes of burden in Australia for 2003. Of these causes, the
greatest difference between jurisdictions with the lowest and highest rates occurred (in order
of magnitude of difference) in diabetes, injuries, genitourinary conditions and chronic
respiratory diseases. The causes that contributed most in terms of the absolute difference
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Table 5.5 provides a comparison between burden rates for jurisdictions and the national
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of magnitude of difference) in diabetes, injuries, genitourinary conditions and chronic
respiratory diseases. The causes that contributed most in terms of the absolute difference
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observed between jurisdictions were cardiovascular disease (19.7%), diabetes (15.5%) and
injuries (13.6% for intentional and unintentional combined).
Table 5.5: Differentials in burden (DALYs) by state/territory jurisdiction for the 10 leading broad
cause groups, Australia, 2003
 Rate Standardised rate ratio(b) % diff. % of
Broad cause group Aust.(a)  NSW Vic Qld SA WA Tas NT ACT high/low(c) total diff.(d)
Cancer 25.1  1.00 1.02 0.98 1.06 0.96 1.13 1.15 0.87 31.3 6.9
Cardiovascular 23.8  1.04 0.94 1.02 1.09 0.88 1.13 1.61 0.78 104.8 19.7
Mental 17.6  1.03 0.97 1.01 1.06 0.94 1.15 1.05 0.76 52.1 7.0
Neurological 15.7  0.99 0.97 1.00 1.13 1.04 1.02 0.97 0.78 44.3 5.5
Chronic respiratory 9.4  0.99 0.98 0.99 1.20 0.94 1.18 1.72 0.81 111.6 8.6
Diabetes 7.2  0.88 1.15 0.95 1.14 1.00 1.15 2.71 0.57 371.8 15.5
Unintentional injuries 6.3  0.96 0.95 1.08 1.01 1.06 1.13 2.03 0.68 196.7 8.6
Musculoskeletal 5.3  0.96 1.00 1.05 1.02 1.05 1.18 0.96 0.87 35.5 1.7
Genitourinary 3.3  1.01 1.04 0.93 1.06 0.94 1.01 1.76 0.77 127.9 3.3
Intentional injuries 3.0  0.94 0.89 1.11 1.10 1.05 1.18 2.46 0.79 210.3 5.0
All causes 132.4  1.00 0.99 1.00 1.09 0.96 1.12 1.50 0.79 88.7 100.0
(a) DALY rate for Australia per 1,000.
(b) Ratio of age-standardised DALYs per 1,000 population for area to DALYs per 1,000 population for Australia.
(c) Calculated for each cause as the greatest difference in DALY rates between areas as a proportion of lowest rate for that cause.
(d) Calculated for each cause as the greatest difference in DALY rates between areas as a proportion of greatest difference for all causes.
Table 5.6 lists the 10 leading specific causes of burden for Australia and summarises for each
jurisdiction these causes in terms of rank order and percentage of total burden. Diseases of
old age, such as ischaemic heart disease and dementia, contributed less to the total burden in
jurisdictions with younger populations (for example the Northern Territory and the
Australian Capital Territory).
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Table 5.6: Differentials in burden (DALYs) by state/territory jurisdiction for the 10 leading specific
causes, Australia, 2003
 Rank Per cent of total
Specific cause(a) NSW Vic Qld SA WA Tas NT ACT NSW Vic Qld SA WA Tas NT ACT
Ischaemic heart disease 1 1 1 1 1 1 3 2  10.4  9.6 10.2 10.8  8.8  10.7  6.5  8.1
Anxiety & depression 2 2 2 2 2 2 1 1  7.2  7.1  7.9  6.0  8.0  7.3  8.4  9.3
Type 2 diabetes 4 3 3 3 3 3 2 4  4.4  5.9  4.8  5.3  5.4  5.0  7.9  3.5
Stroke 3 4 4 4 5 4 11 3  5.0  4.3  4.4  4.5  3.9  4.4  2.0  3.9
Dementia 5 5 7 5 4 8 15 10  3.8  3.4  3.2  4.0  4.3  2.5  1.2  2.5
Lung cancer 7 6 5 7 6 6 10 7  3.4  3.4  3.3  3.2  3.5  3.8  2.3  2.8
COPD 6 7 6 6 7 5 7 8  3.4  3.1  3.3  3.7  2.8  4.0  3.3  2.6
Adult-onset hearing loss 10 10 8 8 10 9 35 12  2.2  2.5  2.9  2.6  2.4  2.4  0.7  2.3
Colorectal cancer 8 8 10 9 9 7 22 11  2.3  2.6  2.3  2.4  2.5  2.7  0.9  2.4
Asthma 11 9 9 11 8 10 8 5  2.2  2.5  2.5  2.3  2.7  2.4  2.3  3.3
 (a) Sorted according to the leading specific causes for Australia.
5.4 Differentials by socioeconomic status
Populations in areas with lower socioeconomic status experienced proportionally more
burden than populations in areas with higher socioeconomic status (Table 5.7). Females
experienced slightly more burden than males in areas with the highest socioeconomic status.
Conversely, males experienced more burden than females in areas with the lowest
socioeconomic status. The highest proportion of burden that was fatal was in the moderately
low and average socioeconomic areas, and the lowest (47.6%) was in the low socioeconomic
area.
Table 5.7: Burden (DALYs) for socioeconomic quintiles by proportions of total, proportions by sex,
and proportions due to mortality, Australia, 2003
Area DALYs (’000) Per cent of total Per cent male Per cent fatal burden
Low SES  562.5  21.4  52.8  47.6
Moderately low SES  564.2  21.4  52.7  49.3
Average SES  523.6  19.9  52.1  49.5
Moderately high SES  507.7  19.3  52.0  48.0
High SES  474.8  18.0  49.1  48.4
Australia  2,632.8  100.0  51.8  48.6
Total burden per head of population increased with decreasing socioeconomic status, with
the most disadvantaged populations having 31.7% greater burden than the most advantaged
populations. Again, this was due to higher rates of burden for most causes, but particularly
for mental disorders and cardiovascular disease (Figure 5.4).
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Figure 5.4: Age-standardised DALY rates per 1,000 by socioeconomic quintile, broad cause group
and sex, Australia, 2003
Table 5.8 provides a comparison between burden rates for areas by socioeconomic category
and the national average for the 10 leading broad causes of burden in Australia for 2003. Of
these causes, the greatest difference between areas with the lowest and highest rates
occurred (in order of magnitude of difference) in diabetes, injuries, mental disorders and
chronic respiratory diseases. The causes that contributed most in terms of the absolute
difference observed between socioeconomic quintiles were mental disorders (20.9%),
cardiovascular disease (17.6%) and diabetes (12.2%). Lifestyle-related (that is behavioural)
risk factors are important underlying risks for these conditions; the much greater burden
from these causes in lower socioeconomic areas is likely to be due to the greater prevalence
of lifestyle risk factors in these areas compared with higher socioeconomic areas. Limited
data availability on exposures by socioeconomic status, however, prevented further
exploration of this association.
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Table 5.8: Differentials in burden (DALY rates) by socioeconomic quintile for the 10 leading broad
cause groups, Australia, 2003
 Rate Standardised rate ratio(b) % diff. % of
Broad cause group Aust.(a) Low Mod. low Average Mod. high High  high/low(c) total diff.(d)
Cancer 25.1 1.05 1.05 1.05 0.97 0.88  19.3 12.0
Cardiovascular 23.8 1.10 1.08 1.05 0.95 0.84  31.8 17.6
Mental 17.6 1.22 1.05 1.02 0.92 0.80  53.5 20.9
Neurological 15.7 1.02 1.02 1.03 1.00 0.93 10.2 4.2
Chronic respiratory 9.4 1.15 1.07 1.01 0.95 0.83 38.8 8.4
Diabetes 7.2 1.30 1.05 1.09 0.91 0.70  87.2 12.2
Unintentional injuries 6.3 1.14 1.12 1.12 0.93 0.72 57.8 7.3
Musculoskeletal 5.3 1.08 1.02 1.05 0.97 0.89  20.5 2.7
Genitourinary 3.3 1.07 1.02 1.04 0.97 0.92  16.0 1.4
Intentional injuries 3.0 1.28 1.11 1.00 0.91 0.73 75.1 4.6
All causes 132.4 1.12 1.05 1.04 0.96 0.85  31.7 100.0
(a) DALY rate for Australia per 1,000.
(b) Ratio of age-standardised DALYs per 1,000 population for area to DALYs per 1,000 population for Australia.
(c) Calculated for each cause as the greatest difference in DALY rates between areas as a proportion of lowest rate for that cause.
(d) Calculated for each cause as the greatest difference in DALY rates between areas as a proportion of greatest difference for all causes.
Table 5.9 lists the 10 leading specific causes of burden for Australia and summarises for each
socioeconomic quintile these causes in terms of rank order and percentage of total burden.
Ischaemic heart disease and anxiety & depression were the leading causes of burden across
all socioeconomic quintiles.
Table 5.9: Differentials in burden (DALYs) by socioeconomic quintile for the 10 leading specific
causes, Australia, 2003
Rank Per cent of total
Specific cause(a) Low
Mod.
low
Aver-
age
Mod.
high High Low
Mod.
low
Aver-
age
Mod.
high High
Ischaemic heart disease 1 1 1 1 1  9.8  10.5  10.2  9.6  9.8
Anxiety & depression 2 2 2 2 2  8.1  7.3  6.8  7.5  6.6
Type 2 diabetes 3 3 3 3 5  5.9  5.0  5.3  4.8  4.2
Stroke 4 4 4 4 3  4.0  4.6  4.6  4.5  4.9
Dementia 7 6 5 5 4  2.9  3.5  3.7  3.7  4.2
Lung cancer 6 5 6 6 6  3.5  3.6  3.5  3.2  3.0
COPD 5 7 7 7 7  3.7  3.5  3.3  3.1  2.8
Adult-onset hearing loss 9 8 9 8 11  2.4  2.5  2.5  2.6  2.4
Colorectal cancer 10 9 8 9 9  2.1  2.4  2.5  2.5  2.6
Asthma 8 10 11 11 10  2.5  2.4  2.2  2.5  2.5
(a) Sorted according to the leading specific causes for Australia.
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Table 5.9 lists the 10 leading specific causes of burden for Australia and summarises for each
socioeconomic quintile these causes in terms of rank order and percentage of total burden.
Ischaemic heart disease and anxiety & depression were the leading causes of burden across
all socioeconomic quintiles.
Table 5.9: Differentials in burden (DALYs) by socioeconomic quintile for the 10 leading specific
causes, Australia, 2003
Rank Per cent of total
Specific cause(a) Low
Mod.
low
Aver-
age
Mod.
high High Low
Mod.
low
Aver-
age
Mod.
high High
Ischaemic heart disease 1 1 1 1 1  9.8  10.5  10.2  9.6  9.8
Anxiety & depression 2 2 2 2 2  8.1  7.3  6.8  7.5  6.6
Type 2 diabetes 3 3 3 3 5  5.9  5.0  5.3  4.8  4.2
Stroke 4 4 4 4 3  4.0  4.6  4.6  4.5  4.9
Dementia 7 6 5 5 4  2.9  3.5  3.7  3.7  4.2
Lung cancer 6 5 6 6 6  3.5  3.6  3.5  3.2  3.0
COPD 5 7 7 7 7  3.7  3.5  3.3  3.1  2.8
Adult-onset hearing loss 9 8 9 8 11  2.4  2.5  2.5  2.6  2.4
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(a) Sorted according to the leading specific causes for Australia.
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5.5 Differentials by remoteness
The majority (64.5%) of the burden was experienced by people in the major cities as they
account for 67% of the population.  Regional areas accounted for 33.1% of the burden and
remote areas 2.5% (Table 5.10). Males experienced more of this burden than females in all
areas, but particularly in remote areas. Remote areas experienced proportionately slightly
less fatal burden than other areas.
Table 5.10: Burden (DALYs) for remoteness categories by proportions of total, proportions by sex,
and proportions due to mortality, Australia, 2003
Area DALYs (’000) Per cent of total Per cent male Per cent fatal burden
Major cities  1,698.0  64.5  51.0  48.2
Regional  870.1  33.1  53.1  49.6
Remote  64.6  2.5  57.5  46.2
Australia  2,632.8  100.0  51.8  48.6
Total burden per head of population increased with remoteness, with remote populations
having 26.5% greater burden than populations in major cities. Again, this is due to higher
rates of burden for most causes, but particularly for injuries (Figure 5.5).
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Figure 5.5: Age-standardised DALY rates per 1,000 by remoteness category, broad cause group
and sex, Australia, 2003
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 Table 5.11: Differentials in burden (DALY rates) by remoteness category for the 10 leading broad
cause groups, Australia, 2003
 Rate Standardised rate ratio(b) % diff. % of
Broad cause group Aust.(a)  Major cities Regional Remote high/low(c) total diff.(d)
Cancer 25.1  0.98 1.04 0.98 7.0 4.6
Cardiovascular 23.8  0.96 1.07 1.10 14.6 9.1
Mental 17.6  0.98 1.05 1.06 8.5 4.0
Neurological 15.7  0.99 1.03 1.03 4.2 1.8
Chronic respiratory 9.4 0.97 1.04 1.30 33.6 8.3
Diabetes 7.2  0.94 1.08 1.93 105.6 19.5
Unintentional
injuries 6.3  0.87 1.24 1.92 121.3 18.1
Musculoskeletal 5.3  0.95 1.10 0.99 16.0 2.2
Genitourinary 3.3  1.00 0.99 1.11 12.3 1.1
Intentional injuries 3.0  0.90 1.13 2.26 151.5 11.0
All causes 132.4  0.97 1.06 1.22 26.5 100.0
(a) DALY rate for Australia per 1,000.
(b) Ratio of age-standardised DALYs per 1,000 population for area to DALYs per 1,000 population for Australia.
(c) Calculated for each cause as the greatest difference in DALY rates between areas as a proportion of lowest rate for that cause.
(d) Calculated for each cause as the greatest difference in DALY rates between areas as a proportion of greatest difference for all causes.
Table 5.11 provides a comparison between burden rates for areas by remoteness category
and the national average for the 10 leading broad causes of burden in Australia for 2003. Of
these causes, the greatest difference between areas with the lowest and highest rates
occurred (in order of magnitude of difference) in injuries, diabetes, chronic respiratory
diseases, musculoskeletal disorders and cardiovascular disease. The cause that contributed
by far the greatest proportion in terms of the absolute difference observed between
remoteness categories was injuries (29.1% for intentional and unintentional combined),
followed by diabetes (19.5%) and cardiovascular disease (9.1%).
Table 5.12 lists the 10 leading specific causes of burden for Australia and summarises for
each remoteness category these causes in terms of rank order and percentage of total burden.
Type 2 diabetes was the leading cause of burden in remote areas whereas dementia was
ranked twelfth, reflecting the younger age structure and higher proportion of Indigenous
people in these areas compared with the rest of Australia.
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Table 5.11 provides a comparison between burden rates for areas by remoteness category
and the national average for the 10 leading broad causes of burden in Australia for 2003. Of
these causes, the greatest difference between areas with the lowest and highest rates
occurred (in order of magnitude of difference) in injuries, diabetes, chronic respiratory
diseases, musculoskeletal disorders and cardiovascular disease. The cause that contributed
by far the greatest proportion in terms of the absolute difference observed between
remoteness categories was injuries (29.1% for intentional and unintentional combined),
followed by diabetes (19.5%) and cardiovascular disease (9.1%).
Table 5.12 lists the 10 leading specific causes of burden for Australia and summarises for
each remoteness category these causes in terms of rank order and percentage of total burden.
Type 2 diabetes was the leading cause of burden in remote areas whereas dementia was
ranked twelfth, reflecting the younger age structure and higher proportion of Indigenous
people in these areas compared with the rest of Australia.
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Table 5.12: Differentials in burden (DALYs) by remoteness category for the 10 leading specific
causes, Australia, 2003
Rank Per cent of total
Specific cause(a) Major cities Regional Remote Major cities Regional Remote
Ischaemic heart disease 1 1 2  9.8  10.6  7.3
Anxiety & depression 2 2 3  7.4  7.1  6.4
Type 2 diabetes 3 3 1  4.9  5.1  7.7
Stroke 4 4 8  4.6  4.4  2.8
Dementia 5 7 12  3.8  3.3  2.0
Lung cancer 6 6 10  3.4  3.5  2.6
COPD 7 5 4  3.1  3.6  3.8
Adult-onset hearing loss 11 8 11  2.3  2.7  2.1
Colorectal cancer 9 9 15  2.4  2.5  1.4
Asthma 8 10 9  2.5  2.3  2.7
(a) Sorted according to the leading specific causes for Australia.
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6 Past, present and future burden of
disease and injury in Australia
6.1 Overview
This chapter presents trends in population health dynamics over a thirty-year period. The
analyses involved consideration of health statistics over the last 25 years or more, although
the discussion about the past is linked to health trends over the last decade. Also presented
are the projected levels of the burden of disease and injury if these trends were to continue
20 years into the future. Since mortality is the starting point for many of these analyses,
observed and projected trends in mortality by broad cause group are summarised in Table
6.1. The methods underlying all analyses presented in this chapter are described in detail in
Chapter 2.
Table 6.1: Changes in mortality by broad cause group and sex, Australia, 1993 to 2023
Standardised rate ratio(a)
Rate per 100,000
for 2003  Males  Females
Broad cause group Males Females 1993 2003 2013 2023 1993 2003 2013 2023
 Infectious  14.8  9.5  0.93  1.00  0.97  0.92  0.95  1.00  0.92  0.83
 Acute respiratory(b)  16.5  20.9  0.43  1.00  1.00  1.00  0.40  1.00  1.00  1.00
 Maternal —  0.1 — — — —  1.87  1.00  1.26  1.19
 Neonatal  3.6  2.7  1.74  1.00  0.63  0.41  1.01  1.00  0.66  0.46
 Nutritional  0.2  0.6  2.83  1.00  1.24  1.09  1.72  1.00  0.74  0.65
 Cancer  211.1  163.7  1.20  1.00  0.89  0.75  1.12  1.00  0.92  0.82
 Other neoplasms  4.3  4.1  1.06  1.00  0.88  0.74  0.92  1.00  0.96  0.91
 Diabetes  19.5  16.6  1.01  1.00  0.96  0.90  1.13  1.00  0.88  0.76
 Endocrine  5.6  7.0  1.73  1.00  1.00  0.89  0.95  1.00  1.07  1.06
 Mental  10.4  3.4  1.18  1.00  0.90  0.75  1.10  1.00  0.91  0.79
 Neurological  27.8  41.7  1.10  1.00  0.99  0.91  0.93  1.00  1.04  1.05
 Cardiovascular  237.9  252.6  1.61  1.00  0.71  0.47  1.52  1.00  0.76  0.52
 Chronic respiratory  48.1  37.7  1.38  1.00  0.82  0.69  1.00  1.00  1.04  1.07
 Digestive  14.7  19.4  1.18  1.00  0.74  0.55  1.13  1.00  0.80  0.63
 Genitourinary  16.7  20.1  1.01  1.00  0.95  0.87  0.86  1.00  0.98  0.93
 Skin  1.2  2.0  1.06  1.00  0.96  0.83  0.88  1.00  1.03  1.04
 Musculoskeletal  2.6  5.1  1.29  1.00  0.94  0.79  1.10  1.00  0.95  0.90
 Congenital  4.2  3.4  1.17  1.00  0.75  0.60  1.30  1.00  0.75  0.58
 Oral  0.0  0.1  1.61  1.00  1.29  1.11  0.39  1.00  0.73  0.74
 Ill defined  0.5  0.6  3.13  1.00  0.54  0.25  2.01  1.00  0.69  0.52
 Injuries  52.4  27.7  1.13  1.00  0.87  0.73  1.00  1.00  0.87  0.74
All causes  692.1  639.0  1.32  1.00  0.83  0.67  1.22  1.00  0.87  0.73
(a) Ratio of age-standardised mortality rates for year to mortality rates for 2003.
(b) Age-specific rates for pneumonia post-2003 held at 2003 rates due to coding discontinuities between ICD-9 and ICD-10 for this cause.
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6.2 Health-adjusted life expectancy
This section begins, as did Chapter 5, by presenting life expectancy and health-adjusted life
expectancy, but this time with a temporal dimension rather than with a focus on differentials
between subpopulations. Over the last decade, total life expectancy in Australia improved
from 78.0 years in 1993 to 80.7 years in 2003. This was an annual growth of 0.35% (or 0.28 of a
year per year). If past mortality trends continue into the future as projected (that is, at an
exponentially declining rate), life expectancy will increase to 82.6 years in 2013 and 84.6 years
in 2023, an increase of 3.9 years from 2003. This represents an annual growth of 0.24% (or
0.20 of a year per year) over the 20-year period (Table 6.2).
Table 6.2: Life expectancy and health-adjusted life expectancy by sex, Australia, 1993 to 2023
1993 2003 2013 2023
Males Females Both Males Females Both Males Females Both  Males Females Both
Population(a)
(millions)  8.8  8.9  17.7 9.9 10.0 19.9 11.0 11.2 22.2  12.1  12.3 24.5
Proportion of population at selected ages (%)
0–59 years 85.8 82.8 84.3 84.1 81.6 82.8 79.8 77.6 78.7 75.1 72.7 73.9
60–79 years 12.5 14.1 13.3 13.5 14.2 13.9 16.9 17.3 17.1 20.3 21.1 20.7
80+ years 1.6 3.2 2.4 2.4 4.2 3.3 3.4 5.1 4.2 4.6 6.1 5.4
Life expectancy (years)
At birth 75.0 81.0 78.0 78.3 83.2 80.7 80.6 84.8 82.6 83.3 86.5 84.6
At age 60 19.5 23.8 21.7 22.1 25.6 23.9 23.7 26.8 25.2 25.9 28.1 26.8
At age 80 7.2 9.1 8.4 8.4 9.9 9.3 9.1 10.5 9.8 10.6 11.3 10.7
Health-adjusted life expectancy (years)
At birth 68.0 73.5 70.7 70.6 75.2 72.9 72.5 76.6 74.5 74.7 78.0 76.2
At age 60 15.2 19.2 17.3 17.1 20.5 18.9 18.4 21.5 19.9 20.1 22.5 21.2
At age 80 4.7 6.3 5.6 5.4 6.8 6.2 5.9 7.2 6.6 6.8 7.7 7.1
Healthy life expectancy lost due to disability (years)
At birth 7.0 7.5 7.3 7.7 7.9 7.8 8.0 8.2 8.1 8.6 8.5 8.5
At age 60 4.4 4.6 4.5 5.0 5.1 5.0 5.3 5.3 5.2 5.8 5.6 5.6
At age 80 2.5 2.8 2.7 3.0 3.2 3.1 3.2 3.3 3.3 3.7 3.6 3.5
Healthy life expectancy lost due to disability as proportion of total life expectancy (%)
At birth 9.4 9.2 9.3 9.8 9.6 9.7 9.9 9.6 9.8 10.3 9.9 10.0
At age 60 22.3 19.3 20.6 22.6 19.8 21.1 22.2 19.7 20.8 22.6 19.9 21.0
At age 80 35.2 31.1 32.5 35.8 31.8 33.2 35.3 31.8 33.1 35.4 31.9 33.3
(a) Estimated resident population figures as at 30 June 1993 and 2003 (ABS 2006, Cat. no. 3201.0, Table 9) and ABS population projections
series 8 (ABS 2003a, Cat. no. 3222.0).
Health-adjusted life expectancy, on the other hand, increased from 70.7 years to 72.9 years in
the decade to 2003, an annual growth of 0.31% (or 0.22 of a year per year). If, in addition to
past mortality trends, trends in non-fatal health conditions that give rise to disability
continue into the future as projected, health-adjusted life expectancy will increase to 74.5
years in 2013 and 76.2 years in 2023. This represents an annual growth of 0.22% (or 0.16 of a
year per year) over the 20-year period.
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Complex dynamics in population health will drive the slower gains in health-adjusted life
expectancy relative to total life expectancy. The most important of these is the decline in
mortality rates between 1993 and 2023 across the life span, but particularly in the elderly
(Figure 6.1a). One of the consequences of declining mortality is that, in combination with
ongoing declines in fertility, Australia’s population will continue to age. Of particular
relevance is the number of people aged 80 years and older. Over the last decade, the
proportion of the total population in this age group increased from 2.4% in 1993 to 3.3% in
2003. Based on recent Australian Bureau of Statistics (ABS) projections (ABS 2003a), this is
expected to increase to 4.2% in 2013 and 5.4% in 2023 (Table 6.2).
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Figure 6.1: Age-specific (a) mortality, and (b) total prevalence-based years lived with
disability (PYLD) expressed as rates per 1,000 in the elderly for both sexes combined,
Australia, 1993 and 2023
The impact on life expectancy of declining mortality rates is straightforward—it will
increase. The impact on health-adjusted life expectancy and its corollary, life expectancy lost
due to disability, however, is perhaps less intuitive at first. The key point is that, in most
populations, even if the prevalence of disability at each age were to remain at constant levels,
a decline in mortality would mean an increase in life expectancy lost due to disability in the
future (Figure 6.2). This is because reductions in mortality result in more people surviving
through to ages when the probability of being disabled is highest. Ultimately, though, this
relationship depends on changes in the rate at which mortality increases with age relative to
changes in the rate at which disability increases with age.
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Complex dynamics in population health will drive the slower gains in health-adjusted life
expectancy relative to total life expectancy. The most important of these is the decline in
mortality rates between 1993 and 2023 across the life span, but particularly in the elderly
(Figure 6.1a). One of the consequences of declining mortality is that, in combination with
ongoing declines in fertility, Australia’s population will continue to age. Of particular
relevance is the number of people aged 80 years and older. Over the last decade, the
proportion of the total population in this age group increased from 2.4% in 1993 to 3.3% in
2003. Based on recent Australian Bureau of Statistics (ABS) projections (ABS 2003a), this is
expected to increase to 4.2% in 2013 and 5.4% in 2023 (Table 6.2).
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Figure 6.1: Age-specific (a) mortality, and (b) total prevalence-based years lived with
disability (PYLD) expressed as rates per 1,000 in the elderly for both sexes combined,
Australia, 1993 and 2023
The impact on life expectancy of declining mortality rates is straightforward—it will
increase. The impact on health-adjusted life expectancy and its corollary, life expectancy lost
due to disability, however, is perhaps less intuitive at first. The key point is that, in most
populations, even if the prevalence of disability at each age were to remain at constant levels,
a decline in mortality would mean an increase in life expectancy lost due to disability in the
future (Figure 6.2). This is because reductions in mortality result in more people surviving
through to ages when the probability of being disabled is highest. Ultimately, though, this
relationship depends on changes in the rate at which mortality increases with age relative to
changes in the rate at which disability increases with age.
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Figure 6.2: Impact on life expectancy lost due to disability (years) of declining mortality
and constant (1993) levels of disability, Australia, 1993 to 2023
In addition to the increase in the proportion of total life expectancy lost due to disability
through reductions in mortality, is the impact of temporal trends in diseases and injuries that
give rise to the prevalence of disability. By estimating separately the epidemiology of these
causes in a fully temporal model, changes in total prevalence of disability by age, sex and
cause can be quantified for the first time over the past as well as into the future.
While the prevalence of overall disability appears to decrease when the effect of population
ageing is removed (by standardising for age), it will consistently increase over the next two
decades in crude terms (Figure 6.3). In other words, the proportion of overall time lived with
disability will increase from 7.8% in 2003 to 8.9% in 2023, an increase of 14.1%.
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Figure 6.3: Age-standardised and crude total prevalence-based years lived with disability
(PYLD) for both sexes combined, Australia, 1993 to 2023
This is for two reasons. First, the number of people aged 80 years and over is set to expand
rapidly due to declining mortality (Figure 6.1a). Second, while the prevalence of disability
will drop at most ages, it will actually increase in this age group (Figure 6.1b). In the decade
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to 2003, disability in people aged 80 years and over increased by 2.0%; if past trends
continue, by 2023 disability will have increased a further 1.7% (Figure 6.4). This lends
support to the hypothesis which predicts that as population health improves, disability is
increasingly concentrated towards the end of the life span.
0.0
-6.2
-11.0
-13.8
0.0
-0.5
-6.3
-9.4
0.0
2.0
3.3 3.7
-15
0
15
1993 2003 2013 2023 1993 2003 2013 2023 1993 2003 2013 2023
60-69 years 70-79 years 80+ years
Ch
an
ge
 fr
om
 19
93
 (%
)
Year
Figure 6.4: Per cent change in the rates of total prevalence-based years lived with disability
(PYLD) since 1993 at selected age groups for both sexes combined, Australia, 2003 to 2023
The effect on health-adjusted life expectancy of the increasing concentration of disability
towards the end of life, which until now has been largely unexplored using empirical data,
can be illustrated by gains in expectation of life in a model in which disability is included as
a dynamic force over time, compared with a counterfactual scenario in which the probability
of disability is held constant (Figure 6.5 and Figure 6.6). Such a comparison provides insights
into the question ‘What impact will concentration of disability towards the end of the
lifespan have on health-adjusted life expectancy?’
Health-adjusted life expectancy at birth is the most commonly cited measure, and
summarises mortality and disability risks across the life span. In males, this will increase at a
rate faster than would have been observed through reductions in mortality alone, with the
net effect of morbidity being increasingly concentrated towards the end of life. From 1993 to
2003 the gain was about 0.2 years. Over the longer term, however, the gain will be larger, at
around 0.8 years of healthy life for males born in 2023. At adult ages, the gains are less and,
in the elderly, where gains in health expectancy due to declines in mortality are more easily
offset by increases in disability, there were losses in healthy life due to this dynamic in the
decade to 2003, but these disappear in the subsequent decade (Figure 6.5).
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Figure 6.5: Net years gained in health-adjusted life expectancy (years) from changes in
prevalence of disability compared with baseline (1993) levels of disability for males,
Australia, 2003 to 2023
In females, the impact of morbidity being increasingly concentrated towards the end of life is
not readily apparent in the decade to 2003. Over the next two decades this dynamic will start
to have an impact, although the gains in health expectancy at birth will be smaller than for
males (around 0.3 years in 2023) and the losses in the elderly will be greater and will be
experienced earlier in life.
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Figure 6.6: Net years gained in health-adjusted life expectancy (years) from changes in
prevalence of disability compared with baseline (1993) levels of disability for females,
Australia, 2003 to 2023
The correct answer to the question ‘What impact will the concentration of disability in the
latter part of the lifespan have on health-adjusted life expectancy?’, therefore, is: ‘It depends’.
This is because health expectancy at any particular age is a summary measure based on the
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combination of mortality and disability risks at that age and all subsequent ages. While a
detailed decomposition of the drivers of this complex dynamic is beyond the scope of this
report, growth in prevalent disability in the elderly is likely to come from increases in
diabetes and neurological conditions. Disability from diabetes, in particular, grew 10.4% in
the decade to 2003, and will grow a further 29.3% over the next two decades if current trends
in obesity continue (Figure 6.7). Neurological conditions grew 2.5% in the decade to 2003,
and are likely to grow a further 6.6% in the 20 years to 2023. Most other causes of prevalent
disability are likely to decline.
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Figure 6.7: Percentage change in disability (PYLD) prevalence rates since 1993 for selected
causes in people aged 80 years and over, Australia, 2003 to 2023
Figure 6.8 shows the number of healthy years lost due to prevalent disability (PYLD) by
cause and age for 1993 and 2023. This figure demonstrates the absolute growth in PYLD that
is expected to occur over this period due to increases in population size. It also shows the
shift in the distribution of PYLD towards older ages that will occur as a result of population
ageing. Trends in epidemiology will interact with these demographic factors to influence the
composition of causes of prevalent disability at each age. Neurological conditions will grow
substantially over the period 1993 to 2023 and will remain the largest contributor to
disability prevalence at older ages. Mental disorders, on the other hand, will grow only
slightly from 1993 levels but will remain the largest contributor to disability prevalence until
age 60. Disability from cardiovascular disease is expected to decline from middle age
onwards over this period but this decline will be more than offset by increases from diabetes.
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Figure 6.8: Prevalence of disability (PYLD) due to selected broad cause groups for both
sexes combined by age, Australia, 1993 and 2023
Changes in the age-specific trends described above reflect changes in the prevalence of
disability experienced at all ages (Figure 6.9). Mental disorders decreased from 26% to 25% of
total prevalence of disability in the decade to 2003. The effects of population ageing will
mean that mental disorders, which are largely experienced in early to middle adulthood, will
further decline to 22% of total prevalent disability in 2023, although they will remain the
leading cause of overall prevalent disability. Neurological & sense disorders, on the other
hand, will increase as a consequence of population ageing because they are experienced later
in life. In the decade to 2003 this group increased from 15% to 17% of total prevalent
disability in 2003, and over the next two decades, through population ageing alone, will
increase to 21% in 2023.
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Figure 6.9: Proportion of total prevalence of disability (PYLD) due to selected
broad cause groups, Australia, 1993 to 2023
Diabetes was the other strong growth area at all ages, increasing from 5% of total prevalent
disability in 1993 to 6% in 2003. If current trends in obesity continue, this figure is set to
increase by a further 50% to 9% of total prevalent disability in 2023.
6.3 Burden
The remainder of this chapter presents past, present and future burden using the standard
burden measure—DALYs. It is worth reiterating at this point that, unlike prevalent years
lived with disability (PYLD), DALYs are incidence-based and include, in addition to non-
fatal health outcomes, time lost due to premature mortality. Observed and projected trends
in burden (DALYs) by broad cause group are summarised in Table 6.3. The methods
underlying these figures are described in detail in Chapter 2. More detailed data on past,
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present and future burden by age, sex and cause is available on the web at
<www.aihw.gov.au/bod>.
Table 6.3: Changes in burden rates (DALYs) by broad cause group and sex, Australia, 1993 to 2023
Standardised rate ratio(a)
Rate per 1,000
 for 2003  Males  Females
Broad cause group Males Females 1993 2003 2013 2023 1993 2003 2013 2023
 Infectious 2.8 1.7  0.93 1.00 1.02 0.99  0.99 1.00 0.93 0.85
 Acute respiratory(b) 1.7 1.8  0.67 1.00 1.00 1.00  0.61 1.00 1.00 1.00
 Maternal — 0.2  — — — — 1.09 1.00 1.03 1.02
 Neonatal 1.9 1.6  1.32 1.00 0.80 0.68  1.00 1.00 0.82 0.71
 Nutritional 0.1 0.5  1.12 1.00 1.03 1.02  1.03 1.00 0.99 0.98
 Cancer 26.8 23.5  1.20 1.00 0.85 0.70  1.16 1.00 0.88 0.74
 Other neoplasms 0.5 0.6  1.03 1.00 0.83 0.68  0.94 1.00 0.89 0.81
 Diabetes 7.8 6.6  0.87 1.00 1.15 1.32  0.89 1.00 1.18 1.40
 Endocrine 1.5 1.4  1.88 1.00 1.08 1.03  0.89 1.00 1.16 1.31
 Mental 16.8 18.5  1.03 1.00 1.01 0.99  0.99 1.00 1.01 1.01
 Neurological 14.9 16.6  0.96 1.00 1.02 1.03  0.96 1.00 1.03 1.05
 Cardiovascular 25.6 22.1  1.56 1.00 0.69 0.48  1.51 1.00 0.74 0.53
 Chronic respiratory 10.0 8.8  1.22 1.00 0.83 0.73  1.04 1.00 0.96 0.93
 Digestive 2.9 2.9  1.01 1.00 0.81 0.71  1.03 1.00 0.85 0.75
 Genitourinary 2.9 3.7  0.97 1.00 0.97 0.96  0.97 1.00 0.98 0.95
 Skin 1.0 1.0  1.00 1.00 1.00 0.99  1.00 1.00 1.00 0.99
 Musculoskeletal 4.5 6.1  0.98 1.00 1.03 1.05  0.97 1.00 1.02 1.02
 Congenital 1.9 1.4  1.11 1.00 0.84 0.74  1.19 1.00 0.84 0.72
 Oral 1.2 1.3  0.99 1.00 1.02 1.03  0.98 1.00 1.01 1.02
 Ill defined 0.5 0.7  1.70 1.00 0.83 0.73  1.31 1.00 0.93 0.89
 Injuries 13.1 5.5  1.16 1.00 0.91 0.79  1.08 1.00 0.89 0.76
All causes 138.2 126.7  1.18 1.00 0.90 0.81  1.11 1.00 0.93 0.87
(a) Ratio of age-standardised DALY rates for year to DALY rates for 2003.
(b) Age-specific rates for pneumonia post-2003 held at 2003 rates due to coding discontinuities between ICD-9 and ICD-10 for this cause.
As observed with PYLD, total burden will most likely decrease after the effect of population
ageing is removed (that is, age-standardisation) over the next two decades, yet in crude
terms it will most likely increase (Figure 6.10). Again, this is due to a larger proportion of the
population alive at older ages.
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Figure 6.10: Age-standardised and crude burden (DALY) rates for both sexes combined,
Australia, 1993 to 2023
Chapter 3 described the decline of cardiovascular disease relative to cancer as a proportion of
overall burden, and stated that for the first time, cancer accounted for the largest share of
overall burden experienced by the Australian population in 2003. This is primarily because
Australia has been relatively successful at curbing the impact of the cardiovascular disease
epidemic, but not nearly as successful to date with cancer. If these trends continue, the
burden of cardiovascular disease will further decline to about 13% of the total burden in
2023. The age-standardised rates of cancer mortality and disability are expected to fall
somewhat in the future but cancer as a whole will retain its share of around 19% of total
burden two decades from now and will remain the largest contributor to total burden in 2023
(Figure 6.11).
Despite the steady decline in cardiovascular disease burden over the next two decades, there
is likely to be a strong increase in burden due to diabetes, primarily as a consequence of the
obesity epidemic. If current trends in obesity continue unabated, diabetes will account for
around 9% of total burden in 2023, up from around 5% in 2003 (Figure 6.11).
A major consequence of population ageing will be the steady growth in burden from
neurological & sense disorders, up from 12% in 2003 to around 16% in 2023. The main
contributors here will be dementia and adult-onset hearing loss, both causes for which
current treatments are largely ineffectual. The economic consequences of the former in terms
of the provision of appropriate care services are likely to be significant and will be evident in
the home and community sectors before they are felt in the residential aged care sector.
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Figure 6.11: Proportion of total burden (DALYs) due to selected broad cause
groups, Australia, 1993 to 2023
The proportion of burden due to major causes experienced at different ages throughout the
life span is unlikely to change dramatically over the next two decades (Figure 6.12). The
decline of cardiovascular disease as a proportion of total burden will be experienced at all
ages, although, in absolute terms, most notably in the elderly. This will be partially offset by
the increase in the proportion due to diabetes at all ages. The proportion of total burden due
to cancer at different ages is unlikely to change.
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Figure 6.12: Burden (DALYs) due to selected broad cause groups for both sexes combined
by age, Australia, 1993 and 2023
In terms of specific causes of disease burden, ischaemic heart disease is the leading cause in
males across three of the four time periods. Its share of burden declined from 14.7% in 1993
to 11.1% in 2003 (Table 6.4). If this trend continues, ischaemic heart disease will decline a
further 36% to 7.1% of the total burden in 2023. Type 2 diabetes, on the other hand, rose from
sixth place to second in the decade to 2003, and is likely to increase a further 65% to first
place or 8.6% of the total burden in 2023. Anxiety & depression will retain its third place, at
around 4.5% of the total burden in 2023, but lung cancer will drop to sixth place, largely
because of the dramatic decline in smoking prevalence in males over the last two decades. In
its place, dementia will occupy fourth position in 2023, up from 11th place in 2003.
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Table 6.4 Leading causes of burden (DALYs) in males, Australia, 1993 to 2023
 Rank(a) Per cent of total
Specific cause 1993 2003 2013 2023 1993 2003 2013 2023
Ischaemic heart disease 1 1 1 2 14.7 11.1 8.9 7.1
Type 2 diabetes 6 2 2 1  3.6 5.2 6.8 8.6
Anxiety & depression 2 3 3 3 4.5 4.8 4.7 4.5
Lung cancer 3 4 4 6  4.4 4.0 3.8 3.4
Stroke 5 5 6 7  4.2 3.9 3.5 3.2
COPD 4 6 9 11  4.4 3.6 2.9 2.2
Adult-onset hearing loss 11 7 5 5 2.5 3.1 3.7 4.2
Suicide & self-inflicted injuries 8 8 10 10 2.9 2.8 2.8 2.4
Prostate cancer 10 9 8 8  2.5 2.7 3.0 3.1
Colorectal cancer 9 10 11 9 2.6 2.5 2.6 2.4
Dementia 14 11 7 4  1.8 2.5 3.3 4.4
Road traffic accidents 7 12 14 18 3.0 2.3 1.8 1.3
Asthma 12 13 12 12  2.2 2.1 2.0 1.9
Alcohol dependence & harmful use 13 14 13 14 2.0 2.0 1.9 1.6
Personality disorders 16 15 17 19  1.1 1.2 1.2 1.2
Schizophrenia 15 16 20 23  1.1 1.1 1.1 1.0
Osteoarthritis 24 17 15 15  0.8 1.1 1.3 1.6
Back pain 23 18 18 17  0.9 1.1 1.2 1.3
Melanoma 20 19 21 20  0.9 1.0 1.1 1.1
Parkinson’s disease 25 20 16 13  0.8 1.0 1.3 1.6
 (a) Sorted according to the leading specific causes for Australia in the year 2003.
Anxiety & depression is ranked first in females across three of the four time periods,
although in percentage terms its share of the total burden will decrease from 10.0% in 2003 to
8.7% in 2023 (Table 6.5). Ischaemic heart disease will remain in second place over the next
decade, but fall to fourth place by 2023. In its place will be dementia, which increased by 1.1
percentage points to 4.8% of the total burden in the decade to 2003, and, if current projections
of population ageing eventuate, will be ranked third at 7.4% of the total burden in 2023. As
with males, Type 2 diabetes is set to increase steadily and is likely to occupy second position
in 2023, at around 8% of the total burden.
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Table 6.5 Leading causes of burden (DALYs) in females, Australia, 1993 to 2023
 Rank(a) Per cent of total
Specific cause 1993 2003 2013 2023 1993 2003 2013 2023
Anxiety & depression 2 1 1 1 9.8 10.0 9.6 8.7
Ischaemic heart disease 1 2 2 4 12.4 8.9 7.5 6.1
Stroke 3 3 5 5  5.9 5.1 4.4 3.8
Type 2 diabetes 6 4 3 2 3.7 4.9 6.4 8.0
Dementia 5 5 4 3 3.7 4.8 5.9 7.4
Breast cancer 4 6 6 6 5.1 4.8 4.3 3.5
COPD 7 7 8 8  3.1 3.0 2.9 2.8
Lung cancer 10 8 7 7  2.3 2.7 3.1 3.5
Asthma 8 9 9 9  2.9 2.7 2.5 2.4
Colorectal cancer 9 10 10 12  2.6 2.3 2.2 1.9
Adult-onset hearing loss 11 11 11 11 1.5 1.8 2.0 2.2
Osteoarthritis 12 12 12 10  1.4 1.6 1.9 2.2
Personality disorders 15 13 14 16  1.2 1.3 1.3 1.3
Migraine 14 14 17 18 1.3 1.3 1.2 1.1
Back pain 16 15 15 15  1.1 1.2 1.3 1.3
Lower respiratory tract infections 38 16 13 13 0.5 1.1 1.3 1.6
Falls 20 17 18 19  0.9 1.0 1.1 1.1
Parkinson’s disease 19 18 16 14  0.9 1.0 1.2 1.5
Schizophrenia 17 19 20 25  1.0 1.0 1.0 0.9
Rheumatoid arthritis 21 20 19 20  0.9 1.0 1.0 1.0
 (a) Sorted according to the leading specific causes for Australia in the year 2003.
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7 Discussion and conclusions
7.1 Potential applications
A detailed description of the burden of disease and injury in a population is not sufficient for
setting priorities in public health. It is, however, an important foundation on which to build
assessments and evaluations that underpin health policies. This report contributes most
obviously by identifying the magnitude of health problems in a population and by
quantifying the contribution to these problems of major modifiable risks to health. The
present study greatly extends the scope of the previous study in this respect by presenting
burden estimates for a greater range of population subgroups in Australia. It also provides a
cogent analysis of past trends in burden in this country, and suggests the likely state of the
population’s health in 20 years from now if these trends were to continue. Furthermore, it
quantifies the contribution to overall burden of an expanded set of risks to health.
Equally important, however, is the contribution of burden estimation to down-stream
analyses by the creation of a consistent set of epidemiological parameters for a full range of
health conditions, and a detailed description of the relationship between these parameters
and risks to health. Again, the study upon which this report is based expands the scope of
such analyses through the creation of a comprehensive database of all relevant
epidemiological and burden parameters both for a number of different subpopulations and
through time. The most obvious synergy here is with cost-effectiveness analyses of the
potential outcomes of health interventions. Estimates from the previous study have been
used extensively in a number of economic evaluation studies to date (for example, Nelson et
al. 2005; Stone et al. 2004; Vos et al. 2005). This new set of results has been incorporated into
models under development for the project funded by the National Health and Medical
Research Council ‘Assessing Cost-Effectiveness (ACE)—Prevention’, at the University of
Queensland and University of Melbourne, the aim of which is to comprehensively model the
cost-effectiveness of preventive intervention options for non-communicable disease in
Australia.
The essential link between burden of disease and injury data and cost-effectiveness results is
acknowledged by the Pharmaceutical Benefits Advisory Committee, which now requires
companies to present evidence on the likely uptake of a new drug in the population. This
requires knowledge about the number of people with a particular condition or risk profile
for whom the drug is intended. This report will be invaluable as a common reference point.
An important new application of the results of this study will be to further improve
estimates of future health expenditure in this country. As life expectancy continues to
increase and populations continue to age, this is an area of concern to governments, not only
in Australia but around the world. Projections for the 2002 Intergenerational Report relied on
models that do not take into account major shifts in epidemiology and expenditure for some
diseases. The projections in this report have already been linked to health expenditure data
(AIHW 2005c), thus enabling more detailed health expenditure projections for these causes
(for example, Vos et al. 2007).
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7.2 Policy implications
The preceding section illustrated that the analyses underpinning this report are not sufficient
on their own as a basis for setting future directions in health policy. A number of other
inputs are also necessary, not the least of which is evidence on the costs and effectiveness of
available interventions.  Nevertheless a number of important implications for policy arise
from the findings presented in the preceding chapters.
This report has presented for the first time a comprehensive overview of the likely effects of
population ageing on patterns of disease and injury in Australia over the next 20 years.
These projections are based on analyses of past trends in health and are presented as a
‘business as usual’ scenario (that is, the rate of change in policy responses to emerging
problems in the future is consistent with the rate observed in the historical period upon
which the projections are based). While all projections regarding the future are uncertain,
including those presented in this report, some are more uncertain than others. This is
particularly true for the projections for diabetes, where information on trends is limited to
one cross-sectional survey and some assumptions regarding changes in case-fatality relative
to those observed for ischaemic heart disease (assumptions which are corroborated by the
second round of the Australian Diabetes, Obesity and Lifestyle study). Notwithstanding
these caveats, the general tenor of these analyses is clear.
A key finding of this study is that while life expectancy is likely to continue increasing
steadily, growth in health-adjusted life expectancy will not be as rapid. This is because the
number of very old people is set to expand rapidly, mostly due to declining mortality. In
addition, while the prevalence of disability will drop at most ages, it is expected to increase
for people aged 80 years and over.
A major consequence of this population dynamic will be the steady growth in the burden
from diseases associated with old age such as dementia, Parkinson’s disease, hearing and
vision loss, and osteoarthritis, all causes for which current prevention and (with the
exception of osteoarthritis and cataract) treatment strategies are largely ineffectual. The
impact of increasing disability from these diseases is likely to be significant and will be felt in
the home and the community care sectors before it is felt in the residential aged care and
palliative care sectors. While future research into prevention and treatment may yield
unexpected results, relevant stakeholders should be planning for growth in the number of
elderly people requiring appropriate services in each of these care settings. The economic
consequences of these changes on future health care expenditure have been quantified in a
separate report (Vos et al. 2007), which it is hoped might assist the development of
appropriate policy responses in this area.
In addition, cardiovascular disease are likely to continue to decline relative to cancer as a
proportion of the overall burden, primarily because current health care has been relatively
successful at curbing the effects of the former, but not nearly as successful with the latter.
Successful reductions of cardiovascular disease should not obscure the fact that additional
gains could be made by further reductions in levels of cholesterol, blood pressure and
smoking, the primary risk factors for these diseases (Taylor et al. 2006).  Increasing the
coverage and targeting of interventions known to be effective (for example dietary
modification, cholesterol and blood pressure lowering drugs, and smoking cessation) is one
way of achieving this. There is also likely to be scope for increased efficiency through the
adoption of a more cost-effective mix of interventions.
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Lastly, the projected strong growth in the burden from diabetes over the next 20 years is an
area of concern. This is mostly a consequence of increases in body weight. The consequences
of increasing obesity will be further magnified by reductions in case-fatality from
cardiovascular disease — the major cause of mortality in people with diabetes — through
successful tobacco control and cholesterol and blood pressure lowering strategies. This
increased survival will mean an increase in the risk of developing other largely non-fatal but
disabling consequences of diabetes such as renal failure, retinopathy, neuropathy and
peripheral vascular disease. Efforts to find new approaches to stem rising levels of obesity
need to continue.
7.3 Precision of estimates
Fatal burden
The calculation of fatal burden (YLL) is relatively straightforward and the precision of these
estimates is almost entirely dependent on the quality of information on underlying cause of
death in official mortality data. While every effort has been made to remedy likely
distortions to the overall reported cause of death structure by reallocating deaths with
certain codes known to be non-specific to valid and specific underlying causes of death, by
world standards the extent of these distortions is small (around 6% to 10%, depending on the
codes included in this definition). Of greater concern are the deaths coded to valid and
specific causes of death. With the exception of a few studies on sensitivity and specificity for
specific conditions, relatively little is known about the accuracy of causal attribution for the
majority of cases. It is likely that accuracy varies with the location of the death due to
differential access to diagnostic information (for example in an institutional setting versus at
home), but the assumption that these inaccuracies will cancel each other out at the
population level is largely speculative. Further research in this area would greatly enhance
the integrity of the vital registration system in this country.
Non-fatal burden
The accuracy of estimates of disability is not quantifiable using formal statistical techniques.
This is because, in the construction of these estimates, data of widely varying levels of
quality, ranging from population level disease registers and high quality research findings at
one end to ‘guesstimates’ and expert opinion at the other, was drawn upon. Precision is
likely to vary greatly between different individual estimates, and ultimately depends on the
type of model used and the source and nature of the underlying data. Using simulation
methods, it is feasible to quantify an uncertainty interval for each estimate that accounts for
confidence in the underlying epidemiological data as well as uncertainties associated with
the various assumptions and additional information used. Such an analysis has not been
possible in the time frame of this report, however, but may constitute the subject of future
research.
In the absence of such analyses, it is worth noting where major sources of uncertainty are
likely to lie in more qualitative terms. Among major causes of burden presented in this
report, uncertainty is probably highest for hearing loss, neurological conditions,
osteoarthritis and cirrhosis. The reasons for suspecting higher levels of uncertainty in these
conditions are discussed below.
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Hearing loss — although population data on measured hearing loss thresholds were used to
estimate disability for this condition, there was considerable uncertainty associated with the
modelling of the average durations associated with progressing from mild through moderate
to severe hearing loss and, to a lesser extent, the effect of hearing aids on reducing the
severity of disability from hearing loss.
Osteoarthritis — estimates for this condition were based on the same overseas studies of
incidence and severity used in the previous Australian Burden of Disease and Injury Study.
These estimates are lower than would be suggested by the Australian self-reported
population data on osteoarthritis. Considerable uncertainty remains about the true incidence
of this condition at the population level.
Selected neurological conditions — information on dementia and Parkinson’s disease came
from meta-analyses of international community-based studies of prevalence. For the
estimates presented in this report, these analyses were updated to include all such studies in
Western countries. There is uncertainty about the variations in the level of disease among
these countries.
Cirrhosis — there is no easy way to measure the prevalence of cirrhosis at a population
level. This report relied on a published modelling effort that projects the progression to
cirrhosis in people with hepatitis C. These figures were used to extrapolate cirrhosis from
hepatitis B, alcohol dependence and other causes. Considerable uncertainty surrounds these
extrapolations.
Mental disorders — these estimates were based on the mental health survey conducted in
1997; more recent data on this large cause of non-fatal burden would have been desirable.
Because of high levels of comorbidity between depression and anxiety, as well as the largely
similar treatment pathways, these conditions were combined into one entity and modelled
over a life course. This departs from the approach taken in the previous study where each
condition was treated separately and depression was modelled as an episodic condition.
General levels of uncertainty
In more general terms, it is likely that uncertainty in the estimates of burden presented in
this report may not be excessive. Overall, about half of the total burden in Australia was
attributable to mortality, for which estimates are fairly robust. Of the remainder, half was
attributable to non-fatal burden from a small number of diseases (including cardiovascular
disease, cancers, diabetes, common mental disorders, and injuries) for which reasonably
good Australian data are available. This leaves around a quarter of the total burden with
varying and probably higher levels of uncertainty.
What is clear is that a number of key estimates presented in this report are likely to be much
more accurate than those of the previous study. This is due to the availability of considerably
better quality data in some cases, one source of which deserves special mention. Access to
the linked hospital and mortality databases in Western Australia allowed greater accuracy in
the modelling of cardiovascular disease, the second leading cause of burden in Australia. As
Western Australia adds more health information data sets to its linkage program—including
health surveys, disease registries, Medicare and Pharmaceutical Benefits Scheme (PBS)
data—this will become an even more valuable resource, both for Western Australia and
nationally. Various efforts are in train to encourage data linkage in other jurisdictions and at
the national level. For example, the Statistical Information Management Committee (a multi-
jurisdictional committee established by health CEOs) has commissioned the development of
a framework for national data linkage, which takes careful account of such concerns as
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privacy, data protection, and custodianship. These efforts are to be encouraged, as they will
underpin improvements in future analyses of the burden of disease and injury in Australia.
Aside from data inputs, it is also worth mentioning the tools used. The second version of the
epidemiological modelling software DisMod allowed much more accurate modelling of
consistent epidemiological parameters than was possible in the previous study. In using this
software, particular attention was directed towards a consistent application of the concept of
‘excess risk’ (that is, people with a condition are often more at risk of dying than would be
indicated by the mortality actually coded to that condition) by accessing information from
international cohort studies and the linked hospital and death databases in Western
Australia.
DisMod also allows for past trends in incidence and case-fatality to be modelled, which is
particularly important for diseases with prevalence as the main observed parameter and for
which there have been significant trends in the past. This is because prevalence is a ‘stock’
variable and is simply a reflection of past trends in incidence and case-fatality. In this study,
there was a strong upward trend in the incidence of diabetes, accompanied by an
improvement in case-fatality. Ignoring these trends would have lead to an underestimate of
the true incidence of this disease. One area where DisMod was unable to help, however, was
in replicating final epidemiological models to multiple subpopulations and to various points
through time. For this application a custom-built routine was developed within a statistical
package environment based on DisMod’s underlying equations.
A final issue that is relevant to precision considerations is the set of disability weights
assigned to each health state. To date, a comprehensive set of weights has not been derived
in the Australian context. It was therefore necessary to continue to use an assortment of
weights derived largely from a Dutch study supplemented with weights from the original
Global Burden of Disease study and weights derived from a regression model on the Dutch
weights and the six domains of the EQ5D+ (an instrument to quantify quality of life).
Funding requested as part of the current study to validate these disability weights in the
Australian context has not been forthcoming. Also, internationally there has not been the
expected further development of measuring health state preferences to determine disability
weights. The large effort of collecting data in the World Health Surveys by the World Health
Organization in the first part of this decade has not yet resulted in any publication.
While this may raise concerns about the construct validity of the non-fatal estimates of
burden presented in this report, it should be noted that the rank order of weights for most
conditions has strong face validity and has been documented to be reasonably constant for a
set of ‘tracer conditions’ when replicated in different countries. Of greater concern are the
disability weights for common but low-severity conditions such as mild hearing loss, mild
vision loss, uncomplicated diabetes, asthma and anaemia. Existing health state evaluation
methods do not seem to accurately capture differences in severity between such conditions.
The lack of valid disability weights for distinguishing between high-prevalence low-severity
conditions is more important than it sounds because a small absolute difference in the
disability weight for a highly prevalent condition has a major bearing on the size of the
burden attributable to that condition. This is an area in need of further development.
Lastly, with respect to disability weights, a major improvement of this study compared with
most burden studies has been a comprehensive correction for coexisting health states. In the
previous study, an attempt was made to deal with comorbidities within mental disorders,
injuries and common causes of burden in the elderly, although each group was treated
separately and the latter was not comprehensive. Furthermore, the methods used assumed
no dependence between health states (that is, groups of conditions being more likely to
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coexist due to common causal pathways). The methods developed for the present study
drew upon multiple surveys and hospital data to derive probabilities of coexistence for all
possible combinations of health states that were modelled using an innovative
microsimulation approach. Dependence is implicitly accounted for in this approach.
Corrections for comorbidity in burden estimates are necessary because disability weights are
typically derived in isolation from each other, meaning that coexisting disability in the same
person is unlikely to be simply additive across two or more health states.
7.4 Access to data
Previous burden estimation work has been done mostly within a spreadsheet environment.
The benefits of this approach are that transparency and portability are maximised and, to
date, no other approach has achieved the level of flexibility afforded by working in this way.
However, accuracy can be a problem in that, in a spreadsheet, location is critical and
incorrect cell references are common. More importantly, spreadsheets rapidly become
unwieldy when more than several dimensions are being represented. In this study,
spreadsheets were retained for all basic disability modelling work, but a statistical package
environment was used for all subsequent analyses. The first practical implication of this
decision is that a set of spreadsheets containing all disability models exists and will be made
available to those who are interested. Users of this resource should note, however, that the
disability estimates in these spreadsheets will usually not correspond exactly with final
estimates in this report because comorbidity corrections and some trend corrections occur
outside this environment.
The other more interesting implication is that having extracted all relevant information from
the spreadsheets and derived final burden estimates outside this environment, the results
can be reassembled in any requested structure. This is particularly relevant for the estimates
for subpopulations and for various points through time. In collaboration with various
jurisdictional stakeholders, this information can be grouped into meaningful aggregations
for specific health policy and planning purposes. In addition, a web-based interface could be
developed whereby users could extract the desired information by cause, age, gender, time
and subpopulation. The website developed for disseminating the 1996 and 2001 Victorian
Burden of Disease study results is a useful model (see
<www.dhs.vic.gov.au/health/healthstatus/bod/bod_reg.htm>).
7.5 Future directions
This study comes seven years after the original Australian Burden of Disease and Injury
Study. It has taken three years to complete, with the equivalent of 2–3 full-time staff and
considerable intermittent assistance from researchers from several state health departments
and masters students. Such a commitment of resources to this type of research is unlikely to
occur again in this country in the short term. One of the aims of the study, therefore, was to
develop a less resource-intensive way of retaining an up-to-date set of burden estimates
going forward in time. To this end, a database of estimates for each year between 2003 and
2023 has been developed. This will provide an invaluable set of ‘base-level’ results for those
wanting to make assessments of burden in the period prior to the next major update. Such
assessments may entail varying levels of sophistication, from simple updates of fatal burden
using the most recent mortality data to ad hoc changes to specific non-fatal estimates based
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on advances in knowledge and better data. Through the adoption of strategies such as these,
a major revision may not be needed for at least another five years.
The final report of the previous Australian Burden of Disease and Injury Study identified
seven areas where it was felt priority should be placed in future research. Progress has been
made in a number of these areas over the last seven years, four of which are addressed
specifically by the present study. These include the development of burden estimates for
Indigenous Australians, a more detailed assessment of differentials in burden across
Australia, including estimates by socioeconomic status, remoteness and jurisdictional
boundaries, and more detailed modelling of National Health Priority Area diseases. A fifth
suggestion regarding the value of linking burden research to cost-effectiveness analyses has
been picked up in a number of separate studies around the country over this period.
Progress on two recommendations, however, has been less rapid. It has not been possible to
estimate and validate a set of disability weights in the Australian context and this remains an
important area requiring further development. Finally, there has been no formal evaluation
of the usefulness of burden of disease and injury analyses for policy makers and health
planners. There has been enough informal feedback from planners, researchers and the
media to know that there is consistent demand for this type of information. But a more
formal analysis of the impact on health assessment, policy and planning of this research over
the last seven years would be welcome.
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Appendix 1: Methods for estimating
disability burden
In this section we describe our methods for calculating disability for the large number of
diseases and injuries and their sequelae for which models were developed, including all
those that make significant contributions to the total non-fatal burden. While this list is
extensive, it is not exhaustive, and explicit models were not developed for many conditions.
Table A1.1 lists the full names of many of the data sources underlying our models and our
abbreviations of these names, which we use in this section for ease of reference.
Table A1.1: List of full and abbreviated names of commonly used data sources
Abbreviated name Full name
AusDiab The Australian Diabetes, Obesity and Lifestyle Study, 1999–2000 (Dunstan et al.
2001)
Australian dialysis and transplant data 2002 Australian and New Zealand Dialysis and Transplant Registry (McDonald &
Russ 2002). The interpretation of this data is the responsibility of the authors of this
report and should not be seen as the interpretation of the Australian and New Zealand
Dialysis and Transplant Registry.
Australian disability survey Survey of Disability, Ageing and Carers (1993, 1998 or 2003) (ABS 1993, 1998b,
2003b)
Australian general practitioner data 2000–01 and 2002–03 Bettering the Evaluation and Care of Health (AIHW: Britt et al.
2001)
Australian hospital data 2002–03 National hospital morbidity database (AIHW 2003a)
Australian mortality data 2003 Cause of Death dataset (ABS 2005)
Australian notification data National Notifiable Infectious Disease Surveillance System (CDA, 2003) except for
HIV/AIDS which is from the National Centre for HIV Epidemiology and Research
(National Centre in HIV Epidemiology and Clinical Research, 2003)
Australian perinatal data 2002 Australia’s mothers and babies and various state and territory perinatal data
collections (AIHW: Laws & Sullivan 2004; Queensland Health 2004; Riley & King
2003).
Disability weight regression model Regression model of Dutch disability weights which requires inputs of health state
description based on the six domains of the EQ5D+ (p. 158 of AIHW: Mathers et al.
1999)
DisMod DisMod version II (Barendregt et al. 2003)
GBD study Global burden of disease and risk factors, 2000 (Lopez et al. 2006)
Low prevalence study 1997–98 Low Prevalence (Psychotic) Disorders Study  (Jablensky et al. 1999)
National Health Survey 2001 National Health Survey (unless otherwise specified as the 1995 National Health
Survey) (ABS 1995, 2001c)
National mental health survey 1997 National Survey of Mental Health and Wellbeing (ABS 1997)
National Trachoma Survey 1980 National Trachoma and Eye Health Program (Royal Australian College of
Ophthalmologists 1980)
Previous Australian burden study Australian Burden of Disease and Injury Study, 1996 (AIHW: Mathers et al. 1999)
Victorian birth defect data 2001–02 Victorian Birth Defects Register (Riley & Halliday 2004)
Victorian linked hospital dataset Analyses of Victorian hospital data 1996–2002 & 2001–02 from the 2001 Victorian
Burden of Disease and injury study (DHS, 2005)
Women’s health Australia Australian longitudinal study on women’s health (Lee et al. 2005)
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1A Infectious and parasitic diseases
Tuberculosis
We estimate the incidence of tuberculosis using Australian notification data on new cases of
tuberculosis. We assume that the average duration for tuberculosis is 8 months, reflecting 6
months for the shortest treatment cycle available and another 2 months of symptoms before
treatment.
Sexually transmitted diseases (excluding HIV/AIDS)
We base our incidence estimates for syphilis, chlamydia and gonorrhoea on Australian
notification data. Following expert advice, we assume that annual notifications for syphilis
and gonorrhoea represent all incident cases. We model syphilis using a staged approach
applying proportionate distributions for primary, secondary, and tertiary syphilis from the
GBD study. We adjust our estimates for chlamydia to account for under-reporting due to
asymptomatic infections and the reluctance of some patients to consult general practitioners
about sexually transmitted diseases. We base our incidence estimates of pelvic inflammatory
disease, a complication of both chlamydia and gonorrhoea in women, on Australian hospital
data. Following expert advice we adjust these estimates to account for under-identification.
Common sequelae of pelvic inflammatory disease include ectopic pregnancy, chronic pelvic
pain, infertility and tubo-ovarian abscess. We base our rates of complications following
pelvic inflammatory disease on GBD assumptions. We adjust our incident estimates of
infertility resulting from pelvic inflammatory disease for women who do not wish to have a
child and therefore do not experience disability. In the absence of Australian data on ‘child
wish’, we make this adjustment using findings from a recent German study (Stobel-Richter et
al. 2005). The GBD reports urethral stricture and epididymitis as complications following
chlamydial and gonorrhoeal urethritis in men. These complications were thought by experts
to be rare, and so have not been included in the Australian estimates. We model disability
weights and durations for syphilis, chlamydia and gonorrhoea and their sequelae using the
assumptions of the GBD study.
HIV/AIDS
We model HIV as a progressive condition with four stages: (1) asymptomatic HIV; (2)
symptomatic HIV; (3) AIDS prior to terminal phase; and (4) terminal AIDS. We assume that
the annual number of new HIV diagnoses from Australian notification data represent all
incident cases of HIV. We use the Dutch disability weights for each of the stages (stage
1—0.2, stage 2—0.31, stage 3—0.56 and stage 4—0.95) and adjust the weight for stage 1 to
account for the estimated proportion of undiagnosed asymptomatic HIV cases to whom we
assign a disability weight of 0 (Aalen et al. 1997). We calculate the mean durations for stages
1 to 3 using Weibull regressions of published data accounting for background mortality
(Kaldor & McDonald 2003; Mocroft et al. 1997; Porter et al. 2003). This gives average
durations of 30 years for the combined stages 1 and 2 and 5.5 years for stage 3. We adjust our
duration estimates for stage 1 and 2 based on the assumption that an equal amount of time is
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spent in each stage based on work by Aalen and colleagues (1997). In the absence of new
evidence, we assume that stage 4 lasts an average 0.5 of a year.
Diarrhoeal diseases
Diarrhoeal diseases include a number of notifiable diseases as well as non-notifiable
diseases. Given that notifications are generally considered a gross underestimate of the
incidence for notifiable diarrhoeal diseases, and that there is often even less reliable
information on the incidence of non-notifiable diarrhoeal diseases, we do not model
diarrhoeal diseases using notification data or by specific cause. Instead, we derive the
incidence of diarrhoea not requiring hospitalisation using annualised self-reported data from
the 2001–02 National Gastroenteritis Survey (Hall & OzFoodNet Working Group 2004). We
base our duration of 2 days from the findings of this survey and use age-specific weights for
uncomplicated diarrhoea (average weight of 0.093) from the GBD study. We use Australian
hospital data to estimate the incidence of diarrhoea cases requiring hospitalisation. We use
the age-specific GBD weight for diarrhoea (0.093) since the Dutch weight is implausible. We
assume 2 weeks duration for complicated diarrhoea and derive an average weight (0.42)
based on 1 week of disability equivalent to the regression model of health state (323311) and
1 week of disability for uncomplicated diarrhoea.
Childhood immunisable diseases
We do not model poliomyelitis and diphtheria for 2003. This is because there were no
notifications of poliomyelitis from 1993 to 2003 and only one notification of diphtheria in
2001.
Pertussis
We estimate the incidence of pertussis using Australian notification data averaged over
2000–2003, an epidemic cycle. We adjust our incidence estimates for under-reporting based
on the literature (Andrews et al. 1997; Torvaldsen et al. 2002). We apply the age-specific GBD
disability weights for untreated cases for pertussis (0–4 years: 0.178; 5–14 years: 0.166; 15
years or over: 0.156), since the weight for treated cases is implausible, along with the GBD
duration of 1 month. Following expert advice we estimate the incidence of intellectual
disability attributable to pertussis as the proportion of intellectual disability cases from the
total episodes of infection for 0–4 year olds in the GBD study (that is, 0.3% of pertussis cases).
We derive a disability weight (0.58) for pertussis-related intellectual disability by weighting
the number of cases of intellectual disability due to infectious diseases by the level of severity
(using the Dutch weights for intellectual disability).
Tetanus
We estimate the incidence of tetanus using Australian notification data and apply the GBD
disability weight for 60 years or over of 0.612, and duration of 2 weeks.
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Measles
We derive the incidence of measles using Australian notification data. We assume annual
notifications in 2003 represent all cases of measles due to enhanced surveillance (Brotherton
et al. 2004). For acute measles episodes we apply the GBD duration and disability weights (2
weeks, 0.152). We use Australian hospital data to estimate the incidence of measles sequelae.
In 2003 there were no hospitalisations for measles encephalitis, and only one for sub-acute
sclerosing panencephalitis. For the latter sequelae we apply the Dutch disability weight for
end stage disease with a duration of 9 months.
Rubella
We derive the incidence of rubella using Australian notification data which we adjust for
over-reporting. Enhanced surveillance of rubella notifications in Victoria found that 27%
were laboratory confirmed (Guy et al. 2004). As there is no GBD or Dutch weight for rubella
we use the measles disability weight (0.152) with a duration of one week. We use Australian
notification data to derive incidence estimates of congenital defects due to rubella; there were
only three such cases in 2003. The classic triad of complications associated with congenital
rubella infection are cataract, heart disease, and deafness. In the absence of more specific
information, we derive an average disability weight and durations to reflect each of these
complications.
Haemophilus influenzae type b
We derive the incidence of Haemophilus influenzae type b from Australian notification data.
We only model the disability associated with the following sequelae—meningitis,
epiglottitis, septicaemia, pneumonia and ‘other’ using data from an Australian study (Herceg
1997). Following expert advice we assume that all cases of epiglottitis and meningitis are
confined to the 0–14 year age group and pneumonia and septicaemia to the 15 years or older
age group. We assume that meningitis from Haemophilus influenzae type b is included in the
hospitalisation-based estimates of total meningitis and subtract these cases from the total
incidence estimates of meningitis to avoid double-counting. We use the same disability
weights and durations for these sequelae as per the previous Australian burden study.
Meningitis
We estimate the incidence of meningitis from Australian hospital data which we adjust to
avoid double-counting of meningitis from Haemophilus influenzae type b. We model
meningitis as a progressive condition with acute episodes of one month, after effects lasting
up to six months and subsequent lifelong effects, in some, for a range of conditions
(including hearing loss, ventriculoperitoneal shunt, seizure disorder, less severe
developmental problems, mental retardation and motor deficit and physical deformities).
We make minor modifications to the assumptions in the Dutch study regarding proportions
of meningitis cases progressing to sequelae and their associated disability using the results of
a seven-year follow-up study of meningitis in Melbourne children (Grimwood et al. 1995)
and expert opinion.
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Septicaemia
We estimate incident cases of septicaemia from Australian hospital data. We do not adjust
our estimates to account for meningitis-related septicaemia as Victorian data suggests that
less than 2% of cases are due to meningitis. In the absence of a weight for this condition in its
uncomplicated state, we use the Dutch weight for meningitis for an average duration of 1
month (Stouthard et al. 1997).
Arbovirus infections
We estimate the incidence of arbovirus infections using Australian notification data. Because
there are no specific disability weights for arboviruses we use comparable weights from the
Dutch study. For Ross River and Barmah Forest viruses we adjust estimates by 100% to
account for under-reporting in endemic areas. We model Ross River and Barmah Forest
viruses as a febrile illness in children aged up to 14 years and as an illness with acute and
chronic stages for incident cases aged 15 years or over. Based on Australian literature we use
the Dutch weight for influenza for children (1 month duration) and the Dutch weights for
moderate rheumatoid arthritis (1 month duration) and mild arthritis (3.5 months in Ross
River fever and half of this duration for Barmah Forest virus) for acute and chronic stages
respectively in adults (Mylonas et al. 2002; Russell 2002). In general, arthralgia persists
longer in Ross River virus infection than in Barmah Forest virus infection (Mackenzie et al.
1998; Russell & Dwyer 2000), therefore we halve the duration of the chronic phase in the
latter.
We adjust notifications for dengue fever by 10% to account for under-reporting. Based on the
literature we use the Dutch weight for malaria with a duration of 6 days (Russell & Doggett
1998; Solomon & Mallewa 2001). We use Australian hospital data to estimate the incidence of
the rare and disabling sequelae dengue haemorrhagic fever. There were only two cases in
2003. The GBD weight for this condition appears too low and so we apply the Dutch weight
for meningitis for just over 1 week.
We model the following flavivirus infections as ‘other arbovirus infections’: Murray Valley
encephalitis, Kunjin virus infection, Japanese encephalitis, and flavivirus not elsewhere
classified. In 2003 there were no notifications for Murray Valley encephalitis and only one
case of Japanese encephalitis notified. We apply GDB estimates of the incidence of sequelae
(episodes, cognitive impairment and neurologic sequelae), average disability weights, and
duration for Japanese encephalitis to all other arbovirus infections.
Hepatitis
Hepatitis A
We estimate the total incidence of hepatitis A using Australian notification data, which we
adjust for under-reporting (Amin et al. 1999). We assume that the 10% of incident cases
represent prolonged hepatitis A. We assume that Australian hospital data on hepatitis A
represent all cases of complicated hepatitis A. We calculate the number of incident cases of
uncomplicated hepatitis A by deducting the prolonged and complicated cases from our total
estimate. Due to the implausibility of the Dutch weight for uncomplicated hepatitis A we use
the average GBD weight of 0.093 with a duration of 3 weeks (Amin et al. 1999). We assume
that prolonged hepatitis A cases experience depression or fatigue for 6 months at disability
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weight equivalent to the Dutch weight for mild depression (0.14) (McIntyre 1990;  Willner et
al. 1998). We assume durations of 4 weeks for children and 6 weeks for adults (Melnick
1995). We apply a severe disability weight for half of this time (DW 0.747), and the remaining
time at the same weight as uncomplicated cases. This gives an average weight of 0.42.
Hepatitis B
We estimate the incidence of acute hepatitis B using Australian notification data and assume
that all infections reported as incident are symptomatic.
We derive incidence estimates for acute symptomatic hepatitis B infection in infants from
birth data and probabilities of perinatal transmission for ‘at risk’ mothers as reported by
Kaldor and colleagues (1996). Based on the literature we assume a 40% probability of
transmission if exposed. Using this estimate we can calculate the number of infants who
would be infected in the absence of vaccination (Kaldor et al. 1996). As current vaccination
coverage in children born to mothers ‘at risk’ is 95% (Menzies et al. 2004), we reduce the
number of carriers from perinatal transmission accordingly. Similarly we adjust the number
of perinatal infections for the probability of symptomatic infection which is 5% (Kaldor et al.
1996). Based on expert opinion, we assume a similar number of infections by casual contact
in childhood and for males and females.
We base our estimates of chronic hepatitis B on a series of DisMod models. First we estimate
the prevalence of adult carriers using an overall prevalence of 0.47% (O’Sullivan et al. 2004),
a remission of 0.5%, and an overall relative risk of mortality of 1.5. Next we estimate the
prevalence of adult carriers using incidence estimates of carriers from perinatal and casual
childhood transmission assuming no vaccination had occurred. We then subtract the
prevalence of carriers from childhood infections from the first model so we can use DisMod
to derive the incidence of chronic hepatitis B infection in adults. This model assumes a
steady state of hepatitis B infection in the population, with vaccination only recently
affecting perinatal and childhood transmission rates. This is unlikely to reflect the pattern of
disease over time, but in the absence of data on the trends over time, this was considered the
most plausible method of modelling the disease following expert consultation.
We assume the average duration for an acute symptomatic episode to be 4 weeks (Lee 1997).
We use the Dutch disability weight for acute hepatitis infection (0.21). We adjust the Dutch
weight for chronic hepatitis B infection with active viral replication (0.36) following expert
advice that only 15% of chronic cases have a symptomatic episode for 2 weeks each year
(giving an average weight of 0.002). The methods we use to derive YLD for
hepatitis B-related cirrhosis and liver cancer are described in the following section on
hepatitis C. test
Hepatitis C
Due to the asymptomatic nature of hepatitis C infection we assume that all YLD are a result
of hepatitis C sequelae, that is, cirrhosis and liver cancer.
There is a paucity of information on the occurrence of cirrhosis at a population level. Instead,
we make use of estimates of hepatitis C-related cirrhosis occurrence from an Australian
study which modelled the progression rates to various sequelae from hepatitis C incidence
(Law et al. 2003). The major problem in estimating the occurrence of hepatitis C-related
cirrhosis is the dramatic change in hepatitis C incidence over the last 5 decades, the relevant
time period for the development of current cirrhosis cases. The best available approximation
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of the pattern of hepatitis C epidemiology over the last 40 years is based on the pattern of
injecting drug use over time (Law et al. 2003).
We make largely the same assumptions in the modelling of hepatitis C-related cirrhosis as in
Law and colleagues (2003):
• 75% of people exposed to hepatitis C develop chronic infection
• an annual progression rate of 2% to cirrhosis
• a hepatitis C-related mortality rate of 1.5% following cirrhosis
• mean age of hepatitis C seroconversion among injecting drug users of 25 years
• a male to female ratio of 2:1 for persons who inject drugs and are hepatitis C-infected
• unlike in Law et al. (2003), we assume that 80% of those exposed to the hepatitis C (the
estimated proportion of hepatitis C carriers exposed through injecting drug use) have a
relative risk of mortality of 13 (Darke & Ross 2002) for an average of 14 years from the
moment of exposure (as estimated for heroin dependence)
• background mortality is calculated from life tables constructed from Australian
mortality and population data from 1950 to 2003.
Based on this model, we estimate 447 new cases of hepatitis C-related cirrhosis and 5,804
people living with cirrhosis due to hepatitis C in 2003. Next, we examine the Australian
hospital data for cirrhosis. In all cases in 2003 with a stated underlying cause, 49.4% are
alcohol related and 50.6% non-alcohol related. Based on expert opinion we attribute 5% of
non-alcohol related cirrhosis to other causes and the remainder to hepatitis. We estimate the
occurrence of cirrhosis due to other causes (that is, hepatitis B, alcohol abuse, and ‘other’) by
adjusting Australian hospital data by the admissions-to-prevalence ratio observed in
hepatitis C-related cirrhosis cases. We only give a disability weight for the last 3 years lived
with cirrhosis at 0.31 (minus 2 months) and 0.84 for the last 2 months (effectively interpreting
the Dutch weight for compensated cirrhosis as relevant for the time spent in decompensated
cirrhosis and the decompensated cirrhosis weight of the Dutch as the weight for terminal
liver failure).
In the previous study we assumed liver cancer occurred in around 19% of people with
hepatitis C and hepatitis B. More recent data, including from a large multi-centre study of
liver cancer patients in Europe, indicates that hepatitis B and C are responsible for around
19% and 40% of liver cancer respectively (Brechot et al. 1998; CDC 2001).
Malaria
We derive incidence estimates for malaria from Australian notification data. We model two
aspects of malaria, episodes and neurologic sequelae and adopt GBD assumptions for
disability weights and durations.
Trachoma
We model the disability associated with mild, moderate and severe vision impairment
resulting from trachoma infection. We assume that trachoma related visual impairment is a
problem only in remote Australia. We estimate the prevalence of trachoma-related visual
impairment using the 1980 National Trachoma and Eye Health Program. Based on expert
advice we adjust the prevalence downwards by one-third to account for observed decreases
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in the prevalence of scarring stages that follow infectious trachoma since the national survey
was conducted (Landers et al. 2005; Mak & Plant 2001). In the absence of more specific
information we assume that mild and moderate vision loss have the same cause distribution
by age as severe vision loss. We make minor adjustments to the prevalence of each stage by
age to ensure plausibility and to reflect published estimates. We estimate the incidence and
duration of trachoma in DisMod using our derived prevalence estimates. We initially model
the prevalence of severe vision loss in DisMod assuming no remission and a relative risk of
mortality of 1. We then use the incidence of severe vision loss from the DisMod output as
‘mortality’ in the moderate vision loss DisMod model. This takes the cases of severe vision
loss out of the pool of susceptible cases for moderate vision loss and therefore gives more
accurate average durations than if we were to use remission as remitted cases in the DisMod
model, as the cases continue to be subject to the hazard of incidence. Similarly we use the
incidence of moderate vision loss as ‘mortality’ in mild vision loss.
1B Acute respiratory infections
Lower respiratory tract infections
We base our incidence estimates for lower respiratory tract infections, including episodes of
influenza, acute bronchitis and pneumonia, on Australian general practitioner data. For
pneumonia, general practitioner data was thought to be more representative than hospital
data as it should include those who do and do not go to hospital. We use the same
assumptions for disability and durations as in the previous Australian burden study. GBD
duration estimates were halved to 3.5 days for acute bronchitis, and left at 1 and 2 weeks
respectively for influenza and pneumonia. Disability weights were derived using the
regression model (influenza 0.047; acute bronchitis 0.132; pneumonia 0.373).
Upper respiratory tract infections
We base our incidence estimates for episodes of acute nasopharyngitis and acute sinusitis on
annualised self-report data from the National Health Survey, while we model tonsillitis and
pharyngitis using Australian general practitioner data. We use the data from the 1995
National Health Survey because the 2001 survey did not include questions on acute
conditions. We adjust the tonsillitis and pharyngitis incidence estimate upwards by twofold
to reflect the much higher rate (13 times) for the broader condition of ‘sore throat’ that was
reported in the survey. We use derived weights and assume GBD durations, with minor
adjustments where we consider this to be appropriate. For employed adults, the average
number of days off work due to upper respiratory tract infections was around 0.5 of a day.
The GBD assumed an average duration of 3.5 days. The self-report prevalence data probably
includes a considerable number of minor infections with minimal disability. Hence we use
days off work plus half a day on either side to give an average duration of 1.5 days for acute
nasopharyngitis. For tonsillitis and pharyngitis and sinusitis we use the GDB durations of
3.5 days.
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Otitis media
We model the following stages of otitis media; acute infection, bilateral chronic infection, and
life-long deafness. We estimate the incidence of acute episodes using Australian general
practitioner data. We assume that those who have relatively low disability do not seek
treatment and base YLD estimates on treated numbers. We adjust our incidence estimates to
allow for a higher rate of acute otitis media in Indigenous Australians in remote areas based
on findings from the 1980 National Trachoma and Eye Health Program. We use the disability
weight regression model to derive an appropriate weight (0.090) and assume a duration of
1 week.
We estimate the prevalence of chronic otitis media in non-Indigenous and Indigenous
Australians from the National Health Survey for those people reporting otitis media as a
long-term health problem. We assume that these estimates represent non-Indigenous
Australians in all areas and Indigenous Australians in major city or regional areas. We adjust
these prevalence estimates downwards to account only for bilateral cases using a ratio of
bilateral to unilateral cases from the 1980 National Trachoma survey. We estimate the
prevalence of bilateral chronic otitis media in Indigenous Australians in remote areas from
the 1980 National Trachoma survey and assume that the epidemiology of bilateral chronic
otitis media has not changed since the survey was undertaken. We derive the incidence and
duration of bilateral chronic otitis media in DisMod using prevalence, a relative risk of 1 and
remissions equivalent to durations of 3 months and 3 years for non-Indigenous and
Indigenous Australians, respectively, based on Australian data (McGilchrist & Hills 1986).
We base our estimates for permanent hearing loss resulting from acute infections on the GBD
study. For chronic infection we apply the Dutch weight for early acquired mild to moderate
hearing loss (0.110). For the small number of cases that experience lifelong deafness, we use
the Dutch weight for early acquired severe hearing loss (0.233).
1C Maternal conditions
We base our incidence estimates for maternal haemorrhage, maternal sepsis, hypertension in
pregnancy, obstructed labour, abortion and other maternal conditions on Australian hospital
data. We adopt GBD methods except in the following instances. On expert advice we assume
hypertension in pregnancy results in restricted activity (due to advised bed rest or
hospitalisation) for 2 months at a derived weight of 0.117 (health state 122111), with 1 in
2,500 cases developing neurological sequelae. We model the sequela caesarean section with
2 weeks of disability at a derived weight of 0.349 (health state 222111). We base our incidence
estimates for abortions using South Australian data on terminations of pregnancy as a
proportion of total births (Chan et al. 2003). For abortion we model the disability of infertility
resulting from the sequela pelvic inflammatory disease. We assume that 20% of hospitalised
cases of pelvic inflammatory disease following abortion experience infertility from age at
infection to post-reproductive age which we assume to be 45 years. We adjust our incident
estimates of infertility, in the abortion and maternal sepsis models, for women who do not
wish to have a child and who therefore do not experience disability. In the absence of
Australian data on ‘child wish’, we make this adjustment using findings from a recent
German study (Stobel-Richter et al. 2005). Although stress incontinence was considered a
sequela of obstructed labour in the GBD study, most stress incontinence occurs in the
absence of such a history. We therefore treat this condition as a category in its own right,
classified under ‘genitourinary conditions’.
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1D Neonatal causes
Birth trauma and asphyxia
We estimate the incidence of mild, moderate and severe birth asphyxia using Australian
hospital data. We separate the mild and moderate incident cases using data from the GBD
study. We base our sequela estimates of neurological disability by severity of birth asphyxia
(0% of mild, 25% of moderate and 100% of severe) on the GBD study.
We use the estimates of intellectual disability due to birth trauma from the overall
calculations for intellectual disability by all underlying causes (see Section 2K). Stanley and
colleagues (1995) estimated that 8% of cerebral palsy is associated with birth trauma. The
balance of the incident cases of permanent disability is divided equally between deafness
and seizures.
We assume that the duration of cerebral palsy without intellectual disability and severe
hearing loss is the same as those with mild intellectual disability. We base the duration of
seizure on life expectancy at birth assuming a twofold risk of dying to indicate a greater
likelihood of premature mortality.
Low birth weight
We estimate the incidence of low birth weight (>=1500g and <2500g) and very low birth
weight (<1500g) in neonatal survivors using Australian perinatal data. We apply the sex
distribution of low birth weight from the 2002 Victorian perinatal data to the Australian
combined proportion for both sexes which we then apply to the total number of live births in
Australia in 2003 (ABS 2004). We adjust our estimates of total neonatal deaths in 2003 (ABS
2005) using a proportion for those due to low birth weight. This was derived using an
average of 2002 Victorian, Queensland, and South Australian data.
We assume the probability of disability among low birth weight survivors is 25% for very
low birth weight (<1500g) and 5% for low birth weight (>=1500g and <2500g) as per the GBD
study. This corresponds to a total of 1,230 incident cases (596 males, 634 females) of disability
in low birth weight survivors in 2003.
For hearing loss, vision loss, epilepsy, and other disability we distribute the incident cases of
disability in low birth weight survivors to disability type from the GBD study. We use the
estimates of intellectual disability due to low birth weight from the overall estimates of
intellectual disability (see Section 2K). In addition we attribute 60% of total incident cerebral
palsy cases (at 2.25 per 1,000 live births) to low birth weight.
Just over one half of the low birth weight survivors with permanent disability do not have
severe neuro-developmental disability. In the absence of a defined disability weight for this
health state we assume that these cases have a level of disability similar to the Dutch weight
for permanent early childhood acquired moderate hearing loss. For all other sequelae we
apply the relevant Dutch disability weight.
We assume the duration of cerebral palsy without intellectual disability, severe hearing loss,
moderate vision loss, and mild permanent disability to be the same as those with mild
intellectual disability. We base the duration of epilepsy on life expectancy at birth assuming
a twofold risk of dying as compared to the mortality rates of the general population.
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Neonatal infections
We estimate the incidence of neonatal infections from Australian hospital data. We assume
1 month of acute disability using the Dutch weight of 0.894 (same as for meningitis) for acute
episodes.
The main long-term sequelae are deafness, motor deficit disability and intellectual disability.
We estimate intellectual disability attributable to neonatal infections as part of overall
estimates for all causes of intellectual disability (see Section 2K).
Other conditions arising in the perinatal period
Here we include YLD for intellectual disability due to other conditions arising in the
perinatal period.
1E Nutritional deficiencies
Iron deficiency anaemia
We model the following levels of severity for iron deficiency: non-anaemic, mild anaemia,
moderate anaemia and severe anaemia. We define anaemia in terms of blood haemoglobin
levels as per the GBD study. We derive our incidence estimates for iron deficiency anaemia
using DisMod. We base our prevalence estimates for mild, moderate and severe anaemia for
men and women aged 25 years and above from AusDiab. For the younger ages we use a
variety of Australian studies, assuming 60% of cases are mild and the remaining 40%
moderate (English & Bennett 1990; Karr et al. 1996; Nguyen et al. 2004; Oti-Boateng et al.
1998; Sadler 1996;). Iron deficiency causes anaemia but people can be iron-deficient and not
anaemic and vice versa. To calculate iron deficiency without anaemia, we first have to
estimate the prevalence of total iron deficiency which includes those with and without
anaemia. We assume prevalence estimates of 10% and 1% in children aged 0–4 years and
5–14 years respectively (English & Bennett 1990; Mira et al. 1996; Oti-Boateng et al. 1998;
Rangan et al. 1998; Ranmuthugala et al. 1998; Sadler 1996), with figures for other ages taken
directly from 1989 National Risk Factor Prevalence Survey—Iron status study. In the absence
of population data on the overlap between iron-deficiency and anaemia, we assume half the
cases with mild anaemia and all cases with moderate anaemia are also iron-deficient. For
adults aged 15 years or over, we subtract the prevalence of iron deficiency combined with
anaemia from the total prevalence of iron deficiency to avoid double-counting the disability.
We use the same assumptions for disability and duration as in the previous Australian
burden study.
2F Malignant neoplasms
As in the previous study, the basis of YLD estimation for malignant neoplasms is a series of
models of disease progression developed by the Dutch burden of disease study team for
26 cancers for which they determined disability weights (Stouthard et al. 1997).
The disease model commences with an initial phase of diagnosis and primary therapy, with
a duration of up to 12 months. After this, cases are classified as those who will and will not
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be cured. Those who will be cured enter a phase of up to 5 years after which they are
considered cured and have (with some exceptions as discussed below) no further cancer-
related disability. Those who will not be cured enter a phase (of variable length) of remission
followed by a phase of disseminated carcinoma (lasting 12 months or less), then a terminal
phase (lasting 1 month) and death.
We allocate a Dutch weight to each of these phases. Where no Dutch weights were available
for a specific cancer site, we extrapolate weights based on the cancer that it most resembles.
The Dutch study did not derive a weight for the terminal phase of any of the cancers, so we
use instead the Dutch weight for general end-stage disease.
We modify this general model to each cancer site with results from studies in the peer-
reviewed literature and input from local clinicians to reflect local treatment practices.
Disease incidence data
The primary source of cancer incidence data is the AIHW & AACR National Cancer Statistics
Clearing House database (AIHW & AACR 2001). This database records all cancer cases
(except non-melanoma skin cancer) notified in Australia from 1982 to 2001. Cancer incidence
rates in the Australian population change very slowly (AIHW et al. 2005). We apply the 2001
age- and sex-specific cancer incidence rates to the 2003 Australian population counts to
estimate the 2003 cancer incidence.
Two exceptions to this approach are breast cancer and non melanoma skin cancer. The breast
cancer disease model requires details of size of tumour at diagnosis which are not available
from the Clearing House database. Instead, we extrapolate the proportion of new cases in
each size category from 2001 BreastScreen Australia data (AIHW 2005a) and all incident
cases from the AIHW breast cancer size and nodal status report for 1997 (AIHW et al. 2001).
We then apply these proportions to the 2003 incident cases projected from the Clearing
House database. Non-melanoma skin cancer is not a notifiable disease in Australia and so is
not within the scope of the Clearing House database. Instead, we extrapolate the incidence
from the results of a 2002 Australian population survey of the incidence of non-melanoma
skin cancer (NCCI 2003).
Cure rate and mean survival time
To estimate the cure rate and mean time to death for those not cured for each cancer we
assume a Weibull distribution for the time from diagnosis to death and apply a non-linear
model to the survival curves for each cancer (Verdecchia et al. 1998). We base the survival
curves on all cases recorded in the Clearing House database with a diagnosis date between
1982 and 1997 which we follow-up for death until the end of 1999 (AIHW & AACR 2001).
We base the durations of the initial treatment, disseminated and terminal stages separately
for each cancer, using Dutch study assumptions, peer-reviewed literature and input from
local clinicians. For those not cured, we base duration of the remission stage as the total
average time to death (estimated from the Weibull model) less the sum of the other stages.
For those cured, we base the duration of the stage following initial treatment as 5 years less
the duration of the initial treatment stage.
Again, breast cancer and non melanoma skin cancer are the two exceptions to this approach.
Since the Clearing House database does not record tumour size, we base the survival times
and cure rates on an analysis of breast cancer cases by tumour size published by the South
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Australian Cancer Registry (South Australian Cancer Registry 2000). Because there are no
national data on non melanoma skin cancer we estimate survival times and cure rates using
assumptions modelled from published studies.
Long-term sequelae of cancer
The model for cancer in the previous Australian burden study assumed, with the exception
of bone cancer, that cancer sufferers have no further burden following cancer cure. However,
there are some cancers that are likely to have major sequelae causing long-term burden
following successful treatment. The GBD study included long-term sequelae for colorectal
cancer, breast cancer, female reproductive cancers and male genitourinary cancers. In
addition, we include removal of one eye for eye cancer, removal of the larynx for larynx
cancer, amputation for bone cancer and long-term brain injury for brain cancer. These
sequelae and their associated severity weights are listed in the table below (Table A1.2).
We estimate cancer-related rates of amputation, stoma, mastectomy, larynx, eye removal and
infertility from Australian hospital data. We estimate infertility rates from cancer-related
hysterectomies and assume these only apply to survivors under 40 years of age. We derive
impotence and incontinence rates from a review of the literature. Results published in the
literature note the similarity between the effects of treatment for brain cancer and other
forms of traumatic head injury, so we assume that the rates of long-term brain injury from
brain cancers are the same as the equivalent rates for head injury.
We use the GBD disability weights for stoma, mastectomy, infertility, impotence and
incontinence. For the disability associated with removal of an eye, amputation, and long-
term brain injury we use comparable weights from the Australian study for long-term
weight for an injury to an eye, major amputation and long-term effects of a brain injury in a
non-fatal accident or injury, respectively. For removal of the larynx we assume that the
Dutch weight for mild hearing loss, which is defined as ‘some difficulty in actively
participating in a conversation with one or more persons’, is appropriate.
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Table A1.2: Extra sequelae for cancer model
Site/sequelae Proportion of survivors with sequelae (%) Severity weight
Colorectal cancer—stoma 0.09 0.21
Bone & connective tissue—amputation 0.08 0.30
Breast cancer—mastectomy 0.51 0.09
Female reproductive cancer—infertility
Cervix: 0.46
Uterus: 1.00
Ovary: 0.64
0.18
(ages under 40)
Male genitourinary cancer—impotence
and incontinence
Prostate: 0.53
Bladder: 0.12 0.20
Brain cancer—long-term brain injury 0.05 0.35
Eye cancer—removal of an eye 0.45 0.30
Larynx cancer—removal of the larynx 0.35 0.04
2G Other neoplasms
Benign neoplasms are not notifiable in Australia. As a result we base our incidence estimates
for uterine myoma and benign brain tumour on Australian hospital data.
Specifically, for uterine myoma we use the numbers of myomectomies and hysterectomies
for fibroids. We assume that surgical treatment is undertaken for all cases of rapidly growing
or large tumours and myoma-related symptoms. We assume a six month pre-operative state
equivalent to the GBD weight for chronic pelvic pain and an additional three-week post-
operative state equivalent to laparotomy (derived weight of 0.349 for health state 222211).
Based on expert advice, we assume reproductive disability occurs in 3% of hysterectomy
cases to whom we apply the GBD weight for infertility. We assume the additional burden
associated with menorrhagia in undiagnosed women is included in our YLD estimates for
this condition under the ’other genitourinary’ category.
Our model for benign brain tumour is based on the model for malignant brain tumours
where we model the disease in stages for survivors (diagnosis and initial treatment, and
post-curative treatment) and non-survivors (diagnosis and initial treatment, pre-terminal
and terminal). We adjust our incidence estimates on the assumption that 20% of
hospitalisations are readmissions (Jaaskelainen 1986; Simoca et al. 1994). We base our
survival estimates on Australian mortality data and assume successfully treated cases
recover normal efficiency (Steiner et al. 1998) with a period of ‘worry’ after treatment of
2 years. In the absence of specific disability weights, we use those for malignant brain
tumours.
2H Diabetes
Diabetes cases
We estimate the incidence of insulin dependent diabetes mellitus (Type 1) from the National
Diabetes Register (AIHW 2003b). We use DisMod to estimate prevalence and duration,
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assuming no remission and age-specific risks of dying for all diabetes from the Asia Pacific
Cohort Studies Collaboration — a meta-analysis of 24 cohort studies from Asia, Australia,
and New Zealand that assessed the effects of diabetes on the risks of major cardiovascular
disease and death (Woodward et al. 2003). We estimate the incidence of non-insulin
dependent diabetes mellitus (Type 2) for ages less than 25 years from the National Diabetes
Register. We estimate the incidence of Type 2 diabetes for ages 25 years and above by
subtracting the prevalence of Type 1 diabetes from the total prevalence of diabetes from
AusDiab and then deriving incidence and duration in DisMod including an annual trend for
the period 1980–1999 for incidence of 2.5% for males and 1.5% for females (Dunstan et al.
2002). There is no direct measurement of the trend in incidence/prevalence of Type 2
diabetes in Australia. Instead, we analyse the historical trend in diabetes mortality (which is
relatively ‘flat’) and assume that this reflects the net effect of an increase in incidence and a
decrease in case-fatality which in turn we assume to be equivalent to the trend in
cardiovascular disease case-fatality (as the main causes of death in people with diabetes are
of cardiovascular origin). Thus, we also incorporate a 20 year trend for the case-fatality rate
(–2% annual for males and –1% for females). We then project incidence and case-fatality
forward to the year 2003 using the same trends as above and enter these into a DisMod
model for total diabetes for 2003.
We subtract out those with diabetic nephropathy to avoid double-counting as the Dutch
disability weight for diabetic nephropathy includes the disability associated with diabetes
per se. We use the Dutch disability weight for an uncomplicated diabetes case (0.070).
Complications from diabetes for which we calculate YLD include retinopathy, cataract,
glaucoma, renal failure, neuropathy, peripheral vascular disease, diabetic foot, amputations,
ischaemic heart disease and stroke.
Retinopathy
We estimate the prevalence of mild and moderate vision loss from proliferative diabetic
retinopathy in the Melbourne Visual Impairment Project (Weih et al. 2000). Experts
confirmed that most retinopathy is treated before it leads to more serious vision loss.
Therefore we estimate the incidence and duration of diabetic retinopathy in DisMod from
the prevalence estimates from the Melbourne project, assuming no remission and twice the
excess risk of mortality as for all diabetes. We base the proportion of cases due to Type 1 and
Type 2 diabetes on the ratio of expected cases derived from modelling data on the
progression of proliferative diabetic retinopathy from time of diagnosis (NHMRC 1997b;
Tapp et al. 2003b). The Dutch disability weights for mild and moderate vision loss apply.
Cataract and glaucoma
We estimate the proportion of YLD from cataract and glaucoma attributable to Type 1 and
Type 2 diabetes using population attributable fractions. We base the risks of cataract and
glaucoma in diabetics from the Blue Mountain Eye Study (Mitchell et al. 1997) and use
severity distributions from the Melbourne Visual Impairment Project (Weih et al. 2000).
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Renal failure
We estimate the incidence of diabetes-related renal failure using 2002 data from the
Australian dialysis and transplant data. We use DisMod to estimate the average duration for
people on dialysis, assuming a case-fatality rate reflecting observed deaths from the register.
We base our annual remission estimates on observed transplant data: 85% in  Type 1
diabetes cases aged 0–85 years or over for males and females combined; 6% in Type 2 cases
under 65 years for males and females combined; and 0% in Type 2 cases aged 65 years or
over for males and females combined. We use the Dutch disability weight for diabetic
nephropathy (0.29). We estimate YLD for transplant patients assuming a case-fatality ratio
reflecting observed deaths from the register and 3% ‘remission’ due to graft failure (as these
patients return back to the pool of dialysis cases). We assume a high disability weight (0.29)
for the first 6 months following the transplant and a GBD weight of 0.11 thereafter.
Neuropathy
Tapp and colleagues provide estimates of diabetic neuropathy prevalence by time since
diagnosis (2003a). We estimate by linear regression an annual increment in prevalence,
which we then apply to survivors of incident cases of Type 1 and Type 2 diabetes by age as
they progress to other age groups. Based on the Rochester Diabetic Neuropathy Study only
15% of Type 1 and 13% of Type 2 cases with diabetic neuropathy are symptomatic, of which
6% of Type 1 and 1% of Type 2 are severely affected (Dyck et al. 1993). The disability weight
for Type 1 is 0.099 using the disability weight regression model (health state: 111111—85%;
222221—9%; and 222331—6%) and for Type 2 is 0.074 (using the corresponding percentages
of 87%, 12% and 1%).
Peripheral vascular disease
Tapp and colleagues provide estimates of peripheral vascular disease incidence and
prevalence (Tapp et al. 2003a). We assume that only those with claudication are
symptomatic. We estimate by linear regression an annual increment in the prevalence of
diabetes-related peripheral vascular disease in order to derive incidence, similar to the
approach for diabetic retinopathy. In the absence of Dutch or GBD disability weights for this
condition we derive a weight of 0.19 using the disability weight regression model. Remission
from surgery by vascular grafts is assumed to be 20%.
Amputation and diabetic foot
We estimate the incidence of diabetes-related amputations from Australian hospital data. We
use GBD disability weights for these conditions and base our durations and proportions
treated on expert opinion. We use amputation rate data for diabetics with foot ulcers from
the Diabetes Research Foundation (Yue & Molyneaux 2005). From 1994–2005 the amputation
rate for diabetics with foot ulcers was 5.3%. We calculate an average duration of 8.9 months
after fitting a log normal function to follow-up data on the duration of foot ulcers. As there is
no Dutch disability weight, we apply the GBD weight of 0.113.
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Ischaemic heart disease and stroke
We estimate the proportion of ischaemic heart disease YLD attributable to Type 1 and Type 2
diabetes using a population attributable fraction  based on prevalence and the relative risk
(2.0 and 2.5 for males and females respectively) of dying from ischaemic heart disease and
stroke (2.0 for both males and females) amongst diabetics from the Asia Pacific Cohort
Studies Collaboration (Woodward et al. 2003).
2I Endocrine and metabolic disorders
Haemolytic anaemia
We use Australian hospital data to estimate the incidence of hereditary haemolytic anaemia,
assuming that annual admissions at age 0 years represent incidence. We model beta
thalassaemia and ‘other’ haemolytic anaemia separately to account for different durations.
We assume that the average duration for beta thalassaemia is 35 years based on a USA
review (US Preventive Services Taskforce 1996) and we assume that the life expectancy of
persons with ‘other’ haemolytic anaemia is the same for sickle cell anaemia, that is, around
25 years lower than the population average. In the absence of specific weights we use the
GBD weight for very severe anaemia (0.25) and severe anaemia (0.09) for beta thalassaemia
and other haemolytic anaemias respectively.
Other non-deficiency anaemia
We model the disability associated with aplastic anaemia and autoimmune anaemia. We
base the prevalence of aplastic anaemia on Australian hospital data. We derive incidence and
duration in DisMod using prevalence data, Australian mortality data where aplastic anaemia
was an underlying condition and a remission of zero. We estimate the incidence of
autoimmune anaemia using hospital data and assume that the average duration is 3 months.
In the absence of a specific weight for other non-deficiency anaemias we use the GBD weight
for very severe anaemia (0.25).
Cystic fibrosis
Massie and colleagues (2000) found the incidence of cystic fibrosis in Victoria over a 9-year
period to be 3.5 per 10,000. This estimate is very similar to information from Queensland and
Western Australia (Bower et al. 2004; Queensland Health 2004). We apply the Victorian
estimate to the whole of Australia. We estimate the duration of cystic fibrosis in DisMod
using the above incidence, no remission, and an age- and sex- specific risk of mortality from
a patient-based USA study (Kulich et al. 2003). There is no disability weight for cystic fibrosis
available. As obstructive lung disease is a major sequela, and the disease is progressive and
fatal, we use the disability weight for severe chronic obstructive pulmonary disease (0.53).
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Haemophilia
We base our estimate of the incidence of moderate and severe haemophilia on Australian
data (Street & Ekert 1996). We do not model mild cases of haemophilia since we assume they
have zero disability, as bleeding only occurs as a result of injury. We use the same
assumptions about severity distribution, duration and disability weights as the previous
Australian burden study.
2J Mental disorders
The 1997 National Survey of Mental Health and Wellbeing, including the child mental health
and low prevalence disorder components, remains the only population-based data source for
our estimates of most mental disorders (ABS 1998a; Jablensky et al. 1999; Sawyer et al. 2000).
Table A1.3 summarises the mental disorders for which we calculated YLD, along with the
sources of data on which our incidence estimates are based.
Table A1.3: Sources of data for mental disorders
Data source Mental disorder
National Survey of  Mental Health and Wellbeing 1997 Depression & anxiety; bipolar disorder; most substance abuse
(alcohol, sedative and cannabis drug dependence or abuse);
and borderline personality disorder
Low Prevalence  (Psychotic) Disorders Study Psychotic disorders
Child and Adolescent Component of the National Survey of
Mental Health and Wellbeing 1997 (Sawyer et al. 2000)
Childhood disorders (separation anxiety disorder, attention-
deficit hyperactivity disorder)
Epidemiological Study—National Drug and Alcohol Research
Centre Technical Report No. 198 (Degenhardt et al. 2004)
Heroin dependence
Alcohol and Other Drug Treatment Services National Minimum
Data Set (AODTS-NMDS) collection
<www.aihw.gov.au/drugs/datacubes/index.cfm> (accessed 15
December 2005)
Stimulant dependence
Reviews of epidemiological studies Eating disorders (anorexia nervosa and bulimia nervosa),
autism, and Asperger’s syndrome
Depression & anxiety, substance abuse (excluding heroin and
stimulant dependence), borderline personality disorder and bipolar
disorder
While the data sources have remained mostly the same as were used for the previous
Australian burden study, there are a number of key methodological changes. First, we have
grouped all anxiety disorders (panic, agoraphobia, social phobia, generalised anxiety
disorder, obsessive-compulsive disorder, post-traumatic stress disorder and separation
anxiety disorder) and the unipolar depressive disorders (major depression and dysthymia)
that were previously modelled separately into a single disease category. This is based on the
argument that the high degree of comorbidity and the similarity in psychological and drug
treatment means that all these disorders can be considered as part of the same entity, with a
continuum between mostly depressed to mostly anxious (for example (Andrews et al. 1990;
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Andrews & Slade 2002). The advantage of this approach is that it takes away some of the
difficulties of dealing with the frequent comorbidity among these disorders.
Second, disability weights for all conditions derived from the national mental health survey
continue to be based on the mental component score of the SF-12 but for this update we
calculate a per unit change in disability weight for each unit change in the mental component
score and apply this to all disorders. Dutch disability weights exist for mild, moderate and
severe depression as well as for six different anxiety disorders for a combined mild–
moderate state and a severe state. Assuming that mild, moderate and severe are 1, 2 and 3
standard deviations, respectively, below the population mean of the mental component score
we sought a mathematical function that best describes the range of disability weights. A
second-order polynomial function gave the best fit. This transformation of categorical
weights into a continuous scale allows us to calculate a disability weight for each respondent
in the survey. Any mental component score value greater than the population mean of 52 is
set to 0 and the weight for a mental component score of 20 is taken as the highest disability
weight even if the mental component score is lower (this is done because otherwise the
lowest mental component scores would correspond with a disability weight of greater
than 1).
Third, to deal with comorbidity, we apportion the disability weights calculated in the
National mental health survey equally between the comorbid mental health diagnoses for
each individual. In the previous Australian burden study we did the correction for
comorbidity at the level of the number of people affected and hence reported lower than
actual numbers of incident and prevalent cases.
Our general model for these conditions derives incidence figures from the National mental
health survey prevalence figures, using DisMod and assuming appropriate remission rates
and relative risks of mortality from a meta-analysis (Harris & Barraclough 1998). We use the
proportion of one-year prevalent cases reporting symptoms in the previous two weeks as an
approximation of the proportion of time with symptoms and thus assume that all these
conditions have a chronic nature with periods of remission in between.
For children aged 5–17 years, we use prevalence estimates for depression and anxiety from
the Child and Adolescent Component of the national mental health survey (Sawyer et al.
2000). In DisMod we use a remission rate of 0.043, a pooled estimate from follow-up studies
of people with various anxiety disorders (Steketee et al. 1999; Wewetzer et al. 2001; Yonkers
et al. 2003) and an increased relative risk of mortality of 1.5, a value in between the range of
meta-analysis estimates reported for anxiety and depressive disorders (Harris & Barraclough
1998).
The prevalence estimates for bipolar disorder in the previous Australian burden study were
based on the international literature. This was because the prevalence figures from the
National mental health survey were considered inaccurate due to a technical problem during
the conduct of the survey. Subsequently Mitchell and colleagues (2004) have re-analysed the
data and defined the prevalence of ‘euphoric hypomanic/manic syndrome’. They argue that
with this definition around 95% of cases of bipolar disorder are captured. For the current
estimates we use the same definition and adjust the 12-month prevalence by 100/95. In
DisMod we use a remission rate of 0.035 calculated from a follow-up study (Angst & Preisig
1995) and an increased relative risk of mortality of 1.96 in men and 1.76 in women (Harris &
Barraclough 1998).
In this study we include all personality disorders—rather than borderline personality
disorder only—but limit our estimates to those without any comorbid mental disorders. The
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proportion of comorbidity between personality disorders and other mental disorders is so
high that we argue that in most cases it ought to be seen as a risk factor rather than a
separate condition. However, in order to capture all disability from mental disorders we
include a category ‘isolated personality disorder’. The remission estimate of 17% is consistent
between two follow-up studies (Grilo et al. 2004; Zanarini et al. 2003). The relative risk of
mortality is 1.84 (Harris & Barraclough 1998).
In the previous Australian burden study, estimates for alcohol use disorder were made
separately for alcohol dependence and harmful alcohol use, and then presented as one
disease category. In the current update we combine the two categories and create one
DisMod model based on 12 month prevalence of any alcohol use disorder in the National
mental health survey. The two other parameters in DisMod are a remission rate of 23.7%
calculated from a two-year follow-up study (Booth et al. 2001), and an elevated mortality risk
of 1.8 in males and 3.84 in females (Harris & Barraclough 1998).
For cannabis dependence, we assume a remission of 8% (Swift et al. 2000) and no excess risk
of mortality. There are no follow-up studies of people with sedative dependence. We use the
same remission as in the cannabis model and apply an excess mortality risk of 2.1 reported
for ‘legal’ drug use (Harris & Barraclough 1998).
Heroin dependence and harmful use
Household surveys are likely to underestimate the true prevalence of heroin use (differential
response between users and non-users and a greater proportion of users not living in
households). Instead, we use higher estimates of regular heroin users based on triangulation
between five data sources: ABS opioid deaths, ambulance attendances for drug overdose in
New South Wales, New South Wales Health heroin pharmacotherapy client database, New
South Wales data on arrests for drug offences, and data from the Alcohol and Drug
Information Service on calls related to heroin use (Degenhardt et al.  2004). While the
detailed comparison of databases was done for New South Wales, extrapolations were made
for all jurisdictions by extrapolation of relationship between numbers under treatment or in
contact with police and opioid mortality figures from New South Wales and the opioid
deaths in each jurisdiction.
In the previous Australian burden study, we assumed very high remission after age 45 years
to reflect the low prevalence of heroin use. However, expert advice that this is a cohort effect
rather than a high remission effect explains the drop in prevalence at older ages. In current
estimates we ‘allow’ DisMod to build up prevalence figures at older ages.
Back projection methods by the National Drug and Alcohol Research Centre assumes a risk
of dying from overdose of 0.8% per year (Law et al. 2001). We assume a case-fatality rate of
1% to account for raised mortality from other causes. The overall relative risk calculated in
DisMod is of the same order of magnitude as reported elsewhere (AIHW: Ridolfo &
Stevenson 2001; Darke & Ross 2002). The disability weight for heroin dependence of 0.27 was
derived by Victorian mental health experts for the previous Australian burden study and is
close to the GBD disability weight estimate of 0.252.
Stimulant dependence
We decided to use treatment figures rather than the estimates of prevalence of stimulant
dependence from the National mental health survey as there has been a marked increase in
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the use of stimulants since 1997 and the survey results show an erratic age pattern as only
few cases were identified. Instead we estimate the prevalence of stimulant dependence from
the number of closed treatment episodes in 2002–2003 where the principal drug of concern
was listed as amphetamines (Alcohol and Other Drug Treatment Services National
Minimum Data Set) collection. We inflate these figures by 5.5 as described by McKetin and
colleagues (2005).
We estimate remission by first entering prevalence, a relative risk of 0 and a case-fatality rate
of 0, into DisMod. We thus get DisMod to produce an estimate of remission that best
replicates the age pattern of prevalence. The average remission across all ages was 12%. We
then run the DisMod model again with same prevalence, this remission rate and a relative
risk of 2.1 for excess mortality as reported for ‘legal drug use’ (Harris & Barraclough 1998).
We derive a disability weight for stimulant dependence as we have done for all other
conditions in the National mental health survey and thus assume that the same average
severity found among the lower number of cases with stimulant dependence in the survey
reflects that of all cases in the population.
Psychotic disorders
Estimates for psychotic disorders are based on prevalence from the Low Prevalence
(Psychotic) Disorders Study conducted in Australia in 1997 as part of the National Survey of
Mental Health and Wellbeing. This survey measured an overall estimate of 4.7 per 1,000
population. The low prevalence study suffered from a low response rate by general
practitioners contacted in the study areas and therefore under-represented people with
psychotic disorders who are solely managed by their general practitioner (Lewin & Carr
1998). Before conducting further analysis, we adjust upwards to one in three the number of
people in the survey who are wholly treated by a general practitioner and adjust downwards
by a factor of 0.841 to reflect only those with schizophrenia and related diagnoses and not
those with a diagnosis of bipolar or affective psychosis. Annual remission is based on a
number of longer term studies and is set at the median of the reported rates (1.5%) (Ciompi
1980; Harding et al. 1987; Harrison et al. 2001; Helgason 1990; Huber et al. 1980). We derive
incidence and duration figures from DisMod using a 54% higher risk of mortality overall for
people with schizophrenia (Harris & Barraclough 1998), with an age pattern imposed by the
relative frequency by age that schizophrenia is mentioned in death records. The DisMod
incidence output indicates that almost all psychotic disorders have their beginning in late
adolescence or early adulthood, with a small second peak in post-menopausal women. We
assume that the average time spent in psychosis is 30% (Leff et al 1992). We use a composite
weight based on 30% of the GBD weight for psychosis corresponding to the estimated time
spent in this state and 70% of the treated weight (0.3 x 0.627 + 0.7 x 0.351 = 0.434). The low
prevalence study reported a higher proportion (61%) of people with a psychotic disorder
having current delusions or hallucinations. It also stated that 86% are taking prescribed
medication and that 83% of the total reported that their psychotic symptoms respond to
pharmacological treatment. The first finding would indicate that our composite disability
weight is too low but the second finding would support a lower weight. For the Assessing
Cost-Effectiveness (ACE)–Mental Health study, disability weights for each individual in the
low prevalence study were estimated using a sliding scale between the highest and lowest of
Dutch disability weights for schizophrenia and anchoring individuals on this scale based on
their score on the diagnostic interview for psychosis disability module that was included in
the survey (Haby et al. 2004). The mean disability weight across the sample using this
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method is 0.39. We decided to continue to use the 0.434 disability weight as in the previous
Australian burden study.
Eating disorders
Estimates for bulimia are based on a prevalence rate of 0.7% among Swiss 14–17 year old
females (Steinhausen et al. 1997). This is the mid-point in the range of prevalence between
0.5% and 1% reported from more rigorous epidemiological studies (Gilchrist et al. 1998). We
calculate a remission rate of 0.21 from figures reported in a review of follow-up studies (Keel
et al. 1999). We derive incidence and duration estimates for women from these figures using
DisMod, assuming the age at onset is between 14 and 29 years with no increased risk of
mortality. Estimates for anorexia are based on a 0.5% prevalence among females older than
15 years (Gilchrist et al. 1998; Keel et al. 1999) and a remission rate of 0.11 calculated from a
follow-up study (Strober et al. 1997). We use DisMod to derive incidence and duration
estimates for women from these figures, assuming the age at onset is between 14 and 29
years with an increased annual risk of mortality of 0.59% (Sullivan 1995). We assume the
incidence in males is 10% of the rate in females. We use the Dutch weight of 0.28 for both
types of eating disorder.
Childhood disorders
Australian prevalence data for childhood attention deficit with hyperactivity disorder come
from the Child and Adolescent Component of the 1997 National Survey of Mental Health
and Wellbeing (Sawyer et al. 2000). We define attention deficit with hyperactivity disorder to
include children with a diagnosis on the survey and whose parents report the child having
more emotional or behavioural problems than have other children of the same age. The
estimates of burden of attention deficit with hyperactivity disorder were derived from
prevalence rates of 6% in male children, 3% in female children, 2% in male adolescents and
1% in female adolescents. Our incidence figures were derived from DisMod, assuming an
age at onset of 3–6 years and a remission rate of 0.15 (Hill & Schoener 1996). To reproduce
the prevalence pattern we use a higher remission rate of 0.25 in adolescents aged 10–19 years
and 0.3 thereafter. We assume no increased risk of mortality. We use the Dutch weights for
both mild and moderate-to-severe attention deficit with hyperactivity disorder (0.02 and
0.15), and weight these by the severity distribution found in the 1997 survey to derive a
composite disability weight.
Autism is part of pervasive developmental disorders; the other important condition in that
category is Asperger’s syndrome, which was described at about the same time as autism.
Autism is characterised by the triad of language or communication impairment, social
impairment and behavioural impairment (obsessions, rituals). However, Asperger’s
syndrome has only the latter two components and is not associated with intellectual
disability, as is the case with 80% of autistic children. Behavioural problems are a
predominant feature in children with Asperger’s syndrome.
We derive the incidence of autism and Asperger’s syndrome from an Australian study with
data from treatment and educational support services in Western Australia and New South
Wales. We assume no remission and an elevated risk of mortality as reported by Shavelle
and colleagues (2001). We use the average duration of mild intellectual disability and the
Dutch disability weight of 0.55 for autism, and for Asperger’s syndrome an estimated weight
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of 0.25 based on expert advice that the condition is worse than moderate to severe attention
deficit with hyperactivity disorder but much less severe than autism.
2K Nervous system and sense organ disorders
Dementia
A door-to-door population-based two-phase investigation method (screening followed by
detailed neurological examination by a psychiatrist) is the most accurate epidemiologic
approach to estimate the epidemiology of dementia and Parkinson’s disease (Benito-Leon et
al. 2004).
We base our estimates of the prevalence of dementia for people aged 65 years or over on a
recent European meta-analysis of population-based door-to-door studies conducted by the
Neurologic Diseases in the Elderly Research Group (Lobo et al. 2000). We proportionately
redistribute the one-third of cases that constitute ‘other or mixed type’ to Alzheimer’s and
vascular dementia. We estimate the prevalence of dementia below the age of 65 years from a
recent UK study of patients aged 30–64 years (Harvey et al. 2003).
We use relative risks of mortality for Alzheimer’s disease and vascular dementia from a
survival study of incident cases that controlled for comorbidity (Aguero-Torres et al. 1999).
The estimated mortality risk for all dementia from this is comparable to the results of the
meta-analyses of dementia prevalent cases and survival (Dewey & Saz 2001; Jagger et al.
2000). We prefer using the former because it provides type-specific survival data.
We derive incidence and duration using DisMod, based on the aforementioned
representative population-based studies of prevalence, assuming no remission and relative
risks from the incident-based survival study. This model gives average durations across all
ages for both sexes of around 4 years which was in keeping with the literature on the
survival of prevalent cases (Aguero-Torres et al. 1999; Helmer et al. 2001). We model
dementia as a progressive illness and discount the latter stages back to incidence of disease.
We use the disability weights derived by the previous Australian burden study (which
combined the Dutch weights with a severity distribution from a European population-based
cohort study).
Epilepsy
We base our incidence estimates for primary epilepsy on the 1980–84 Rochester
Epidemiology Project medical record linkage system (Zarrelli et al. 1999). We use these
incidence estimates, assuming no differentials by sex, with age-specific remissions (Annegers
et al. 1979) and an overall standardised mortality ratio of 1.3 (Tomson 2000) to derive
estimates of incidence and duration using DisMod. We use the Dutch disability weight for
epilepsy (0.110).
Parkinson’s disease
We only explicitly model primary Parkinson’s disease (ICD-10 code G20). We assume that
secondary Parkinsonism is accounted for under other relevant disease categories.
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We base our estimates of the prevalence of Parkinson’s disease from a recent European meta-
analysis of population-based door-to-door studies conducted by the Neurologic Diseases in
the Elderly Research Group (de Rijk et al. 2000). There are no sex differences in the
prevalence of Parkinson’s disease. We do not use the Australian studies on the prevalence of
Parkinson’s disease since we consider them to be outliers; they give prevalence estimates two
to three times higher than most of the literature (Chan et al. 2001, 2005).
We base our relative risk of mortality on the meta-analysis of prevalent cases of Parkinson’s
disease and survival undertaken by the Neurologic Diseases in the Elderly Research Group
(Berger et al. 2000). We plot and fit the risk of mortality by age using an exponential
trendline to smooth the irregular pattern by age.
We derive incidence and duration using DisMod assuming no remission and a relative risk
of mortality for males and females of 3.1 and 1.8 respectively, resulting in average durations
of 4.5 and 9.8 years. These durations are broadly consistent with durations reported in the
literature (Elbaz et al. 2003; Fall et al. 2003; Herlofson et al. 2004; Hughes et al. 2004;
Morgante et al. 2000).
We derive disability weights from an Australian patient-based cohort study (Hely et al. 1999)
reporting on the distribution of Hoehn and Yahr stages (which corresponds with the
descriptions of the severity states of Parkinson’s disease for which Dutch disability weights
are available) and survival at each 2-year interval. We model Parkinson’s disease assuming
that all cases start with mild symptoms and progress over time to moderate and then severe
symptoms over time. From simple linear regression lines we derive an annual increase in
those with moderate and severe symptoms. The proportion of cases over time who are in the
moderate category is the balance between those moving from mild to moderate and those
exiting moderate by shifting to the severe category. For each age group we calculate the
average disability weight during the estimated average duration. As severity progresses with
time since incidence and younger age groups have longer durations, disability weights are
highest in the younger age groups.
Motor neurone disease
We base our incidence estimates for motor neurone disease on Australian mortality data. We
assume that incident cases equal annual deaths due to motor neurone disease. Our estimates
for males and females are consistent with international literature for males (Chancellor et al.
1993). We assume average durations of 2.9 years for those aged 0–64 years and 1.9 years for
people aged 65 years or over. We base our duration assumptions on Australian and
international literature (Forbes et al. 2004; Sach 1995). In the absence of a specific disability
weight we use the Dutch weight for progressive multiple sclerosis (0.67).
Multiple sclerosis
We estimate the prevalence of multiple sclerosis using 1981 and 1996 estimates of multiple
sclerosis for some Australian states and territories (Barnett et al. 2003; Simmons et al. 2001)
with extrapolations based on latitudinal differences for jurisdictions with no estimates. We
assume that changes over time represent improvements in identification rather than changes
in epidemiology. We derive incidence and duration using DisMod assuming no remission
and age and sex specific case-fatality rates based on a 25-year New Zealand cohort study
(Miller et al. 1992).
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In 10.8% of patients the disease has a progressive course from the onset (Roxburgh et al.
2005). The median time it takes to reach an Expanded Disability Status Scale score of 6
(equivalent to having to use a cane) in those with a relapsing-remitting course is 30 years
(Tremlett et al. 2006). We use the Dutch weights for relapsing-remitting (0.33) and
progressive (0.67) phases and assume that those with relapsing-remitting disease have 30
years at the lower disability weight and the remainder at the higher disability weight level.
Huntington’s chorea
Huntington’s chorea is modelled in DisMod using prevalence from the literature (McCusker
et al. 2000), assuming no remission and mortality data. We assume a duration of 20 years for
the younger age groups and apply the durations from DisMod for ages 65 years or over.
Assuming similar progression of disease as in Parkinson’s, we adopt the weights for the
three stages of this disease.
Muscular dystrophy
For muscular dystrophy in males, we use the average incidence rates from New South
Wales, Victoria, Queensland, Western Australia and the Australian Capital Territory (Cowan
et al. 1980; Emery 1991). The incidence for females is calculated by applying the sex ratio
from mortality data. In the absence of specific weights for this condition, we assume the
initial symptomatic phase is similar to the initial stage of Parkinson’s disease, the phase in
which walking becomes impossible is similar to that of paraplegia, and the final stage is
equivalent to quadriplegia.
Vision loss
Our incidence estimates for vision loss are based on the results of the Melbourne Visual
Impairment Project, which assessed visual acuity and the prevalence by cause of mild,
moderate and severe visual impairment in a sample representative of Victorians (Weih et al.
2000). For glaucoma, refraction errors, macular degeneration and the category ‘other vision
loss’, we derive incidence and duration of related visual impairment using DisMod,
assuming no remission and a relative mortality risk of 1. For glaucoma we use Dutch
disability weights for mild, moderate and severe vision loss to derive a composite disability
weight from the severity pattern across all ages (as the age-specific data are based on small
numbers). For macular degeneration, refraction errors and ‘other vision loss’ we derive age-
specific disability weights.
We estimate the incidence of mild and moderate cataract-related vision impairment using
Australian hospital data assuming that 50% of surgically corrected cases had vision loss in
both eyes prior to operation for 1 year on average and that 90% of cases are mild and 10% are
moderate. We estimate the prevalence of un-operated cataracts as the difference between the
prevalence of cataract-related visual impairment estimated by the Melbourne study and the
number of surgical corrections. This leads to a small estimate of un-operated cataracts in the
elderly over 80 years of age. We use this to estimate the incidence of un-operated cases of
cataract-related severe vision loss in DisMod, assuming no remission and a relative risk of
1.5. For cataract-related vision loss at ages 0–14 years we assume duration of 2 years and for
ages 15 years or over we assume a 1-year duration. Incident cases of un-operated cataract
were assumed to be prevalent cases waiting on average 1 year for cataract surgery. We use
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Dutch disability weights for mild and moderate cataract-related vision loss. For severe
cataract-related vision loss we estimate a combined disability weight using the Dutch
weights for each of the stages along with prevalence data from the Melbourne study to
derive combined stages age-specific disability weights. The proportion of glaucoma and
cataract-related vision loss attributable to diabetes is then determined from relative risks
from the Blue Mountain Eye Study (Mitchell et al. 1997) and only non-diabetes-related vision
loss is included in the YLD estimates for these categories.
Hearing loss
We model hearing loss as a progressive condition with mild (25–34 dB and 35–44 dB),
moderate and severe stages so that prevalent cases with moderate or severe impairment are
regarded as incident cases of mild impairment at an earlier age. We use survey prevalence
data from South Australia (Wilson et al. 1999), initially modelling the prevalence of severe
hearing loss, no remission and a relative risk of 1 in DisMod. We use incidence of severe
hearing loss from the DisMod output as ‘mortality’ in the moderate hearing loss DisMod
model; this takes the cases of severe hearing loss out of the pool of susceptible cases for
moderate hearing loss and hence gives more accurate average durations than if remission
were used as remitted cases in the DisMod model, as the cases continue to be subject to the
hazard of incidence. Similarly, we use incidence of moderate hearing loss as ‘mortality’ in
mild hearing loss (35–44 dB) and incidence of mild hearing loss (35–44 dB) as ‘mortality’ in
mild hearing loss (25–34 dB). From examination of the prevalence data by level of severity
and age, and assuming that all cases progress from the mildest to most severe category, it
seems reasonable to assume that on average progression to the next severity level occurs at 5
year intervals between mild (25–34 dB) and mild (35–44 dB), and at 10 year intervals from
mild (35–44 dB) to moderate and moderate to severe. From the cross-sectional data on
prevalence it is not possible to estimate these progression times exactly. However, to be
consistent with other disease models where subsequent severity levels for the same health
state are discounted back to first incidence, we apply a 25-year lag for severe hearing loss, 15
years for moderate and 5 years for the mild (35–44 dB) categories. Dutch weights of 0.04, 0.12
and 0.37 apply for mild (35–44 dB), moderate and severe hearing loss, respectively. For the
mild (25–34 dB) category we assume a disability weight of 0.02, half that of the mild
(35–44dB) category.
Intellectual disability
Intellectual disability is categorised into the following levels:  mild, moderate, severe and
profound, with intelligence quotient (IQ) ranges of 50–69, 35–49, 20–34, <20 respectively.
This categorisation is based on the Dutch disability weight criteria.
We estimate the incidence of mild-moderate and severe intellectual disability using the
Intellectual Disability Exploring Answers Database, a Western Australian population-based
dataset of children with intellectual disability identified through disability and educational
services between 1983–1996. We adjust the severity distribution of incidence data to account
for unspecified cases and redistribute cases so that the severity level as defined by IQ is
comparable to the Dutch disability weight criteria. Then we extrapolate incident cases by the
two severity levels (mild-moderate and severe) to four levels of severity (mild, moderate,
severe and profound) using the average severity distribution from two Australian studies
(Einfeld & Tonge 1996; Wellesley et al. 1992). We assume that because neither study
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recruited cases from school services, mild cases were underestimated and base our
estimation of mild cases on the balance of the mild-moderate category. This gives the
following proportionate distribution of incident cases by severity: mild (76%), moderate
(14%), severe (7%) and profound (3%).
In order to derive plausible durations of intellectual disability by the four stages of severity
we calculate the proportional difference in life expectancy by level of severity of intellectual
disability in comparison to the life expectancy of the general population from a 35-year
Finnish follow-up study (Patja et al. 2000).
We model the incidence and duration of intellectual disability in DisMod assuming that 90%
of intellectual disability, based on Australian population data, occurs in the first year of life
and the remaining 10% occurs in the 1–4 age group, no remission, and a relative risk of
mortality that gives an average duration by severity level based on the extrapolation of
Finnish data to the 2003 Australian life table.
We do not include the YLD for intellectual disability as a discrete category in the main
listings of this burden study. Instead, incident cases of intellectual disability are attributed to
underlying causes (such as congenital disorders, epilepsy, autism, perinatal conditions,
meningitis, brain tumours and cerebral palsy) using findings from the Australian Child to
Adult Development Study, a longitudinal study of behavioural and emotional problems in
429 young people with intellectual disabilities. We use data from two publications of this
study to produce the proportionate distribution of the underlying cause of intellectual
disability by severity level and sex (Mowat et al. unpublished; Partington et al. 2000). We
calculate YLD for each underlying cause using incidence and duration derived from DisMod
and the Dutch disability weights for mild, moderate, severe, and profound intellectual
disability.
Migraine
We base our prevalence estimates for migraine on the National Health Survey data and our
incidence estimates for migraine on international data (Stewart et al. 1991). We estimate the
incidence and duration of migraine in DisMod using prevalence, incidence, and a case-
fatality rate of zero. Within DisMod, we use manual smoothing to extrapolate incidence to
older ages. We assume that 20% of cases receive treatment in developed countries. We
assume that the average duration for untreated and treated episodes is 24 hours and 6 hours
respectively. We derive average disability weights for untreated and treated models using
frequency, severity, and disability weight data from Global burden of migraine in the year 2000
(Leonardi & Mathers 2003).
2L Cardiovascular disease
Ischaemic heart disease
Three health states are modelled separately for ischaemic heart disease: angina pectoris,
acute myocardial infarction and heart failure. We model the incidence of angina pectoris as
the number of admissions to hospital without any mention of angina in any previous
admission in 15 years of linked hospital records in Western Australia (Department of Health
of Western Australia et al. 2005; Holman et al. 1999) and adjust by the ratio of admissions for
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angina pectoris between Western Australia and the whole country. We model angina
pectoris pre- and post-myocardial infarct together. The duration is determined in DisMod,
assuming remission estimated from the number of revascularisation procedures from
Australian hospital data and age- and sex-specific case-fatality rates calculated over the
period 1998–2003 in ‘prevalent cases’ of angina pectoris (that is, anyone with an admission
for angina pectoris since 1988 and still alive over the follow-up period).
Assuming that about half of the declining ischaemic heart disease mortality reflects change
in the case-fatality rate rather than incidence (Unal et al. 2004), we apply half of the ischaemic
heart disease mortality trend observed over the period 1979–2003 in DisMod to incidence
and the other half to case-fatality.
We assume 95% of angina is experienced at the mild-moderate level with the corresponding
Dutch disability weight of 0.08, and the remaining 5% with a weight of 0.57.
For people discharged alive following acute myocardial infarction in 2003, we calculate a
period of 3 months of disability at the GBD treated disability weight of 0.395.
Heart diseases resulting in heart failure
Population-level prevalence or incidence information on heart failure is absent in Australia
and scarce elsewhere. In 2001, by extrapolation from US studies a rough estimate was made
of about 300,000 prevalent cases of heart failure in Australia (Krum 2001). Complicating
factors in the estimation of heart failure prevalence are that estimates from other countries
and different time periods may not apply to the current Australian situation. Ischaemic heart
disease is the underlying cause of heart failure in the majority of cases, and there has been a
steady decline in the risk of ischaemic heart disease since the early 1970s combined with
improved survival due to improvements in therapeutic options. The first would cause a
reduction in prevalence, while the latter would lead to higher prevalence. It is not clear what
the net effect of these two influences would be on the prevalence of heart failure.
Using hospital data is also not straightforward as the current wisdom is that there has been a
change in the case load of people presenting to tertiary health facilities with this condition,
following the wider use of improved pharmacological treatment combinations since the
1990s, resulting in a greater proportion of cases being successfully treated in primary care.
Nevertheless, our model for heart failure starts with a description of the epidemiology of
hospitalised heart failure, for which we have extensive information from Western Australia.
From the linked data set of all hospitalisations and deaths in this state, we identify people
who presented to hospital with heart failure (either as a primary diagnosis or as an
associated condition) at any time in the period 1990–2003. To derive case-fatality, we
calculate the number of years lived between 1998 and 2003 by anyone who had ever been
admitted with a diagnosis of heart failure since 1990. The case-fatality rate was then taken as
the number of deaths over person-years of follow-up in 5-year age groups after subtracting
out the background mortality.
The complete descriptive epidemiology in this group is derived in DisMod from incidence
and case-fatality, the third parameter being zero remission (that is, people do not recover
from heart failure). We include in this model a declining trend in case-fatality over the last
10 years of 3% per year for males and 1% per year for females (derived from our survival
model), and a 2% decline in incidence per year for both males and females over the last
35 years. This latter figure is half the annual decline we observe for ischaemic heart disease
mortality over this period, ischaemic heart disease being the major driver of heart failure
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risk. The other half of the decline in ischaemic heart disease mortality we assume to be due to
improvements in case-fatality (see above) (Unal et al. 2004).
There is little information on the incidence of heart failure in the community (that is, not yet
diagnosed cases and those diagnosed but treated in the primary case setting without
requiring hospitalisation). We assume that this group has less severe disease with better
survival compared to their hospitalised counterparts. We also assume that when they die, it
is less likely that heart failure will be mentioned as the underlying cause of death. We have
data on the number of hospitalised cases of heart failure who died with heart failure as the
underlying cause of death and we know the overall number of deaths coded to heart failure.
Assuming that the linkage of hospital and death records in Western Australia is complete,
we then assume that the balance of heart failure coded deaths occur in never-hospitalised
cases of heart failure. In the absence of data to characterise the never-hospitalised cases of
heart failure we make two assumptions. First, to account for lower severity we assume that
their case-fatality rate is lower by 25%. Second, we assume that deaths in non-hospitalised
heart failure cases are 25% less likely to be coded to heart failure.
Among hospitalised cases that die, the probability of receiving an underlying cause of death
code of heart failure (428 in ICD-9 and I58 in ICD-10) is 3.6% in males and 5.3% in females. If
non-hospitalised cases are 25% less likely to be assigned a code of heart failure the
percentage of total excess deaths coded to heart failure would be 2.7% in males and 3.9% in
females. From this we can derive the total number of deaths due to heart failure in non-
hospitalised cases (3,199 in males and 3,958 in females over the period 2001–2003). By adding
in the 3,833 deaths from ever-hospitalised cases of heart failure in males and 4,186 in females,
we can calculate the average population mortality rate of heart failure over the period. These
rates (calculated by age and sex) are the inputs to a second iteration of DisMod, together
with zero remission and the case-fatality rate of the first DisMod model of hospitalised heart
failure cases adjusted downwards to reflect the proportion of never-hospitalised cases
having 25% lower case-fatality. We continue to use the same assumptions on trends in case-
fatality and incidence as in the first model. The output of the second DisMod iteration then
gives us the incidence, prevalence and average durations for all heart failure, which feed into
our YLD calculations. The total prevalence of heart failure in Australia in 2003 is thus
estimated to be 220,000 cases.
We then identify the underlying causes for all heart failure cases—rheumatic heart disease,
hypertensive heart disease, ischaemic heart disease, pulmonary heart disease, inflammatory
heart disease, non-rheumatic valvular heart disease—in the Victorian linked hospital
admission dataset between 1996 and 2002, if any of these were mentioned as a cause in the
six years of hospital admission data. We then adjust the proportions, by age and sex, of all
underlying causes so they add up to 100% to account for cases with none or more than one
underlying cause identified. We use the duration, together with the incidence and
prevalence estimates initially obtained from the heart failure model described above,
multiplied by the proportion of heart failure cases for each of the above six underlying
causes, to calculate the YLD for each of these conditions (including ischaemic heart disease).
Stroke
We model stroke in terms of the following health states:  a short period of disability for those
who die in the first 28 days, survival beyond 28 days with no permanent impairment at one
year after onset, and survival beyond 28 days with permanent impairment. Admissions for
stroke in the year 2003 are the starting point for our estimate of incidence. To get an
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approximation of first-ever stroke incidence we take the ratio of hospital admission figures
from the North-East Melbourne Stroke Incidence Study (NEMESIS) area during the time of
the study to the reported NEMESIS first-ever incidence figures (Thrift et al. 2000) and apply
this ratio to 2003 Australian hospital admissions for stroke. Next, we subtract a proportion of
cases that die, using a 28-day case-fatality rate by stroke subtype as reported by Thrift and
colleagues.
The case-fatality rate of stroke comes from the Western Australian linked database using a
similar approach to that described above for heart failure. The case-fatality rate for DisMod
is the excess mortality in prevalent cases, defined in our analyses as anyone still alive at the
beginning of the follow-up period (mid 1998–mid 2004) with a mention of stroke during any
admission between 1989 and 1998 as well as any new cases of admitted stroke during follow-
up. Follow-up time and numbers of deaths were analysed for each 5-year age group and the
overall case-fatality rate reduced by the relevant background mortality.
Analyses by Judy Katzenellenbogen in Western Australia for her PhD indicate that after the
first 28 days the case-fatality rate does not vary significantly by type of stroke and that the
DisMod assumption of a case-fatality hazard that varies with age but not with time since
stroke is plausible.
Disability weights are derived from one-year follow-up data of stroke survivors in the Perth
Community Stroke Study analysed by Judy Katzenellenbogen to compare health status
information before and at 4 months and 1 year after the stroke event.
Other cardiovascular disease
Heart failure is the main disability from rheumatic heart disease, non-rheumatic valvular
disease, hypertensive heart disease and the group of inflammatory heart diseases (including
myocarditis, cardiomyopathy, endocarditis and pericarditis). The proportions of heart failure
cases for each of these causes are derived as described above for all heart failure. For
rheumatic heart disease and non-rheumatic heart disease we do a separate DisMod model
based on heart failure prevalence for these causes and taking into account the remission
through surgical interventions using Australian hospital data.
For aortic aneurysm, we assume the hospitalisation rate reflects incidence. For peripheral
vascular disease, we assume the hospitalisation rate reflects prevalence at all ages. We derive
the incidence from DisMod, assuming a relative risk of 2 and a remission rate of 0.1, which
approximates the number of surgical interventions as a proportion of total prevalent cases.
For aortic aneurysm, we assume a one-month period of disability during treatment and no
residual disability for those who survive treatment. Without a disability weight for this
health state, we use the derived weight for laparotomy (0.349). For peripheral vascular
disease, we use derived weights of 0.243 and 0.257 for men and women respectively, based
on severity distributions from the 1993 Australian disability survey. Weights for amputations
are from the GBD study.
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2M Chronic respiratory diseases
Chronic obstructive pulmonary disease
We estimate the prevalence of chronic obstructive pulmonary disease for cases with a forced
expiratory volume in one second of less than 70% of predicted (excluding those with a doctor
defined diagnosis of asthma) using the 1994–95 Busselton Study (Knuiman et al. 1999). While
this study sample comprises a selected rural population in Western Australia, we assume the
data are representative of prevalence in all areas of Australia. We use DisMod to estimate the
incidence of chronic obstructive pulmonary disease in 1994, assuming no remission and a
relative risk equivalent to that calculated from death rates attributed to smoking (see section
on risk factors). We include a trend of –2% per year for males and 3% per year for females
based on trends in chronic obstructive pulmonary disease mortality since 1979. We calculate
2003 incidence estimates by applying age- and sex-specific trends (based on mortality) to the
1994 incidence estimates. We then use DisMod with the same assumptions about remission
and relative risk of mortality to model prevalence, age of onset and duration for 2003. We
derive a composite average disability weight for males (0.168) and females (0.159) using the
Dutch weights for mild, moderate and severe chronic obstructive pulmonary disease and the
proportionate distribution by level of severity of dyspnoea from the Busselton Study. We
add the proportion of heart failure cases attributed to ‘pulmonary heart disease’ on the basis
that chronic lung disease is the underlying cause.
Asthma
We estimate the prevalence of asthma for cases that have a positive airway hyper-
responsiveness test and wheezing in the last 12 months from the literature (Bauman et al.
1992a; Peat et al. 1992, 1994, 1995; Toelle et al. 2004). Although these two criteria may
underestimate the ‘true’ prevalence of asthma, a reliance on self-reported wheeze alone
overestimates figures by up to a third (Toelle et al. 1992; Van Asperen 1995). We estimate the
prevalence of asthma in children aged 1–2 years to be 5.75%, using a report of ‘wheeze’ from
the US (Martinez et al. 1995) which we adjust by 42% to obtain an estimate that reflects those
with wheeze having asthma (Peat et al. 1994, 1995; Toelle et al. 2004). We estimate the
prevalence of asthma to be 12.3% in boys and 8.8% in girls aged 3–18 years, using an average
of 3 studies from 1992 to 2002 (Peat et al. 1994, 1995; Toelle et al. 2004) and a male-to-female
ratio of 1.4:1 (Gergen et al. 1988). For adults, we average the prevalence data from the early
1990 studies (Bauman et al. 1992a; Peat et al. 1992, 1994, 1995) since these were the last
studies in adults to have used a positive airway hyper-responsiveness test and assume no
change in the prevalence of asthma over time based on the literature and the observed trend
in children. We use a male-to-female ratio of 1:1.5 (DHS 2002) to give an estimated 2003
asthma prevalence of 5% and 7.5% in male and female adults. We derive incidence estimates
from DisMod assuming age-specific remission rates from a follow-up study in the US
(Bronnimann & Burrows 1986), which are consistent with overall remissions reported by
Australia studies (Xuan et al. 2002). From findings reported by Bauman and colleagues, we
calculate that asthmatics are symptomatic 12% of the time (Bauman et al. 1992b). Rather than
use the Dutch weight for this health state (0.36), which we consider to be for a more severe
health state than the average for symptomatic asthmatics in the population, we use a derived
weight of 0.229 based on the severity distributions found in the 1998 Australian disability
survey (ABS 1998b) and the disability weight regression model. The remainder of the time
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we assume is spent in a state equivalent to the Dutch weight for asthma controlled by
treatment (0.03). This results in a combined weight of 0.054.
2N Diseases of the digestive system
Peptic ulcer disease
In the absence of Australian population data on the frequency of peptic ulcer disease, we
assume that all incident cases of peptic ulcer disease visit a general practitioner and base our
estimates on the Australian general practitioner data. We assume that 83% of cases are
treated by Helicobacter pylori eradication therapy, which has a cure rate of 90% (Mollison et al.
1999). We model those who are cured using eradication therapy as being symptomatic for
one month, with no residual disability. We assume that the remainder of those who are
treated but not cured (including those receiving alternative treatments) receive relief from
their treatment but remain with the condition for the GBD duration. Untreated cases we
assume to be symptomatic for the same period. Because the annualised Dutch weight for
peptic ulcer disease is implausible, we use derived weights from the Dutch study for both
symptomatic and treated states.
Cirrhosis of the liver
The methods of deriving estimates of alcohol-related cirrhosis and the category of ‘other’
cirrhosis have been described in the section on hepatitis.
Inflammatory bowel disease
We model two manifestations of inflammatory bowel disease: Crohn’s disease and ulcerative
colitis. We estimate the incidence of inflammatory bowel disease in adults from a European
study (Shivananda et al. 1996) and for children we pool estimates from a number of
international studies based on a recent review (Griffiths 2004). The relative risks of mortality
due to the two types of inflammatory bowel disease were based on the findings of a recent
large UK study which showed that inflammatory bowel disease was associated with a small
overall increase in mortality after controlling for smoking and sex (Card et al. 2003). We
assume no remission and derive a composite disability weight (0.224), assuming that 20% of
time is spent with active exacerbation and the remainder is in ‘remission’ (Griffiths 1995;
Hendriksen et al. 1985; Stonnington et al. 1987).
For inflammatory bowel disease (and vascular insufficiency of the intestine, diverticulitis
and intestinal obstruction), we assume that a proportion of cases have more complicated
surgery involving the creation of a stoma (a surgical opening in the skin of the abdomen for
excretion of faeces) that can be either permanent or temporary. We estimate the incidence of
inflammatory bowel disease cases that receive a temporary or permanent stoma from
Australian hospital data. We apply the ratio of stoma for Crohn’s disease to stoma for
ulcerative colitis from an analysis of Victorian linked hospital data. Similarly the average
duration of temporary stoma was estimated from Victorian hospital data from 1998–99 to
2001–02 to determine if they were closed and, if closed, the time to closure. The duration of
permanent stoma was taken to be the same as the duration of the respective condition. We
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assume stomas not yet closed within this period remain open indefinitely. In the absence of a
specific weight for this condition, we derive a weight (0.204) from the disability weight
regression model.
Other diseases of the digestive system
We base the incidence estimates for appendicitis, intestinal obstruction, diverticulitis, gall
bladder and bile duct disease, pancreatitis and vascular insufficiency of the intestine on the
numbers of people with a relevant hospital procedure or diagnosis from Australian hospital
data. With the exception of appendicitis, these conditions were not considered in either the
GBD or Dutch studies. We adopt a 2-week duration for appendicitis, and a 3-week duration
for gall bladder and bile duct disease, intestinal obstruction, vascular insufficiency and
pancreatitis. For each of these conditions, we assume the GBD weight for appendicitis. For
gall bladder and bile duct disease, we use cholecystectomies or bile duct incisions but ignore
people admitted with un-operated cholelithiasis on the assumption that these people are
largely asymptomatic.
2O Genitourinary diseases
Nephritis & nephrosis
We base the incidence of dialysis and transplant patients on the Australian dialysis and
transplant data from which we derive durations for both categories of patients using
DisMod. For dialysis patients, we use case-fatality rates to match observed deaths and
remission through transplant, and apply the Dutch weight for diabetic nephropathy (0.290).
In the first 6 months after transplant, we assume a health state equivalent to the Dutch
weight for diabetic nephropathy (0.290). For the remaining period with the transplant, we
use a weight of 0.11, which is equivalent to both the GBD weight for treated renal failure and
the Dutch weight for ‘uncertain prognosis’. We derive untreated end stage renal failure from
the difference between dialysis or transplant deaths and total renal deaths, to which we
apply an average duration of 1 year prior to death at the GBD weight for untreated renal
failure (0.104). We use Australian dialysis and transplant data on underlying renal disease
distribution to attribute YLD from diabetic nephropathy to diabetes, analgesic nephropathy
to the injury category of medical misadventure, and congenital dysplasia and polycystic
kidney disease to congenital urogenital disease, and retain only those for primary renal
disease in the ‘nephritis & nephrosis’ category.
Benign prostatic hypertrophy
We base the incidence of benign prostatic hypertrophy on Australian hospital data. Based on
expert advice we adjust the number of benign prostatic hypertrophy cases upwards to
account for the proportion of cases that receive medical instead of surgical treatment. We
also assume, based on expert opinion, that half of all benign prostatic hypertrophy cases
receive surgical treatment, a proportion of whom experience complications or continuing
symptoms following surgery (1% with lifelong incontinence at a derived weight of 0.204,
15% with lifelong impotence at the GBD weight of 0.195, and 5% with urethral stricture for
4 weeks at the GBD weight of 0.151). Of those opting for medical treatment, we assume 70%
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use alpha-blocker drugs, of which half are cured. The other half may then try surgery. We
assume none of those receiving drugs other than alpha-blockers are cured. We apply the
GBD weight for symptomatic benign prostatic hypertrophy to each of these intervention
pathways assuming the following durations: 1.5 years for surgery, 1 year for successful
medical treatment, 2 years for unsuccessful medical treatment then surgery, and lifelong for
unsuccessful medical treatment but no surgery.
Urinary incontinence
We derive incidence rates of incontinence from DisMod using prevalence figures reported in
a review of Australian and international literature (AIHW: Lea 1993) and from Women’s
Health Australia. We assume that a number of diseases and injuries are associated with this
condition, most of which are more prevalent at older ages, and that the underlying causes
are multi-factorial and interrelated. Based on a multivariate analysis (Chiarelli et al. 1999),
we assume that, while all disability from incontinence among younger men and younger and
middle-aged women belongs under this category, half that experienced by middle-aged and
older men and older women is already captured under other conditions either explicitly (for
example, as a sequela for benign prostatic hypertrophy among men) or implicitly as part of
the overall weightings for these conditions (for example, severe stroke). For unaccounted
incontinence, we apply an average of the GBD weight for moderate incontinence and the
derived weight for benign prostatic hypertrophy-related severe incontinence using severity
distributions from the 1998 Australian disability survey.
Infertility
We estimate the prevalence of infertility from a 1988 population survey of infertility, surgical
sterility and associated reproductive disability in Perth, Western Australia (Webb & Holman
1992). This survey indicates that of the 3.5% of couples with non-surgical infertility, 68%
have an associated reproductive disability defined in terms of the couple being unable to
achieve a desired level of reproductive function. From a review of patients at an Adelaide
infertility clinic indicating that 83% of couples with reproductive disability seek assisted
reproductive technologies, 30% of whom achieve a pregnancy within 2 years (Weiss et al.
1992), we derive a net prevalence of 1.02% and 0.73% for short-term reproductive disability
and 0.67% and 0.48% for long-term reproductive disability in females and males respectively.
The causes of infertility are derived from recent national data on assisted conception and
reproduction (AIHW: Dean & Sullivan 2003; AIHW: Ford et al. 2003). For short-term cases,
we assume incident cases equal prevalent cases divided by the duration, which we assume is
2 years. For long-term cases, we derive incidence and durations from DisMod assuming non-
zero remission rates from ages 45 years or over to account for declining prevalence of
reproductive disability reflecting adoptions and changes in reproductive goals. For women,
we subtract from the total number of long-term incident cases the estimated incidence of
infertility as a sequela to maternal sepsis, abortion and pelvic inflammatory disease, the
disability of which is calculated under chlamydia and gonorrhoea. We determine the
duration of long-term infertility by subtracting the age at onset estimated in DisMod from
45 years. GBD weights are used for both short- and long-term reproductive disability.
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Other genitourinary diseases
For this residual category, we assume the application of a simple YLD to YLL ratio of one
across the age groups is sufficient to capture the morbidity from other genitourinary diseases
in men. This method, however, does not capture the significant burden experienced by
women, particularly at younger ages. We therefore calculate separate models for menstrual
disorders and hysterectomies for menorrhagia, genital prolapse and endometriosis.
We base our estimates for menstrual disorders on women who report they often have severe
period pain or premenstrual tension in the last 12 months from Women’s health Australia.
For severe period pain we assume a duration of 1 day per month and a disability weight
similar to that for caesarean section. For menstrual tension we assume a duration of 2 days
each month and we use the disability weight for mild depression. We use DisMod to model
the conditions, assuming no excess mortality and remission of 0.1 for ages less than 50 years.
We model disability from hysterectomies associated with menorrhagia, genital prolapse and
endometriosis in terms of disability from both the procedure and the resulting infertility. We
derive the number of procedures from hospital data and we assume a 2-week duration at the
derived weight for laparotomy of 0.349 (compare with estimates for caesarean section).
Following the findings of a survey of surgical sterility in Perth (Webb & Holman 1992), we
assume the majority of women who undergo a hysterectomy have completed their
reproductive objectives, and that infertility leads to disability in 3.3% of cases with
endometriosis. We apply the GBD weight for infertility.
2P Skin diseases
Eczema, acne and psoriasis
We model the incidence of severe eczema (that is, an episode in the past 12 months that
disrupts sleep on average one or more nights per week) using self-reported prevalence data
from a study of Melbourne school children (Robertson et al. 2004) and from the National
Health Survey for adults (ABS 2001c). For other skin conditions we limit our estimates to
severe acne and moderate and severe psoriasis. Prevalence figures for acne are based on a
study of Australian school children and a study of adults in Central Victoria (Kilkenny et al.
1998; Marks et al. 1999). Prevalence figures for psoriasis were derived from the National
Health Survey and from the central Victorian study (Marks et al. 1999; Plunkett et al. 1999).
We derive incidence and duration estimates from DisMod assuming no excess mortality and
a remission rate of 0.1 for eczema (Thestrup-Pedersen 2003), 0.27 for acne (assuming 70%
spontaneous remission after 4 to 5 years) and 0.3 for psoriasis. For eczema we derive a
disability weight (0.019) from the disability weight regression model which we adjust for
3 symptomatic episodes per year lasting 6 weeks in total. For acne we use the unadjusted
disability weight for eczema from the disability weight regression model (0.056) and for
psoriasis we apply the GBD weight for vitiligo.
Other skin diseases
We model the disability associated with chronic leg, skin and varicose ulcers, excluding
decubitus and cellulitis which we assume are captured elsewhere. We use the weighted
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incident cases of skin ulcers from Australian general practitioner data to estimate the
incidence of other chronic skin ulcers. YLD for diabetic foot is included within the diabetes
mellitus model. To avoid double-counting diabetic foot we adjust our incident estimates for
skin ulcers using Western Australian aetiological data on the proportion of leg ulceration
cases that had diabetes (Baker et al. 1992). In the absence of more specific information we use
the same assumptions for duration (8.9 months) and disability (0.131) as the diabetic foot
model.
2Q Musculoskeletal diseases
Musculoskeletal diseases are highly prevalent in the population. The fair to good test–retest
reliability of self-reported musculoskeletal diseases and the consistent correlation with pain
make health survey self-reports of some use to measure musculoskeletal conditions.
Although the prevalence of most musculoskeletal diseases differs substantially depending
on the measurement method, with self-report showing the highest prevalence, the pattern of
prevalence in men and women is often similar. A higher prevalence of herniated disc of the
back and gout is found in men, whereas for most other musculoskeletal diseases the
prevalence is higher among women than among men (Picavet & Hazes 2003).
Rheumatoid arthritis
Given the small numbers in Australian studies on rheumatoid arthritis and problems with
proper incidence and remission measurement, we base our incidence estimates for this
condition on the international literature. For juvenile chronic arthritis, we use findings from
a population study during 1984–1988 in Sweden (Gare & Fasth 1992). For adults, we use
results from a 40-year follow-up study of a population-based cohort in Rochester, Minnesota,
USA (Doran et al. 2002). We derived durations from DisMod assuming a relative risk of
mortality of 1.6 at ages 15 years or over (Pincus et al. 1994), with no increased risk for
children, and a remission rate of 0.04 (Prevoo et al. 1996) indicating that, while drug
treatment may slow the disease process and remission is the ultimate endpoint of treatment,
most therapeutic options have fallen short of achieving this (Sesin & Bingham 2005). Because
progression through the three stages of rheumatoid arthritis described by the Dutch weights
is relatively rapid, we do not model this condition as progressive. Rather we apply an
average of the Dutch weights using severity distributions for American adults (Hakala et al.
1994) and those relating to Swedish children (Gare & Fasth 1992).
Osteoarthritis
While there are a few Australian population-based studies on self-reported osteoarthritis
(Jones et al. 1995; March et al. 1998), we prefer to base our estimates for this condition on
reported findings of radiographic osteoarthritis (grade 2 and above) by affected joint, age
and sex from a large-scale study in Massachusetts, USA (Jones et al. 1995; March et al. 1998).
We model hip and knee osteoarthritis only, given the high correlation between osteoarthritis
of the hip, hand and fingers (Spector et al. 1997). We used DisMod to derive average
durations, assuming a slightly increased risk of mortality (1.1) and the observed remission
rate from joint replacement surgery. Because osteoarthritis is a relatively slow progressive
disease, with few patients showing symptomatic progression over an 11-year period (Ahern
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& Smith 1997), we apply an average of the relevant Dutch weights, assuming a severity
distribution based on the Framingham study (Guccione et al. 1990).
Back pain
Back pain is a very common condition, with about 70–90% of people suffering from it in
some form at some point in their lives (Hicks et al. 2002). Back pain may be viewed as
running either an acute or chronic course. Acute back pain is usually considered to have a
short duration and tends to resolve within days to weeks. However, recurrence of acute
episodes is common and there is some contention as to the difference between recurring
acute back pain and long-term chronic back pain. A duration of back pain lasting at least 3
months commonly underlies the definition of chronic back pain (NINDS 2006), and is often
likely to continue indefinitely (Von Korff & Saunders 1996). Our estimates for back pain are
based on self-reported prevalence of recent episodes, and long-term back pain from the 2003
Australian disability survey and the 1995 National health survey. We model recent episodes
of (acute) back pain and long-term (chronic) back pain separately. Prevalence of long-term
back pain resulting in at least mild disability is obtained from the Australian disability
survey. Of these, the cases that were due to recent episodes of back pain were not identified
separately. We therefore estimated the proportion due to recent episodes by applying the
percentage of recent cases of long-term back pain from the 1995 National Health Survey. We
use the Dutch weight for low back pain (0.06) as the disability weight for recent episodes of
back pain, which applies to an average health state involving some problems in walking
about and in usual activities, as well as moderate pain or discomfort. We assume an average
duration of 4 days for painful and limiting episodes of back pain. To model chronic back
pain, we use the prevalence of long-term back pain (not identified as recent episodes as
described above) from the 2003 Australian disability survey. We use DisMod to derive the
incidence and duration of chronic back pain, assuming a remission rate of 10% and no
increased risk of mortality. For many people, there are few treatment alternatives and
complete relief is rare (Atkinson 2004). We assume that 14% of long-term cases experience
constant or persistent pain (Quittan 2002), and 86% experience pain 1 day per week. We use
the GBD disability weight for chronic intervertebral disc pain of 0.103.
Slipped disc
Our estimates for slipped disc are based on numbers of intervertebral disc procedures from
Australian hospital data. We assume only 7.5% of incident cases of disc displacement receive
surgery (Deyo et al. 1990), and derive total annual episodes from this proportion. We assume
on average an episode of discomfort lasts 4 weeks. For those who receive surgery, we take
the median time of 224 days from onset of symptoms to recovery reported in the literature
(Rasmussen 1996). In the absence of weights for both these health states, we use the Dutch
weight for low back pain (0.06). Based on a 5-year follow-up study (Kurth et al. 1996), we
model 14% of operated cases as going on to experience long-term chronic pain with a
lifelong duration at the GBD disability weight for chronic intervertebral disc of 0.103.
Occupational overuse syndrome
Occupational overuse syndrome (formerly known as repetition strain injury) is a contentious
condition with considerable disagreement within the literature about its aetiology and
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pathophysiology (Byrne 1992; Cohen et al. 1992; Helme et al. 1992). Our model uses self-
report prevalence data on ‘repetition strain injury’ from the 2003 Australian disability survey
from which we derive incidence figures using DisMod assuming an average duration of
3 years and no mortality. In the absence of Dutch or GBD weights for this condition, we use
sex-specific derived weights to account for the fact that all males in the 1993 Australian
disability survey had mild or no handicap, whereas 26% of females had moderate handicap
and 17% had severe or profound handicap.
Gout
Our estimates for gout are based on self-reported prevalence from the National Health
Survey which has the same overall result as found in a general practitioner study in the UK
(Mikuls et al.  2005). We assume a slight increased risk of mortality associated with gout
(relative risk=1.1) and no remission, based on information that at  1 year 62%, at 2 years 78%
and at 10 years 93% has had at least one repeat attack (Alamo Family Foot and Ankle Care
2005). Fitting a Weibull function to these figures gives an average time to the next episode of
2.2 years, but this is rather high because of the skewness of the function. The median time to
next episode is 0.44 years. We assume that 10% has chronic symptoms and the remaining
90% has an attack of 1 week every 0.44 years. Given that people may suffer gout at varying
levels, from acute attacks of a short duration to chronic gout, we assume on average one
attack per 2 months lasting 1 week in 90% of people and the remaining 10% suffer chronic
ongoing disease at the GBD disability weight of 0.061.
Other musculoskeletal disorders
Because mortality for musculoskeletal conditions is low and because 49% of deaths from
musculoskeletal disorders do not fall within the above categories, a derivation of disability
for this rest category by applying a ratio of YLD to YLL for the explicitly modelled
musculoskeletal conditions is not plausible. Therefore we try to model disability from all
other conditions explicitly. In the absence of detailed information, we define an ‘other’
category comprising both prevalent minor conditions and more serious diseases (for
example joint derangement and disorders; osteopathies; chondropathies and other bone
disorders; connective tissue diseases; and soft tissue problems such as rheumatism,
ganglions, bunions, bursitis, cramps, tenosynovitis and tennis elbow). We base our estimates
for these conditions on the prevalence of other musculoskeletal disorders that have not been
accounted for in each of the musculoskeletal models described above from the 2001 National
Health Survey. Based on figures from the 2003 Australian disability survey, we assume a
proportion of prevalent cases report on refer to musculoskeletal sequelae of other diseases or
injuries, which we account for by adjusting overall prevalence figures downwards by 50%.
For recent non-chronic cases, we assume the same duration and weight as for recent episodes
of back pain. For chronic cases, we derive incidence rates and durations from DisMod
assuming no excess mortality and a remission rate of 0.1. We take the proportion reporting
symptoms in the 2 weeks before interview as an approximation of the proportion of time
spent symptomatic and assume symptomatic chronic cases experience a health state
equivalent to the weight for low back pain.
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2R Congenital anomalies
Congenital heart disease
We model the disability associated with four types of congenital heart disease for live-born
infants: surgically treated atrial or ventricular septal defect, surgically treated Fallot’s
tetralogy or transposition of great vessels, surgically treated pulmonary stenosis, and
complex but not curatively operable congenital heart disease. We derive the incidence of the
first three conditions from Australian hospital data by assuming that all curative procedures
represent an incident case with disability. We assume a duration of 1 year before operation
with disability equivalent to the Dutch weight for moderate heart failure (0.35) and post-
surgery we use relevant Dutch weights and assume reduced life expectancy, except for those
with septal defects (Miyamura et al. 1993; Nollert et al. 1997a, 1997b). We assume disability
starts at birth and we discount YLD back to birth to account for this. We derive the incidence
of other congenital heart malformations from Victorian birth defects data. Following expert
advice, we assume that 50% of these cases are complex but not curatively operable. We
assume that duration is half of those with surgically treatable conditions and use the relevant
Dutch weight (0.72).
Digestive system malformations
We model the disability for anorectal and oesophageal atresia and other digestive system
malformations. We estimate the incidence of digestive system atresia for cases surviving
28 days using Victorian birth defects data. We assume 26 weeks of disability from birth at the
GBD weight for anorectal atresia (0.85). After this period, we assume that a proportion of
both types of atresia cases have lifelong problems (15% and 20% respectively) and decreased
life expectancy (by 10 and 5 years respectively) and disability equivalent to health state
111211 for two-thirds of the time (0.037) (Ludman & Spitz 2003). We estimate the incidence
of other digestive system malformations using data from the Australian congenital
malformations dataset (AIHW: Hurst et al. 2001). We assume no long-term disability, and a
1-month period of disability from birth equivalent to the GBD weight for anorectal atresia.
Renal agenesis
We estimate the incidence of unilateral and bilateral renal agenesis for cases surviving
28 days using Victorian birth defects data. For unilateral cases we assume that 20% of
survivors have ongoing problems, with a life expectancy of 70 years and a disability of 0.067.
For bilateral cases we assume an average duration of 3.5 days and use the GBD weight for
renal agenesis (0.85). We also calculate YLD for renal failure due to renal dysplasia based on
attributions from Australian dialysis and transplant data.
Other urogenital tract malformations
We model the disability associated with the following urogenital tract malformations: cystic
kidney disease, obstructive defects of renal pelvis and ureter, and other urinary tract
malformations. We estimate the incidence of cases of other urogenital tract malformations
surviving beyond 28 days from the Victorian, Western Australian and Australian birth
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defects data. We assume 30% of cases have chronic lifelong problems, with a life expectancy
of 50 years and a disability weight of 0.067. YLD were also calculated for end-stage renal
failure due to cystic kidney disease.
Other congenital anomalies
We estimate the incidence of anencephaly using Australian mortality data for newborns,
assuming deaths are equivalent to incident cases. We assume a duration of 1 week with a
disability weight of 1. For spina bifida, we estimate the average annual number of live births
that survive the first 28 days from Victorian birth defect data (Riley & Halliday 2004). We
derive an average disability weight (0.52) based on the Dutch weights for each level of
severity combined with severity distributions from expert advice. We estimate the incidence
of surgically treated cleft lip and cleft palate from Australian hospital data, assuming that all
curative procedures represent a case and that all cases are treated within the first year. We
assume disability equivalent to the ‘treated’ GBD weights (0.016, 0.015 respectively). YLD
estimates for Down syndrome and ‘other chromosomal anomalies’ are calculated as
described in the section on intellectual disability (see Section 2K).
We estimate the incidence of abdominal wall defects (exomphalos and gastroschisis) in
infants surviving >28 days using 2001 Australian birth defects data (AIHW NPSU 2004) and
survival data from the Victorian birth defects data. We assume a duration of 4 weeks based
on Australian and international literature (Dimitriou et al. 2000; Sharp et al. 2000) and apply
the GBD weight for abdominal wall defect. Based on expert advice we assume that 20% of
cases have lifelong problems, a shortened life expectancy by 20 years, and disability weight
of 0.200 (the Dutch weight for young adult in permanent stage after surgical repair to Fallot’s
tetralogy).
2S Oral conditions
Caries
The incidence of caries is measured by one or more new dental cavities (caries increment).
The occurrence of dental caries in an individual is measured using the DMFT or DMFS
index: the number of decayed (D), missing (M) and filled (F) primary or permanent teeth (T)
or surfaces (S). A review of the relationship between DMFT and DMFS suggests that DMFS
data should be adjusted by a factor of 1/3.5 to be consistent with DMFT data (Carvalho et al.
2004; Hopcraft & Morgan 2005; Rosen et al. 2004).
For children and adults we estimate the incidence from representative Australian caries
prevalence data: the 2000 Child Dental Health Survey (AIHW: Armfield et al. 2004) and the
1987–88 National Oral Health Survey of Australia (Barnard 1993). Fitting linear regression
lines to the prevalence data gives slopes in children (1–14 years) of 0.25 (AIHW: Armfield et
al. 2004; Davies et al. 1997) and in adults (15–59 years) of 0.27 (Barnard 1993). For older
adults (60 years or over) and nursing home residents (60 years or over) we estimate the
incidence of caries from the South Australia Dental Longitudinal Study (AIHW DSRU 2002)
and the 1998 Adelaide Dental Study of Nursing Homes (AIHW: Chalmers et al. 2001),
respectively. Based on the 5-year increment of all new carious surfaces, the 1-year increment
(assuming that the incidence of carious surfaces over the 5-year period was evenly
177
distributed) is 0.98 (AIHW DSRU 2002). The 1-year increment of new carious surfaces in
nursing home residents is 3.5 (AIHW: Chalmers et al. 2001). We use our DMFT/DMFS
adjustment factor to give annual caries increments of 0.28 and 1.0 respectively for older
adults in the general population and nursing homes.
The previous Australian burden study assumed a symptomatic duration of 10 weeks based
on advice from the Australian Research Centre for Population Oral Health. More recent
work, based on patient self-report, by this group suggests durations in the order of 81 weeks
(Brennan & Spencer 2004, 2005). However, both of these estimates refer to time spent with
and without symptoms. A review of the literature shows that there is a paucity of
information on symptomatic caries, specifically mean duration of symptoms and proportion
of people who are symptomatic. A patient-based study in children in the UK reported that
78% of the children sampled presented within 1 month of pain onset (Mason et al. 1997)
whereas a patient-based study in New Zealand observed that 67% of adults presented within
1 month of pain onset (Whyman et al. 1996). Patient-based samples are biased as they do not
reflect all cases of caries in the community. Neither of these studies provided data on the
mean durations for those people experiencing symptoms for greater than 1 month. We
estimate the average time symptomatic for those people presenting with caries problems by
fitting a lognormal distribution to the midpoint of the observed durations. This gives mean
durations of symptomatic caries of 28 days in children and 55 days in adults. We base our
estimate of people with symptomatic caries (32.4%) on the findings of the 1998 Australian
Longitudinal Study of Dentists’ Practice Activity (Brennan & Spencer 2002).
Following the first Australian burden of disease study the Australian Research Centre for
Population Oral Health developed disability weights for oral disease using a patient-based
sample in South Australia (Brennan & Spencer 2004, 2005). Disability weights for caries
(0.044), periodontal disease (0.023) and denture problems (0.026) in this study were higher
than comparable Dutch weights used in the previous Australian burden study (0.005 for
caries involving a filling and 0.014 for caries involving an extraction, 0.007 for periodontal
disease, and 0.004 for edentulism). We did not use these Australian-derived disability
weights because patient-based samples are likely to under-represent asymptomatic people,
and questions with limited response categories are likely to bias results. For instance, the
duration-related question was ‘During the period that you have had this dental problem,
what percentage of the time (0% = none of the time, 50% = half of the time, 100% = all of the
time) have you experienced the limitations listed above in relation to: mobility, self-care,
usual activities, pain/discomfort, anxiety/depression, cognition?’ (Brennan & Spencer 2004,
2005). Both of these limitations are likely to over-estimate the percentage of people reporting
problems for each of the health dimensions as well as the duration of their symptoms.
We follow expert advice and derive a disability weight for symptomatic caries (0.057) using
the disability weight regression model (health states: 20%—111211 and 80%—111111).
Edentulism
We estimate the prevalence of edentulism (loss of all natural teeth) for the general
population and nursing home residents using the 2002 National Dental Telephone Interview
Survey (AIHW: Carter & Stewart 2003) and the 1998 Adelaide Dental Study of Nursing
Homes (AIHW: Chalmers et al. 2001), respectively. We derive incidence and duration using
DisMod, based on these studies, assuming no remission and no excess case-fatality. We
model a 2% declining time trend to reflect the observed decline of the prevalence of
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edentulism from 20.5% in 1979 to 8.0% in 2002 (Sanders et al. 2004). We use the same
disability weight as in the previous Australian burden study.
Periodontal disease
We estimate the prevalence of periodontal pockets larger than 6 mm using data from the
1987–88 National Oral Health Survey of Australia (Barnard 1993). Expert advice suggested
that periodontal disease is a largely asymptomatic risk factor for tooth loss; pain occurs in
around 1% of time when an abscess forms in a periodontal pocket; and the typical duration
of periodontal disease is around 15 years. We derive incidence and duration using DisMod
based on the Australian prevalence data, remission rates that reflect 15 years average
duration and no case-fatality. A new disability weight for periodontal abscess was estimated
(0.056) based on the disability weight regression model (health state 111211).
Pulpitis
We estimate the incidence of pulpitis using the proportion of patients sampled in the 1998
Longitudinal Study of Dentists’ Practice Activity (AIHW: Spencer & Brennan 2002) who had
a main diagnosis of pulpal infection and the total number of dental consultations in Australia
in 2003. We assume that most people with pulpal infection will visit a dentist. We estimate
the total number of dental consultations by multiplying the proportion of people who visited
a dentist in the last 12 months by the mean number of dental visits per person (from the 2002
National Dental Telephone Information Survey (AIHW: Carter & Stewart 2003)) and 2003
population data (excluding the edentulous population). Expert consultation suggests that a
symptomatic duration of 1 month is plausible for pulpitis with the first few weeks consisting
of intermittent pain and the last week being of more severe and consistent pain. We assume
that 71.3% of people with pulpitis presenting in pain, a figure which we derive from the 1998
Longitudinal Study of Dentists’ Practice Activity. We use the disability weight regression
model to estimate a disability weight for pulpitis assuming that 1 week is spent in moderate
pain and 3 weeks are spent at a level of the disability for moderate pain for 10% of the time.
2Z Chronic fatigue syndrome
We base our model for chronic fatigue syndrome on the internationally accepted US Centers
for Disease Control and Prevention criteria, which state that for a patient to receive a
diagnosis of chronic fatigue syndrome, they must have severe chronic fatigue of 6 months or
longer duration with other known medical conditions excluded by clinical diagnosis, and
concurrently have four or more of the following symptoms: substantial impairment in short-
term memory or concentration; sore throat; tender lymph nodes; muscle pain; multi-joint
pain without swelling or redness; headaches of a new type, pattern or severity; unrefreshing
sleep; and post-exertional malaise lasting more than 24 hours. The symptoms must have
persisted or recurred during six or more consecutive months of illness and must not have
predated the fatigue (Fukuda et al. 1994).
Following expert consultation we conceptualise two manifestations of chronic fatigue
syndrome: (a) post-infective fatigue syndrome which constitutes between 30–40% of cases
and is characterised as an acute outcome of viral and non-viral infections, has a disability
starting point of moderate severity, a median duration of 12 months, and around 99%
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recovery at 2 years (Hickie et al. submitted 2005; Wilson et al. 2001); and (b) protracted
chronic fatigue syndrome, which constitutes the remaining 60–70% of chronic fatigue
syndrome cases, where cases have an insidious onset with initially severe disability followed
by cases fluctuating around 50–80% of their previous healthy state, and a median duration of
around 7 years. We assume that the disability associated with post-infective fatigue
syndrome is included within the disability weights and durations in the relevant infectious
disease models (explicitly in the arbovirus estimates but not for other viral infections such as
Q fever and Epstein-Barr virus which are subsumed in the rest of infectious disease
category).
We base our estimates of prevalence for protracted chronic fatigue syndrome on the
population-based study of chronic fatigue syndrome conducted in Wichita, Kansas, USA in
1997 (Reyes et al. 2003). In the previous Australian burden study we used prevalence
estimates based on an Australian prevalence study of chronic fatigue syndrome (Lloyd et al.
1990). This study’s applicability in the current context is limited due to the different
diagnostic criteria used and the physician referral sample. The population-based study by
Reyes and colleagues (2003) showed that only 16% of people identified with chronic fatigue
syndrome had previously been diagnosed as such by a medical practitioner. Although it is
not clear how similar the epidemiology of chronic fatigue syndrome is between the US and
Australia, the findings from an international multi-centre study of the prevalence of chronic
fatigue syndrome in patients lend support to the notion that the epidemiology of chronic
fatigue syndrome is similar in the two countries (Wilson et al. 2001).
We model incidence and duration using DisMod, assuming no excess mortality and
remission rates which gave an average duration of 7.3 years (Reyes et al. 2003). We assume
that 90% of the time people with chronic fatigue syndrome are symptomatic, using findings
from the 1993 Australian disability survey. In the absence of an established disability weight
for chronic fatigue syndrome we use the disability weight estimated for the previous
Australian burden study.
3 Injuries
We model the disability from non-fatal injuries where a person has an injury severe enough
to warrant emergency department or inpatient hospital treatment but that does not lead to
death. This method assumes that injuries treated outside the hospital system do not result in
significant disability. We derive non-fatal incident injuries from Australian hospital data. We
classify incident cases according to a matrix of 14 ‘external cause of injury’ categories (12
unintentional and two intentional) and 32 ‘nature of injury’ categories (for example fractures,
burns, wounds, brain injury, spinal cord injury). We exclude admissions for the same ICD-10
code within 90 days, on the assumption that these are re-admissions, as well as, those
resulting in death. Given that it is not uncommon for multiple sites of the body to be
damaged from a single accident, we estimate disability for only the most disabling ICD-10
code associated with each incident, on the assumption that the disability for the other ICD-10
codes is captured in the weight for the more severe injury. We redistribute ill defined injuries
and adjust estimates for ‘amputated finger’ as in the previous Australian burden of disease
study. We use disability weights, durations and the risk of mortality as per the GBD study.
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Appendix 2: Methods for attributing risk 
In this section we describe our methods for assessing the contribution of 14 health risks to 
the total burden of disease and injury in Australia. For most risks, our analyses are based on 
methods developed by the WHO CRA project and described in detail elsewhere (Ezzati et al. 
2004a). Briefly, the main inputs are the prevalence of exposure to a health risk in a 
population and information on the risk of disease, injury or death (referred to here as relative 
risk or hazard) from this exposure, which is typically derive from systematic reviews of the 
international literature. Our analyses are not comprehensive since choices had to be made 
about which risks to include on the basis of certain criteria, as outlined at the beginning of 
Chapter 4. We begin by describing the methodological basis of our analyses, the population 
attributable fraction. 
Estimating population attributable fractions
The population attributable fraction (PAF) is a subtype of a more general measure—the 
‘potential impact fraction’ (PIF). The PIF measures the proportional reduction in disease or 
injury burden experienced by a population that would occur if the population were 
subjected to an alternative or ‘counterfactual’ distribution of exposure to a particular health 
risk. If the alternative exposure scenario is set to a level such that it represents the lowest 
possible risk in a population (no exposure, for example), the PIF represents the total amount 
of burden that is attributable to that risk; in this instance it is called the ‘population 
attributable fraction’ (Eide & Heuch 2001; Miettinen 1974). For health risks that are measured 
on a continuous scale, the PIF can be defined thus: 
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Where RR(x) = relative risk at exposure level, P(x) = population distribution of exposure, 
P’(x) = counterfactual distribution of exposure, and m = maximum exposure level  
(Equation 1) 
When a risk is measured on a categorical scale, the discrete version of the PIF formula is 
(Eide & Heuch 2001; Walter 1980): 
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Where c = an index for category, P = prevalence, and P* = prevalence after a change, and  
RR = relative risk 
(Equation 2) 
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The difference between Equation 1 and Equation 2 in practical terms is that the latter can
easily be resolved in a spreadsheet environment, whereas the former requires more
advanced mathematical techniques. Equation 2 is mathematically the same as the PAF
formula for risk factors with multiple categories given by English and colleagues (Equation
3), if the counterfactual is set as the hypothetical minimum distribution (English et al. 1995).
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Choice of theoretical minimum
Calculating a PAF requires the explicit characterisation of an exposure distribution that
represents the lowest possible level of risk in a population. This has been termed the
‘theoretical minimum exposure distribution’ and corresponds to zero exposure for some
risks (for example smoking). For other risks, however, zero exposure is inappropriate
because it is physiologically impossible (for example systolic blood pressure, BMI and
cholesterol). In this case the lowest levels observed in specific populations and
epidemiological studies described in the literature are used instead. For example, a
theoretical minima of 115 mmHg for systolic blood pressure and 3.8 mmol/L for total
cholesterol (each with a small standard deviation) are the lowest levels at which the dose-
response relationships have been characterised (Chen et al. 1991; Eastern Stroke and
Coronary Heart Disease Collaborative Research Group 1998; Law et al. 1994). For factors
with protective effects (fruit and vegetable consumption and physical activity), the
theoretical minimum exposure distribution is based on information from high exposure
populations about the level to which the benefits continue to accrue given current scientific
evidence.
Estimating attributable burden
Age- and sex-specific PAFs are calculated for each health risk and heath outcome pair using
the relationships in Equations 1 and 2. Where a relative risk of disease or injury is different to
the relative risk for death, two PAFs are calculated, one for non-fatal burden and the other
for fatal burden. PAFs are then multiplied with the relevant burden estimates for that health
outcome and the sum of the burden across all outcomes affected by a health risk constitutes
the total attributable burden for that risk. For example, if there are 1,000 deaths from
ischaemic heart disease and 500 from stroke in a particular age and sex category, and the
PAFs for cholesterol leading to ischaemic heart disease and stroke are 0.5 and 0.3
respectively, the mortality attributable to high cholesterol equals 1,000 × 0.5 + 500 × 0.3 = 650.
In other words, if the population had been exposed to the hypothetical minimum cholesterol
distribution instead of the current distribution, 650 fewer deaths would have occurred.
Table A2.3 summarises the exposure levels, theoretical minima, health outcomes and sources
of relative risks for each of the 14 health risks analysed in this report. Table A2.4 summarises
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our estimates of exposure in the Australian population to each of these risks. A brief
description the specific methods we used for each risk is provided below.
Tobacco
Given the long lag time between exposure to tobacco smoke and the occurrence of cancers
and COPD, the attributable burden cannot be estimated from the current prevalence of
smoking. Even with good historical information on smoking prevalence, it is not
straightforward to determine the current amount of illness that is due to smoking because
the lag time between the relevant exposure and disease is variable. Therefore, we used the
method of Peto and colleagues, who proposed an artificial compound prevalence measure of
the relevant past exposure to tobacco (Peto et al. 1992). This ‘smoking impact ratio’ is derived
from a comparison of lung cancer mortality rates in the population of interest and lung
cancer mortality rates among non-smokers and smokers observed in a large long-term
follow-up study in the United States. We used this smoking impact ratio instead of the
current prevalence in the standard calculation of attributable fractions for the other cancers
and COPD. Compared with cancers and COPD, the mean time between exposure to tobacco
and all other adverse health outcomes is considerably shorter. We therefore used prevalence
estimates of smoking for adults aged 18 years and over in 2001, two years before our baseline
year of 2003 (ABS 2001c).
Our previous calculations of attributable mortality burden included only those diseases for
which English and colleagues report strong evidence of an association (English et al. 1995).
For this report, we added other conditions for which reasonable evidence of an association
with tobacco exists (AIHW: Ridolfo & Stevenson 2001): cancer of the stomach, endometrial
cancer, peripheral vascular disease, pneumonia, inflammatory bowel disease, injuries from
fires and Parkinson’s disease. Tobacco has a small protective effect against Parkinson’s
disease and endometrial cancer. We omitted peptic ulcer disease, given evidence of its
largely infectious aetiology. We also added the burden attributable to smoking from macular
degeneration (Mitchell et al. 1999; Tomany et al. 2004).
In addition, we calculated the burden from passive smoking using attributable fractions for
lung cancer, ischaemic heart disease, and asthma in children (NHMRC 1997a). For lower
respiratory tract infection, sudden infant death syndrome and otitis media in children due to
passive smoking, we used the prevalence of maternal smoking (Turrell et al. 2002) and
relative risks from the US Surgeon General’s Report (US Department of Health and Human
Services 2006) and NHMRC (NHMRC 1997a). We also estimated the burden of low birth
weight due to smoking during pregnancy using the relative risk from Ridolfo and Stevenson
(2001) and estimates of smoking during pregnancy from Laws and Sullivan (2005).
High blood pressure
We used the AusDiab study (Dunstan et al. 2002) to estimate distributions of high blood
pressure by age and sex in the Australian population. Despite a low response rate AusDiab is
the only recent and representative study that has measured this risk in Australia. Relative
risks came from Lawes and colleagues (2004a). We used the CRA theoretical minimum
distribution for blood pressure (mean 115, SD 6 mmHg) as the counterfactual in this analysis.
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High body mass
We used the AusDiab study (Dunstan et al. 2002) to estimate distributions of body mass
index (BMI) by age and sex in the Australian population. Relative risk of type 2 diabetes
came from the Asia Pacific Cohort Collabortation (2006); the relative risk of all remaining
conditions associated with high body mass came from James and colleagues (2004). We used
the CRA theoretical minimum distribution for BMI (mean 21, SD 1 kg/m2) as the
counterfactual in this analysis.
Physical inactivity
Recent developments have led to the treatment of physical inactivity as a four-level
categorical variable by subdividing the exposure group labelled as ‘sufficiently active’ in the
CRA project into those ‘meeting current recommendations’ and ‘highly active’. While
physical activity levels equivalent to 2.5 hours per week of moderate-intensity activity
(approximately 4000kJ/week) are considered an important target for population health
benefits, the protective effects are expected to continue to higher levels. Therefore, the
theoretical minimum exposure distribution was chosen to be the whole population in the
‘high active’ category to increase consistency with the counterfactual exposure distribution
of other risk factors (Bull 2003; Murray et al. 2003; Powles & Day 2002) (Table A2.1). The
required prevalence data were derived from the NHS 2001 (ABS 2001c). The exercise related
questions in this survey relate to physical exercise undertaken for recreation, sport, health or
fitness purposes, conceptually excluding physical activity undertaken as a part of work or
for other purposes. This may underestimate the amount of physical activity undertaken, and
therefore our analyses may overestimate the burden of disease attributable to physical
inactivity.
The associated hazards were modified to correspond to the new referent category of ‘highly
active’. Given no available quantitative meta-analysis with comparable categories, risk
estimates were derived from a synthesis of recent reviews (Kelley & Goodpaster 2001;
Kesaniemi et al. 2001; Kohl 2001; Oguma et al. 2002; Thune & Furberg 2001; Williams 2001)
and findings from several recent studies in which the results were reported separately by
intensity of activity as well as total volume of activity (Manson et al. 2002; Sesso et al. 2000).
The relative risk of ischaemic heart disease for the inactive group compared to ‘high active’
was set at 2.0, based on reviews of studies with both physical activity and fitness measures as
well as a recent study’s differential results for moderate versus vigorous activity. The likely
linear dose-response relationship (Kesaniemi et al. 2001) was represented by the arithmetic
midpoints for those classified as ‘meeting current recommendations’ and ‘insufficiently
active’. For stroke, the mean of nine studies summarised in the systematic review and meta-
analysis by Blair and colleagues (2001) was used (relative risk of 2.0). The findings from the
review by Thune and Furberg (2001) were used to derive the risk estimate for colon and
breast cancer. There has been no quantitative review of diabetes and physical activity;
therefore the relative risks from the CRA project were adjusted by the same magnitude as for
ischaemic heart disease. It is recognised that these estimates of risk are derived from a
synthesis of the available scientific evidence and alternative interpretations are possible.
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Table A2.1 Physical activity exposure categories
Physical activity level Definition
High 3 sessions x at least average 40 minutes vigorous AND total of at least 1500 METmins/week(a)
Recommended
3 sessions x at least average 20 minutes vigorous OR 5 x 30 minutes moderate OR 600
METmins/week
Insufficient Some activity but not meeting recommendation
Inactive No activity
(a) The standard metabolic equivalent, or MET, level. This unit is used to estimate the amount of oxygen used by the body during physical
activity. One MET = the energy (oxygen) used by the body sitting quietly, perhaps while talking on the phone or reading a book.
The harder the body works during the activity, the higher the MET.
High blood cholesterol
We used the AusDiab study (Dunstan et al. 2002) to estimate distributions of high blood
cholesterol by age and sex in the Australian population. Relative risks came from Lawes and
colleagues (2004b). We used the CRA theoretical minimum distribution for serum cholesterol
(mean 3.8, SD 0.5 mmol/L) as the counterfactual in this analysis.
Alcohol
There are a number of recent data sources on the prevalence of alcohol consumption in the
Australian population, including the 2004 National Drug Strategy Household Survey
(NDSHS 2004) (AIHW & DoHA 2005) and the 2001 National Health Survey (NHS 2001) (ABS
2001c). The NHS 2001 focuses on the quantity of alcohol consumption on the three most
recent days on which alcohol was consumed in the week prior to interview, while the
NDSHS 2004 explicitly quantifies the amount of alcohol drunk on the day prior to interview.
Of these, only the NHS 2001 collected information on the type and brand of alcoholic drinks
consumed as well as the number. Also, the NHS 2001 gives average daily alcohol
consumption over the previous week in millilitres. For this reason, we used the NHS 2001 to
estimate the prevalence of alcohol consumption for adults aged 18 years or over.
We categorised the prevalence of alcohol consumption into the four levels used in English
and colleagues’ analysis of the risks of alcohol consumption (English et al. 1995), and with
the NHMRC’s recommendations on alcohol consumption (NHMRC 1992) (Table A2.2). The
prevalence of each level of alcohol intake was estimated by age and sex from the average
weekly consumption of alcohol after conversion to standard drinks per day. Data for people
interviewed on each day of the week were reweighted to obtain prevalence of alcohol
consumption based on equal samples for each day of the week. Those that last drank alcohol
more than 1 week ago were classified as abstainers.
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Table A2.2 Classification and prevalence of alcohol intake levels used in this report
Average number of standard drinks (= 10 g alcohol) per day
Alcohol intake Male Female
Abstinence 0–0.25 0–0.25
Low 0.26–4.00 0.26–2.00
Hazardous 4.01–6.00 2.01–4.00
Harmful >6 >4
Source: English et al. 1995
We used relative risks and population attributable fractions from Ridolfo and Stevenson
(AIHW: Ridolfo & Stevenson 2001) for conditions for which there is evidence of causation by
alcohol consumption. English and colleagues (1995) estimated that 44% of fire injuries are
attributable to alcohol; this was not updated by Ridolfo and Stevenson (AIHW: Ridolfo &
Stevenson 2001). We revised these estimates with the addition of more recent studies, and
produced a separate PAF for fire injuries and scalds or other burns for both YLD and YLL.
We also updated the drowning PAF of 0.34 from Ridolfo and Stevenson (AIHW: Ridolfo &
Stevenson 2001) with age-specific estimates from Driscoll and colleagues (AIHW: Driscoll et
al. 2004) who found that 17% of unintentional drownings were attributed to alcohol (blood
alcohol content of at least 0.10 g/100 ml). English and colleagues (1995) derived a PAF of 0.07
for alcohol, and occupational and machine injuries. We applied this to all machinery
accidents, and to the occupational YLD PAFs for injury codes not already covered elsewhere
in alcohol. For YLL we applied a PAF of 0.051 (Driscoll et al. 2001) to the occupational YLL
PAFs for injury codes not already covered elsewhere in alcohol.
Low fruit and vegetable consumption
We used the National Health Survey (ABS 2001c) to estimate distributions of fruit and
vegetable consumption by age and sex in the Australian population. Relative risks came
from Lock and colleagues (2004). We used the CRA theoretical minimum risk distribution for
fruit and vegetable consumption (mean 600, SD 50g/day) as the counterfactual in this
analysis.
Illicit drugs
In addition to being a direct cause of death, illicit drugs are also risk factors for conditions
such as HIV/AIDS, hepatitis, low birth weight, inflammatory heart disease, poisoning, and
suicide & self-inflicted injuries. By definition, heroin, benzodiazepine, cannabis and other
drug dependence and harmful use are due to illicit drug use; therefore the entire burden due
to these conditions was attributed to this risk factor category. For infective endocarditis and
suicide we used the attributable fractions for illicit drugs developed by English and
colleagues (1995). The proportion of inflammatory heart disease that was due to infective
endocarditis was derived from hospital data. The infective endocarditis PAF was then
applied to this proportion only.
The proportion of HIV due to injecting drug use was based on diagnosed HIV from the
Australian HIV Public Access Dataset (National Centre in HIV Epidemiology and Clinical
Research 2005b).We use diagnosed rather than newly acquired HIV, which is in keeping
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with YLD estimates, and due to the apparent stabilisation of HIV incidence over recent years.
AIDS cases and deaths attributable to injecting drug use were from the Australian AIDS
Public Access Dataset (National Centre in HIV Epidemiology and Clinical Research 2005a).
Time to death (year of death minus year of AIDS diagnosis) was added to the midpoint of
the age at diagnosis range to approximate age range at death. For those age-at-death ranges
available in the AIDS Public Access Dataset, we used the age-specific proportion attributable
to injecting drug use. For all other ages we applied the all-age proportion. For cases of HIV
and AIDS, and AIDS deaths, we assumed that all cases with exposure category ‘male
homosexual contact and injecting drug use’ were attributable to male homosexual contact.
The proportion of newly acquired hepatitis B and C cases due to injecting drug use was from
the HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual
Surveillance Report 2004 (National Centre in HIV Epidemiology and Clinical Research 2004).
The proportion of road traffic accidents due to illicit drug use was derived from Drummer
and colleagues (2004). We applied the methodology used by Ridolfo and Stevenson on
earlier data from Drummer (1994).
For low birth weight we used prevalence of cannabis and opioid diagnosis during pregnancy
in New South Wales and relative risks from Burns and colleagues (2006). The relative risk for
antepartum haemorrhage attributable to illicit drug use was from English and colleagues
(1995), with the prevalence being heroin or cocaine use in past 12 months for females aged
15–49 years from the NDSHS 2004.
The odds ratio for schizophrenia attributable to cannabis use was from Semple and
colleagues (2005). This odds ratio is the result of a meta-analysis of seven studies with
different classifications of psychosis and cannabis use. Despite these differences, there was
consistency in the unadjusted odds ratios. We used prevalence of daily cannabis use over the
last 12 months from the 2004 NDSHS (AIHW  & DoHA 2005) to calculate the PAF to be
applied to schizophrenia.
Occupational exposures and hazards
The attributable burden of occupational exposures and hazards was based on the following
methods. Work-related fatal injuries were derived from the National Worker’s
Compensation Statistics Database accessed online via National Occupational Health and
Safety Commission (NOHSC) Online Statistics Interactive (NOSI)
<www.nosi2.nohsc.gov.au/>. Since compensation statistics do not cover all occurrences of
occupational injury deaths, we inflated these figures according to a study carried out by
Driscoll and colleagues (AIHW: Driscoll et al. 2004), that investigated the coverage of work-
related traumatic deaths by official occupational health and safety and compensation
agencies in Australia. Work-related deaths by mechanism, nature and industry from the
NOSI database were inflated according to the proportion of all work-related deaths in 1989–
92 covered by compensation agencies by industry (Table 3 in AIHW: Driscoll et al. 2004).
In the absence of more reliable information, the attributable fractions for non-fatal injuries
were derived from an analysis of the National Hospital Morbidity Database 2002–03. For
each age–sex–injury group, the attributable fraction for occupational injuries was estimated
as the ratio of hospital episodes where ‘workplace’ was specified as the place where the
injury occurred to the total hospital episodes where a place of occurrence was specified.
Where possible we derived non-injury attributable fractions by following the CRA methods
(Concha-Barrientos et al. 2004). This produced age- and sex-specific attributable fractions for
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lung cancer, leukaemia, COPD, asthma, adult onset hearing loss, and chronic back pain
(which we also applied to slipped disc). For each of the remaining cancer categories, we
derived attributable fractions from a study carried out for the National Institute of
Occupational Health and Safety (Kerr et al. 1996). This study also provided attributable
fractions for a number of other chronic diseases, including neurological disorders,
cardiovascular diseases, chronic respiratory diseases and renal disease. Attributable fractions
for osteoarthritis were derived separately, based on relative risks of self-reported arthritis for
blue collar workers compared to managers, administrators and professionals (AIHW: Turrell
et al. 2006).
Child sexual abuse and intimate partner violence
Girls that experience child sexual abuse are more likely to experience intimate partner
violence than non-abused girls (Mouzos & Makkai 2004). Women that experience multiple
types of abuse, including child sexual abuse and intimate partner violence, have a higher risk
of depression than those subject to only one form of abuse (Arias 2004; Messman-Moore et al.
2000; Nicolaidis et al. 2004). The 2001 Victorian Burden of Disease Study produced estimates
of the burden attributable to intimate partner violence but did not calculate the burden
attributable to child sexual abuse (DHS 2005; Vos et al. in press). Conversely the CRA project
(Andrews et al. 2004) produced estimates of the burden attributable to child sexual abuse but
not intimate partner violence. In this study we estimated the burden attributable to child
sexual abuse and intimate partner violence. Further, to avoid over-estimating the burden
when both of these risk factors are present we estimated an adjusted relative risk to account
for the combined exposure state of having experienced both child sexual abuse and intimate
partner violence.
We estimated the prevalence of ‘intimate partner violence without child sexual abuse’ and
‘child sexual abuse and intimate partner violence combined’ from the Women’s Safety
Survey (ABS 1996). We used two categories of exposure to intimate partner violence, namely
physical or sexual violence by a partner in the last 12 months, and physical or sexual violence
by a partner more than 12 months ago. Given that the Women’s Safety Survey asks only one
question regarding child sexual abuse (‘Whether experienced sexual abuse when a child’) we
used the CRA project priors for Australia for the prevalence of child sexual abuse (based
upon epidemiological studies) and assumed no trend in prevalence of child sexual abuse. We
subtracted the prevalence of ‘child sexual abuse and intimate partner violence combined’
from the child sexual abuse priors to estimate the prevalence of child sexual abuse without
intimate partner violence.
Messman-Moore and colleagues (2000) looked at the mean psychological functioning indices
for women who had experienced (a) both contact child sexual abuse and adult victimisation
(revictimisation); (b) adult victimisation only (multiple or once only); (c) contact child sexual
abuse only; and (d) no abuse history. From these group means and standard errors we
calculated an effect size using Hedges’ adjusted g for standardised mean difference (Egger et
al. 2001). We then converted the effect sizes into odds ratios for risk of depression, anxiety
and post-traumatic stress disorder by exposure group using the methods described by
Hasselblad and Hedges (1995).
These odds ratios, along with relative risks for contact child sexual abuse from the CRA
project (Andrews et al. 2004), and relative risks for intimate partner violence from the
Women’s health Australia study (see DHS 2005: page 29) were then used to derive relative
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risks for ‘contact child sexual abuse only’, ‘intimate partner violence only’, and ‘child sexual
abuse and intimate partner violence combined’.
Since Messman-Moore and colleagues (2000) define child sexual abuse as contact only, for
non-contact child sexual abuse we used the CRA project relative risks and prevalence for
that category unadjusted. In our main results we combined anxiety and depression together
into one category. We therefore found the mean relative risk from the derived relative risks
for depression, anxiety, and post-traumatic stress disorder symptoms. We applied the same
relativities from the anxiety and depression relative risks for child sexual abuse only,
intimate partner violence only, and combined child sexual abuse and intimate partner
violence, to the intimate partner violence and child sexual abuse relative risks for other
conditions (alcohol use disorders, other drug use disorders, and self-inflicted injuries).
For ease of reporting, the population attributable fraction calculated for the ‘combined child
sexual abuse and intimate partner violence category’ was proportionately redistributed to
either child sexual abuse or intimate partner violence. To calculate the population
attributable fractions for those disease categories that only apply to intimate partner violence
(smoking, cervical cancer, sexually transmitted diseases, eating disorders and physical
injuries) we used the relative risks for intimate partner violence from the Women’s health
Australia study, and the prevalence of intimate partner violence (including those women
who may have also experience child sexual abuse) from the Women’s Safety Survey. The
proportion of homicide due to intimate partner violence (52%) was from the 2003–2004
National Homicide Monitoring Program Annual Report (Mouzos 2005). Violence YLD was
based on the proportion of hospitalisations for assaults where the relationship of the victim
of assault to the perpetrator was recorded as spouse or domestic partner (including ex-
spouse and ex-partner). The assaults where this relationship was unspecified were
proportionately redistributed.
Due to a lack of data on the prevalence of intimate partner violence among males, and on the
related health outcomes, for males we only estimated the burden due to child sexual abuse.
Analyses were based on methods developed for the CRA project described elsewhere
(Andrews et al. 2004). We used the CRA priors for Australia for the prevalence of male child
sexual abuse (based upon epidemiological studies).
Urban air pollution
Numerous studies have documented that urban air pollution has a range of effects on health,
from irritated eyes to death. The effects of short-term exposure are generally demonstrated
through time-series studies on daily events (for example mortality, hospitalisations,
emergency department attendance) (Cohen et al. 2004; Simpson et al. 2005a, 2005b). The
effects of long-term exposure have been demonstrated in large cohort and cross-sectional
studies, mainly in the US and Europe (Cohen et al. 2004; Pope et al. 2002). We estimated the
burden due to both long- and short term exposure to urban air pollution, and present the
results for long-term exposure only as a minimum estimate, and the combination of long-
and short-term exposure as a more inclusive but less certain higher estimate.
Long-term exposure
For chronic exposure to urban air pollution, our analyses are based on methods developed
for the CRA project (Cohen et al. 2004). The main data inputs were: (a) annual 24-hour
average particulate matter concentrations (particulate matter with an aerodynamic diameter
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10 and PM2.5) as an indicator of exposure to pollution
from combustion sources; and (b) information on the relative risk of mortality. In the CRA
method, the population attributable fraction was calculated from these inputs as the
difference in disease experience in a population and the hypothetical disease experience if
the population were exposed to the hypothetical minimum of particulate matter (PM2.5
7.5g/m3; PM10 15g/m3). However, there is evidence that there may be no safe level of
exposure to particulate matter (WHO Europe 2004). We therefore set the theoretical
minimum to zero in our analyses.
Our estimates for long-term exposure are based on the contributions of two health outcomes:
cardiopulmonary disease and lung cancer in adults aged 30 years and older. Attributable
burden was estimated using risk coefficients from a large cohort study of adults in the
United States (Pope et al. 2002). We did not use the CRA method of attributing acute
respiratory infection in children aged 0–4 years as this method applies a relative risk based
on daily exposure to annual exposure levels. Given the availability of daily urban air
pollution data in Australia, and more appropriate relative risk estimates from Australian
pollution concentration and mortality data, we used the estimates generated using the short-
term effects methods described below.
We based exposure on annual mean levels for 2002 in the following urban areas: Sydney,
Newcastle, Wollongong, Melbourne, Geelong, Brisbane, Perth, Adelaide, Canberra
(including Queanbeyan), and Hobart. Annual concentrations were derived from data
supplied by the state and territory environmental protection authorities, except for Adelaide
and Hobart where we used published estimates (DPIWE 2004; Gooding & Riordan 2004).
PM2.5 concentration was not available for Geelong, Hobart or Canberra. For Geelong, we
estimated the concentration from Melbourne’s PM10:PM2.5 ratio. For Hobart and Canberra,
we based our estimates on the average PM10:PM2.5 ratio for those cities with original data
(that is, Brisbane, Melbourne, Perth, Sydney, Adelaide, Newcastle and Wollongong). Due to
temporal trends in particulate matter concentration, the linking of current exposure to
chronic outcomes may underestimate the attributable burden if exposure levels were higher
in the past. However, the use of recent exposure data is in keeping with the CRA methods.
Short-term exposure
Short-term exposure to urban air pollution has been associated with day-to-day variations in
hospital admissions and mortality (Simpson et al. 2005a, 2005b). However, translating these
findings into burden of disease estimates is not straightforward. The difficulty with
estimating attributable morbidity is that published risks are established for the impact on
hospitalisations only. An increase in hospitalisations for causes related to urban air pollution
is likely to largely reflect exacerbation of existing disease rather than new disease events. Our
YLD estimates are based on incident cases and their average duration at a particular level of
severity. Thus the impact of urban air pollution on morbidity needs to be estimated as either
a proportion of new cases of disease or a worsening of the condition for an undefined period
of time. Until these methodological issues can be resolved we consider only a mortality
component of the short-term health consequences of urban air pollution.
The problem with attributing mortality to the short-term impact of urban air pollution is that
there is equivocal evidence regarding the extent of ‘harvesting’, that is, imminent deaths
brought forward by only a short period of time (less than a month) that were imminent
anyway, or ‘new deaths’ that would not have occurred in the absence of urban air pollution.
This has a major bearing on our estimates of YLL: if harvesting occurs, YLL will be only a
of less than 10 and 2.5 micrometres,  PM
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fraction of that normally calculated for each death. There is much debate in the literature on
this topic. There are some arguments that harvesting does not play a role in the effects of
urban air pollution. For instance there is an increase in deaths when longer lags between
exposure and outcomes (up to 4 months) of urban air pollution are estimated, rather than a
decrease (Schwartz 2001; Zeger et al. 1999). (The need to control for seasonal variation in
these analyses makes it difficult to extend these analyses over the longer term as longer lags
become strongly correlated with seasonal changes). This finding has been interpreted to
indicate that harvesting is not an important issue. However, it could also be the case that
urban air pollution exposure leads to chronic rather than acute effects on mortality. A further
argument put forward by the same authors is that the largest increase in deaths was seen in
people dying outside a hospital, while one would have expected a greater increase in
hospital deaths if harvesting were bringing deaths forward in people who were already ill.
The authors do not comment, however, on whether this may be due to the protective effect
of the hospital environment. We concluded that there is no consensus on the relative
contribution of deaths brought forward by urban air pollution nor on the size of the true
acute impact on mortality. We therefore present the chronic impact as a lower estimate of the
burden due to urban air pollution and add an alternative estimate of the combined short-
term and long-term effects, ignoring any harvesting, as an upper bound.
Recent Australian research has provided the most applicable risk coefficients describing the
effect of short-term exposure to urban air pollution on mortality (Simpson et al. 2005b). We
applied these to daily urban air pollution data to estimate the attributable mortality burden
of this risk. Following expert advice, our estimates were based on an averaged 0–1 day lag
(that is, exposure to urban air pollution on the day of death and the day before death) of the
contributions of two pollutants to two causes of death: all cause mortality (excluding
accidental and other external causes of death) due to particle exposure (in units of light
scattering by nephlometry, bsp), and respiratory deaths due to exposure to ozone. The choice
of including these two pollutants and excluding others was made after discussion with the
researchers (Simpson, Williams and Barnett) and justified by the finding that the impact on
mortality of NO2, CO and particles largely overlaps and hence including all three would lead
to overestimation. The impact of SO2 is considered small in Australia but ozone has a
significant impact on respiratory mortality independent of that of other pollutants.
Estimates were calculated with a theoretical minimum exposure level of zero. This is based
on evidence that at the population level there appears to be no safe level of exposure to
particles or ozone (WHO Europe 2004).
A decision was made to work with exposure data from 2002 rather than 2003 (the reference
year for our study) because 2003 is considered an outlier year by the environmental
protection authorities for pollutant readings. Daily urban air pollution data were supplied by
the Victorian, New South Wales, Australian Capital Territory, Queensland and Western
Australian environmental protection authorities. We calculated a PAF for each day by urban
area, pollutant, and underlying cause of death, with the assumption that the entire
population of that urban area was exposed. This was applied to daily 2002 mortality data,
and aggregated to age- and sex-specific annual PAFs. We aggregated the number of deaths
and YLL attributable to urban air pollution in specific areas (Sydney, Newcastle,
Wollongong, Melbourne, Geelong, Brisbane, Perth, Adelaide, Canberra including
Queanbeyan, and Hobart), calculated this as a proportion of all deaths or YLL in Australia
and, finally, applied this proportion to 2003 mortality estimates.
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We did not gain access to daily Tasmanian or South Australian urban air pollution data.
Particle levels for Adelaide and Hobart were therefore extrapolated from published annual
mean PM10 levels (Air Monitoring Unit, EPA SA 2003; DPIWE 2004), and the average ratio of
bsp:PM10 for Brisbane, Sydney and Melbourne from Simpson and colleagues (2005b). The
ratio of the extrapolated mean bsp for Adelaide and Hobart to the annual mean bsp level for
the cities for which we had detailed exposure data was then applied to the annualised PAF
for these cities to extrapolate the PAFs for the two cities with missing exposure data. Ozone
levels for Adelaide were based on the published average for 2002 (Gooding & Riordan 2004).
Ozone is not routinely monitored in Hobart (DPIWE 2006); we therefore did not include this
region in our analysis of respiratory deaths due to ozone exposure.
Unsafe sex
All sexually transmitted diseases were attributed to unsafe sex. The PAFs for HIV/AIDS and
hepatitis B and C due to unsafe sex were derived as described in the section on illicit drugs.
Previous Australian and Victorian burden of disease studies have used a PAF of 0.90 for
cervical cancer. In this study we attributed all cervical cancer to sexual transmission of the
human papilloma virus. Munoz and colleagues (2003) found that 90.7% cases had HPV DNA
detected. Similarly, in a meta-analysis Clifford and colleagues (2003) found that HPV DNA
was present in 80–89% of cases. However, research by Walboomers and colleagues (1999), in
which they revisited a previous study, suggests that nearly all cases that were negative for
HPV DNA were false negatives. They revised up the estimates of cases testing positive for
HPV DNA from 93% to 99.7%. Bosch and Munoz (2002) suggest that in most studies where
5–15% of cases are negative for HPV these are false negatives.
Osteoporosis
Osteoporosis causes no disability or death per se; it does, however, increase the risk of
fracture. Therefore we treated osteoporosis as a risk factor in this study rather than as a
disease in its own right, as was done in the previous Australian burden study. The WHO
Task-Force for Osteoporosis recommends that the condition be defined by level of bone
mineral density (BMD). We therefore based our PAF calculations on the population
distribution of BMD, and relative risks associated with decreasing BMD.
In Australia there are two large studies that have measured population BMD, one based in
Geelong and the other in Dubbo. Both the Geelong Osteoporosis Study and the Dubbo
Osteoporosis Epidemiology Study state that the population they cover is representative of
the Australian population (Nguyen et al. 2001; Sanders et al. 1998). Mean BMD and standard
deviations (SDs) for the Geelong and Dubbo studies were supplied by the study custodians.
We used Geelong data for ages <60 and combined Geelong and Dubbo data for 60 years or
over by fitting a Weibull distribution. From this distribution we plotted BMD by age for ages
25 years or over and fitted a polynomial distribution (R2=0.998). We then predicted mean
BMD from this equation for 5-year age groups from 60 years.
For males, we assumed that the difference between the Dubbo and Geelong BMD means for
women would also apply to males if Geelong data were available. We therefore increased
Dubbo means by the ratio of female Dubbo sampled mean to the combined mean. We
assumed deviations from the line were sampling error, and predicted mean BMD by age
group from the fitted quadratic equation (R2=0.925). We assumed the SD for Dubbo applied.
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The WHO Task-Force for Osteoporosis recommends that the condition be defined in
Caucasian women as a BMD 2.5 SDs or more below the young female reference mean
(Genant et al. 1999). The Australia and New Zealand Bone and Mineral Society and
Osteoporosis Australia recommended that data from the Geelong Osteoporosis Study be
used to establish a standardised reference range for Australia (Henry et al. 2004). We
therefore used the mean BMD and SD for young women aged 20–29 from this study as the
theoretical minimum, and also used this population for the osteoporosis cut-off (Henry et al.
2004).
There is currently no Australian reference mean BMD and SD for young adult men. We
estimated these values by multiplying the Australian young female mean and SD (Henry et
al. 2004) by the ratio of male to female mean and SD from the USA’s National Health and
Nutrition Examination Survey (NHANES) (Looker et al. 1998). The NHANES used Hologic
densitometers while both the Dubbo and Geelong studies used Lunar densitometers. These
machines do not give standardised results. We therefore converted the Hologic estimates to
Lunar by applying the formula available at <www.courses.washington.edu/bonephys/
opBMDs.html>.
Relative risks and odds ratios from a number of studies were pooled to estimate the relative
risk of low impact fracture per 0.1g/cm2 decrease in BMD measured at the femoral neck
(EPOS Group 2002; Fujiwara et al. 2003; Kroger et al. 1995; Nguyen et al. 2005a, 2005b;
Papaioannou et al. 2005; Schott et al. 2005; Schuit et al. 2004; Stone et al. 2003). Where a study
used Hologic or Norland densitometers, and the relative risk was per SD change in BMD, we
converted the study’s SD estimates to Lunar.
We derived PAFs for a number of fracture sites. Where possible these sites were linked
directly to a single nature of injury category. In some cases (for example hip) we applied the
PAF to a proportion of a category based on the distribution of fracture sites in the National
Hospital Morbidity Database 2002–03. Since most studies that we included in the calculation
of relative risks excluded fractures resulting from high impact causes, we applied the PAFs
to fractures resulting from falls, striking and crushing accidents, and other unintentional
injuries.
For attributable YLL, we applied the site-specific fracture YLD PAFs to the site-specific
mortality distribution for vertebral, pelvis and femur fracture to derive a site-specific YLL
PAF. This was applied to deaths with an underlying cause of falls, striking and crushing
accidents, other unintentional injuries, ill-defined falls or osteoporosis, where a fractured
spine, pelvis or femur was mentioned. If more than one fracture was mentioned we applied
the larger PAF, that is, for fractured pelvis and femur we applied the PAF for femur. We
assumed that all deaths with an underlying cause of osteoporosis but no mention of
vertebral, pelvis, or femur fracture, were attributable to osteoporosis. To determine the
burden of disease code-specific YLL PAF for osteoporosis we calculated the proportion of
burden of disease code-specific deaths attributable to osteoporosis. Osteoporosis and ill-
defined fall deaths were redistributed to falls. If we were to limit the deaths attributable to
osteoporosis to only those that were coded to osteoporosis, the overall number of deaths
would have been considerably smaller.
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Annex Table 1: Disease and injury categories and ICD-10 codes
Cause ICD–10 codes
I.  Communicable diseases, maternal and
neonatal conditions
A.  Infectious and parasitic diseases
1. Tuberculosis A15–19;B90;K230,673,930;M011,490,900;N330,7401;O980;P370
2. Sexually transmitted diseases(a)
a. Syphilis A50–53;I980;K672;M031,731;N290,742
b. Chlamydia A56;K670;N744
c. Gonorrhoea A54;K671;M730;N743;O982
d. Other sexually transmitted diseases A55,57–64
3. HIV/AIDS B20–24;F024
4. Diarrhoeal diseases A00–09
5. Childhood immunisable diseases
a. Diphtheria A36
b. Whooping cough A37
c. Tetanus A33–35
d. Poliomyelitis A80;B91
e. Measles B05
f. Rubella B06;M014;P350
g. Haemophilus influenzae type b (Hib) A413,492;G000;J051,14,201
6. Meningitis A39;G001–9,03
7. Septicaemia A40,410–2,414–8
8. Arbovirus infection
a. Ross River virus B331
b. Barmah Forest virus A92.8
c. Dengue A90–91
d. Other arbovirus infection A83–84,852,92–99
9. Hepatitis
a. Hepatitis A B15
b. Hepatitis B(b) B16,170,180–1
c. Hepatitis C(c) B171,182
d. Other hepatitis B172–8,188–9,19;P353
10. Malaria B50–54
11. Trachoma A71;B940
12. Other infectious and parasitic diseases A20–32,38,42–48,490–1,493–9,65–70,74–79,81–82,850–1, 858,
86–89;B00–04,07–09,25–30,330,332–8,34–49,55–89,92
(excluding 92.8),941, 948–9,95–99;G01–02,04–
07;K231;M00,010,012–3,015–8, 030
B. Acute respiratory infections
1. Lower respiratory tract infections J10–13,15–18,200,202–9,21–22
2. Upper respiratory tract infections J00–04,050,06
3. Otitis media H65–66
C. Maternal conditions
1. Maternal haemorrhage O441,45–46,67,72
2. Maternal sepsis O411,85–86
3. Hypertensive disorders of pregnancy O10–16
4. Obstructed labour O64–66,711,713
5. Abortion O00–08
(continued)
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Annex Table 1 (continued): Disease and injury categories and ICD-10 codes
Cause ICD–10 codes
6. Other maternal conditions O09,20–24,26–40,410,418–9,42–43,440,47–63,68–70, 710,712,
714–9,73–82,87–97,981,983–9,99
D. Neonatal causes
1. Birth trauma and asphyxia P03,10–21,24–28
2. Low birthweight P05–07,22
3. Neonatal infections P23,351–2,358–9,36,371–9,38–39
4. Other conditions arising in the perinatal period P04,08,29,50–96
E. Nutritional deficiencies
1. Protein-energy malnutrition E40–45,640;M833;O25
2. Deficiency anaemia D50–53
3. Other nutritional deficiencies E00–02,031,50,51–1,518–9,52–61,630–8,641–9
II. Non-communicable diseases
F. Malignant neoplasms
1. Mouth and oropharynx cancers C00–14
2. Oesophagus cancer C15
3. Stomach cancer C16
4. Colorectal cancer C18–21
5. Liver cancer(d) C22
6. Gallbladder cancer C23–24
7. Pancreas cancer C25
8. Lung cancer C33–34
9. Bone and connective tissue cancer C40–41,490–9
10. Melanoma C43
11. Non-melanoma skin cancers C44
12. Breast cancer C50
13. Cervix cancer C53
14. Corpus uteri cancer C54
15. Ovary cancer C56,570–4
16. Prostate cancer C61
17. Testicular cancer C62
18. Bladder cancer C67
19. Kidney cancer C64–66,68
20. Brain cancer C71
21. Thyroid cancer C73
22. Lymphoma C81–85,96
23. Multiple myeloma C88–90
24. Leukaemia C91–95
25. Larynx cancer C32
26. Eye cancer C69
27. Other malignant neoplasms C17,26–31,37–39,45–48,51–52,577–9,58–60,63,70,72,74–75
G. Other neoplasms
1. Uterine myomas D25
2. Benign neoplasms of meninges and brain D32–33
3. Other benign neoplasms D00–24,26–31,34–48
H. Diabetes mellitus
1. Type 1 diabetes E10
2. Type 2 diabetes E11–13
(continued)
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Annex Table 1 (continued): Disease and injury categories and ICD-10 codes
Cause ICD–10 codes
I. Endocrine and metabolic disorders
1. Non-deficiency anaemia
a. Haemolytic anaemia D55–58
b. Other non-deficiency anaemia D59–63,640–8
2. Cystic fibrosis E84
3. Haemophilia D66–67,681
4. Other endocrine and metabolic disorders D680,682–9,69–72,730–4,738–9,74–89;E030,032–9,04–07,15–35,
65,660–2,67–77,781–4,786–9,79–83,85,873–4,878,88–90;
D65,735;E668–9,86,870–2,875–7
J. Mental disorders
1. Substance use disorders
a. Alcohol dependence and harmful use(e) E512;F10;G312;X45
b. Heroin or polydrug dependence and harmful
use
F11;X42
c. Benzodiazepine dependence and harmful
use
F13
d. Cannabis dependence and harmful use F12
e. Other drug dependence and harmful use F14–16,18–19
2. Schizophrenia F20–29
3. Anxiety and depression F30,32–39,400–1,410–2,42,431,930
4. Bipolar disorder F31
5. Personality disorders(f) F603
6. Eating disorders
a. Anorexia nervosa F500–1
b. Bulimia nervosa F502–3
c. Other eating disorders F504–9
7. Childhood conditions
a. Attention-deficit hyperactivity disorder F90
b. Autism spectrum disorders F84
8. Other mental disorders F05–09, 402–9,413–9,430,432–9,44–48,51–59,600–2,604–9,
61-69,80–83,88–89,91–92,931–9,94–99
K. Nervous system and sense organ disorders
1. Dementia F00–01,020–1,023,03;G30,310–1,318–9
2. Epilepsy G40–41
3. Parkinson’s disease G20
4. Multiple sclerosis G35
5. Motor neurone disease G122
6. Huntington’s chorea F022;G10
7. Muscular dystrophy G710
8. Sense organ disorders
a. Glaucoma-related blindness H40
b. Cataract-related blindness H25–27
c. Macular degeneration H353
d. Adult-onset hearing loss H90–91
e. Refractive errors H520–7
f. Other vision loss H54
9. Migraine G43
10. Other nervous system and sense organ
disorders
F028,04,70–79;G08–09,11,120–1,128–9,13,21–26,32,36–37,44,
46–70,711–932,72–92,934–9,94–H22;H28–34,350–2,354-9,36,
42–51,53,55–62,67–83,92–95
(continued)
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Annex Table 1 (continued): Disease and injury categories and ICD-10 codes
Cause ICD–10 codes
L. Cardiovascular disease
1. Rheumatic heart disease I00–09
2. Ischemic heart disease I20–25
3. Stroke G45;I60–69
4. Inflammatory heart disease I30–33,40–42
5. Hypertensive heart disease I11,130,15
6. Non-rheumatic valvular disease I34–39
7. Aortic aneurysm I71
8. Peripheral vascular disease I700–8,720–9,73–74
9. Other cardiovascular disease I26,271,28,43–45,470–1,479,48,491–9,510–4,52,77–84,86–97,
981–8,99
M. Chronic respiratory disease
1. Chronic obstructive pulmonary disease
(COPD)
I270,278–9;J40–44
2. Asthma J45–46
3. Other chronic respiratory diseases J30–39,47–99
N. Diseases of the digestive system
1. Peptic ulcer disease K25–27
2. Cirrhosis of the liver(g) I85;K70,717,721–9,73–74,766–7
3. Appendicitis K35–37
4. Intestinal obstruction K400–1,403–4,410–1,413–4,420–1,430–1,440–1,450–8,460–1,56
5. Diverticulitis K57
6. Gallbladder and bile duct disease K80–83
7. Pancreatitis K85,860–1
8. Inflammatory bowel disease K50–51
9. Vascular insufficiency bowel K55
10. Other digestive system diseases K20–22,238,28–31,38,402,409,412,419,429,439,449,469,52,
58-66, 678,710–6,718–9,720,75,760–5,768–9,77,862–9,
87-91,928–9, 931–8
O. Genitourinary diseases
1. Nephritis and nephrosis(h) I12,131;N00–01,03–16,17–19
2. Benign prostatic hypertrophy N40
3. Urinary incontinence N393–4
4. Infertility N46,97
5. Other genitourinary diseases N02,20–28,291–8,30–32,338–392,34–37,398–9,41–45,47–64,
75-96, 98–99
P. Skin diseases
1. Eczema L20–27
2. Acne L70
3. Psoriasis L40
4. Ulcers L03,088–9,89,97,984
5. Other skin diseases L00–02,04–05,080–1,10–14,28–30,41–68,71–88,90–95,980–3,
985–9,99
Q. Musculoskeletal diseases
1. Rheumatoid arthritis M05–06,080,120,465–8
2. Osteoarthritis M15–19
3. Back pain(i) M469,47,480–3,488–9,538–9,545–9
4. Slipped disc M464,50–51,543–4,961
5. Occupational overuse syndrome
6. Systemic lupus erythematosus (SLE) M32
(continued)
206
Annex Table 1 (continued): Disease and injury categories and ICD-10 codes
Cause ICD–10 codes
7. Gout M10
8. Other musculoskeletal diseases M02,032–6,07,081–9,09,11,121–8,13–14,20–31,33–45,460–3,
484–5,491–8,530–3,540–2,60–72,738,75–79,830–2,834–9,
84-89,901–960,91–95,962–9,99
R. Congenital anomalies
1. Anencephaly Q00
2. Spina bifida Q05
3. Congenital heart disease Q20–28
4. Cleft lip and/or palate Q35–37
5. Digestive system malformations
a. Anorectal atresia Q42
b. Oesophageal atresia Q390–1
c. Other digestive system malformations Q38,392–9,40–41,43–45
6. Urogenital tract malformations
a. Renal agenesis(j) Q60
b. Other urogenital tract malformations(k) Q50–56,61–64
7. Abdominal wall defect Q792–5
8. Down syndrome Q90
9. Other chromosomal disorders Q91–99
10. Other congenital anomalies Q01–04,06–18,30–34,65–78,790–1,796–9,80–89
S. Oral conditions
1. Dental caries K02
2. Periodontal disease K05
3. Edentulism
4. Pulpitis K04
5. Other oral conditions K00–01,03,06–14
Z. Ill-defined conditions
1. Sudden infant death syndrome R95
2. Chronic fatigue syndrome G933;R53
III. Injuries
T. Unintentional injuries
1. Road traffic accidents V011–9,021–9,031–9,041–9,061–9,092–3,104–9,114–9,124–9,
134–9,144–9,154–9,164–9,174–9,184–9,194–9,204–9,214–9,
224–9,234–9,244–9,254–9,264–9,274–9,284–9,294–9,305–9,
315–9,325–9,335–9,345–9,355–9,365–9,375–9,385–9,394–9,
405–9,415–9,425–9,435–9,445–9,455–9,465–9,475–9,485–9,
494–9,505–9,515–9,525–9,535–9,545–9,555–9,565–9,575–9,
585–9,594–9,605–9,615–9,625–9,635–9,645–9,655–9,665–9,
675–9,685–9,694–9,705–9,715–9,725–9,735–9,745–9,755–9,
765–9,775–9,785–9,794–9,803–5,809,811,821–9,830–3,840–3,
850–3,860–4,870–8,892,899;Y85
2. Other transport accidents V010,020,030,040,05,060,090–1,099,100–3,110–3,120–3,130–3,
140–3,150–3,160–3,170–3,180–3,190–3,200–3,210–3,220–3,
230–3,240–3,250–3,260–3,270–3,280–3,290–3,300–4,310–4,
320–4,330–4,340–4,350–4,360–4,370–4,380–4,390–3,400–4,
410–4,420–4,430–4,440–4,450–4,460–4,470–4,480–4,490–3,
500–4,510–4,520–4,530–4,540–4,550–4,560–4,570–4,580–4,
590-3,600–4,610–4,620–4,630–4,640–4,650–4,660–4,670–4,
680–4,690–3,700–4,710–4,720–4,730–4,740–4,750–4,760–4,
770–4,780–4,790–3,800–2,806–8,810,812–9,820,834–9, 844–9,
854–9,865–9,879,88,890–1,893,90–99
3. Poisoning X40–41,43–44,46–49
4. Falls W00–19; M80–82
5. Fires, burns and scalds X00–19
(continued)
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Annex Table 1 (continued): Disease and injury categories and ICD-10 codes
Cause ICD–10 codes
6. Drowning W65–74
7. Sports injuries W21;X50
8. Natural and environmental factors W53–59,64,85–99;X20–39,51–57
9. Machinery accidents W24,27–31
10. Other unintentional injuries
Suffocation and foreign bodies W44, W75–W84
Adverse effects of medical treatment Y40–Y59, Y60–Y69, Y70–Y84, Y88
Other unintentional injuries n.e.c. W20, W22–W23, W25–W26, W32–W44, W45, W49, W51, W50,
W52, W60, W75–84; X58; Y40–Y59, Y60–Y84, Y86, Y880–Y883
U. Intentional injuries
1. Suicide and self-inflicted injuries X60–84;Y870
2. Homicide and violence X85–Y09;Y871
3. Legal intervention and war Y35–36,890–1
Redistribution categories
1. Pelvic inflammatory disease N70–73,748
2. Unspecified septicaemia A419
3. Hepatitis sequelae B942
4. Neonatal causes coded based on maternal
condition
P00–02
5. Ill-defined nutritional E46,639
6. Ill-defined malignant neoplasms C76–80,97
7. Uterus cancer—unspecified C55
8. Unspecified diabetes mellitus E14
9. Other anaemia D649
10. Smoking listed as cause F17
11. Hypertensive heart and renal disease I132–9
12. Heart failure I50
13. Essential hypertension I10
14. Ill-defined cardiovascular conditions E780,785;I46,472,490,515–9,709
15. Gastric haemorrhage K920–2
16. Ill-defined unintentional accidents (fall if also
fracture)
X59;Y90–98
17. Other accidents—intent undetermined Y20,22–25,28–29,33,34,872,899
18. Road traffic accidents—intent undetermined Y32
19. Poisoning—intent undetermined Y10–19
20. Falls—intent undetermined Y30–31
21. Burns—intent undetermined Y26–27
22. Drowning—intent undetermined Y21
23. Ill-defined non-injuries R00–52,54–94,96–99
Notes
(a) Excluding HIV/AIDS.
(b) Including hepatitis B-related liver cancer and cirrhosis.
(c) Including hepatitis C-related liver cancer and cirrhosis.
(d) Excluding hepatitis B and C related liver cancer.
(e) Including alcoholic cirrhosis.
(f) Excludes those with any other comorbid mental disorders.
(g) Excluding alcoholic and hepatic cirrhosis.
(h) Excluding diabetic-, congenital- and poisoning-related renal failure.
(i) Includes both acute and chronic back pain.
(j) Including renal failure due to dysplasia.
(k) Including polycystic renal failure.
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Annex Table 2: Principal data sources for epidemiological modelling
Primary data source
Prevalence/
Incidence
Reference
period Disease and injury categories
A. Disease registers, surveillance and notification systems
Incidence 2003 A1 Tuberculosis
Incidence 2003 A2a Syphilis
Incidence 2003 A2b Chlamydia
Incidence 2003 A2c Gonorrhoea
Incidence 2003 A5a Diphtheria
Incidence 2000–03 A5b Pertussis
Incidence 2003 A5c Tetanus
Incidence 2003 A5d Poliomyelitis
Incidence 2003 A5e Measles
Incidence 2003 A5f Rubella
Incidence 2003 A5g Haemophilus influenzae type B
Incidence 1993–96 A5g Hib B  sequela
Incidence 2003 A8 Arbovirus infections
Incidence 2003 A9a Hepatitis A
Incidence 2003 A9b Hepatitis B
National Notifiable Diseases Surveillance System:
includes: notifications; and reports: annual report
Communicable diseases intelligence
Incidence 2003 A10 Malaria
HIV/AIDS National Registry Incidence 2003 A3 HIV/AIDS
National Perinatal Data Collection Incidence 2003 D2 Low birthweight
Victorian Perinatal Data Collection Unit Incidence 2001–02 D2 Low birthweight
Queensland Perinatal Data Collection Incidence 2002 D2 Low birthweight
National Cancer Statistics Clearing House Incidence 2001 F Malignant neoplasms
State and territory cancer registries Incidence 1997 F12 Breast cancer
BreastScreen Australia Incidence 2001–02,
1997
F12 Breast cancer
National Diabetes Register Incidence 2001 H Diabetes mellitus
Incidence 2002 H Diabetes mellitus sequelaAustralia and New Zealand Dialysis and
Transplant Registry Incidence 2002 O1 Nephritis and nephrosis
Victorian Cystic Fibrosis Screening program Incidence 1989–1998 I2 Cystic fibrosis
Incidence 2003 K5 Motor neurone diseaseABS Causes of death data set
Incidence 2003 R1 Anencephaly
Western Australian Intellectual Disability
Exploring Answers database Incidence 1983–1996 K9 Intellectual disability
Incidence 2001–02 R2 Spina bifida
Incidence 2001–02 R5 Digestive system malformation
Victorian Perinatal Data Collection Unit Birth
Defects Register
Incidence 2001–02 R6a Renal agenesis
Incidence 2001–02 K9 Intellectual disability
Incidence 1997 R3 Congenital heart disease
Incidence 1997 R5 Digestive system malformation
Incidence 1997 R6b Other urogenital tract
malformations
Congenital malformations, Australia
Incidence 2001 R7 Abdominal wall defect
Western Australian Birth Defects Registry Incidence 2003 R6b
Other urogenital tract
malformations
(continued)
208
Annex Table 2: Principal data sources for epidemiological modelling
Primary data source
Prevalence/
Incidence
Reference
period Disease and injury categories
A. Disease registers, surveillance and notification systems
Incidence 2003 A1 Tuberculosis
Incidence 2003 A2a Syphilis
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Incidence 2000–03 A5b Pertussis
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Incidence 2003 A9a Hepatitis A
Incidence 2003 A9b Hepatitis B
National Notifiable Di ases Surveillance System:
includes: notifications; and reports: annual report
Communicable diseases intelligence
Incidence 2003 A10 Malaria
HIV/AIDS National Registry Incidence 2003 A3 HIV/AIDS
National Perinatal Data Collection Incidence 2003 D2 Low birthweight
Victorian Perinatal Data Collection Unit Incidence 2001–02 D2 Low birthweight
Queensland Perinatal Data Collection Incidence 2002 D2 Low birthweight
National Cancer Statistics Clearing House Incidence 2001 F Malignant neoplasms
State and territory cancer registries Incidence 1997 F12 Breast cancer
BreastScreen Australia Incidence 2001–02,
1997
F12 Breast cancer
National Diabetes Register Incidence 2001 H Diabetes mellitus
Incidence 2002 H Diabetes mellitus sequelaAustralia and New Zealand Dialysis and
Transplant Registry Incidence 2002 O1 Nephritis and nephrosis
Victorian Cystic Fibrosis Screening program Incidence 1989–1998 I2 Cystic fibrosis
Incidence 2003 K5 Motor neurone diseaseABS Causes of death data set
Incidence 2003 R1 Anencephaly
Western Australian Intellectual Disability
Exploring Answers database Incidence 1983–1996 K9 Intellectual disability
Incidence 2001–02 R2 Spina bifida
Incidence 2001–02 R5 Digestive system malformation
Victorian Perinatal Data Collection Unit Birth
Defects Register
Incidence 2001–02 R6a Renal agenesis
Incidence 2001–02 K9 Intellectual disability
Incidence 1997 R3 Congenital heart disease
Incidence 1997 R5 Digestive system malformation
Incidence 1997 R6b Other urogenital tract
malformations
Congenital malformations, Australia
Incidence 2001 R7 Abdominal wall defect
Western Australian Birth Defects Registry Incidence 2003 R6b
Other urogenital tract
malformations
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Annex Table 2 (continued): Principal data sources for epidemiological modelling
Primary data source
Prevalence/
Incidence
Reference
period Disease and injury categories
B. Health service utilisation data
Incidence 2002–03 A2b Chlamydia sequela
Incidence A2c Gonorrhoea sequela
Incidence A4 Diarrhoea
Incidence A5e Measles sequela
Incidence A6 Meningitis
Incidence A7 Septicaemia
Incidence A8c Dengue fever sequela
Incidence A9a Hepatitis A
Incidence A9c Hepatitis B sequela (D)(a)
Incidence A9c Hepatitis C sequela (D)
Incidence C1 Maternal haemorrhage (P)(b)
Incidence C3 Hypertension in pregnancy (P)
Incidence C4 Obstructed labour (P)
Incidence C5 Abortion (P)
Incidence C6 Other maternal conditions (P)
Incidence D1 Birth trauma & asphyxia
Incidence D3 Neonatal infections
Incidence G Benign neoplasms (P)
Incidence H Diabetes sequela (P)
Incidence I1a Haemolytic anaemia
Prevalence I1b Other non-deficiency anaemia
Incidence K8b Cataract-related blindness (P)
Incidence L2 Ischemic heart disease—AMI
Incidence L3 Stroke
Incidence L7 Aortic aneurysm
Prevalence L8 Peripheral vascular disease (P)
Incidence L8 Peripheral vascular disease
sequela
Prevalence N2 Cirrhosis of the liver (D)
Incidence N3 Appendicitis (P)
Incidence N4 Intestinal obstruction (P)
Incidence N5 Diverticulitis (P)
Incidence N6 Gall bladder and bile duct disease
(P)
Incidence N7 Pancreatitis
Incidence N8 Inflammatory bowel disease (P)
Incidence N9 Vascular insufficiency of intestine
(P)
Incidence O2 Benign prostatic hypertrophy (P)
Incidence Oot Other genitourinary diseases (P)
Incidence Q4 Slipped disc (P)
Incidence R3 Congenital heart disease (P)
Incidence R4 Cleft lip and or palate (P)
Incidence T Unintentional injuries
National Hospital Morbidity Database (diagnoses
or procedures)
Incidence U Intentional injuries
Bettering the Evaluation and Care of Health Incidence 2000–01 B1 Lower respiratory tract infections
Incidence 2000–01 B2 Upper respiratory tract infections
(continued)
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Annex Table 2 (continued): Principal data sources for epidemiological modelling
Primary data source
Prevalence/
Incidence
Reference
period Disease and injury categories
 Incidence 2000–01 B3 Otitis media
 Incidence 2003–04 N1 Peptic ulcer disease
 Incidence 2003–04 P4 Skin ulcers
Alcohol and Other Drug Treatment Services
National Minimum Data Set Prevalence 2002–03 J1c Stimulant dependence
Incidence 1990–2003 L1 Heart failure
Incidence 1990–2003 L2 Ischemic heart disease
Western Australian Data Linkage System
Incidence 1990–2003 L3 Stroke
Incidence 1996–2002 L Heart failureVictorian Linked Admitted Episodes Database
Incidence 1996–2002 N9 Vascular insufficiency of intestine
C. Population health surveys
2001–02 National Gastroenteritis Survey Incidence 2001–02 A4 Diarrhoea
1980 National Trachoma and Eye Health Program Prevalence 1976–78 A11 Trachoma sequela
 Incidence 1976–78 B3 Otitis media
Incidence 1995 B2 Upper respiratory tract infections
Incidence 2001 B3 Otitis media
Prevalence 2001 K10 Migraine
Prevalence 2001 P1 Eczema
Prevalence 2001 Poth Other skin diseases
Prevalence 1995 Q3 Chronic back pain (U)(c)
Incidence 2001 Q7 Gout
Prevalence
& incidence
2001 Qot Other musculoskeletal disorders
National Health Survey
Prevalence
& incidence
1995 Qot Other musculoskeletal disorders
Incidence 1999–2000 E2 Deficiency anaemiaAustralian Diabetes, Obesity and Lifestyle Study
(AusDiab) Prevalence 1999–2000 H Diabetes mellitus
Risk Factor Prevalence Study, 1989 Incidence 1989 E2 Deficiency anaemia
2002 National non-melanoma skin cancer survey Incidence 2002 F11 Non-melanoma skin cancer
Prevalence 1997 J1a Alcohol dependence
Prevalence 1997 J1c Benzodiazepine dependence
Prevalence 1997 J1d Cannabis dependence
Prevalence 1997 J2 Psychotic disorders
Prevalence 1997 J3 Anxiety and depression
Prevalence 1997 J4 Bipolar disorder
Prevalence 1997 J5 Personality disorders (isolated)
National Mental Health and Wellbeing Survey,
1997—adult component, Low prevalence
(psychotic) disorders component, and child &
adolescent component
Prevalence 1997 J7a ADHD
Australian Child to Adult Development Study Incidence 1990–96 K9 Intellectual disability
Prevalence 1996–2002 O3 Urinary incontinenceAustralian Longitudinal Study on Women’s
Health(d) Prevalence 1996–2002 Oot Menstrual problems
Prevalence 1998 O3 Urinary incontinence
Prevalence 2003 Q3 Chronic back pain
Prevalence 2003 Q5 Occupational overuse syndrome
Survey of Disability, Ageing and Carers
Prevalence 1993 Qot Other musculoskeletal disorders
Child Dental Health Survey, Australia Incidence 2000 S1 Dental caries
Prevalence 1987–88 S1 Dental cariesNational Oral Health Survey of Australia
Prevalence 1987–88 S2 Periodontal disease
South Australian Dental Longitudinal Study Incidence 1991–1996 S1 Dental caries
(continued)
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Annex Table 2 (continued): Principal data sources for epidemiological modelling
Primary data source
Prevalence/
Incidence
Reference
period Disease and injury categories
The Adelaide Dental Study of Nursing Homes,
one year follow up 1999 Incidence 1999 S1 Dental caries
The Adelaide Dental Study of Nursing Homes
1998 Prevalence 1998 S3 Edentulism
The Longitudinal Study of Dentists’ Practice
Activity Incidence 1998–99 S4 Pulpal infection
Prevalence 2002 S3 EdentulismNational Dental Telephone Interview Survey
Incidence 2002 S4 Pulpal infection
D. Epidemiological studies
Incidence A2 STIs (apart from HIV/AIDS)
Incidence A5b Pertussis sequela
Incidence A10 Malaria—sequela
Incidence B3 Otitis media—sequela
Incidence C2 Maternal sepsis—sequela
GBD study
Incidence C3 Hypertensive disorders in
pregnancy—sequela
Incidence A6 Meningitis sequela
Prevalence A9b Hepatitis B
Prevalence A9c Hepatitis C sequela
Incidence D4 Other neonatal causes
Prevalence E2 Deficiency anaemia
Incidence H Diabetes mellitus sequela
Prevalence I3 Haemophilia
Prevalence J1b Heroin dependence
Prevalence J6b Anorexia
Incidence J7b Autism spectrum disorders
Prevalence K4 Multiple sclerosis
Incidence K6 Huntington’s chorea
Incidence K7 Muscular dystrophy
Prevalence K8 Sense organ disorders
Incidence K9 Intellectual disability
Prevalence L3 Stroke
Prevalence M1 Chronic obstructive pulmonary
disease
Prevalence M2 Asthma
Prevalence N2 Cirrhosis of the liver
Prevalence O4 Infertility
Prevalence P1 Eczema
Australian epidemiological studies
Prevalence Poth Other skin diseases
Incidence A2b Chlamydia sequela (i.e. childwish)
Prevalence A9b Hepatitis B sequela
Incidence A9c Hepatitis C sequela
Incidence D1 Birth trauma & asphyxia—sequela
Incidence D2 Low birthweight—sequela
Incidence J6a Bulimia
Incidence K2 Epilepsy
Incidence K10 Migraine
Prevalence M2 Asthma
International epidemiological studies
Incidence N8 Inflammatory bowel disease
(continued)
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Primary data source
Prevalence/
Incidence
Reference
period Disease and injury categories
 Prevalence O3 Urinary incontinence
 Incidence Q1 Rheumatoid arthritis
Incidence Q2 Osteoarthritis
Incidence Q4 Slipped disc
Prevalence Z2 Chronic fatigue syndrome
Prevalence K1 DementiaMeta-analyses of epidemiological studies
Prevalence K3 Parkinson’s disease
E. Estimates that are distributed to other models
Incidence D1 Birth trauma & asphyxia
D2 Low birthweight
D3 Neonatal infections
D4 Other perinatal conditions
R8 Down syndrome
K9 Intellectual disability
R9 Other chromosomal anomalies
Prevalence 1996–2002 L1 Rheumatic heart disease
Incidence 1996–2002 L2 Ischemic heart disease
Incidence 1996–2002 L4 Inflammatory heart disease
Prevalence 1996–2002 L5 Hypertensive heart disease
Incidence 1996–2002 L6 Non-rheumatic valvular disease
L Heart failure
Incidence 1996–2002 M1 Chronic obstructive pulmonary
disease
F. Indirect estimation
A12 Other infectious and parasitic
diseases
D4 Other perinatal conditions
I4 Other endocrine and metabolic
diseases
L9 Other cardiovascular disease
M3 Other chronic respiratory diseases
N10 Other digestive system diseases
R10 Other congenital anomalies
YLL to YLD ratio from rest of category
Oot Other genitourinary diseases
Notes
(a) (D) refers to distributions which are used to estimate incidence to underlying causes.
(b) (P) refers to hospital data on procedures—may or may not be in addition to information on principal diagnosis.
(c) (U) proportion by underlying cause or type of problem (recent versus long-term).
(d) The research on which this report is based was conducted as part of the Australian Longitudinal Study on Women’s Health, The University
of Newcastle and The University of Queensland. We are grateful to the Australian Government Department of Health and Ageing for funding
and to the women who provided the survey data.
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GDP gross domestic product
GISCA National Centre for Social Applications of Geographic Information
Systems
HALE Health-adjusted life expectancy
HCC Hepatocellular cancer
HIV Human immunodeficiency virus
ICD-10 International Classification of Diseases—10th revision
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PYLL Potential years of life lost due to premature death
QALY Quality-adjusted life year
RR Relative risk
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SDs Standard deviations
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